2026 Incentive Formulary:

This Incentive Formulary applies to members of an employer/retiree, union, or trust fund health plan

For Medicare Part D: 5 Tier Incentive Formulary

Please click here.

For Medicare Part D: Prior Authorization Criteria

Please click here.

For Medicare Part D: Step Therapy Criteria

Please click here.

For more recent information or other questions, please contact:

Freedom Blue PPO (DE) Pharmacy Service at 1-844-576-1246
Freedom Blue PPO (PA) Pharmacy Service at 1-800-550-8722
Freedom Blue PPO (WV) Pharmacy Service at 1-888-459-4020
Security Blue HMO-POS Pharmacy Service at 1-800-935-2583
Community Blue Medicare HMO Pharmacy Service at 1-888-234-5397
Community Blue Medicare PPO Pharmacy Service at 1-888-757-2946
Community Blue Medicare Plus PPO Pharmacy Service at 1-888-757-2946
Blue Rx PDP Pharmacy Service at 1-800-290-3914

For TTY users, *711 National Relay Service*, Monday through Sunday, 8 a.m. to 8 p.m.
Visit medicare.highmark.com.

Formulary ID: 26016 Version: 9

Updated: 9/2025

Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

When this Drug List (formulary) refers to “we,” “us,” or “our,” it means Highmark Senior Health Company, Highmark Choice Company, Highmark Senior Solutions Company, Highmark BCBSD Inc, or Highmark Health Insurance Company..

When it refers to “plan” or “our plan,” it means Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, and Blue Rx PDP.

This document includes a Drug List (formulary) for our plan, which is current as of January 1, 2026. For an updated Drug List (formulary), please contact us. Our contact information, along with the date we last updated the Drug List (formulary), appears on the front and back cover pages.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2027, and from time to time during the year.

What is the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, and Blue Rx PDP formulary?

In this document, we use the terms Drug List and formulary to mean the same thing. A formulary is a list of covered drugs selected by our plan in consultation with a team of health care providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program. Our plan will generally cover the drugs listed in our formulary as long as the drug is medically necessary, the prescription is filled at a Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, or Blue Rx PDP network pharmacy, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage.

Can the formulary change?

Most changes in drug coverage happen on January 1, but we may add or remove drugs on the formulary during the year, move them to different cost-sharing tiers, or add new restrictions. We must follow the Medicare rules in making these changes. Updates to the formulary are posted monthly to our website, **medicare.highmark.com/formulary**.

Changes that can affect you this year: In the below cases, you will be affected by coverage changes during the year:

- **Immediate substitutions of certain new versions of brand name drugs and original biological products.** We may immediately remove a drug from our formulary if we are replacing it with a certain new version of that drug that will appear on the same or lower cost-sharing tier and with the same or fewer restrictions. When we add a new version of a drug to our formulary, we may decide to keep the brand name drug or original biological product on our formulary, but immediately move it to a different cost-sharing tier or add new restrictions.

  We can make these immediate changes only if we are adding a new generic version of a brand name drug, or adding certain new biosimilar versions of an original biological product, that was already on the formulary (for example, adding an interchangeable biosimilar that can be substituted for an original biological product by a pharmacy without a new prescription.)

  If you are currently taking the brand name drug or original biological product, we may not tell you in advance before we make an immediate change, but we will later provide you with information about the specific change(s) we have made.

  If we make such a change, you or your prescriber can ask us to make an exception and continue to cover for you the drug that is being changed. For more information, see the section below titled "How do I request an exception to the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, and Blue Rx PDP's formulary?"

  Some of these drug types may be new to you. For more information, see the section below titled "What are original biological products and how are they related to biosimilars?"

- **Drugs removed from the market.** If a drug is withdrawn from sale by the manufacturer or the Food and Drug Administration (FDA) determines to be withdrawn for safety or effectiveness reasons, we may immediately remove the drug from our formulary and later provide notice to members who take the drug.

- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may remove a brand name drug from the formulary when adding a generic equivalent or remove an original biological product when adding a biosimilar. We may also apply new restrictions to the brand name drug or original biological product, or move it to a different cost-sharing tier, or both. We may make changes based on new clinical guidelines. If we remove drugs from our formulary, add prior authorization, quantity limits and/or step therapy restrictions on a drug, or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective. Alternatively, when a member requests a refill of the drug, they may receive a 31-day supply of the drug and notice of the change.

If we make these other changes, you or your prescriber can ask us to make an exception for you and continue to cover the drug you have been taking. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled “How do I request an exception to the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, and Blue Rx PDP’s formulary?”

Changes that will not affect you if you are currently taking the drug. Generally, if you are taking a drug on our 2026 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2026 coverage year except as described above. This means these drugs will remain available at the same cost-sharing and with no new restrictions for those members taking them for the remainder of the coverage year. You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the formulary for the new benefit year for any changes to drugs.

The enclosed formulary is current as of September 1, 2025. To get updated information about the drugs covered by our plan, please contact us. Our contact information appears on the front and back cover pages. In the event of mid-year non-maintenance formulary changes, members will be notified by mail and prospective members will receive an update with this formulary. The most up-to-date formulary is available on our website, **medicare.highmark.com/formulary**.

How do I use the formulary?

There are two ways to find your drug within the formulary:

Medical Condition

The formulary begins on page 9. The drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs used to treat a heart condition are listed under the category, “Cardiovascular – Hypertension & Lipids.” If you know what your drug is used for, look for the category name in the list that begins on page 9. Then look under the category name for your drug.

Alphabetical Listing

If you are not sure what category to look under, you should look for your drug in the Index that begins on page 9. The Index provides an alphabetical list of all of the drugs included in this document. Both brand name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to your drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of your drug in the first column of the list.

What are generic drugs?

Our plan covers both brand name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand name drug. Generally, generic drugs work just as well as and usually cost less than brand name drugs. There are generic drug substitutes available for many brand name drugs. Generic drugs usually can be substituted for the brand name drug at the pharmacy without needing a new prescription, depending on state laws.

What are original biological products and how are they related to biosimilars?

On the formulary, when we refer to drugs, this could mean a drug or a biological product. Biological products are drugs that are more complex than typical drugs. Since biological products are more complex than typical drugs, instead of having a generic form, they have alternatives that are called biosimilars. Generally, biosimilars work just as well as the original biological product and may cost less. There are biosimilar alternatives for some original biological products. Some biosimilars are interchangeable biosimilars and, depending on state laws, may be substituted for the original biological product at the pharmacy without needing a new prescription, just like generic drugs can be substituted for brand name drugs.

For discussion of drug types, please see the Evidence of Coverage, Chapter 3, Section 3.1, “The ‘Drug List’ tells which Part D drugs are covered.”

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

- **Prior Authorization:** Our plan requires you or your prescriber to get prior authorization for certain drugs. This means that you will need to get approval from our plan before you fill your prescriptions. If you don’t get approval, our plan may not cover the drug.
- **Quantity Limits:** For certain drugs, our plan limits the amount of the drug that we will cover. For example, our plan provides 31 tablets, per 31 days, for 100mg Drug A. This may be in addition to a standard one-month or three-month supply.
- **Step Therapy:** In some cases, our plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, our plan may not cover Drug B unless you try Drug A first. If Drug A does not work for you, our plan will then cover Drug B.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 9. You can also get more information about the restrictions applied to specific covered drugs by visiting our website. We have posted online document(s) that explain(s) our prior authorization and step therapy restrictions. You may also ask us to send you a copy. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You can ask our plan to make an exception to these restrictions or limits or for a list of other, similar drugs that may treat your health condition. See the section, "How do I request an exception to the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, and Blue Rx PDP's formulary?" on page 6 for information about how to request an exception.

What if my drug is not on the formulary?

If your drug is not included in this formulary (list of covered drugs), you should first contact Pharmacy Service and ask if your drug is covered.

If you learn that our plan does not cover your drug, you have two options:

- You can ask Pharmacy Service for a list of similar drugs that are covered by our plan. When you receive the list, show it to your doctor and ask them to prescribe a similar drug that is covered by our plan.
- You can ask our plan to make an exception and cover your drug. See below for information about how to request an exception.

How do I request an exception to the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, and Blue Rx PDP's formulary?

You can ask our plan to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make.

- You can ask us to cover a drug even if it is not on our formulary. If approved, this drug will be covered at a pre-determined cost-sharing level, and you would not be able to ask us to provide the drug at a lower cost-sharing level.
- You can ask us to waive a coverage restriction including prior authorization, step therapy, or a quantity limit on your drug. For example, for certain drugs, our plan limits the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover a greater amount.
- You can ask us to cover a formulary drug at a lower cost-sharing level unless the drug is on the specialty tier. If approved, this would lower the amount you must pay for your drug.

Generally, our plan will only approve your request for an exception if the alternative drugs included on the plan's formulary, the lower cost-sharing drug, or applying the restriction would not be as effective for you and/or would cause you to have adverse effects.

You or your prescriber should contact us to ask for a tiering or, formulary exception, including an exception to a coverage restriction. ***When you request an exception, your prescriber will need to explain the medical reasons why you need the exception.*** Generally, we must make our decision within 72 hours of getting your prescriber's supporting statement. You can ask for

an expedited (fast) decision if you believe, and we agree, that your health could be seriously harmed by waiting up to 72 hours for a decision. If we agree, or if your prescriber asks for a for a fast decision, we must give you a decision no later than 24 hours after we get your prescriber's supporting statement.

What can I do if my drug is not on the formulary or has a restriction?

As a new or continuing member in our plan you may be taking drugs that are not on our formulary. Or, you may be taking a drug that is on our formulary but has a coverage restriction, such as prior authorization. You should talk to your prescriber about requesting a coverage decision to show that you meet the criteria for approval, switching to an alternative drug that we cover, or requesting a formulary exception so that we will cover the drug you take. While you and your doctor determine the right course of action for you, we may cover your drug in certain cases during the first 90 days you are a member of our plan.

For each of your drugs that is not on our formulary or has a coverage restriction, we will cover a temporary 31-day supply. If your prescription is written for fewer days, we'll allow refills to provide up to a maximum 31-day supply of medication. If coverage is not approved after your first 31-day supply, we will not pay for these drugs, even if you have been a member of the plan less than 90 days.

If you are a resident of a long-term care facility and you need a drug that is not on our formulary or if your ability to get your drugs is limited, but you are past the first 90 days of membership in our plan, we will cover a 31-day emergency supply of that drug while you pursue a formulary exception.

The above transition process will be implemented to accommodate you if you have an immediate need for a non-formulary drug or a drug that requires prior authorization due to a change in your level of care while you are waiting for an exception request to be processed.

For more information

For more detailed information about your plan's prescription drug coverage, please review your Evidence of Coverage and other plan materials.

If you have questions about your plan, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you have general questions about Medicare prescription drug coverage, please call Medicare at 1-800-MEDICARE (1-800-633-4227) 24 hours a day/ seven days a week. TTY users should call 1-877-486-2048. Or visit **http://www.medicare.gov**.

Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, and Blue Rx PDP formulary

The formulary that begins on the next page provides coverage information about the drugs covered by your plan. If you have trouble finding your drug in the list, turn to the Index that begins on page 9.

The first column of the chart lists the drug name. Brand name drugs are capitalized (e.g., ABELCET) and generic drugs are listed in lower-case italics (e.g., *abacavir*).

The information in the Requirements/Limits column tells you if your plan has any special requirements for coverage of your drug.

The following is a formulary Format Example Only:

Drug Name	Performance Drug Tier	Requirements/ Limits
Anti-Infectives		
XYZ DRUG	NF	QL-28

Table of Contents

Anti - Infectives 3
Antineoplastic / Immunosuppressant Drugs 15
Autonomic / Cns Drugs, Neurology / Psych 25
Cardiovascular, Hypertension / Lipids 58
Dermatologicals/Topical Therapy 69
Diagnostics / Miscellaneous Agents 80
Ear, Nose / Throat Medications 83
Endocrine/Diabetes 84
Gastroenterology 92
Immunology, Vaccines / Biotechnology 99
Miscellaneous Supplies 103
Musculoskeletal / Rheumatology 103
Obstetrics / Gynecology 107
Ophthalmology 114
Respiratory And Allergy 118
Urologicals 123
Vitamins, Hematinics / Electrolytes 125

lowercase italics = Generic drugs
UPPERCASE BOLD = Brand name drugs

Drug Tier
T1 = Cost-Sharing Tier 1 includes preferred generic drugs. This is the lowest cost-sharing tier.
T2 = Cost-Sharing Tier 2 includes generic drugs.
T3 = Cost-Sharing Tier 3 includes preferred brand name drugs and may include some single-sourced drugs (those generic drugs made by a single manufacturer).
T4 = Cost-Sharing Tier 4 includes non-preferred brand name drugs and may include some single-sourced generic drugs (those generic drugs made by a single manufacturer).
T5 = Cost-Sharing Tier 5 includes specialty drugs. This is the highest cost-sharing tier.

Requirements/Limits
LA = Limited access
PA = Prior authorization required
PA-BvD = This drug may be covered under Medicare part B or D depending on the circumstance. Information may need to be submitted describing the use and setting of the drug to make the determination.
PA-NS = Prior authorization required for new starts only
QL = Quantity limit applies. The quantity limit is noted for each drug. For example, if the quantity limit is QL (90 EA per 180 days), the quantity limit would be 90 units per 180-day supply.
ST = Step therapy applies
ST-NS = Step therapy applies to new starts only

Drug Name	Drug Tier	Requirements/Limits
Anti - Infectives		
abacavir	T3	
abacavir-lamivudine	T4	
acyclovir oral capsule	T2	
acyclovir oral suspension 200 mg/5 ml	T2	
acyclovir oral tablet	T2	
acyclovir sodium intravenous solution	T2	PA-BvD
adefovir	T4	
albendazole	T4	
amantadine hcl oral capsule	T2	QL (124 EA per 31 days)
amantadine hcl oral solution	T2	
amantadine hcl oral tablet	T2	
AMBISOME	T5	PA-BvD
amikacin injection solution 500 mg/2 ml	T4	
amoxicillin oral capsule	T1	
amoxicillin oral suspension for reconstitution	T1	
amoxicillin oral tablet	T1	
amoxicillin oral tablet,chewable 125 mg, 250 mg	T1	
amoxicillin-pot clavulanate oral suspension for reconstitution	T2	
amoxicillin-pot clavulanate oral tablet	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
amoxicillin-pot clavulanate oral tablet extended release 12 hr	T2	
amphotericin b	T4	PA-BvD
amphotericin b liposome	T5	PA-BvD
ampicillin oral capsule 500 mg	T2	
ampicillin sodium injection recon soln 1 gram, 10 gram	T2	
ampicillin-sulbactam injection	T2	
ANCOBON	T5	PA
APTIVUS	T5	
ARIKAYCE	T5	PA
atazanavir	T4	
atovaquone	T4	
atovaquone-proguanil	T2	
AUGMENTIN ES-600	T4	
AUGMENTIN ORAL SUSPENSION FOR RECONSTITUTION 125-31.25 MG/5 ML	T4	
AVYCAZ	T5	
AZACTAM	T4	
azithromycin intravenous	T2	
azithromycin oral suspension for reconstitution	T2	
azithromycin oral tablet	T2	
aztreonam	T4	
BACTRIM	T4	
BACTRIM DS	T4	
BARACLUDE	T5	
BAXDELA	T5	
BETHKIS	T5	PA
BICILLIN C-R	T3	
BICILLIN L-A INTRAMUSCULAR SYRINGE 1,200,000 UNIT/2 ML, 600,000 UNIT/ML	T3	
BICILLIN L-A INTRAMUSCULAR SYRINGE 2,400,000 UNIT/4 ML	T4	
BIKTARVY	T5	QL (31 EA per 31 days)
caspofungin	T4	
CAYSTON	T5	PA
cefaclor oral capsule	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
cefaclor oral suspension for reconstitution 250 mg/5 ml	T2	
cefaclor oral tablet extended release 12 hr	T4	
cefadroxil oral capsule	T2	
cefadroxil oral suspension for reconstitution 250 mg/5 ml, 500 mg/5 ml	T2	
cefadroxil oral tablet	T2	
cefazolin injection recon soln 1 gram, 10 gram, 500 mg	T2	
cefdinir	T2	
cefepime injection	T2	
cefixime	T2	
cefotetan injection	T2	
cefoxitin	T2	
cefpodoxime	T2	
cefprozil	T2	
ceftazidime	T2	
ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg	T2	
cefuroxime axetil oral tablet	T2	
cefuroxime sodium injection recon soln 750 mg	T2	
cefuroxime sodium intravenous recon soln 1.5 gram	T2	
cephalexin	T2	
chloroquine phosphate oral tablet 250 mg	T3	QL (50 EA per 30 days)
chloroquine phosphate oral tablet 500 mg	T3	QL (25 EA per 30 days)
CIMDUO	T5	QL (31 EA per 31 days)
CIPRO ORAL SUSPENSION,MICROCAPSULE RECON	T3	
CIPRO ORAL TABLET 250 MG, 500 MG	T4	
ciprofloxacin hcl oral tablet 250 mg, 500 mg, 750 mg	T1	
ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 ml	T2	
clarithromycin	T2	
CLEOCIN HCL	T4	
CLEOCIN INJECTION	T4	
CLEOCIN PEDIATRIC	T4	
clindamycin hcl	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
clindamycin in 5 % dextrose	T2	
CLINDAMYCIN PEDIATRIC	T2	
clindamycin phosphate injection	T2	
clotrimazole mucous membrane	T2	
COARTEM	T4	
colistin (colistimethate na)	T4	
COMPLERA	T5	
CRESEMBA ORAL	T5	PA
cycloserine	T4	
DALVANCE	T5	
dapsone oral	T3	
daptomycin intravenous recon soln 350 mg	T4	
daptomycin intravenous recon soln 500 mg	T5	
DARAPRIM	T5	PA
darunavir oral tablet 600 mg	T4	
darunavir oral tablet 800 mg	T5	
DELSTRIGO	T5	QL (31 EA per 31 days)
demeclocycline oral tablet 150 mg	T2	
demeclocycline oral tablet 300 mg	T4	
DESCOVY	T5	QL (31 EA per 31 days)
dicloxacillin	T2	
DIFICID ORAL SUSPENSION FOR RECONSTITUTION	T5	QL (136 ML per 12 days)
DIFICID ORAL TABLET	T5	QL (20 EA per 10 days)
DIFLUCAN ORAL SUSPENSION FOR RECONSTITUTION 40 MG/ML	T4	
DORYX MPC ORAL TABLET,DELAYED RELEASE (DR/EC) 60 MG	T5	
DOVATO	T5	QL (31 EA per 31 days)
DOXY-100	T3	
doxycycline hyclate intravenous	T2	
doxycycline hyclate oral capsule	T2	
doxycycline hyclate oral tablet 100 mg	T2	
doxycycline hyclate oral tablet 150 mg, 50 mg, 75 mg	T4	
doxycycline hyclate oral tablet 20 mg	T1	
doxycycline hyclate oral tablet,delayed release (dr/ec) 100 mg	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
doxycycline hyclate oral tablet,delayed release (dr/ec) 150 mg, 200 mg, 50 mg	T3	
doxycycline hyclate oral tablet,delayed release (dr/ec) 75 mg	T1	
doxycycline hyclate oral tablet,delayed release (dr/ec) 80 mg	T4	
doxycycline monohydrate oral capsule 100 mg, 50 mg	T2	
doxycycline monohydrate oral capsule 150 mg, 75 mg	T4	
doxycycline monohydrate oral capsule,ir - delay rel,biphase	T4	
doxycycline monohydrate oral suspension for reconstitution	T4	
doxycycline monohydrate oral tablet 100 mg, 50 mg, 75 mg	T2	
doxycycline monohydrate oral tablet 150 mg	T4	
E.E.S. 400 ORAL TABLET	T4	
EDURANT	T5	
EDURANT PED	T5	
efavirenz oral tablet	T3	
efavirenz-emtricitabin-tenofov	T5	
efavirenz-lamivu-tenofov disop	T5	QL (31 EA per 31 days)
EMROSI	T5	PA; QL (31 EA per 31 days)
emtricitabine	T3	
emtricitabine-tenofovir (tdf) oral tablet 100-150 mg, 167-250 mg, 200-300 mg	T4	
emtricitabine-tenofovir (tdf) oral tablet 133-200 mg	T5	
emtricita-rilpivirine-tenof df	T5	
EMTRIVA ORAL CAPSULE	T4	
EMTRIVA ORAL SOLUTION	T3	
EMVERM	T5	
entecavir	T4	
EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG	T5	PA; QL (28 EA per 28 days)
EPCLUSA ORAL PELLETS IN PACKET 200-50 MG	T5	PA; QL (56 EA per 28 days)
EPCLUSA ORAL TABLET	T5	PA; QL (28 EA per 28 days)
EPIVIR	T4	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ERAXIS(WATER DILUENT) INTRAVENOUS RECON SOLN 100 MG	T5	
ERAXIS(WATER DILUENT) INTRAVENOUS RECON SOLN 50 MG	T4	
ertapenem	T4	
ERYTHROCIN INTRAVENOUS RECON SOLN 500 MG	T4	
erythromycin ethylsuccinate oral suspension for reconstitution 200 mg/5 ml	T4	
erythromycin ethylsuccinate oral suspension for reconstitution 400 mg/5 ml	T5	
erythromycin ethylsuccinate oral tablet	T4	
erythromycin oral	T4	
ethambutol	T2	
etravirine	T5	
EVOTAZ	T5	
famciclovir	T2	
FIRVANQ	T4	
fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml	T2	
fluconazole in nacl (iso-osm) intravenous piggyback 400 mg/200 ml	T3	
fluconazole oral suspension for reconstitution	T3	
fluconazole oral tablet	T2	
flucytosine	T5	
fosamprenavir	T5	
fosfomycin tromethamine	T4	
gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml	T2	
gentamicin injection	T1	
GENVOYA	T5	
griseofulvin microsize	T2	
griseofulvin ultramicrosize oral tablet 125 mg, 250 mg	T2	
griseofulvin ultramicrosize oral tablet 165 mg	T5	PA; QL (124 EA per 31 days)
HARVONI	T5	PA; QL (28 EA per 28 days)
HUMATIN	T4	
hydroxychloroquine oral tablet 100 mg	T4	QL (93 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
hydroxychloroquine oral tablet 200 mg	T2	QL (93 EA per 31 days)
hydroxychloroquine oral tablet 300 mg	T4	QL (62 EA per 31 days)
hydroxychloroquine oral tablet 400 mg	T4	QL (31 EA per 31 days)
imipenem-cilastatin	T2	
IMPAVIDO	T5	
INTELENCE ORAL TABLET 100 MG, 200 MG	T5	
INTELENCE ORAL TABLET 25 MG	T4	
INVANZ INJECTION	T4	
ISENTRESS HD	T5	
ISENTRESS ORAL POWDER IN PACKET	T5	
ISENTRESS ORAL TABLET	T5	
ISENTRESS ORAL TABLET,CHEWABLE 100 MG	T5	
ISENTRESS ORAL TABLET,CHEWABLE 25 MG	T3	
isoniazid oral solution	T2	
isoniazid oral tablet	T1	
itraconazole oral capsule	T2	PA
itraconazole oral solution	T5	PA
ivermectin oral	T2	PA
JULUCA	T5	
KALETRA ORAL SOLUTION	T5	
KALETRA ORAL TABLET	T4	
ketoconazole oral	T2	
KITABIS PAK	T4	PA
KRINTAFEL	T4	
lamivudine	T2	
lamivudine-zidovudine	T2	
LAMPIT	T4	PA
ledipasvir-sofosbuvir	T5	PA; QL (28 EA per 28 days)
levofloxacin in d5w intravenous piggyback 500 mg/100 ml, 750 mg/150 ml	T2	
levofloxacin oral	T2	
linezolid in dextrose 5%	T4	
linezolid oral suspension for reconstitution	T5	
linezolid oral tablet	T4	
LIVTENCITY	T5	PA; QL (372 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
lopinavir-ritonavir oral tablet	T4	
MACROBID	T4	QL (90 EA per 365 days)
MACRODANTIN ORAL CAPSULE 100 MG	T4	QL (90 EA per 365 days)
MACRODANTIN ORAL CAPSULE 25 MG	T4	QL (360 EA per 365 days)
MACRODANTIN ORAL CAPSULE 50 MG	T4	QL (180 EA per 365 days)
MALARONE	T4	
MALARONE PEDIATRIC	T4	
maraviroc oral tablet 150 mg	T5	
maraviroc oral tablet 300 mg	T3	
MAVYRET ORAL PELLETS IN PACKET	T5	PA; QL (140 EA per 28 days)
MAVYRET ORAL TABLET	T5	PA; QL (84 EA per 28 days)
mefloquine	T2	
MEPRON	T5	
meropenem intravenous recon soln 1 gram, 500 mg	T2	
methenamine hippurate	T2	
metronidazole in nacl (iso-os)	T2	
metronidazole oral capsule	T2	
metronidazole oral tablet 125 mg	T4	PA
metronidazole oral tablet 250 mg, 500 mg	T1	
micafungin	T4	
minocycline oral capsule	T2	
minocycline oral tablet	T2	
minocycline oral tablet extended release 24 hr 105 mg, 115 mg, 135 mg, 45 mg, 65 mg, 80 mg, 90 mg	T2	
minocycline oral tablet extended release 24 hr 55 mg	T4	
moxifloxacin oral	T3	
moxifloxacin-sod.chloride(iso)	T4	
MYCAMINE INTRAVENOUS RECON SOLN 50 MG	T4	
nafcillin injection recon soln 1 gram	T2	
nafcillin injection recon soln 10 gram	T5	
nafcillin injection recon soln 2 gram	T4	
NEBUPENT	T4	PA-BvD
neomycin	T2	
nevirapine oral suspension	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
nevirapine oral tablet	T2	
nevirapine oral tablet extended release 24 hr 400 mg	T4	
nitazoxanide	T5	
nitrofurantoin macrocrystal oral capsule 100 mg	T2	QL (90 EA per 365 days)
nitrofurantoin macrocrystal oral capsule 25 mg	T2	QL (360 EA per 365 days)
nitrofurantoin macrocrystal oral capsule 50 mg	T2	QL (180 EA per 365 days)
nitrofurantoin monohyd/m-cryst	T2	QL (90 EA per 365 days)
nitrofurantoin oral suspension 25 mg/5 ml	T5	QL (1800 ML per 365 days)
nitrofurantoin oral suspension 50 mg/5 ml	T5	QL (900 ML per 365 days)
NORVIR ORAL POWDER IN PACKET	T3	
NORVIR ORAL TABLET	T4	
NOXAFIL ORAL SUSP,DELAYED RELEASE FOR RECON	T5	PA; QL (32 EA per 31 days)
NOXAFIL ORAL SUSPENSION	T5	PA
NUZYRA	T5	
nystatin oral	T2	
ODEFSEY	T5	QL (31 EA per 31 days)
ofloxacin oral tablet 300 mg, 400 mg	T2	
ORACEA	T4	PA; QL (31 EA per 31 days)
oseltamivir oral capsule 30 mg	T2	QL (170 EA per 365 days)
oseltamivir oral capsule 45 mg, 75 mg	T2	QL (90 EA per 365 days)
oseltamivir oral suspension for reconstitution	T3	QL (1080 ML per 365 days)
oxacillin in dextrose(iso-osm) intravenous piggyback 2 gram/50 ml	T2	
oxacillin injection recon soln 1 gram, 2 gram	T2	
oxacillin injection recon soln 10 gram	T4	
PAXLOVID ORAL TABLETS,DOSE PACK 150 MG (10)- 100 MG (10)	T3	QL (180 EA per 365 days)
PAXLOVID ORAL TABLETS,DOSE PACK 150 MG (6)- 100 MG (5)	T3	QL (99 EA per 365 days)
PAXLOVID ORAL TABLETS,DOSE PACK 300 MG (150 MG X 2)-100 MG	T3	QL (270 EA per 365 days)
penicillin g pot in dextrose intravenous piggyback 2 million unit/50 ml, 3 million unit/50 ml	T4	
penicillin g potassium injection recon soln 20 million unit	T2	
penicillin g sodium	T5	
penicillin v potassium	T1	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
PENTAM	T4	
pentamidine inhalation	T4	PA-BvD
pentamidine injection	T4	
PIFELTRO	T5	QL (62 EA per 31 days)
piperacillin-tazobactam intravenous recon soln 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram	T4	
PLAQUENIL	T4	QL (93 EA per 31 days)
polymyxin b sulfate	T2	
posaconazole oral	T5	PA
praziquantel	T4	
pretomanid	T4	PA; QL (31 EA per 31 days)
PREVYMIS ORAL PELLETS IN PACKET	T5	PA; QL (124 EA per 31 days)
PREVYMIS ORAL TABLET	T5	QL (31 EA per 31 days)
PREZCOBIX ORAL TABLET 800-150 MG-MG	T5	
PREZISTA ORAL SUSPENSION	T5	
PREZISTA ORAL TABLET 150 MG, 600 MG, 800 MG	T5	
PREZISTA ORAL TABLET 75 MG	T4	
PRIFTIN	T3	
primaquine	T3	
PRIMAXIN IV INTRAVENOUS RECON SOLN 500 MG	T4	
pyrazinamide	T2	
pyrimethamine	T5	PA
quinine sulfate	T3	PA; QL (42 EA per 28 days)
RELENZA DISKHALER	T3	
RETROVIR ORAL CAPSULE	T4	
RETROVIR ORAL SYRUP	T4	
REYATAZ ORAL CAPSULE 200 MG, 300 MG	T5	
REYATAZ ORAL POWDER IN PACKET	T5	
ribavirin oral capsule	T3	
ribavirin oral tablet 200 mg	T2	
rifabutin	T2	
rifampin intravenous	T4	
rifampin oral	T2	
rimantadine	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ritonavir	T3	
RUKOBIA	T5	QL (62 EA per 31 days)
SELZENTRY ORAL SOLUTION	T5	
SELZENTRY ORAL TABLET 150 MG, 300 MG	T5	
SEYSARA	T5	PA
SIRTURO	T5	PA
SIVEXTRO INTRAVENOUS	T5	
SIVEXTRO ORAL	T5	QL (6 EA per 31 days)
sofosbuvir-velpatasvir	T5	PA; QL (28 EA per 28 days)
SOLOSEC	T4	
SOVALDI	T5	PA; QL (28 EA per 28 days)
SOVUNA ORAL TABLET 200 MG	T4	QL (93 EA per 31 days)
SOVUNA ORAL TABLET 300 MG	T4	QL (62 EA per 31 days)
SPORANOX ORAL CAPSULE	T5	PA
streptomycin	T5	
STRIBILD	T5	
STROMECTOL	T4	PA
sulfadiazine	T2	
sulfamethoxazole-trimethoprim oral	T1	
SUNLENCA ORAL	T5	
SYMFI	T5	QL (31 EA per 31 days)
SYMTUZA	T5	QL (31 EA per 31 days)
TAMIFLU ORAL CAPSULE 30 MG	T3	QL (170 EA per 365 days)
TAMIFLU ORAL CAPSULE 45 MG, 75 MG	T3	QL (90 EA per 365 days)
TAMIFLU ORAL SUSPENSION FOR RECONSTITUTION	T3	QL (1080 ML per 365 days)
TARGADOX	T4	
TAZICEF INJECTION	T4	
TEFLARO	T5	
tenofovir disoproxil fumarate	T3	
terbinafine hcl oral	T1	QL (90 EA per 180 days)
tetracycline oral capsule	T4	
tigecycline	T4	
tinidazole	T2	
TIVICAY ORAL TABLET 50 MG	T5	
TIVICAY PD	T5	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
TOBI	T5	PA
TOBI PODHALER	T5	PA; QL (224 EA per 56 days)
tobramycin in 0.225 % nacl	T5	PA
tobramycin inhalation	T5	PA
tobramycin sulfate injection solution	T1	
TOLSURA	T5	PA; QL (130 EA per 31 days)
trimethoprim	T2	
TRIUMEQ	T5	
TRIUMEQ PD	T4	QL (186 EA per 31 days)
TRUVADA	T5	
TYBOST	T3	
TYGACIL	T4	
UNASYN INJECTION RECON SOLN 15 GRAM, 3 GRAM	T4	
VABOMERE	T5	
valacyclovir	T2	
VALCYTE	T5	
valganciclovir oral recon soln	T4	
valganciclovir oral tablet	T3	
VALTREX	T4	
VANCOCIN ORAL CAPSULE 125 MG	T4	QL (124 EA per 31 days)
VANCOCIN ORAL CAPSULE 250 MG	T5	QL (248 EA per 31 days)
vancomycin intravenous recon soln 1,000 mg, 10 gram, 500 mg, 750 mg	T2	
vancomycin oral capsule 125 mg	T4	QL (124 EA per 31 days)
vancomycin oral capsule 250 mg	T4	QL (248 EA per 31 days)
vancomycin oral recon soln	T4	
VEMLIDY	T5	QL (31 EA per 31 days)
VFEND IV	T4	PA
VFEND ORAL SUSPENSION FOR RECONSTITUTION	T5	
VIRACEPT ORAL TABLET	T5	
VIREAD	T5	
VIVJOA	T4	PA; QL (18 EA per 84 days)
voriconazole intravenous	T5	PA
voriconazole oral	T4	
VOSEVI	T5	PA; QL (28 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
XIFAXAN ORAL TABLET 200 MG	T4	QL (27 EA per 365 days)
XIFAXAN ORAL TABLET 550 MG	T5	PA; QL (62 EA per 31 days)
XOFLUZA ORAL TABLET 40 MG, 80 MG	T3	QL (9 EA per 365 days)
ZEMDRI	T5	
ZEPATIER	T5	PA; QL (28 EA per 28 days)
ZERBAXA	T5	
ZEVTERA	T5	
ZIAGEN ORAL SOLUTION	T3	
zidovudine	T2	
ZITHROMAX INTRAVENOUS	T4	
ZITHROMAX ORAL SUSPENSION FOR RECONSTITUTION	T4	
ZITHROMAX ORAL TABLET 250 MG, 500 MG	T4	
ZITHROMAX TRI-PAK	T4	
ZITHROMAX Z-PAK	T4	
ZOSYN IN DEXTROSE (ISO-OSM) INTRAVENOUS PIGGYBACK 2.25 GRAM/50 ML	T4	
ZYVOX INTRAVENOUS PIGGYBACK 600 MG/300 ML	T4	
ZYVOX ORAL SUSPENSION FOR RECONSTITUTION	T4	
ZYVOX ORAL TABLET	T5	
Antineoplastic / Immunosuppressant Drugs		
abiraterone oral tablet 250 mg	T5	PA-NS; QL (124 EA per 31 days)
abiraterone oral tablet 500 mg	T5	PA-NS; QL (62 EA per 31 days)
ABIRTEGA	T3	PA-NS; QL (124 EA per 31 days)
AFINITOR	T5	PA-NS; QL (31 EA per 31 days)
AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG, 5 MG	T5	PA-NS; QL (62 EA per 31 days)
AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 3 MG	T5	PA-NS; QL (93 EA per 31 days)
AKEEGA	T5	PA-NS; QL (62 EA per 31 days)
ALECENSA	T5	PA-NS; QL (248 EA per 31 days)
ALUNBRIG ORAL TABLET 180 MG, 90 MG	T5	PA-NS; QL (31 EA per 31 days)
ALUNBRIG ORAL TABLET 30 MG	T5	PA-NS; QL (186 EA per 31 days)
ALUNBRIG ORAL TABLETS,DOSE PACK	T5	PA-NS; QL (60 EA per 365 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
anastrozole	T2	
ARIMIDEX	T5	
AROMASIN	T5	
ASTAGRAF XL ORAL CAPSULE,EXTENDED RELEASE 24HR 0.5 MG, 1 MG	T3	PA-BvD
ASTAGRAF XL ORAL CAPSULE,EXTENDED RELEASE 24HR 5 MG	T5	PA-BvD
AUGTYRO ORAL CAPSULE 160 MG	T5	PA-NS; QL (62 EA per 31 days)
AUGTYRO ORAL CAPSULE 40 MG	T5	PA-NS; QL (186 EA per 31 days)
AVMAPKI-FAKZYNJA	T5	PA-NS; QL (66 EA per 28 days)
AYVAKIT	T5	PA-NS; QL (31 EA per 31 days)
AZASAN	T4	PA-BvD
azathioprine oral tablet 100 mg, 75 mg	T4	PA-BvD
azathioprine oral tablet 50 mg	T2	PA-BvD
BALVERSA	T5	PA-NS
bexarotene oral	T5	PA-NS
bexarotene topical	T5	PA-NS; QL (60 GM per 28 days)
bicalutamide	T2	
BOMYNTRA	T5	PA-NS
BOSULIF ORAL CAPSULE 100 MG	T5	PA-NS; QL (186 EA per 31 days)
BOSULIF ORAL CAPSULE 50 MG	T5	PA-NS; QL (341 EA per 31 days)
BOSULIF ORAL TABLET 100 MG	T5	PA-NS; QL (93 EA per 31 days)
BOSULIF ORAL TABLET 400 MG, 500 MG	T5	PA-NS; QL (31 EA per 31 days)
BRAFTOVI	T5	PA-NS; QL (186 EA per 31 days)
BRUKINSA ORAL CAPSULE	T5	PA-NS; QL (124 EA per 31 days)
CABOMETYX	T5	PA-NS; QL (31 EA per 31 days)
CALQUENCE (ACALABRUTINIB MAL)	T5	PA-NS; QL (62 EA per 31 days)
CAPRELSA ORAL TABLET 100 MG	T5	PA-NS; QL (62 EA per 31 days)
CAPRELSA ORAL TABLET 300 MG	T5	PA-NS; QL (31 EA per 31 days)
CASODEX	T4	
CELLCEPT	T5	PA-BvD
COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1)	T5	PA-NS; QL (56 EA per 28 days)
COMETRIQ ORAL CAPSULE 140 MG/DAY(80 MG X1-20 MG X3)	T5	PA-NS; QL (112 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
COMETRIQ ORAL CAPSULE 60 MG/DAY (20 MG X 3/DAY)	T5	PA-NS; QL (84 EA per 28 days)
COPIKTRA	T5	PA-NS; QL (62 EA per 31 days)
COTELLIC	T5	PA-NS; LA; QL (63 EA per 28 days)
cyclophosphamide oral	T3	PA-BvD
cyclosporine modified oral capsule	T2	PA-BvD
cyclosporine modified oral solution	T5	PA-BvD
cyclosporine oral capsule	T2	PA-BvD
DANZITEN	T5	PA-NS; QL (124 EA per 31 days)
dasatinib	T5	PA-NS; QL (31 EA per 31 days)
DAURISMO ORAL TABLET 100 MG	T5	PA-NS; QL (31 EA per 31 days)
DAURISMO ORAL TABLET 25 MG	T5	PA-NS; QL (62 EA per 31 days)
ELIGARD	T4	ST-NS; QL (1 EA per 30 days)
ELIGARD (3 MONTH)	T4	ST-NS; QL (1 EA per 90 days)
ELIGARD (4 MONTH)	T4	ST-NS; QL (1 EA per 120 days)
ELIGARD (6 MONTH)	T4	ST-NS; QL (1 EA per 180 days)
ENSPRYNG	T5	PA; QL (1 ML per 28 days)
ENVARSUS XR ORAL TABLET EXTENDED RELEASE 24 HR 0.75 MG, 1 MG	T4	PA-BvD
ENVARSUS XR ORAL TABLET EXTENDED RELEASE 24 HR 4 MG	T5	PA-BvD
ERIVEDGE	T5	PA-NS; QL (31 EA per 31 days)
ERLEADA ORAL TABLET 240 MG	T5	PA-NS; QL (31 EA per 31 days)
ERLEADA ORAL TABLET 60 MG	T5	PA-NS; QL (93 EA per 31 days)
erlotinib	T5	PA-NS; QL (31 EA per 31 days)
EULEXIN	T4	
everolimus (antineoplastic) oral tablet	T5	PA-NS; QL (31 EA per 31 days)
everolimus (antineoplastic) oral tablet for suspension 2 mg, 5 mg	T5	PA-NS; QL (62 EA per 31 days)
everolimus (antineoplastic) oral tablet for suspension 3 mg	T5	PA-NS; QL (93 EA per 31 days)
everolimus (immunosuppressive) oral tablet 0.25 mg	T4	PA-BvD
everolimus (immunosuppressive) oral tablet 0.5 mg, 0.75 mg, 1 mg	T5	PA-BvD
exemestane	T2	
FEMARA	T4	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG	T5	PA-NS
FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 80 MG	T4	PA-NS
FOTIVDA	T5	PA-NS; QL (21 EA per 28 days)
FRUZAQLA ORAL CAPSULE 1 MG	T5	PA-NS; QL (84 EA per 28 days)
FRUZAQLA ORAL CAPSULE 5 MG	T5	PA-NS; QL (21 EA per 28 days)
GAVRETO	T5	PA-NS; QL (124 EA per 31 days)
gefitinib	T5	PA-NS; QL (31 EA per 31 days)
GENGRAF ORAL CAPSULE	T2	PA-BvD
GILOTRIF	T5	PA-NS; QL (31 EA per 31 days)
GLEEVEC ORAL TABLET 100 MG	T5	PA-NS; QL (93 EA per 31 days)
GLEEVEC ORAL TABLET 400 MG	T5	PA-NS; QL (62 EA per 31 days)
GLEOSTINE ORAL CAPSULE 10 MG, 40 MG	T4	PA-NS
GLEOSTINE ORAL CAPSULE 100 MG	T5	PA-NS
GOMEKLI ORAL CAPSULE 1 MG	T5	PA-NS; QL (126 EA per 28 days)
GOMEKLI ORAL CAPSULE 2 MG	T5	PA-NS; QL (84 EA per 28 days)
GOMEKLI ORAL TABLET FOR SUSPENSION	T5	PA-NS; QL (168 EA per 28 days)
HERNEXEOS	T5	PA-NS; QL (93 EA per 31 days)
HYDREA	T4	
hydroxyurea	T2	
IBRANCE	T5	PA-NS; QL (21 EA per 28 days)
IBTROZI	T5	PA-NS; QL (93 EA per 31 days)
ICLUSIG	T5	PA-NS; QL (31 EA per 31 days)
IDHIFA	T5	PA-NS; QL (31 EA per 31 days)
imatinib oral tablet 100 mg	T5	PA-NS; QL (93 EA per 31 days)
imatinib oral tablet 400 mg	T5	PA-NS; QL (62 EA per 31 days)
IMBRUVICA ORAL CAPSULE 140 MG	T5	PA-NS; QL (124 EA per 31 days)
IMBRUVICA ORAL CAPSULE 70 MG	T5	PA-NS; QL (31 EA per 31 days)
IMBRUVICA ORAL SUSPENSION	T5	PA-NS; QL (216 ML per 25 days)
IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG	T5	PA-NS; QL (31 EA per 31 days)
IMKELDI	T5	PA-NS; QL (280 ML per 28 days)
IMURAN	T4	PA-BvD
INLYTA	T5	PA-NS; QL (124 EA per 31 days)
INQOVI	T5	PA-NS; QL (5 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
INREBIC	T5	PA-NS; QL (124 EA per 31 days)
IRESSA	T5	PA-NS; QL (31 EA per 31 days)
ITOVEBI ORAL TABLET 3 MG	T5	PA-NS; QL (62 EA per 31 days)
ITOVEBI ORAL TABLET 9 MG	T5	PA-NS; QL (31 EA per 31 days)
IWILFIN	T5	PA-NS; QL (248 EA per 31 days)
JAKAFI	T5	PA-NS; QL (62 EA per 31 days)
JAYPIRCA ORAL TABLET 100 MG	T5	PA-NS; QL (62 EA per 31 days)
JAYPIRCA ORAL TABLET 50 MG	T5	PA-NS; QL (31 EA per 31 days)
JYLAMVO	T4	PA-BvD
KISQALI FEMARA CO-PACK ORAL TABLET 400 MG/DAY(200 MG X 2)-2.5 MG	T5	PA-NS; QL (70 EA per 28 days)
KISQALI FEMARA CO-PACK ORAL TABLET 600 MG/DAY(200 MG X 3)-2.5 MG	T5	PA-NS; QL (91 EA per 28 days)
KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1)	T5	PA-NS; QL (21 EA per 28 days)
KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2)	T5	PA-NS; QL (42 EA per 28 days)
KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3)	T5	PA-NS; QL (63 EA per 28 days)
KLISYRI (250 MG)	T5	PA
KOSELUGO ORAL CAPSULE 10 MG	T5	PA-NS; QL (279 EA per 31 days)
KOSELUGO ORAL CAPSULE 25 MG	T5	PA-NS; QL (124 EA per 31 days)
KRAZATI	T5	PA-NS; QL (186 EA per 31 days)
lapatinib	T5	PA-NS; QL (186 EA per 31 days)
LAZCLUZE ORAL TABLET 240 MG	T5	PA-NS; QL (30 EA per 30 days)
LAZCLUZE ORAL TABLET 80 MG	T5	PA-NS; QL (60 EA per 30 days)
lenalidomide	T5	PA-NS; QL (21 EA per 28 days)
LENVIMA	T5	PA-NS
letrozole	T2	
leucovorin calcium oral	T2	
LEUKERAN	T5	
leuprolide acetate (3 month)	T4	QL (1 EA per 30 days)
leuprolide subcutaneous kit	T4	QL (2 EA per 28 days)
LONSURF	T5	PA-NS
LORBRENA ORAL TABLET 100 MG	T5	PA-NS; QL (31 EA per 31 days)
LORBRENA ORAL TABLET 25 MG	T5	PA-NS; QL (93 EA per 31 days)
LUMAKRAS ORAL TABLET 120 MG, 240 MG	T5	PA-NS; QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
LUMAKRAS ORAL TABLET 320 MG	T5	PA-NS; QL (93 EA per 31 days)
LUPKYNIS	T5	PA; QL (186 EA per 31 days)
LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG	T5	QL (1 EA per 90 days)
LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 22.5 MG	T5	ST-NS; QL (1 EA per 84 days)
LUPRON DEPOT (4 MONTH)	T5	ST-NS; QL (1 EA per 112 days)
LUPRON DEPOT (6 MONTH)	T5	ST-NS; QL (1 EA per 168 days)
LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 3.75 MG	T5	QL (1 EA per 30 days)
LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 7.5 MG	T5	ST-NS; QL (1 EA per 28 days)
LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG	T5	PA; QL (1 EA per 90 days)
LUPRON DEPOT-PED INTRAMUSCULAR KIT 7.5 MG (PED)	T5	PA; QL (1 EA per 30 days)
LUPRON DEPOT-PED INTRAMUSCULAR SYRINGE KIT	T5	PA; QL (1 EA per 168 days)
LUTRATE DEPOT (3 MONTH)	T4	ST-NS; QL (1 EA per 84 days)
LYNPARZA	T5	PA-NS; QL (124 EA per 31 days)
LYSODREN	T5	
LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3)	T5	PA-NS; QL (93 EA per 31 days)
LYTGOBI ORAL TABLET 16 MG/DAY (4 MG X 4)	T5	PA-NS; QL (124 EA per 31 days)
LYTGOBI ORAL TABLET 20 MG/DAY (4 MG X 5)	T5	PA-NS; QL (155 EA per 31 days)
MATULANE	T5	
megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)	T2	PA
megestrol oral tablet	T2	PA-NS
MEKINIST ORAL RECON SOLN	T5	PA-NS; QL (1260 ML per 31 days)
MEKINIST ORAL TABLET 0.5 MG	T5	PA-NS; QL (93 EA per 31 days)
MEKINIST ORAL TABLET 2 MG	T5	PA-NS; QL (31 EA per 31 days)
MEKTOVI	T5	PA-NS; QL (186 EA per 31 days)
mercaptopurine oral suspension	T5	
mercaptopurine oral tablet	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
mesna oral	T3	
MESNEX ORAL	T4	
methotrexate sodium (pf) injection solution	T2	PA-BvD
methotrexate sodium injection	T2	PA-BvD
methotrexate sodium oral	T1	PA-BvD
MODEYSO	T5	PA-NS; QL (20 EA per 28 days)
MYCAPSSA	T5	PA; QL (124 EA per 31 days)
mycophenolate mofetil oral capsule	T2	PA-BvD
mycophenolate mofetil oral suspension for reconstitution	T5	PA-BvD
mycophenolate mofetil oral tablet	T2	PA-BvD
mycophenolate sodium	T2	PA-BvD
MYFORTIC ORAL TABLET,DELAYED RELEASE (DR/EC) 180 MG	T3	PA-BvD
MYFORTIC ORAL TABLET,DELAYED RELEASE (DR/EC) 360 MG	T5	PA-BvD
MYHIBBIN	T5	PA-BvD
NEMLUVIO	T5	PA; QL (2 EA per 28 days)
NEORAL ORAL CAPSULE	T4	PA-BvD
NEORAL ORAL SOLUTION	T3	PA-BvD
NERLYNX	T5	PA-NS; QL (186 EA per 31 days)
NEXAVAR	T5	PA-NS; QL (124 EA per 31 days)
NILANDRON	T5	
nilotinib hcl	T5	PA-NS; QL (124 EA per 31 days)
nilutamide	T5	
NINLARO	T5	PA-NS; QL (3 EA per 28 days)
NUBEQA	T5	PA-NS; QL (124 EA per 31 days)
octreotide acetate injection solution 1,000 mcg/ml	T3	PA
octreotide acetate injection solution 100 mcg/ml, 50 mcg/ml	T2	PA
octreotide acetate injection solution 200 mcg/ml, 500 mcg/ml	T4	PA
ODOMZO	T5	PA-NS; LA; QL (31 EA per 31 days)
OGSIVEO ORAL TABLET 100 MG, 150 MG	T5	PA-NS; QL (62 EA per 31 days)
OGSIVEO ORAL TABLET 50 MG	T5	PA-NS; QL (186 EA per 31 days)
OJEMDA ORAL SUSPENSION FOR RECONSTITUTION	T5	PA-NS; QL (96 ML per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4)	T5	PA-NS; QL (16 EA per 28 days)
OJEMDA ORAL TABLET 500 MG/WEEK (100 MG X 5)	T5	PA-NS; QL (20 EA per 28 days)
OJEMDA ORAL TABLET 600 MG/WEEK (100 MG X 6)	T5	PA-NS; QL (24 EA per 28 days)
OJJAARA	T5	PA-NS; QL (31 EA per 31 days)
ONUREG	T5	PA-NS; QL (14 EA per 28 days)
ORGOVYX	T5	PA-NS; QL (31 EA per 31 days)
ORSERDU ORAL TABLET 345 MG	T5	PA-NS; QL (31 EA per 31 days)
ORSERDU ORAL TABLET 86 MG	T5	PA-NS; QL (93 EA per 31 days)
OSENVELT	T5	PA-NS
pazopanib	T5	PA-NS; QL (124 EA per 31 days)
PEMAZYRE	T5	PA-NS; QL (14 EA per 21 days)
PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1)	T5	PA-NS; QL (28 EA per 28 days)
PIQRAY ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)	T5	PA-NS; QL (56 EA per 28 days)
POMALYST	T5	PA-NS; QL (21 EA per 28 days)
PROGRAF ORAL CAPSULE 0.5 MG, 1 MG	T4	PA-BvD
PROGRAF ORAL CAPSULE 5 MG	T5	PA-BvD
PROGRAF ORAL GRANULES IN PACKET	T4	PA-BvD
PURIXAN	T5	
QINLOCK	T5	PA-NS; QL (93 EA per 31 days)
RETEVMO ORAL TABLET 120 MG, 160 MG, 80 MG	T5	PA-NS; QL (62 EA per 31 days)
RETEVMO ORAL TABLET 40 MG	T5	PA-NS; QL (93 EA per 31 days)
REVLIMID	T5	PA-NS; QL (21 EA per 28 days)
REVUFORJ ORAL TABLET 110 MG	T5	PA-NS; QL (124 EA per 31 days)
REVUFORJ ORAL TABLET 160 MG	T5	PA-NS; QL (62 EA per 31 days)
REVUFORJ ORAL TABLET 25 MG	T5	PA-NS; QL (248 EA per 31 days)
REZLIDHIA	T5	PA-NS; QL (62 EA per 31 days)
REZUROCK	T5	PA; QL (62 EA per 31 days)
ROMVIMZA	T5	PA-NS; QL (8 EA per 28 days)
ROZLYTREK ORAL CAPSULE 100 MG	T5	PA-NS; QL (155 EA per 31 days)
ROZLYTREK ORAL CAPSULE 200 MG	T5	PA-NS; QL (93 EA per 31 days)
ROZLYTREK ORAL PELLETS IN PACKET	T5	PA-NS; QL (372 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
RUBRACA	T5	PA-NS; QL (124 EA per 31 days)
RYDAPT	T5	PA-NS; QL (248 EA per 31 days)
SANDIMMUNE ORAL CAPSULE 100 MG	T4	PA-BvD
SANDIMMUNE ORAL CAPSULE 25 MG	T3	PA-BvD
SANDOSTATIN INJECTION SOLUTION 100 MCG/ML	T5	PA
SANDOSTATIN INJECTION SOLUTION 50 MCG/ML, 500 MCG/ML	T4	PA
SCEMBLIX ORAL TABLET 100 MG	T5	PA-NS; QL (124 EA per 31 days)
SCEMBLIX ORAL TABLET 20 MG	T5	PA-NS; QL (62 EA per 31 days)
SCEMBLIX ORAL TABLET 40 MG	T5	PA-NS; QL (248 EA per 31 days)
SIGNIFOR	T5	PA
SIKLOS	T4	
sirolimus oral solution	T4	PA-BvD
sirolimus oral tablet	T2	PA-BvD
SOLTAMOX	T4	
sorafenib	T5	PA-NS; QL (124 EA per 31 days)
SPRYCEL	T5	PA-NS; QL (31 EA per 31 days)
STIVARGA	T5	PA-NS; QL (84 EA per 28 days)
sunitinib malate	T5	PA-NS; QL (31 EA per 31 days)
SUTENT	T5	PA-NS; QL (31 EA per 31 days)
TABLOID	T4	
TABRECTA	T5	PA-NS; QL (124 EA per 31 days)
tacrolimus oral capsule	T2	PA-BvD
TAFINLAR ORAL CAPSULE	T5	PA-NS; QL (124 EA per 31 days)
TAFINLAR ORAL TABLET FOR SUSPENSION	T5	PA-NS; QL (930 EA per 31 days)
TAGRISSO	T5	PA-NS; LA; QL (31 EA per 31 days)
TALZENNA	T5	PA-NS; QL (31 EA per 31 days)
tamoxifen	T1	
TARGRETIN ORAL	T5	PA-NS
TARGRETIN TOPICAL	T5	PA-NS; QL (60 GM per 28 days)
TASIGNA	T5	PA-NS; QL (124 EA per 31 days)
TAZVERIK	T5	PA-NS; QL (248 EA per 31 days)
TEPMETKO	T5	PA-NS; QL (62 EA per 31 days)
THALOMID ORAL CAPSULE 100 MG	T5	PA-NS; QL (112 EA per 28 days)
THALOMID ORAL CAPSULE 50 MG	T5	PA-NS; QL (28 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
TIBSOVO	T5	PA-NS; QL (62 EA per 31 days)
toremifene	T4	
TORPENZ	T5	PA-NS; QL (31 EA per 31 days)
TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 11.25 MG	T4	ST-NS; QL (1 EA per 84 days)
TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 22.5 MG	T4	ST-NS; QL (1 EA per 168 days)
TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 3.75 MG	T4	ST-NS; QL (1 EA per 28 days)
tretinoin (antineoplastic)	T5	
TREXALL	T3	PA-BvD
TRUQAP	T5	PA-NS; QL (64 EA per 28 days)
TUKYSA ORAL TABLET 150 MG	T5	PA-NS; QL (124 EA per 31 days)
TUKYSA ORAL TABLET 50 MG	T5	PA-NS; QL (248 EA per 31 days)
TURALIO ORAL CAPSULE 125 MG	T5	PA-NS; QL (124 EA per 31 days)
TYKERB	T5	PA-NS; QL (186 EA per 31 days)
VANFLYTA	T5	PA-NS; QL (62 EA per 31 days)
VENCLEXTA ORAL TABLET 10 MG	T3	PA-NS; QL (62 EA per 31 days)
VENCLEXTA ORAL TABLET 100 MG	T5	PA-NS; QL (186 EA per 31 days)
VENCLEXTA ORAL TABLET 50 MG	T5	PA-NS; QL (31 EA per 31 days)
VENCLEXTA STARTING PACK	T5	PA-NS; QL (84 EA per 365 days)
VERZENIO	T5	PA-NS; QL (62 EA per 31 days)
VIJOICE ORAL GRANULES IN PACKET	T5	PA-NS; QL (31 EA per 31 days)
VIJOICE ORAL TABLET 125 MG, 50 MG	T5	PA-NS; QL (28 EA per 28 days)
VIJOICE ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1)	T5	PA-NS; QL (56 EA per 28 days)
VITRAKVI ORAL CAPSULE 100 MG	T5	PA-NS; QL (62 EA per 31 days)
VITRAKVI ORAL CAPSULE 25 MG	T5	PA-NS; QL (186 EA per 31 days)
VITRAKVI ORAL SOLUTION	T5	PA-NS; QL (310 ML per 31 days)
VIZIMPRO	T5	PA-NS; QL (31 EA per 31 days)
VONJO	T5	PA-NS; QL (124 EA per 31 days)
VORANIGO ORAL TABLET 10 MG	T5	PA-NS; QL (62 EA per 31 days)
VORANIGO ORAL TABLET 40 MG	T5	PA-NS; QL (31 EA per 31 days)
VOTRIENT	T5	PA-NS; QL (124 EA per 31 days)
WELIREG	T5	PA-NS; QL (93 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
WYOST	T5	PA-NS
XALKORI ORAL CAPSULE	T5	PA-NS; QL (124 EA per 31 days)
XALKORI ORAL PELLET 150 MG	T5	PA-NS; QL (186 EA per 31 days)
XALKORI ORAL PELLET 20 MG, 50 MG	T5	PA-NS; QL (124 EA per 31 days)
XATMEP	T4	PA-BvD
XERMELO	T5	PA; QL (93 EA per 31 days)
XGEVA	T5	PA-NS
XOSPATA	T5	PA-NS; QL (124 EA per 31 days)
XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40MG TWICE WEEK (40 MG X 2), 80 MG/WEEK (40 MG X 2)	T5	PA-NS; QL (8 EA per 28 days)
XPOVIO ORAL TABLET 40 MG/WEEK (10 MG X 4)	T5	PA-NS; QL (16 EA per 28 days)
XPOVIO ORAL TABLET 40 MG/WEEK (40 MG X 1), 60 MG/WEEK (60 MG X 1)	T5	PA-NS; QL (4 EA per 28 days)
XPOVIO ORAL TABLET 60MG TWICE WEEK (120 MG/WEEK)	T5	PA-NS; QL (24 EA per 28 days)
XPOVIO ORAL TABLET 80MG TWICE WEEK (160 MG/WEEK)	T5	PA-NS; QL (32 EA per 28 days)
XROMI	T5	
XTANDI ORAL CAPSULE	T5	PA-NS; QL (124 EA per 31 days)
XTANDI ORAL TABLET 40 MG	T5	PA-NS; QL (124 EA per 31 days)
XTANDI ORAL TABLET 80 MG	T5	PA-NS; QL (62 EA per 31 days)
YONSA	T5	PA-NS; QL (124 EA per 31 days)
ZEJULA ORAL TABLET	T5	PA-NS; QL (31 EA per 31 days)
ZELBORAF	T5	PA-NS; QL (248 EA per 31 days)
ZOLINZA	T5	PA-NS
ZORTRESS ORAL TABLET 0.25 MG	T4	PA-BvD
ZORTRESS ORAL TABLET 0.5 MG, 0.75 MG, 1 MG	T5	PA-BvD
ZYDELIG	T5	PA-NS; QL (62 EA per 31 days)
ZYKADIA	T5	PA-NS; QL (93 EA per 31 days)
ZYTIGA ORAL TABLET 250 MG	T5	PA-NS; QL (124 EA per 31 days)
ZYTIGA ORAL TABLET 500 MG	T5	PA-NS; QL (62 EA per 31 days)
Autonomic / Cns Drugs, Neurology / Psych		
ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 720 MG/2.4 ML	T5	QL (2.4 ML per 56 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 960 MG/3.2 ML	T5	QL (3.2 ML per 56 days)
ABILIFY MAINTENA	T5	QL (1 EA per 28 days)
ABILIFY ORAL TABLET	T4	PA-NS
acetaminophen-codeine oral solution 120-12 mg/5 ml	T1	PA; QL (5167 ML per 31 days)
acetaminophen-codeine oral tablet	T2	PA; QL (403 EA per 31 days)
ADDERALL ORAL TABLET 20 MG	T4	ST; QL (93 EA per 31 days)
ADDERALL ORAL TABLET 5 MG, 7.5 MG	T4	ST; QL (62 EA per 31 days)
ADDERALL XR	T4	ST; QL (31 EA per 31 days)
ADLARITY	T4	PA; QL (4 EA per 28 days)
ADZENYS XR-ODT	T4	ST; QL (31 EA per 31 days)
AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML	T3	PA; QL (1 ML per 28 days)
AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 70 MG/ML	T3	PA; QL (2 ML per 28 days)
AJOVY AUTOINJECTOR	T4	PA; QL (1.5 ML per 28 days)
AJOVY SYRINGE	T4	PA; QL (1.5 ML per 28 days)
ALLZITAL	T4	QL (372 EA per 31 days)
almotriptan malate oral tablet 12.5 mg	T2	QL (8 EA per 28 days)
almotriptan malate oral tablet 6.25 mg	T2	QL (16 EA per 28 days)
ALPRAZOLAM INTENSOL	T2	PA
alprazolam oral tablet 0.25 mg, 0.5 mg	T2	PA; QL (93 EA per 31 days)
alprazolam oral tablet 1 mg, 2 mg	T2	PA; QL (155 EA per 31 days)
alprazolam oral tablet extended release 24 hr 0.5 mg, 1 mg	T2	PA; QL (31 EA per 31 days)
alprazolam oral tablet extended release 24 hr 2 mg	T2	PA; QL (155 EA per 31 days)
alprazolam oral tablet extended release 24 hr 3 mg	T2	PA; QL (93 EA per 31 days)
alprazolam oral tablet,disintegrating 0.25 mg, 0.5 mg	T2	PA; QL (93 EA per 31 days)
alprazolam oral tablet,disintegrating 1 mg, 2 mg	T2	PA; QL (155 EA per 31 days)
AMBIEN	T4	PA; QL (31 EA per 31 days)
AMBIEN CR	T4	PA; QL (31 EA per 31 days)
amitriptyline	T2	PA-NS

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
amitriptyline-chlordiazepoxide	T2	PA-NS
amoxapine	T1	
amphetamine sulfate	T4	PA
AMPYRA	T5	PA; QL (62 EA per 31 days)
AMRIX	T5	QL (31 EA per 31 days)
ANAFRANIL	T4	PA-NS
APLENZIN	T5	QL (31 EA per 31 days)
APOKYN	T5	PA; QL (60 ML per 30 days)
apomorphine	T5	PA; QL (60 ML per 30 days)
APTENSIO XR	T4	ST; QL (31 EA per 31 days)
APTIOM ORAL TABLET 200 MG	T4	QL (186 EA per 31 days)
APTIOM ORAL TABLET 400 MG	T5	QL (93 EA per 31 days)
APTIOM ORAL TABLET 600 MG, 800 MG	T5	QL (62 EA per 31 days)
ARICEPT	T4	
aripiprazole oral solution	T3	PA-NS
aripiprazole oral tablet	T3	
aripiprazole oral tablet,disintegrating 10 mg	T4	PA-NS
aripiprazole oral tablet,disintegrating 15 mg	T5	PA-NS
ARISTADA INITIO	T5	QL (4.8 ML per 365 days)
ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 1,064 MG/3.9 ML	T5	QL (3.9 ML per 28 days)
ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 441 MG/1.6 ML	T5	QL (1.6 ML per 28 days)
ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 662 MG/2.4 ML	T5	QL (2.4 ML per 28 days)
ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 882 MG/3.2 ML	T5	QL (3.2 ML per 28 days)
armodafinil	T4	PA; QL (31 EA per 31 days)
ARTHROTEC 50	T4	
ARTHROTEC 75	T4	
ASCOMP WITH CODEINE	T4	PA; QL (372 EA per 31 days)
asenapine maleate	T4	PA-NS; QL (62 EA per 31 days)
ATIVAN ORAL TABLET 0.5 MG	T5	PA; QL (124 EA per 31 days)
ATIVAN ORAL TABLET 1 MG	T5	PA; QL (186 EA per 31 days)
ATIVAN ORAL TABLET 2 MG	T5	PA; QL (155 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
atomoxetine oral capsule 10 mg, 25 mg, 40 mg	T3	QL (62 EA per 31 days)
atomoxetine oral capsule 100 mg, 60 mg, 80 mg	T3	QL (31 EA per 31 days)
atomoxetine oral capsule 18 mg	T3	QL (124 EA per 31 days)
AUBAGIO	T5	PA; QL (31 EA per 31 days)
AUSTEDO ORAL TABLET 12 MG, 6 MG	T5	PA; QL (124 EA per 31 days)
AUSTEDO ORAL TABLET 9 MG	T5	PA; QL (155 EA per 31 days)
AUSTEDO XR	T5	PA; QL (31 EA per 31 days)
AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG	T5	PA; QL (56 EA per 365 days)
AUVELITY	T5	PA-NS; QL (62 EA per 31 days)
AZILECT ORAL TABLET 0.5 MG	T4	
AZILECT ORAL TABLET 1 MG	T5	
AZSTARYS	T4	ST; QL (31 EA per 31 days)
baclofen oral solution 10 mg/5 ml (2 mg/ml)	T4	PA; QL (1240 ML per 31 days)
baclofen oral solution 5 mg/5 ml	T4	PA; QL (2480 ML per 31 days)
baclofen oral suspension	T4	PA; QL (496 ML per 31 days)
baclofen oral tablet 10 mg	T1	
baclofen oral tablet 15 mg	T4	
baclofen oral tablet 20 mg, 5 mg	T2	
BAFIERTAM	T5	PA; QL (124 EA per 31 days)
BANZEL	T5	PA-NS
BELBUCA BUCCAL FILM 150 MCG, 300 MCG, 450 MCG, 600 MCG, 75 MCG	T4	PA; QL (62 EA per 31 days)
BELBUCA BUCCAL FILM 750 MCG, 900 MCG	T5	PA; QL (62 EA per 31 days)
BELSOMRA	T4	ST; QL (31 EA per 31 days)
benztropine oral	T2	PA
BRIVIACT ORAL SOLUTION	T5	QL (620 ML per 31 days)
BRIVIACT ORAL TABLET	T5	QL (62 EA per 31 days)
bromocriptine	T2	
BUCAPSOL ORAL CAPSULE 15 MG	T5	PA; QL (124 EA per 31 days)
buprenorphine	T4	PA; QL (4 EA per 28 days)
buprenorphine hcl sublingual	T3	
buprenorphine-naloxone sublingual film	T2	
buprenorphine-naloxone sublingual tablet	T4	
bupropion hcl oral tablet	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
bupropion hcl oral tablet extended release 24 hr 150 mg	T2	QL (93 EA per 31 days)
bupropion hcl oral tablet extended release 24 hr 300 mg	T2	QL (31 EA per 31 days)
bupropion hcl oral tablet sustained-release 12 hr	T2	QL (62 EA per 31 days)
buspirone	T2	
butalbital-acetaminop-caf-cod oral capsule 50-300-40-30 mg	T4	PA; QL (403 EA per 31 days)
butalbital-acetaminop-caf-cod oral capsule 50-325-40-30 mg	T4	PA; QL (372 EA per 31 days)
butalbital-acetaminophen oral capsule	T4	QL (403 EA per 31 days)
butalbital-acetaminophen oral tablet 50-300 mg	T2	QL (403 EA per 31 days)
butalbital-acetaminophen oral tablet 50-325 mg	T2	QL (372 EA per 31 days)
butalbital-acetaminophen-caff oral capsule 50-300-40 mg	T4	QL (403 EA per 31 days)
butalbital-acetaminophen-caff oral capsule 50-325-40 mg	T4	QL (372 EA per 31 days)
butalbital-acetaminophen-caff oral tablet	T2	QL (372 EA per 31 days)
butalbital-aspirin-caffeine oral capsule	T4	
butorphanol nasal	T2	QL (5 ML per 28 days)
BUTRANS	T4	PA; QL (4 EA per 28 days)
CAMBIA	T4	
CAPLYTA	T5	PA-NS; QL (31 EA per 31 days)
carbamazepine oral capsule, er multiphase 12 hr	T2	
carbamazepine oral suspension 100 mg/5 ml	T1	
carbamazepine oral tablet	T1	
carbamazepine oral tablet extended release 12 hr	T2	
carbamazepine oral tablet,chewable 100 mg	T1	
carbamazepine oral tablet,chewable 200 mg	T4	
CARBATROL	T4	
carbidopa	T4	
carbidopa-levodopa	T2	
carbidopa-levodopa-entacapone	T2	
carisoprodol	T2	PA
CELEBREX	T4	ST; QL (62 EA per 31 days)
celecoxib	T2	QL (62 EA per 31 days)
CELEXA ORAL TABLET	T4	
CELONTIN ORAL CAPSULE 300 MG	T4	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
chlordiazepoxide hcl	T2	PA
chlorpromazine oral	T2	
chlorzoxazone oral tablet 250 mg	T5	PA
chlorzoxazone oral tablet 375 mg, 500 mg, 750 mg	T2	PA
citalopram oral capsule	T4	PA-NS; QL (31 EA per 31 days)
citalopram oral solution	T2	
citalopram oral tablet	T1	
clobazam oral suspension	T4	PA-NS; QL (496 ML per 31 days)
clobazam oral tablet	T3	PA-NS; QL (62 EA per 31 days)
clomipramine	T4	PA-NS
clonazepam oral tablet 0.5 mg	T2	PA-NS; QL (93 EA per 31 days)
clonazepam oral tablet 1 mg	T2	PA-NS; QL (124 EA per 31 days)
clonazepam oral tablet 2 mg	T2	PA-NS; QL (310 EA per 31 days)
clonazepam oral tablet,disintegrating 0.125 mg, 0.25 mg, 0.5 mg	T2	PA-NS; QL (93 EA per 31 days)
clonazepam oral tablet,disintegrating 1 mg	T2	PA-NS; QL (124 EA per 31 days)
clonazepam oral tablet,disintegrating 2 mg	T2	PA-NS; QL (310 EA per 31 days)
clonidine hcl oral tablet extended release 12 hr	T4	PA
clorazepate dipotassium oral tablet 15 mg	T2	PA-NS; QL (186 EA per 31 days)
clorazepate dipotassium oral tablet 3.75 mg, 7.5 mg	T2	PA-NS; QL (93 EA per 31 days)
clozapine oral tablet 100 mg, 25 mg	T2	QL (279 EA per 31 days)
clozapine oral tablet 200 mg	T2	QL (124 EA per 31 days)
clozapine oral tablet 50 mg	T2	QL (93 EA per 31 days)
clozapine oral tablet,disintegrating 100 mg, 25 mg	T2	QL (279 EA per 31 days)
clozapine oral tablet,disintegrating 12.5 mg	T2	QL (93 EA per 31 days)
clozapine oral tablet,disintegrating 150 mg	T4	QL (186 EA per 31 days)
clozapine oral tablet,disintegrating 200 mg	T4	QL (124 EA per 31 days)
CLOZARIL ORAL TABLET 100 MG, 25 MG	T4	QL (279 EA per 31 days)
COBENFY	T5	PA-NS; QL (62 EA per 31 days)
COBENFY STARTER PACK	T5	PA-NS; QL (112 EA per 365 days)
codeine sulfate oral tablet 15 mg, 30 mg	T2	PA; QL (186 EA per 31 days)
codeine sulfate oral tablet 60 mg	T4	PA; QL (186 EA per 31 days)
codeine-butalbital-asa-caff	T4	PA; QL (372 EA per 31 days)
CONCERTA	T4	ST; QL (31 EA per 31 days)
CONZIP	T4	PA; QL (30 EA per 30 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML	T5	PA; QL (31 ML per 31 days)
COPAXONE SUBCUTANEOUS SYRINGE 40 MG/ML	T5	PA; QL (12 ML per 28 days)
COTEMPLA XR-ODT	T4	ST; QL (62 EA per 31 days)
CREXONT	T4	ST
cyclobenzaprine oral capsule,extended release 24hr	T4	QL (31 EA per 31 days)
cyclobenzaprine oral tablet 10 mg, 7.5 mg	T2	QL (93 EA per 31 days)
cyclobenzaprine oral tablet 5 mg	T2	QL (155 EA per 31 days)
dalfampridine	T5	PA; QL (62 EA per 31 days)
DANTRIUM ORAL CAPSULE 25 MG	T4	
dantrolene oral	T2	
DAYBUE	T5	PA; QL (3600 ML per 30 days)
DAYTRANA	T4	PA; QL (30 EA per 30 days)
DAYVIGO	T4	ST; QL (31 EA per 31 days)
DEMEROL (PF) INJECTION SYRINGE 25 MG/ML	T4	PA; QL (496 ML per 31 days)
DEMEROL INJECTION	T4	PA; QL (248 ML per 31 days)
DEPAKOTE	T4	
DEPAKOTE ER ORAL TABLET EXTENDED RELEASE 24 HR 250 MG	T4	
DEPAKOTE ER ORAL TABLET EXTENDED RELEASE 24 HR 500 MG	T5	
DEPAKOTE SPRINKLES	T4	
desipramine	T2	
desvenlafaxine oral tablet extended release 24 hr 100 mg	T4	QL (124 EA per 31 days)
desvenlafaxine oral tablet extended release 24 hr 50 mg	T4	QL (31 EA per 31 days)
desvenlafaxine succinate	T3	QL (31 EA per 31 days)
DEXEDRINE SPANSULE ORAL CAPSULE, EXTENDED RELEASE 10 MG	T5	ST; QL (186 EA per 31 days)
dexmethylphenidate oral capsule,er biphasic 50-50	T4	QL (31 EA per 31 days)
dexmethylphenidate oral tablet 10 mg	T2	QL (62 EA per 31 days)
dexmethylphenidate oral tablet 2.5 mg, 5 mg	T2	QL (93 EA per 31 days)
dextroamphetamine sulfate oral capsule, extended release 10 mg	T4	ST; QL (155 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
dextroamphetamine sulfate oral capsule, extended release 15 mg	T4	ST; QL (124 EA per 31 days)
dextroamphetamine sulfate oral capsule, extended release 5 mg	T4	ST; QL (186 EA per 31 days)
dextroamphetamine sulfate oral solution	T4	
dextroamphetamine sulfate oral tablet 10 mg	T2	QL (186 EA per 31 days)
dextroamphetamine sulfate oral tablet 15 mg, 20 mg, 30 mg	T4	QL (62 EA per 31 days)
dextroamphetamine sulfate oral tablet 5 mg	T2	QL (341 EA per 31 days)
dextroamphetamine-amphetamine oral capsule, er triphasic 24 hr	T4	ST; QL (31 EA per 31 days)
dextroamphetamine-amphetamine oral capsule,extended release 24hr	T3	QL (31 EA per 31 days)
dextroamphetamine-amphetamine oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg	T1	QL (62 EA per 31 days)
dextroamphetamine-amphetamine oral tablet 12.5 mg	T2	QL (62 EA per 31 days)
dextroamphetamine-amphetamine oral tablet 20 mg	T1	QL (93 EA per 31 days)
DHIVY	T4	ST
DIACOMIT ORAL CAPSULE 250 MG	T5	PA-NS; QL (341 EA per 31 days)
DIACOMIT ORAL CAPSULE 500 MG	T5	PA-NS; QL (186 EA per 31 days)
DIACOMIT ORAL POWDER IN PACKET 250 MG	T5	PA-NS; QL (341 EA per 31 days)
DIACOMIT ORAL POWDER IN PACKET 500 MG	T5	PA-NS; QL (186 EA per 31 days)
DIAZEPAM INTENSOL	T2	PA-NS; QL (248 ML per 31 days)
diazepam oral solution 5 mg/5 ml (1 mg/ml)	T2	PA-NS; QL (1500 ML per 31 days)
diazepam oral tablet	T2	PA-NS; QL (124 EA per 31 days)
diazepam rectal	T4	
diclofenac epolamine	T4	PA; QL (62 EA per 31 days)
diclofenac potassium oral capsule	T4	
diclofenac potassium oral powder in packet	T4	
diclofenac potassium oral tablet 25 mg	T5	
diclofenac potassium oral tablet 50 mg	T1	
diclofenac sodium oral	T1	
diclofenac sodium topical drops	T2	QL (450 ML per 28 days)
diclofenac sodium topical solution in metered-dose pump	T5	ST; QL (224 GM per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
diclofenac-misoprostol	T3	
diflunisal	T2	
dihydroergotamine nasal	T5	PA; QL (8 ML per 28 days)
DILANTIN	T3	
DILANTIN EXTENDED	T4	
DILANTIN INFATABS	T4	
DILANTIN-125	T4	
DILAUDID ORAL LIQUID	T4	PA; QL (1240 ML per 31 days)
DILAUDID ORAL TABLET 2 MG, 4 MG	T4	PA; QL (186 EA per 31 days)
DILAUDID ORAL TABLET 8 MG	T5	PA; QL (155 EA per 31 days)
dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg	T4	PA; QL (62 EA per 31 days)
dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg (14)- 240 mg (46)	T5	PA; QL (120 EA per 365 days)
dimethyl fumarate oral capsule,delayed release(dr/ec) 240 mg	T5	PA; QL (62 EA per 31 days)
divalproex oral capsule, delayed rel sprinkle	T2	
divalproex oral tablet extended release 24 hr 250 mg	T2	
divalproex oral tablet extended release 24 hr 500 mg	T3	
divalproex oral tablet,delayed release (dr/ec)	T2	
DOLOBID ORAL TABLET 250 MG	T4	
DOLOBID ORAL TABLET 375 MG	T5	
donepezil oral tablet 10 mg, 5 mg	T1	
donepezil oral tablet 23 mg	T2	QL (31 EA per 31 days)
donepezil oral tablet,disintegrating	T2	
doxepin oral capsule	T2	PA-NS
doxepin oral concentrate	T2	PA-NS
doxepin oral tablet	T2	PA
DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG	T3	PA-NS; QL (93 EA per 31 days)
DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 30 MG, 60 MG	T3	PA-NS; QL (62 EA per 31 days)
DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 40 MG	T3	PA-NS; QL (31 EA per 31 days)
duloxetine oral capsule,delayed release(dr/ec) 20 mg, 60 mg	T2	QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
duloxetine oral capsule,delayed release(dr/ec) 30 mg	T2	QL (31 EA per 31 days)
duloxetine oral capsule,delayed release(dr/ec) 40 mg	T3	QL (31 EA per 31 days)
DUOPA	T5	PA-BvD
DYANAVEL XR ORAL SUSPEN, IR - ER, BIPHASIC 24HR	T4	ST; QL (248 ML per 31 days)
DYANAVEL XR ORAL TABLET, IR - ER, BIPHASIC 24HR	T4	ST; QL (31 EA per 31 days)
EDLUAR	T4	PA; QL (31 EA per 31 days)
EFFEXOR XR ORAL CAPSULE,EXTENDED RELEASE 24HR 150 MG, 37.5 MG	T4	QL (31 EA per 31 days)
EFFEXOR XR ORAL CAPSULE,EXTENDED RELEASE 24HR 75 MG	T4	QL (93 EA per 31 days)
eletriptan oral tablet 20 mg	T4	QL (12 EA per 28 days)
eletriptan oral tablet 40 mg	T4	QL (6 EA per 28 days)
ELYXYB	T4	PA
EMGALITY PEN	T3	PA; QL (1 ML per 28 days)
EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML	T3	PA; QL (1 ML per 28 days)
EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 300 MG/3 ML (100 MG/ML X 3)	T5	PA; QL (3 ML per 28 days)
EMSAM	T5	QL (30 EA per 30 days)
ENDOCET	T3	PA; QL (372 EA per 31 days)
entacapone	T2	
EPIDIOLEX	T5	PA-NS
EPRONTIA	T4	PA-NS; QL (496 ML per 31 days)
EQUETRO	T4	
ERGOMAR	T4	PA
ergotamine-caffeine	T3	PA
ERZOFRI INTRAMUSCULAR SYRINGE 117 MG/0.75 ML	T5	QL (0.75 ML per 30 days)
ERZOFRI INTRAMUSCULAR SYRINGE 156 MG/ML	T5	QL (1 ML per 30 days)
ERZOFRI INTRAMUSCULAR SYRINGE 234 MG/1.5 ML	T5	QL (1.5 ML per 30 days)
ERZOFRI INTRAMUSCULAR SYRINGE 351 MG/2.25 ML	T5	QL (4.5 ML per 365 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ERZOFRI INTRAMUSCULAR SYRINGE 39 MG/0.25 ML	T5	QL (0.25 ML per 30 days)
ERZOFRI INTRAMUSCULAR SYRINGE 78 MG/0.5 ML	T5	QL (0.5 ML per 30 days)
escitalopram oxalate oral solution	T4	QL (620 ML per 31 days)
escitalopram oxalate oral tablet 10 mg	T2	QL (45 EA per 30 days)
escitalopram oxalate oral tablet 20 mg, 5 mg	T2	QL (30 EA per 30 days)
eslicarbazepine oral tablet 200 mg	T4	QL (186 EA per 31 days)
eslicarbazepine oral tablet 400 mg	T5	QL (93 EA per 31 days)
eslicarbazepine oral tablet 600 mg, 800 mg	T5	QL (62 EA per 31 days)
estazolam	T2	PA
eszopiclone	T2	PA; QL (31 EA per 31 days)
ethosuximide oral capsule	T3	
ethosuximide oral solution	T2	
etodolac	T2	
EVEKEO	T4	PA
EVRYSDI ORAL RECON SOLN	T5	PA; QL (240 ML per 31 days)
EVRYSDI ORAL TABLET	T5	PA; QL (31 EA per 31 days)
EXELON PATCH	T4	QL (30 EA per 30 days)
FANAPT ORAL TABLET 1 MG	T4	PA-NS; QL (62 EA per 31 days)
FANAPT ORAL TABLET 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG	T5	PA-NS; QL (62 EA per 31 days)
FANAPT TITRATION PACK A	T4	PA-NS; QL (16 EA per 365 days)
felbamate oral suspension	T4	
felbamate oral tablet	T2	
FELBATOL ORAL TABLET	T5	
fenoprofen oral capsule 400 mg	T4	
FENOPRON	T4	
fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 75 mcg/hr	T3	PA; QL (10 EA per 30 days)
fentanyl transdermal patch 72 hour 25 mcg/hr, 50 mcg/hr	T2	PA; QL (10 EA per 30 days)
fentanyl transdermal patch 72 hour 37.5 mcg/hour, 62.5 mcg/hour	T4	PA; QL (10 EA per 30 days)
fentanyl transdermal patch 72 hour 87.5 mcg/hour	T5	PA; QL (10 EA per 30 days)
FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26)	T4	PA-NS; QL (56 EA per 365 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 40 MG, 80 MG	T4	PA-NS; QL (31 EA per 31 days)
FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 20 MG	T4	PA-NS; QL (93 EA per 31 days)
fingolimod	T5	PA; QL (31 EA per 31 days)
FINTEPLA	T5	PA-NS; QL (360 ML per 30 days)
FIORICET	T4	QL (403 EA per 31 days)
FIORICET WITH CODEINE	T4	PA; QL (403 EA per 31 days)
FIRDAPSE	T5	PA; QL (248 EA per 31 days)
FLECTOR	T4	PA; QL (62 EA per 31 days)
FLEQSUVY	T4	PA; QL (496 ML per 31 days)
fluoxetine (pmdd)	T1	
fluoxetine oral capsule	T1	
fluoxetine oral capsule,delayed release(dr/ec)	T2	
fluoxetine oral solution	T3	
fluoxetine oral tablet 10 mg, 20 mg	T1	
fluoxetine oral tablet 60 mg	T4	
fluphenazine decanoate	T2	
fluphenazine hcl injection	T2	
fluphenazine hcl oral concentrate	T2	
fluphenazine hcl oral elixir	T1	
fluphenazine hcl oral tablet	T1	
flurazepam	T2	PA
flurbiprofen oral tablet 100 mg	T2	
fluvoxamine oral capsule,extended release 24hr	T4	
fluvoxamine oral tablet	T2	
FOCALIN ORAL TABLET 10 MG	T4	ST; QL (62 EA per 31 days)
FOCALIN ORAL TABLET 2.5 MG, 5 MG	T4	ST; QL (93 EA per 31 days)
FOCALIN XR	T4	ST; QL (31 EA per 31 days)
FROVA	T4	QL (12 EA per 28 days)
frovatriptan	T3	QL (12 EA per 28 days)
FYCOMPA ORAL SUSPENSION	T5	QL (744 ML per 31 days)
FYCOMPA ORAL TABLET 10 MG, 12 MG, 4 MG, 6 MG, 8 MG	T5	QL (31 EA per 31 days)
FYCOMPA ORAL TABLET 2 MG	T4	QL (31 EA per 31 days)
gabapentin oral capsule 100 mg, 400 mg	T2	QL (270 EA per 30 days)
gabapentin oral capsule 300 mg	T2	QL (360 EA per 30 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
gabapentin oral solution 250 mg/5 ml	T2	QL (2160 ML per 30 days)
gabapentin oral tablet 600 mg	T2	QL (180 EA per 30 days)
gabapentin oral tablet 800 mg	T2	QL (120 EA per 30 days)
gabapentin oral tablet extended release 24 hr 300 mg	T4	PA; QL (155 EA per 31 days)
gabapentin oral tablet extended release 24 hr 600 mg	T4	PA; QL (93 EA per 31 days)
GABARONE ORAL TABLET 100 MG	T5	PA-NS; QL (558 EA per 31 days)
GABARONE ORAL TABLET 400 MG	T5	PA-NS; QL (279 EA per 31 days)
galantamine oral capsule,ext rel. pellets 24 hr	T2	
galantamine oral solution	T4	
galantamine oral tablet	T2	
GEODON INTRAMUSCULAR	T4	
GEODON ORAL	T5	QL (62 EA per 31 days)
GILENYA	T5	PA; QL (31 EA per 31 days)
glatiramer subcutaneous syringe 20 mg/ml	T5	PA; QL (31 ML per 31 days)
glatiramer subcutaneous syringe 40 mg/ml	T5	PA; QL (12 ML per 28 days)
GLATOPA SUBCUTANEOUS SYRINGE 20 MG/ML	T5	PA; QL (31 ML per 31 days)
GLATOPA SUBCUTANEOUS SYRINGE 40 MG/ML	T5	PA; QL (12 ML per 28 days)
GOCOVRI ORAL CAPSULE,EXTENDED RELEASE 24HR 137 MG	T5	PA; QL (62 EA per 31 days)
GOCOVRI ORAL CAPSULE,EXTENDED RELEASE 24HR 68.5 MG	T5	PA; QL (124 EA per 31 days)
GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 300 MG	T4	PA; QL (155 EA per 31 days)
GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 450 MG	T4	PA; QL (31 EA per 31 days)
GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 600 MG	T4	PA; QL (93 EA per 31 days)
GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 750 MG, 900 MG	T4	PA; QL (62 EA per 31 days)
guanfacine oral tablet extended release 24 hr	T2	PA
HALCION ORAL TABLET 0.25 MG	T4	PA
HALDOL DECANOATE INTRAMUSCULAR SOLUTION 100 MG/ML	T4	
haloperidol	T1	
haloperidol decanoate	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
haloperidol lactate injection	T1	
haloperidol lactate oral	T2	
HETLIOZ	T5	PA; QL (31 EA per 31 days)
HETLIOZ LQ	T5	PA; QL (158 ML per 31 days)
HORIZANT ORAL TABLET EXTENDED RELEASE 300 MG	T4	PA; QL (90 EA per 30 days)
HORIZANT ORAL TABLET EXTENDED RELEASE 600 MG	T4	PA; QL (60 EA per 30 days)
hydrocodone bitartrate oral capsule, oral only, er 12hr	T4	PA; QL (100 EA per 31 days)
hydrocodone bitartrate oral tablet,oral only,ext.rel.24 hr 100 mg, 120 mg	T5	PA; QL (31 EA per 31 days)
hydrocodone bitartrate oral tablet,oral only,ext.rel.24 hr 20 mg, 30 mg, 40 mg, 60 mg, 80 mg	T4	PA; QL (31 EA per 31 days)
hydrocodone-acetaminophen oral solution 10-300 mg/15 ml	T3	PA; QL (6200 ML per 31 days)
hydrocodone-acetaminophen oral solution 10-325 mg/15 ml, 7.5-325 mg/15 ml	T2	PA; QL (5723 ML per 31 days)
hydrocodone-acetaminophen oral tablet 10-300 mg, 5-300 mg, 7.5-300 mg	T2	PA; QL (403 EA per 31 days)
hydrocodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg	T2	PA; QL (372 EA per 31 days)
hydrocodone-ibuprofen oral tablet 10-200 mg	T4	PA; QL (155 EA per 31 days)
hydrocodone-ibuprofen oral tablet 5-200 mg, 7.5-200 mg	T2	PA; QL (155 EA per 31 days)
hydromorphone (pf) injection solution 10 (mg/ml) (5 ml), 10 mg/ml	T4	PA
hydromorphone oral liquid	T4	PA; QL (1240 ML per 31 days)
hydromorphone oral tablet 2 mg, 4 mg	T2	PA; QL (186 EA per 31 days)
hydromorphone oral tablet 8 mg	T3	PA; QL (155 EA per 31 days)
hydromorphone oral tablet extended release 24 hr 12 mg, 16 mg, 8 mg	T4	PA; QL (62 EA per 31 days)
hydromorphone oral tablet extended release 24 hr 32 mg	T4	PA; QL (31 EA per 31 days)
HYSINGLA ER ORAL TABLET,ORAL ONLY,EXT.REL.24 HR 100 MG, 80 MG	T5	PA; QL (31 EA per 31 days)
HYSINGLA ER ORAL TABLET,ORAL ONLY,EXT.REL.24 HR 20 MG, 30 MG, 40 MG, 60 MG	T4	PA; QL (31 EA per 31 days)
IBU ORAL TABLET 600 MG, 800 MG	T1	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ibuprofen oral suspension	T1	
ibuprofen oral tablet 300 mg	T4	
ibuprofen oral tablet 400 mg, 600 mg, 800 mg	T1	
ibuprofen-famotidine	T4	PA; QL (93 EA per 31 days)
imipramine hcl	T2	PA-NS
imipramine pamoate	T2	PA-NS
IMITREX ORAL TABLET 100 MG	T4	QL (9 EA per 28 days)
IMITREX ORAL TABLET 25 MG	T4	QL (36 EA per 28 days)
IMITREX ORAL TABLET 50 MG	T4	QL (18 EA per 28 days)
IMITREX STATDOSE PEN SUBCUTANEOUS PEN INJECTOR 4 MG/0.5 ML	T4	QL (6 ML per 28 days)
IMITREX STATDOSE REFILL SUBCUTANEOUS CARTRIDGE 6 MG/0.5 ML	T5	QL (4 ML per 28 days)
INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE	T5	PA; QL (300 EA per 30 days)
INDOCIN ORAL	T4	
INDOCIN RECTAL	T5	
indomethacin oral capsule	T1	
indomethacin oral capsule, extended release	T1	
indomethacin oral suspension	T4	
indomethacin rectal suppository 50 mg	T5	
INGREZZA INITIATION PK(TARDIV)	T5	PA; QL (56 EA per 365 days)
INGREZZA ORAL CAPSULE 40 MG	T5	PA; QL (62 EA per 31 days)
INGREZZA ORAL CAPSULE 60 MG, 80 MG	T5	PA; QL (31 EA per 31 days)
INGREZZA SPRINKLE	T5	PA; QL (31 EA per 31 days)
INTUNIV ER	T4	PA
INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,092 MG/3.5 ML	T5	QL (3.5 ML per 180 days)
INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,560 MG/5 ML	T5	QL (5 ML per 180 days)
INVEGA ORAL TABLET EXTENDED RELEASE 24HR 3 MG, 9 MG	T4	QL (31 EA per 31 days)
INVEGA ORAL TABLET EXTENDED RELEASE 24HR 6 MG	T4	QL (62 EA per 31 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 117 MG/0.75 ML	T5	QL (0.75 ML per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 156 MG/ML	T5	QL (1 ML per 28 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 234 MG/1.5 ML	T5	QL (1.5 ML per 28 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 39 MG/0.25 ML	T4	QL (0.25 ML per 28 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 78 MG/0.5 ML	T5	QL (0.5 ML per 28 days)
INVEGA TRINZA INTRAMUSCULAR SYRINGE 273 MG/0.88 ML	T5	QL (0.88 ML per 84 days)
INVEGA TRINZA INTRAMUSCULAR SYRINGE 410 MG/1.32 ML	T5	QL (1.32 ML per 84 days)
INVEGA TRINZA INTRAMUSCULAR SYRINGE 546 MG/1.75 ML	T5	QL (1.75 ML per 84 days)
INVEGA TRINZA INTRAMUSCULAR SYRINGE 819 MG/2.63 ML	T5	QL (2.63 ML per 84 days)
JORNAY PM	T4	ST; QL (31 EA per 31 days)
JOURNAVX	T4	PA; QL (29 EA per 90 days)
KEPPRA ORAL SOLUTION	T5	
KEPPRA ORAL TABLET 1,000 MG	T5	
KEPPRA ORAL TABLET 250 MG, 500 MG, 750 MG	T4	
KEPPRA XR	T4	
KESIMPTA PEN	T5	PA; QL (0.4 ML per 28 days)
ketoprofen oral capsule 25 mg, 50 mg	T2	
ketoprofen oral capsule,ext rel. pellets 24 hr 200 mg	T2	
ketorolac oral	T2	
KEVEYIS	T5	PA; QL (124 EA per 31 days)
KLONOPIN ORAL TABLET 0.5 MG	T4	PA-NS; QL (93 EA per 31 days)
KLONOPIN ORAL TABLET 1 MG	T4	PA-NS; QL (124 EA per 31 days)
KLONOPIN ORAL TABLET 2 MG	T4	PA-NS; QL (310 EA per 31 days)
KLOXXADO	T3	
lacosamide oral	T4	
LAMICTAL ODT ORAL TABLET,DISINTEGRATING 100 MG	T5	
LAMICTAL ODT ORAL TABLET,DISINTEGRATING 200 MG, 25 MG, 50 MG	T4	
LAMICTAL ORAL TABLET	T5	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
LAMICTAL ORAL TABLET, CHEWABLE DISPERSIBLE 25 MG, 5 MG	T4	
LAMICTAL STARTER (BLUE) KIT	T4	
LAMICTAL STARTER (GREEN) KIT	T4	
LAMICTAL STARTER (ORANGE) KIT	T4	
LAMICTAL XR ORAL TABLET EXTENDED RELEASE 24HR 100 MG, 200 MG, 25 MG	T5	
LAMICTAL XR ORAL TABLET EXTENDED RELEASE 24HR 250 MG, 300 MG, 50 MG	T4	
LAMICTAL XR STARTER (BLUE)	T4	
LAMICTAL XR STARTER (GREEN)	T4	
LAMICTAL XR STARTER (ORANGE)	T4	
lamotrigine oral tablet	T2	
lamotrigine oral tablet disintegrating, dose pk	T4	
lamotrigine oral tablet extended release 24hr	T4	
lamotrigine oral tablet, chewable dispersible	T2	
lamotrigine oral tablet,disintegrating	T4	
lamotrigine oral tablets,dose pack	T4	
LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG	T5	PA-NS; QL (31 EA per 31 days)
LATUDA ORAL TABLET 80 MG	T5	PA-NS; QL (62 EA per 31 days)
levetiracetam oral solution 100 mg/ml	T2	
levetiracetam oral tablet	T2	
levetiracetam oral tablet extended release 24 hr	T2	
levorphanol tartrate	T5	PA; QL (186 EA per 31 days)
LEXAPRO ORAL TABLET 10 MG	T4	QL (45 EA per 30 days)
LEXAPRO ORAL TABLET 20 MG, 5 MG	T4	QL (30 EA per 30 days)
LICART	T4	PA; QL (31 EA per 31 days)
lisdexamfetamine	T4	ST; QL (31 EA per 31 days)
lithium carbonate	T1	
lithium citrate	T1	
LITHOBID	T4	
LODINE ORAL TABLET	T4	
LODOSYN	T4	
LOFENA	T5	
lofexidine	T5	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
LORAZEPAM INTENSOL	T2	PA; QL (155 ML per 31 days)
lorazepam oral tablet 0.5 mg	T2	PA; QL (124 EA per 31 days)
lorazepam oral tablet 1 mg	T2	PA; QL (186 EA per 31 days)
lorazepam oral tablet 2 mg	T2	PA; QL (155 EA per 31 days)
LOREEV XR ORAL CAPSULE,EXTENDED RELEASE 24HR 1 MG, 3 MG	T4	PA; QL (93 EA per 31 days)
LOREEV XR ORAL CAPSULE,EXTENDED RELEASE 24HR 1.5 MG, 2 MG	T4	PA; QL (155 EA per 31 days)
loxapine succinate	T2	
LUCEMYRA	T5	
LUMRYZ	T5	PA; QL (31 EA per 31 days)
LUMRYZ STARTER PACK	T5	PA; QL (56 EA per 365 days)
LUNESTA	T4	PA; QL (31 EA per 31 days)
lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg	T4	PA-NS; QL (31 EA per 31 days)
lurasidone oral tablet 80 mg	T4	PA-NS; QL (62 EA per 31 days)
LYBALVI	T5	PA-NS; QL (31 EA per 31 days)
LYRICA CR ORAL TABLET EXTENDED RELEASE 24 HR 165 MG	T5	PA; QL (31 EA per 31 days)
LYRICA CR ORAL TABLET EXTENDED RELEASE 24 HR 330 MG, 82.5 MG	T4	PA; QL (31 EA per 31 days)
LYRICA ORAL CAPSULE 100 MG, 150 MG, 200 MG, 25 MG, 50 MG, 75 MG	T4	PA-NS; QL (93 EA per 31 days)
LYRICA ORAL CAPSULE 225 MG, 300 MG	T4	PA-NS; QL (62 EA per 31 days)
LYRICA ORAL SOLUTION	T4	PA-NS; QL (930 ML per 31 days)
MARPLAN	T3	
MAVENCLAD (10 TABLET PACK)	T5	PA; QL (40 EA per 365 days)
MAVENCLAD (4 TABLET PACK)	T5	PA; QL (40 EA per 365 days)
MAVENCLAD (5 TABLET PACK)	T5	PA; QL (40 EA per 365 days)
MAVENCLAD (6 TABLET PACK)	T5	PA; QL (40 EA per 365 days)
MAVENCLAD (7 TABLET PACK)	T5	PA; QL (40 EA per 365 days)
MAVENCLAD (8 TABLET PACK)	T5	PA; QL (40 EA per 365 days)
MAVENCLAD (9 TABLET PACK)	T5	PA; QL (40 EA per 365 days)
MAXALT ORAL TABLET 10 MG	T4	QL (12 EA per 28 days)
MAXALT-MLT ORAL TABLET,DISINTEGRATING 10 MG	T4	QL (12 EA per 28 days)
MAYZENT ORAL TABLET 0.25 MG	T5	PA; QL (155 EA per 31 days)
MAYZENT ORAL TABLET 1 MG, 2 MG	T5	PA; QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
MAYZENT STARTER(FOR 1MG MAINT)	T4	PA; QL (14 EA per 365 days)
MAYZENT STARTER(FOR 2MG MAINT)	T5	PA; QL (24 EA per 365 days)
meclofenamate oral capsule 100 mg	T4	
meclofenamate oral capsule 50 mg	T2	
mefenamic acid	T4	
meloxicam oral tablet	T1	
meloxicam submicronized	T4	PA; QL (31 EA per 31 days)
memantine oral capsule,sprinkle,er 24hr	T3	
memantine oral solution	T3	
memantine oral tablet	T2	
memantine oral tablets,dose pack	T4	
memantine-donepezil	T4	PA
meperidine (pf) injection solution 100 mg/ml, 50 mg/ml	T4	PA; QL (248 ML per 31 days)
meperidine (pf) injection solution 25 mg/ml	T4	PA; QL (496 ML per 31 days)
meperidine oral solution	T2	PA; QL (1860 ML per 31 days)
meperidine oral tablet 50 mg	T4	PA; QL (372 EA per 31 days)
meprobamate oral tablet 200 mg	T3	QL (341 EA per 31 days)
meprobamate oral tablet 400 mg	T3	QL (186 EA per 31 days)
MESTINON ORAL	T5	
MESTINON TIMESPAN	T5	
METADATE CD	T4	ST; QL (31 EA per 31 days)
metaxalone oral tablet 400 mg	T2	PA
metaxalone oral tablet 800 mg	T3	PA
methadone oral solution 10 mg/5 ml	T2	PA; QL (620 ML per 31 days)
methadone oral solution 5 mg/5 ml	T2	PA; QL (1240 ML per 31 days)
methadone oral tablet 10 mg	T2	PA; QL (124 EA per 31 days)
methadone oral tablet 5 mg	T2	PA; QL (248 EA per 31 days)
methamphetamine	T4	PA
methocarbamol oral tablet 1,000 mg	T5	
methocarbamol oral tablet 500 mg, 750 mg	T2	
methsuximide	T4	
METHYLIN ORAL SOLUTION 10 MG/5 ML	T4	ST; QL (930 ML per 31 days)
METHYLIN ORAL SOLUTION 5 MG/5 ML	T4	ST; QL (465 ML per 31 days)
methylphenidate	T4	PA; QL (30 EA per 30 days)
methylphenidate hcl oral cap,er sprinkle,biphasic 40-60	T4	ST; QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
methylphenidate hcl oral capsule, er biphasic 30-70	T4	QL (31 EA per 31 days)
methylphenidate hcl oral capsule,er biphasic 50-50 10 mg	T4	QL (186 EA per 31 days)
methylphenidate hcl oral capsule,er biphasic 50-50 20 mg	T4	QL (93 EA per 31 days)
methylphenidate hcl oral capsule,er biphasic 50-50 30 mg, 40 mg	T4	QL (62 EA per 31 days)
methylphenidate hcl oral capsule,er biphasic 50-50 60 mg	T4	QL (31 EA per 31 days)
methylphenidate hcl oral solution 10 mg/5 ml	T2	QL (930 ML per 31 days)
methylphenidate hcl oral solution 5 mg/5 ml	T2	QL (465 ML per 31 days)
methylphenidate hcl oral tablet	T2	QL (93 EA per 31 days)
methylphenidate hcl oral tablet extended release	T2	QL (93 EA per 31 days)
methylphenidate hcl oral tablet extended release 24hr 18 mg (bx rating), 27 mg (bx rating), 36 mg (bx rating), 45 mg, 54 mg (bx rating), 63 mg, 72 mg	T4	ST; QL (31 EA per 31 days)
methylphenidate hcl oral tablet extended release 24hr 18 mg, 27 mg, 36 mg, 54 mg	T4	QL (31 EA per 31 days)
methylphenidate hcl oral tablet,chewable 10 mg	T4	QL (186 EA per 31 days)
methylphenidate hcl oral tablet,chewable 2.5 mg, 5 mg	T4	QL (93 EA per 31 days)
MIGERGOT	T5	
MIPLYFFA	T5	PA; QL (93 EA per 31 days)
mirtazapine	T2	
modafinil	T2	PA; QL (31 EA per 31 days)
molindone	T4	
morphine concentrate oral solution	T2	PA; QL (310 ML per 31 days)
morphine oral capsule, er multiphase 24 hr 120 mg	T4	PA; QL (51 EA per 31 days)
morphine oral capsule, er multiphase 24 hr 30 mg, 45 mg, 60 mg, 75 mg, 90 mg	T4	PA; QL (62 EA per 31 days)
morphine oral capsule,extend.release pellets	T4	PA; QL (62 EA per 31 days)
morphine oral solution 10 mg/5 ml	T2	PA; QL (2800 ML per 31 days)
morphine oral solution 20 mg/5 ml (4 mg/ml)	T2	PA; QL (1400 ML per 31 days)
morphine oral tablet	T2	PA; QL (186 EA per 31 days)
morphine oral tablet extended release 100 mg	T2	PA; QL (62 EA per 31 days)
morphine oral tablet extended release 15 mg, 30 mg, 60 mg	T2	PA; QL (100 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
morphine oral tablet extended release 200 mg	T3	PA; QL (31 EA per 31 days)
MOTPOLY XR ORAL CAPSULE,EXTENDED RELEASE 24HR 100 MG	T4	PA-NS; QL (31 EA per 31 days)
MOTPOLY XR ORAL CAPSULE,EXTENDED RELEASE 24HR 150 MG, 200 MG	T5	PA-NS; QL (62 EA per 31 days)
MS CONTIN ORAL TABLET EXTENDED RELEASE 15 MG, 30 MG, 60 MG	T4	PA; QL (100 EA per 31 days)
MYDAYIS	T4	ST; QL (31 EA per 31 days)
MYSOLINE	T5	
nabumetone	T1	
NALOCET	T4	PA; QL (403 EA per 31 days)
naloxone injection solution	T2	
naloxone injection syringe	T2	
naltrexone	T2	
NAMZARIC ORAL CAPSULE,SPRINKLE,ER 24HR	T4	PA
NAPRELAN CR	T4	
naproxen oral suspension	T4	
naproxen oral tablet	T1	
naproxen oral tablet,delayed release (dr/ec)	T2	
naproxen sodium oral tablet 275 mg, 550 mg	T1	
naproxen sodium oral tablet, er multiphase 24 hr	T4	
naproxen-esomeprazole	T5	PA; QL (62 EA per 31 days)
naratriptan oral tablet 1 mg	T2	QL (20 EA per 28 days)
naratriptan oral tablet 2.5 mg	T2	QL (9 EA per 28 days)
NARDIL	T4	
NAYZILAM	T4	PA-NS; QL (10 EA per 30 days)
nefazodone	T2	
NEUPRO	T4	
NEURONTIN ORAL CAPSULE 100 MG	T4	PA-NS; QL (270 EA per 30 days)
NEURONTIN ORAL CAPSULE 300 MG	T5	PA-NS; QL (360 EA per 30 days)
NEURONTIN ORAL CAPSULE 400 MG	T5	PA-NS; QL (270 EA per 30 days)
NEURONTIN ORAL SOLUTION	T4	PA-NS; QL (2160 ML per 30 days)
NEURONTIN ORAL TABLET 600 MG	T5	PA-NS; QL (180 EA per 30 days)
NEURONTIN ORAL TABLET 800 MG	T4	PA-NS; QL (120 EA per 30 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
NORGESIC	T4	PA; QL (248 EA per 31 days)
NORGESIC FORTE	T4	PA; QL (124 EA per 31 days)
NORPRAMIN ORAL TABLET 10 MG, 25 MG	T4	
nortriptyline	T2	
NOURIANZ	T5	PA; QL (31 EA per 31 days)
NUCYNTA ER ORAL TABLET EXTENDED RELEASE 12 HR 100 MG, 150 MG, 200 MG, 250 MG	T5	PA; QL (62 EA per 31 days)
NUCYNTA ER ORAL TABLET EXTENDED RELEASE 12 HR 50 MG	T4	PA; QL (62 EA per 31 days)
NUCYNTA ORAL TABLET 100 MG, 75 MG	T5	PA; QL (186 EA per 31 days)
NUCYNTA ORAL TABLET 50 MG	T4	PA; QL (186 EA per 31 days)
NUEDEXTA	T5	PA; QL (62 EA per 31 days)
NUPLAZID	T5	PA-NS; QL (31 EA per 31 days)
NURTEC ODT	T5	PA; QL (18 EA per 28 days)
NUVIGIL ORAL TABLET 150 MG, 200 MG, 250 MG	T5	PA; QL (31 EA per 31 days)
NUVIGIL ORAL TABLET 50 MG	T4	PA; QL (31 EA per 31 days)
olanzapine intramuscular	T2	
olanzapine oral	T2	QL (31 EA per 31 days)
olanzapine-fluoxetine	T2	
ONAPGO	T5	PA; QL (620 ML per 31 days)
ONFI ORAL SUSPENSION	T5	PA-NS; QL (496 ML per 31 days)
ONFI ORAL TABLET	T5	PA-NS; QL (62 EA per 31 days)
ONGENTYS	T4	PA; QL (31 EA per 31 days)
ONYDA XR	T4	PA; QL (120 ML per 30 days)
ONZETRA XSAIL	T4	QL (16 EA per 28 days)
OPIPZA	T5	PA-NS
OPVEE	T4	
ORMALVI	T5	PA; QL (124 EA per 31 days)
orphenadrine citrate oral	T2	PA
orphenadrine-asa-caffeine oral tablet 25-385-30 mg	T4	PA; QL (248 EA per 31 days)
oxaprozin oral tablet	T2	
oxazepam	T2	PA
oxcarbazepine oral suspension	T2	
oxcarbazepine oral tablet	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
oxcarbazepine oral tablet extended release 24 hr 150 mg, 300 mg	T4	
oxcarbazepine oral tablet extended release 24 hr 600 mg	T5	
OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HR 150 MG, 300 MG	T4	
OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HR 600 MG	T5	
oxycodone oral capsule	T2	PA; QL (186 EA per 31 days)
oxycodone oral concentrate	T4	PA; QL (180 ML per 31 days)
oxycodone oral solution	T3	PA; QL (4133 ML per 31 days)
oxycodone oral tablet 10 mg, 15 mg, 20 mg, 5 mg	T2	PA; QL (186 EA per 31 days)
oxycodone oral tablet 30 mg	T3	PA; QL (138 EA per 31 days)
oxycodone oral tablet, oral only	T5	PA; QL (186 EA per 31 days)
oxycodone-acetaminophen oral solution 5-325 mg/5 ml	T4	PA; QL (1907 ML per 31 days)
oxycodone-acetaminophen oral tablet 10-300 mg, 5-300 mg, 7.5-300 mg	T5	PA; QL (403 EA per 31 days)
oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg	T3	PA; QL (372 EA per 31 days)
oxycodone-acetaminophen oral tablet 5-325 mg, 7.5-325 mg	T2	PA; QL (372 EA per 31 days)
OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 10 MG, 15 MG, 20 MG, 30 MG	T4	PA; QL (100 EA per 31 days)
OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 40 MG	T5	PA; QL (100 EA per 31 days)
OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 60 MG	T5	PA; QL (69 EA per 31 days)
OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 80 MG	T5	PA; QL (62 EA per 31 days)
oxymorphone oral tablet 10 mg	T4	PA; QL (186 EA per 31 days)
oxymorphone oral tablet 5 mg	T2	PA; QL (186 EA per 31 days)
oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 5 mg, 7.5 mg	T4	PA; QL (100 EA per 31 days)
oxymorphone oral tablet extended release 12 hr 30 mg	T5	PA; QL (69 EA per 31 days)
oxymorphone oral tablet extended release 12 hr 40 mg	T5	PA; QL (51 EA per 31 days)
OZOBAX DS	T4	PA; QL (1240 ML per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
paliperidone oral tablet extended release 24hr 1.5 mg, 3 mg, 9 mg	T4	QL (31 EA per 31 days)
paliperidone oral tablet extended release 24hr 6 mg	T4	QL (62 EA per 31 days)
PARLODEL	T4	
PARNATE	T4	
paroxetine hcl oral suspension	T4	PA-NS
paroxetine hcl oral tablet	T1	PA-NS
paroxetine hcl oral tablet extended release 24 hr	T2	PA-NS
paroxetine mesylate(menop.sym)	T4	PA
PAXIL CR	T4	PA-NS
PAXIL ORAL TABLET	T4	PA-NS
pentazocine-naloxone	T2	QL (335 EA per 31 days)
perampanel oral tablet 10 mg, 12 mg, 4 mg, 6 mg, 8 mg	T5	QL (31 EA per 31 days)
perampanel oral tablet 2 mg	T4	QL (31 EA per 31 days)
PERCOCET ORAL TABLET 10-325 MG, 5-325 MG, 7.5-325 MG	T5	PA; QL (372 EA per 31 days)
perphenazine	T2	
perphenazine-amitriptyline	T2	PA-NS
PERSERIS	T5	QL (1 EA per 28 days)
phenelzine	T2	
phenobarbital	T2	PA-NS
PHENYTEK	T3	
phenytoin oral suspension 125 mg/5 ml	T2	
phenytoin oral tablet,chewable	T2	
phenytoin sodium extended oral capsule 100 mg	T2	
pimozide	T2	
piroxicam	T2	
PONVORY	T5	PA; QL (31 EA per 31 days)
PONVORY 14-DAY STARTER PACK	T5	PA; QL (28 EA per 365 days)
pramipexole oral tablet	T2	
pramipexole oral tablet extended release 24 hr 0.375 mg, 0.75 mg, 2.25 mg, 3 mg, 4.5 mg	T3	
pramipexole oral tablet extended release 24 hr 1.5 mg, 3.75 mg	T2	
pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg	T2	PA-NS; QL (93 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
pregabalin oral capsule 225 mg, 300 mg	T2	PA-NS; QL (62 EA per 31 days)
pregabalin oral solution	T2	PA-NS; QL (930 ML per 31 days)
pregabalin oral tablet extended release 24 hr	T4	PA; QL (31 EA per 31 days)
primidone oral tablet 125 mg	T3	
primidone oral tablet 250 mg, 50 mg	T2	
PRISTIQ	T4	QL (31 EA per 31 days)
PROCENTRA	T4	
PROLATE ORAL SOLUTION	T4	PA; QL (2066 ML per 31 days)
PROLATE ORAL TABLET 10-300 MG	T5	PA; QL (403 EA per 31 days)
PROLATE ORAL TABLET 5-300 MG, 7.5-300 MG	T4	PA; QL (403 EA per 31 days)
protriptyline	T2	
PROVIGIL ORAL TABLET 200 MG	T5	PA; QL (31 EA per 31 days)
PROZAC ORAL CAPSULE 20 MG	T4	
pyridostigmine bromide oral syrup	T5	
pyridostigmine bromide oral tablet 30 mg	T3	
pyridostigmine bromide oral tablet 60 mg	T2	
pyridostigmine bromide oral tablet extended release 180 mg	T2	
QELBREE ORAL CAPSULE,EXTENDED RELEASE 24HR 100 MG, 200 MG	T4	PA; QL (93 EA per 31 days)
QELBREE ORAL CAPSULE,EXTENDED RELEASE 24HR 150 MG	T4	PA; QL (62 EA per 31 days)
quetiapine oral tablet 100 mg, 200 mg, 300 mg, 400 mg, 50 mg	T2	QL (62 EA per 31 days)
quetiapine oral tablet 150 mg	T3	QL (62 EA per 31 days)
quetiapine oral tablet 25 mg	T1	QL (62 EA per 31 days)
quetiapine oral tablet extended release 24 hr	T3	QL (62 EA per 31 days)
QUILLICHEW ER ORAL TABLET,CHEW,IR-ER.BIPHASIC24HR 20 MG, 40 MG	T4	ST; QL (31 EA per 31 days)
QUILLICHEW ER ORAL TABLET,CHEW,IR-ER.BIPHASIC24HR 30 MG	T4	ST; QL (62 EA per 31 days)
QUILLIVANT XR	T4	ST; QL (360 ML per 30 days)
QULIPTA	T5	PA; QL (31 EA per 31 days)
QUVIVIQ	T4	ST; QL (31 EA per 31 days)
RADICAVA ORS STARTER KIT SUSP	T5	PA; QL (70 ML per 28 days)
RALDESY	T5	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ramelteon	T4	QL (31 EA per 31 days)
rasagiline	T3	
RELAFEN DS	T5	
RELEXXII ORAL TABLET EXTENDED RELEASE 24HR 18 MG, 27 MG, 36 MG, 45 MG, 54 MG, 63 MG	T4	ST; QL (31 EA per 31 days)
RELPAX ORAL TABLET 20 MG	T4	QL (12 EA per 28 days)
RELPAX ORAL TABLET 40 MG	T4	QL (6 EA per 28 days)
REMERON ORAL TABLET 15 MG, 30 MG	T4	
REMERON SOLTAB	T4	
RESTORIL	T4	PA; QL (31 EA per 31 days)
REXULTI ORAL TABLET	T5	PA-NS; QL (31 EA per 31 days)
REYVOW ORAL TABLET 100 MG	T4	PA; QL (8 EA per 28 days)
REYVOW ORAL TABLET 50 MG	T4	PA; QL (4 EA per 28 days)
RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 12.5 MG/2 ML, 25 MG/2 ML	T4	QL (2 EA per 28 days)
RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 37.5 MG/2 ML, 50 MG/2 ML	T5	QL (2 EA per 28 days)
RISPERDAL ORAL SOLUTION	T4	QL (496 ML per 31 days)
RISPERDAL ORAL TABLET 0.5 MG, 1 MG, 2 MG	T4	QL (31 EA per 31 days)
RISPERDAL ORAL TABLET 3 MG	T4	QL (93 EA per 31 days)
RISPERDAL ORAL TABLET 4 MG	T4	QL (124 EA per 31 days)
risperidone microspheres intramuscular suspension,extended rel recon 12.5 mg/2 ml	T4	QL (2 EA per 28 days)
risperidone microspheres intramuscular suspension,extended rel recon 25 mg/2 ml, 37.5 mg/2 ml, 50 mg/2 ml	T5	QL (2 EA per 28 days)
risperidone oral solution	T2	QL (496 ML per 31 days)
risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg	T1	QL (31 EA per 31 days)
risperidone oral tablet 3 mg	T1	QL (93 EA per 31 days)
risperidone oral tablet 4 mg	T1	QL (124 EA per 31 days)
risperidone oral tablet,disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg	T4	QL (31 EA per 31 days)
risperidone oral tablet,disintegrating 3 mg	T4	QL (93 EA per 31 days)
risperidone oral tablet,disintegrating 4 mg	T4	QL (124 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
RITALIN LA ORAL CAPSULE,ER BIPHASIC 50-50 10 MG	T4	ST; QL (186 EA per 31 days)
RITALIN LA ORAL CAPSULE,ER BIPHASIC 50-50 20 MG, 40 MG	T4	ST; QL (31 EA per 31 days)
RITALIN LA ORAL CAPSULE,ER BIPHASIC 50-50 30 MG	T4	ST; QL (62 EA per 31 days)
RITALIN ORAL TABLET 10 MG, 20 MG	T4	ST; QL (93 EA per 31 days)
rivastigmine	T2	QL (30 EA per 30 days)
rivastigmine tartrate	T2	
rizatriptan oral tablet 10 mg	T2	QL (12 EA per 28 days)
rizatriptan oral tablet 5 mg	T2	QL (24 EA per 28 days)
rizatriptan oral tablet,disintegrating 10 mg	T2	QL (12 EA per 28 days)
rizatriptan oral tablet,disintegrating 5 mg	T2	QL (24 EA per 28 days)
ropinirole	T2	
ROWEEPRA ORAL TABLET 500 MG	T2	
ROXICODONE ORAL TABLET 15 MG	T4	PA; QL (186 EA per 31 days)
ROXICODONE ORAL TABLET 30 MG	T5	PA; QL (138 EA per 31 days)
ROXYBOND	T5	PA; QL (186 EA per 31 days)
ROZEREM	T4	QL (31 EA per 31 days)
rufinamide oral suspension	T5	PA-NS
rufinamide oral tablet 200 mg	T4	PA-NS
rufinamide oral tablet 400 mg	T5	PA-NS
RYTARY	T3	ST
SABRIL	T5	PA-NS
SAPHRIS SUBLINGUAL TABLET 10 MG, 2.5 MG	T4	PA-NS; QL (62 EA per 31 days)
SAPHRIS SUBLINGUAL TABLET 5 MG	T5	PA-NS; QL (62 EA per 31 days)
SECUADO	T5	PA-NS; QL (31 EA per 31 days)
selegiline hcl	T2	
SEROQUEL	T4	QL (62 EA per 31 days)
SEROQUEL XR ORAL TABLET EXTENDED RELEASE 24 HR 150 MG, 200 MG, 300 MG, 50 MG	T4	QL (62 EA per 31 days)
SEROQUEL XR ORAL TABLET EXTENDED RELEASE 24 HR 400 MG	T5	QL (62 EA per 31 days)
sertraline oral capsule	T4	PA-NS; QL (31 EA per 31 days)
sertraline oral concentrate	T2	
sertraline oral tablet	T1	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
SILENOR	T4	PA
SINEMET ORAL TABLET 10-100 MG, 25-100 MG	T4	
SKYCLARYS	T5	PA; QL (93 EA per 31 days)
sodium oxybate	T5	PA; QL (540 ML per 30 days)
SOMA	T4	PA
SPRITAM ORAL TABLET FOR SUSPENSION 250 MG, 500 MG	T4	
SPRIX	T5	QL (5 EA per 31 days)
SUBOXONE SUBLINGUAL FILM 12-3 MG, 2-0.5 MG, 8-2 MG	T4	ST
SUBOXONE SUBLINGUAL FILM 4-1 MG	T5	ST
SUBVENITE	T2	
SUBVENITE STARTER (BLUE) KIT	T4	
SUBVENITE STARTER (GREEN) KIT	T5	
SUBVENITE STARTER (ORANGE) KIT	T4	
sulindac	T2	
sumatriptan nasal spray,non-aerosol 20 mg/actuation	T2	QL (8 EA per 28 days)
sumatriptan nasal spray,non-aerosol 5 mg/actuation	T2	QL (32 EA per 28 days)
sumatriptan succinate oral tablet 100 mg	T2	QL (9 EA per 28 days)
sumatriptan succinate oral tablet 25 mg	T2	QL (36 EA per 28 days)
sumatriptan succinate oral tablet 50 mg	T2	QL (18 EA per 28 days)
sumatriptan succinate subcutaneous cartridge 6 mg/0.5 ml	T4	QL (4 ML per 28 days)
sumatriptan succinate subcutaneous pen injector 4 mg/0.5 ml	T4	QL (6 ML per 28 days)
sumatriptan succinate subcutaneous pen injector 6 mg/0.5 ml	T4	QL (4 ML per 28 days)
sumatriptan succinate subcutaneous solution	T4	QL (4 ML per 28 days)
sumatriptan-naproxen	T4	QL (9 EA per 28 days)
SUNOSI	T4	PA; QL (31 EA per 31 days)
SYMBRAVO	T4	QL (9 EA per 30 days)
SYMPAZAN ORAL FILM 10 MG, 20 MG	T5	PA-NS; QL (62 EA per 31 days)
SYMPAZAN ORAL FILM 5 MG	T4	PA-NS; QL (62 EA per 31 days)
TANLOR	T4	
TASCENSO ODT	T5	PA; QL (31 EA per 31 days)
tasimelteon	T5	PA; QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
TASMAR ORAL TABLET 100 MG	T5	
TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 120 MG (14)- 240 MG (46)	T5	PA; QL (120 EA per 365 days)
TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 120 MG, 240 MG	T5	PA; QL (62 EA per 31 days)
TEGRETOL ORAL SUSPENSION	T4	
TEGRETOL ORAL TABLET	T4	
TEGRETOL XR	T4	
temazepam	T4	PA; QL (31 EA per 31 days)
TENCON	T2	QL (372 EA per 31 days)
teriflunomide	T5	PA; QL (31 EA per 31 days)
tetrabenazine oral tablet 12.5 mg	T5	PA; QL (93 EA per 31 days)
tetrabenazine oral tablet 25 mg	T5	PA; QL (124 EA per 31 days)
thioridazine	T2	
thiothixene	T1	
tiagabine	T2	
tizanidine	T2	
tolcapone	T5	
TOLECTIN 600	T5	
tolmetin oral capsule	T2	
tolmetin oral tablet 600 mg	T5	
TOPAMAX ORAL CAPSULE, SPRINKLE	T4	
TOPAMAX ORAL TABLET 100 MG, 200 MG	T5	
TOPAMAX ORAL TABLET 25 MG, 50 MG	T4	
topiramate oral capsule, sprinkle 15 mg, 25 mg	T2	
topiramate oral capsule, sprinkle 50 mg	T4	
topiramate oral capsule,extended release 24hr 100 mg, 25 mg, 50 mg	T4	
topiramate oral capsule,extended release 24hr 200 mg	T5	
topiramate oral capsule,sprinkle,er 24hr	T4	
topiramate oral tablet	T2	
TOSYMRA	T4	QL (12 EA per 28 days)
tramadol oral capsule,er biphase 24 hr 17-83	T4	PA; QL (30 EA per 30 days)
tramadol oral capsule,er biphase 24 hr 25-75 100 mg, 200 mg	T4	PA; QL (30 EA per 30 days)
tramadol oral tablet 100 mg	T4	PA; QL (124 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
tramadol oral tablet 25 mg	T4	PA; QL (496 EA per 31 days)
tramadol oral tablet 50 mg	T1	PA; QL (240 EA per 30 days)
tramadol oral tablet 75 mg	T4	PA; QL (155 EA per 31 days)
tramadol oral tablet extended release 24 hr	T2	PA; QL (30 EA per 30 days)
tramadol-acetaminophen	T2	PA; QL (372 EA per 31 days)
tranylcypromine	T2	
trazodone oral tablet 100 mg, 150 mg, 50 mg	T1	
trazodone oral tablet 300 mg	T2	
TREXIMET	T5	QL (9 EA per 28 days)
triazolam	T2	PA
trifluoperazine	T2	
trihexyphenidyl	T2	
TRILEPTAL ORAL SUSPENSION	T4	
TRILEPTAL ORAL TABLET 150 MG, 600 MG	T5	
TRILEPTAL ORAL TABLET 300 MG	T4	
trimipramine	T3	PA-NS
TRINTELLIX	T4	PA-NS
TROKENDI XR ORAL CAPSULE,EXTENDED RELEASE 24HR 100 MG, 50 MG	T4	
TROKENDI XR ORAL CAPSULE,EXTENDED RELEASE 24HR 200 MG, 25 MG	T5	
TRUDHESA	T5	PA; QL (12 ML per 28 days)
UBRELVY ORAL TABLET 100 MG	T5	PA; QL (17 EA per 28 days)
UBRELVY ORAL TABLET 50 MG	T5	PA; QL (34 EA per 28 days)
UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 100 MG/0.28 ML	T5	QL (0.28 ML per 30 days)
UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 125 MG/0.35 ML	T5	QL (0.35 ML per 30 days)
UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 150 MG/0.42 ML	T5	QL (0.42 ML per 60 days)
UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 200 MG/0.56 ML	T5	QL (0.56 ML per 60 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 250 MG/0.7 ML	T5	QL (0.7 ML per 60 days)
UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 50 MG/0.14 ML	T5	QL (0.14 ML per 30 days)
UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 75 MG/0.21 ML	T5	QL (0.21 ML per 30 days)
VALIUM	T4	PA-NS; QL (124 EA per 31 days)
valproic acid	T2	
valproic acid (as sodium salt) oral solution 250 mg/5 ml	T2	
VALTOCO	T5	PA-NS; QL (10 EA per 30 days)
venlafaxine besylate	T4	PA-NS; QL (62 EA per 31 days)
venlafaxine oral capsule,extended release 24hr 150 mg, 37.5 mg	T2	QL (31 EA per 31 days)
venlafaxine oral capsule,extended release 24hr 75 mg	T2	QL (93 EA per 31 days)
venlafaxine oral tablet	T2	
venlafaxine oral tablet extended release 24hr 150 mg, 37.5 mg, 75 mg	T2	QL (31 EA per 31 days)
venlafaxine oral tablet extended release 24hr 225 mg	T4	QL (31 EA per 31 days)
VERSACLOZ	T5	QL (558 ML per 31 days)
vigabatrin	T5	PA-NS
VIGADRONE	T5	PA-NS
VIGAFYDE	T5	PA-NS
VIGPODER	T5	PA-NS
VIIBRYD ORAL TABLET	T4	PA-NS; QL (31 EA per 31 days)
vilazodone	T3	PA-NS; QL (31 EA per 31 days)
VIMPAT ORAL SOLUTION	T5	
VIMPAT ORAL TABLET 100 MG, 150 MG, 200 MG	T5	
VIMPAT ORAL TABLET 50 MG	T4	
VIVITROL	T5	
VRAYLAR ORAL CAPSULE	T5	PA-NS; QL (31 EA per 31 days)
VUMERITY	T5	PA; QL (124 EA per 31 days)
VYVANSE	T4	ST; QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
VYVGART HYTRULO SUBCUTANEOUS SYRINGE	T5	PA; QL (20 ML per 28 days)
WAINUA	T5	PA; QL (0.8 ML per 30 days)
WAKIX	T5	PA; QL (62 EA per 31 days)
WELLBUTRIN SR	T4	QL (62 EA per 31 days)
WELLBUTRIN XL ORAL TABLET EXTENDED RELEASE 24 HR 150 MG	T5	QL (93 EA per 31 days)
WELLBUTRIN XL ORAL TABLET EXTENDED RELEASE 24 HR 300 MG	T5	QL (31 EA per 31 days)
XANAX ORAL TABLET 0.25 MG, 0.5 MG	T4	PA; QL (93 EA per 31 days)
XANAX ORAL TABLET 1 MG, 2 MG	T4	PA; QL (155 EA per 31 days)
XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 0.5 MG, 1 MG	T4	PA; QL (31 EA per 31 days)
XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 2 MG	T4	PA; QL (155 EA per 31 days)
XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 3 MG	T4	PA; QL (93 EA per 31 days)
XCOPRI	T5	PA-NS
XCOPRI MAINTENANCE PACK	T5	PA-NS
XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 12.5 MG (14)- 25 MG (14)	T4	PA-NS
XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14)	T5	PA-NS
XELSTRYM	T4	ST; QL (30 EA per 30 days)
XENAZINE ORAL TABLET 12.5 MG	T5	PA; QL (93 EA per 31 days)
XENAZINE ORAL TABLET 25 MG	T5	PA; QL (124 EA per 31 days)
XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 13.5 MG, 18 MG, 27 MG, 9 MG	T4	PA; QL (62 EA per 31 days)
XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 36 MG	T5	PA; QL (62 EA per 31 days)
XYREM	T5	PA; QL (540 ML per 30 days)
XYWAV	T5	PA; QL (540 ML per 30 days)
zaleplon oral capsule 10 mg	T2	PA; QL (62 EA per 31 days)
zaleplon oral capsule 5 mg	T2	PA; QL (93 EA per 31 days)
ZANAFLEX ORAL TABLET	T4	
ZARONTIN	T4	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ZAVZPRET	T5	PA; QL (8 EA per 30 days)
ZELAPAR	T5	
ZEMBRACE SYMTOUCH	T5	QL (8 ML per 28 days)
ZENZEDI	T4	QL (62 EA per 31 days)
ZEPOSIA	T5	PA; QL (31 EA per 31 days)
ZEPOSIA STARTER KIT (28-DAY)	T5	PA; QL (56 EA per 365 days)
ZEPOSIA STARTER PACK (7-DAY)	T5	PA; QL (14 EA per 365 days)
ZILBRYSQ SUBCUTANEOUS SYRINGE 16.6 MG/0.416 ML	T5	PA; QL (11.648 ML per 28 days)
ZILBRYSQ SUBCUTANEOUS SYRINGE 23 MG/0.574 ML	T5	PA; QL (16.072 ML per 28 days)
ZILBRYSQ SUBCUTANEOUS SYRINGE 32.4 MG/0.81 ML	T5	PA; QL (22.68 ML per 28 days)
ziprasidone hcl	T2	QL (62 EA per 31 days)
ziprasidone mesylate	T2	
ZIPSOR	T5	
zolmitriptan nasal spray,non-aerosol 2.5 mg	T4	QL (16 EA per 28 days)
zolmitriptan nasal spray,non-aerosol 5 mg	T4	QL (8 EA per 28 days)
zolmitriptan oral tablet 2.5 mg	T2	QL (16 EA per 28 days)
zolmitriptan oral tablet 5 mg	T2	QL (8 EA per 28 days)
zolmitriptan oral tablet,disintegrating 2.5 mg	T2	QL (16 EA per 28 days)
zolmitriptan oral tablet,disintegrating 5 mg	T2	QL (8 EA per 28 days)
ZOLOFT	T4	
zolpidem oral capsule	T4	PA; QL (31 EA per 31 days)
zolpidem oral tablet	T2	PA; QL (31 EA per 31 days)
zolpidem oral tablet,ext release multiphase	T2	PA; QL (31 EA per 31 days)
zolpidem sublingual	T3	PA; QL (31 EA per 31 days)
ZOMIG NASAL SPRAY,NON-AEROSOL 2.5 MG	T4	QL (16 EA per 28 days)
ZOMIG NASAL SPRAY,NON-AEROSOL 5 MG	T4	QL (8 EA per 28 days)
ZOMIG ORAL TABLET 2.5 MG	T4	QL (16 EA per 28 days)
ZOMIG ORAL TABLET 5 MG	T4	QL (8 EA per 28 days)
ZONEGRAN ORAL CAPSULE 100 MG, 25 MG	T5	
ZONISADE	T5	PA-NS; QL (930 ML per 31 days)
zonisamide	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ZTALMY	T5	PA-NS; QL (1100 ML per 30 days)
ZUBSOLV	T3	
ZUNVEYL	T4	PA; QL (62 EA per 31 days)
ZURZUVAE ORAL CAPSULE 20 MG, 25 MG	T5	PA-NS; QL (28 EA per 180 days)
ZURZUVAE ORAL CAPSULE 30 MG	T5	PA-NS; QL (14 EA per 180 days)
ZYPREXA INTRAMUSCULAR	T4	
ZYPREXA ORAL TABLET 2.5 MG, 5 MG	T4	QL (31 EA per 31 days)
ZYPREXA ORAL TABLET 20 MG	T5	QL (31 EA per 31 days)
Cardiovascular, Hypertension / Lipids		
acebutolol	T1	
ALDACTONE	T4	
aliskiren	T4	
ALVAIZ ORAL TABLET 18 MG, 9 MG	T5	PA; QL (31 EA per 31 days)
ALVAIZ ORAL TABLET 36 MG, 54 MG	T5	PA; QL (62 EA per 31 days)
amiloride	T1	
amiloride-hydrochlorothiazide	T1	
amiodarone oral	T2	
amlodipine	T1	
amlodipine-atorvastatin	T2	
amlodipine-benazepril	T1	
amlodipine-olmesartan	T2	QL (31 EA per 31 days)
amlodipine-valsartan	T2	
amlodipine-valsartan-hcthiazid	T4	
ARBLI	T4	QL (330 ML per 31 days)
ARIXTRA SUBCUTANEOUS SYRINGE 10 MG/0.8 ML, 5 MG/0.4 ML, 7.5 MG/0.6 ML	T5	
ARIXTRA SUBCUTANEOUS SYRINGE 2.5 MG/0.5 ML	T4	
aspirin-dipyridamole	T2	
ATACAND	T4	
ATACAND HCT	T4	
atenolol	T1	
atenolol-chlorthalidone	T1	
ATORVALIQ	T4	PA; QL (600 ML per 30 days)
atorvastatin	T1	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ATTRUBY	T5	PA; QL (124 EA per 31 days)
AVALIDE	T4	QL (31 EA per 31 days)
AVAPRO ORAL TABLET 150 MG, 300 MG	T4	QL (31 EA per 31 days)
AZOR	T4	QL (31 EA per 31 days)
benazepril	T1	
benazepril-hydrochlorothiazide	T1	
BENICAR HCT	T4	QL (31 EA per 31 days)
BENICAR ORAL TABLET 20 MG, 40 MG	T4	QL (31 EA per 31 days)
BENICAR ORAL TABLET 5 MG	T4	QL (93 EA per 31 days)
BETAPACE AF	T4	
betaxolol oral	T1	
BIDIL	T4	
bisoprolol fumarate oral tablet 10 mg, 5 mg	T1	
bisoprolol fumarate oral tablet 2.5 mg	T3	
bisoprolol-hydrochlorothiazide	T1	
BRILINTA	T4	
bumetanide	T2	
BYSTOLIC ORAL TABLET 10 MG, 2.5 MG	T4	QL (93 EA per 31 days)
BYSTOLIC ORAL TABLET 20 MG	T4	QL (62 EA per 31 days)
BYSTOLIC ORAL TABLET 5 MG	T4	QL (217 EA per 31 days)
CABLIVI INJECTION KIT	T5	PA; QL (31 EA per 31 days)
CADUET	T4	
CAMZYOS	T5	PA; QL (31 EA per 31 days)
candesartan	T2	
candesartan-hydrochlorothiazid	T2	
captopril	T1	
CARDIZEM CD ORAL CAPSULE,EXTENDED RELEASE 24HR 120 MG, 180 MG	T4	
CARDIZEM CD ORAL CAPSULE,EXTENDED RELEASE 24HR 240 MG, 300 MG, 360 MG	T5	
CARDIZEM LA	T4	
CARDIZEM ORAL TABLET 120 MG	T4	
CARDIZEM ORAL TABLET 30 MG, 60 MG	T5	
CARDURA	T4	
CARDURA XL	T4	
CAROSPIR	T4	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
CARTIA XT	T1	
carvedilol	T1	
carvedilol phosphate	T4	
chlorthalidone oral tablet 25 mg, 50 mg	T1	
cholestyramine (with sugar) oral powder in packet	T2	
CHOLESTYRAMINE LIGHT ORAL POWDER IN PACKET	T2	
cilostazol	T2	
clonidine	T4	
clonidine hcl oral tablet	T1	
clonidine hcl oral tablet extended release 24 hr	T4	ST
clopidogrel oral tablet 75 mg	T1	
colesevelam	T4	
COLESTID ORAL TABLET	T4	
colestipol oral packet	T2	
colestipol oral tablet	T2	
COREG	T4	
COREG CR	T5	
CORLANOR ORAL SOLUTION	T4	PA; QL (420 ML per 28 days)
CORLANOR ORAL TABLET 5 MG	T4	PA; QL (93 EA per 31 days)
CORLANOR ORAL TABLET 7.5 MG	T4	PA; QL (62 EA per 31 days)
COZAAR ORAL TABLET 100 MG	T4	QL (31 EA per 31 days)
COZAAR ORAL TABLET 25 MG	T4	QL (93 EA per 31 days)
COZAAR ORAL TABLET 50 MG	T4	QL (62 EA per 31 days)
CRESTOR	T4	
dabigatran etexilate oral capsule 110 mg	T4	QL (124 EA per 31 days)
dabigatran etexilate oral capsule 150 mg, 75 mg	T4	QL (62 EA per 31 days)
DEMSER	T5	PA
DIBENZYLINE	T5	PA
digoxin oral solution	T2	QL (155 ML per 31 days)
digoxin oral tablet 125 mcg (0.125 mg)	T1	QL (62 EA per 31 days)
digoxin oral tablet 250 mcg (0.25 mg)	T2	QL (31 EA per 31 days)
digoxin oral tablet 62.5 mcg (0.0625 mg)	T4	QL (124 EA per 31 days)
diltiazem hcl oral capsule,extended release 12 hr	T1	
diltiazem hcl oral capsule,extended release 24 hr 360 mg, 420 mg	T1	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg	T1	
diltiazem hcl oral tablet	T1	
diltiazem hcl oral tablet extended release 24 hr	T1	
DILT-XR	T1	
DIOVAN HCT	T4	QL (31 EA per 31 days)
DIOVAN ORAL TABLET 160 MG, 40 MG, 80 MG	T4	QL (62 EA per 31 days)
DIOVAN ORAL TABLET 320 MG	T4	QL (31 EA per 31 days)
dipyridamole oral	T2	
disopyramide phosphate oral capsule	T2	
DIURIL	T4	
dofetilide	T3	
DOPTELET (10 TAB PACK)	T5	PA
DOPTELET (15 TAB PACK)	T5	PA
DOPTELET (30 TAB PACK)	T5	PA
doxazosin	T1	
DYRENIUM	T4	
EDARBI	T4	
EDARBYCLOR	T4	
EDECRIN	T5	
EFFIENT	T4	
ELIQUIS DVT-PE TREAT 30D START	T3	QL (74 EA per 30 days)
ELIQUIS ORAL TABLET 2.5 MG	T3	QL (60 EA per 30 days)
ELIQUIS ORAL TABLET 5 MG	T3	QL (74 EA per 30 days)
eltrombopag olamine oral powder in packet 12.5 mg	T5	PA; QL (372 EA per 31 days)
eltrombopag olamine oral powder in packet 25 mg	T5	PA; QL (31 EA per 31 days)
eltrombopag olamine oral tablet 12.5 mg, 25 mg	T5	PA; QL (31 EA per 31 days)
eltrombopag olamine oral tablet 50 mg, 75 mg	T5	PA; QL (62 EA per 31 days)
enalapril maleate oral solution	T4	
enalapril maleate oral tablet	T1	
enalapril-hydrochlorothiazide	T1	
enoxaparin subcutaneous syringe 100 mg/ml, 120 mg/0.8 ml, 150 mg/ml	T4	
enoxaparin subcutaneous syringe 30 mg/0.3 ml, 40 mg/0.4 ml, 60 mg/0.6 ml, 80 mg/0.8 ml	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ENTRESTO ORAL TABLET 24-26 MG	T4	ST; QL (186 EA per 31 days)
ENTRESTO ORAL TABLET 49-51 MG	T4	ST; QL (93 EA per 31 days)
ENTRESTO ORAL TABLET 97-103 MG	T4	ST; QL (62 EA per 31 days)
ENTRESTO SPRINKLE	T3	PA; QL (248 EA per 31 days)
eplerenone	T2	
ethacrynic acid	T2	
EXFORGE	T4	
EXFORGE HCT	T4	
ezetimibe	T2	
ezetimibe-simvastatin	T3	QL (31 EA per 31 days)
felodipine	T2	
fenofibrate micronized oral capsule 130 mg, 134 mg, 200 mg, 43 mg, 67 mg	T2	
fenofibrate nanocrystallized	T2	
fenofibrate oral capsule	T4	
fenofibrate oral tablet 120 mg, 40 mg	T4	
fenofibrate oral tablet 160 mg, 54 mg	T2	
fenofibric acid (choline)	T3	
FILSPARI	T5	PA; QL (31 EA per 31 days)
flecainide	T2	
FLOLIPID	T4	PA
fluvastatin oral capsule	T1	
fluvastatin oral tablet extended release 24 hr	T3	
fondaparinux subcutaneous syringe 10 mg/0.8 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml	T5	
fondaparinux subcutaneous syringe 2.5 mg/0.5 ml	T4	
fosinopril	T1	
fosinopril-hydrochlorothiazide	T1	
FRAGMIN SUBCUTANEOUS SOLUTION 25,000 ANTI-XA UNIT/ML	T5	
FRAGMIN SUBCUTANEOUS SYRINGE 10,000 ANTI-XA UNIT/ML, 12,500 ANTI-XA UNIT/0.5 ML, 15,000 ANTI-XA UNIT/0.6 ML, 18,000 ANTI-XA UNIT/0.72 ML, 5,000 ANTI-XA UNIT/0.2 ML, 7,500 ANTI-XA UNIT/0.3 ML	T5	
FRAGMIN SUBCUTANEOUS SYRINGE 2,500 ANTI-XA UNIT/0.2 ML	T4	
FUROSCIX	T5	PA; QL (8 EA per 30 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
furosemide injection solution	T2	
furosemide oral solution 10 mg/ml, 40 mg/5 ml (8 mg/ml)	T2	
furosemide oral tablet	T1	
gemfibrozil	T1	
guanfacine oral tablet	T2	
HEMICLOR	T4	QL (248 EA per 31 days)
heparin (porcine) injection solution	T2	PA-BvD
hydralazine oral	T1	
hydrochlorothiazide	T1	
HYZAAR	T4	
icosapent ethyl oral capsule 0.5 gram	T4	QL (248 EA per 31 days)
icosapent ethyl oral capsule 1 gram	T4	QL (124 EA per 31 days)
indapamide	T1	
INDERAL LA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 60 MG, 80 MG	T4	
INDERAL LA ORAL CAPSULE,EXTENDED RELEASE 24 HR 160 MG	T5	
INNOPRAN XL	T5	
INSPRA	T4	
INZIRQO	T4	QL (310 ML per 31 days)
irbesartan	T1	QL (31 EA per 31 days)
irbesartan-hydrochlorothiazide	T1	QL (31 EA per 31 days)
ISORDIL	T5	
ISORDIL TITRADOSE ORAL TABLET 5 MG	T4	
isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 5 mg	T2	
isosorbide dinitrate oral tablet 40 mg	T4	
isosorbide mononitrate	T1	
isosorbide-hydralazine	T4	
isradipine	T2	
ivabradine oral tablet 5 mg	T4	PA; QL (93 EA per 31 days)
ivabradine oral tablet 7.5 mg	T4	PA; QL (62 EA per 31 days)
JANTOVEN	T1	
JUXTAPID ORAL CAPSULE 10 MG, 5 MG	T5	PA; QL (28 EA per 28 days)
JUXTAPID ORAL CAPSULE 20 MG, 30 MG	T5	PA; QL (56 EA per 28 days)
KATERZIA	T4	PA

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
KERENDIA	T4	PA; QL (31 EA per 31 days)
labetalol oral tablet 100 mg, 200 mg, 300 mg	T1	
LANOXIN ORAL TABLET 125 MCG (0.125 MG)	T4	QL (62 EA per 31 days)
LANOXIN ORAL TABLET 250 MCG (0.25 MG)	T4	QL (31 EA per 31 days)
LANOXIN ORAL TABLET 62.5 MCG (0.0625 MG)	T4	QL (124 EA per 31 days)
LASIX	T4	
LESCOL XL	T4	
LIPITOR	T4	
LIPOFEN	T4	
lisinopril	T1	
lisinopril-hydrochlorothiazide	T1	
LIVALO	T4	
LODOCO	T4	PA; QL (31 EA per 31 days)
LOPID	T4	
LOPRESSOR ORAL SOLUTION	T4	QL (1395 ML per 31 days)
LOPRESSOR ORAL TABLET	T4	
losartan oral tablet 100 mg	T1	QL (31 EA per 31 days)
losartan oral tablet 25 mg	T1	QL (93 EA per 31 days)
losartan oral tablet 50 mg	T1	QL (62 EA per 31 days)
losartan-hydrochlorothiazide	T1	
LOTENSIN ORAL TABLET 10 MG, 20 MG, 40 MG	T4	
lovastatin	T1	
LOVAZA	T3	PA; QL (124 EA per 31 days)
LOVENOX SUBCUTANEOUS SYRINGE 100 MG/ML	T5	
LOVENOX SUBCUTANEOUS SYRINGE 120 MG/0.8 ML, 150 MG/ML, 30 MG/0.3 ML, 40 MG/0.4 ML, 60 MG/0.6 ML, 80 MG/0.8 ML	T4	
MATZIM LA	T1	
methyldopa	T4	
metolazone	T2	
metoprolol succinate	T1	
metoprolol ta-hydrochlorothiaz	T1	
metoprolol tartrate oral	T1	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
metyrosine	T5	PA
mexiletine	T3	
MICARDIS HCT	T4	
minoxidil oral	T2	
moexipril	T1	
MULPLETA	T5	PA
MULTAQ	T3	
nadolol	T1	
nebivolol oral tablet 10 mg, 2.5 mg	T2	QL (93 EA per 31 days)
nebivolol oral tablet 20 mg	T2	QL (62 EA per 31 days)
nebivolol oral tablet 5 mg	T2	QL (217 EA per 31 days)
NEXICLON XR	T4	ST
NEXLETOL	T4	PA; QL (31 EA per 31 days)
NEXLIZET	T4	PA; QL (31 EA per 31 days)
niacin oral tablet 500 mg	T4	
niacin oral tablet extended release 24 hr 1,000 mg, 750 mg	T3	
niacin oral tablet extended release 24 hr 500 mg	T3	QL (31 EA per 31 days)
NIACOR	T4	
nicardipine oral capsule 20 mg	T2	
nicardipine oral capsule 30 mg	T4	
nifedipine	T2	
nimodipine oral capsule	T2	
nimodipine oral solution	T5	
nisoldipine	T2	
NITRO-BID	T2	
NITRO-DUR TRANSDERMAL PATCH 24 HOUR 0.1 MG/HR, 0.2 MG/HR, 0.4 MG/HR, 0.6 MG/HR	T4	
NITRO-DUR TRANSDERMAL PATCH 24 HOUR 0.3 MG/HR, 0.8 MG/HR	T5	
nitroglycerin sublingual	T2	
nitroglycerin transdermal patch 24 hour	T2	
nitroglycerin translingual	T3	
NITROLINGUAL	T4	
NITROSTAT	T4	
NORLIQVA	T4	PA; QL (300 ML per 30 days)
NORPACE	T4	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
NORPACE CR	T4	
NORVASC	T4	
NYMALIZE ORAL SYRINGE 60 MG/10 ML	T5	
olmesartan oral tablet 20 mg, 40 mg	T1	QL (31 EA per 31 days)
olmesartan oral tablet 5 mg	T1	QL (93 EA per 31 days)
olmesartan-amlodipin-hcthiazid	T3	
olmesartan-hydrochlorothiazide	T1	QL (31 EA per 31 days)
omega-3 acid ethyl esters	T3	QL (124 EA per 31 days)
ORENITRAM MONTH 1 TITRATION KT	T5	PA; QL (336 EA per 365 days)
ORENITRAM MONTH 2 TITRATION KT	T5	PA; QL (672 EA per 365 days)
ORENITRAM MONTH 3 TITRATION KT	T5	PA; QL (504 EA per 365 days)
ORENITRAM ORAL TABLET EXTENDED RELEASE 0.125 MG	T4	PA; QL (93 EA per 31 days)
ORENITRAM ORAL TABLET EXTENDED RELEASE 0.25 MG, 1 MG	T5	PA; QL (186 EA per 31 days)
ORENITRAM ORAL TABLET EXTENDED RELEASE 2.5 MG	T5	PA; QL (521 EA per 31 days)
ORENITRAM ORAL TABLET EXTENDED RELEASE 5 MG	T5	PA; QL (261 EA per 31 days)
PACERONE ORAL TABLET 100 MG, 200 MG, 400 MG	T2	
pentoxifylline	T2	
perindopril erbumine	T1	
phenoxybenzamine	T5	PA
pindolol	T1	
pitavastatin calcium	T3	
PLAVIX ORAL TABLET 75 MG	T4	
PRADAXA ORAL CAPSULE 110 MG	T4	QL (124 EA per 31 days)
PRADAXA ORAL CAPSULE 150 MG, 75 MG	T4	QL (62 EA per 31 days)
PRADAXA ORAL PELLETS IN PACKET 110 MG, 30 MG, 40 MG, 50 MG	T5	QL (120 EA per 30 days)
PRADAXA ORAL PELLETS IN PACKET 150 MG, 20 MG	T5	QL (60 EA per 30 days)
PRALUENT PEN	T4	PA; QL (2 ML per 28 days)
prasugrel hcl	T3	
pravastatin	T1	
prazosin	T1	
PREVALITE ORAL POWDER IN PACKET	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
PROCARDIA XL	T4	
PROMACTA ORAL POWDER IN PACKET 12.5 MG	T5	PA; QL (372 EA per 31 days)
PROMACTA ORAL POWDER IN PACKET 25 MG	T5	PA; QL (31 EA per 31 days)
PROMACTA ORAL TABLET 12.5 MG, 25 MG	T5	PA; QL (31 EA per 31 days)
PROMACTA ORAL TABLET 50 MG, 75 MG	T5	PA; QL (62 EA per 31 days)
propafenone	T2	
propranolol oral capsule,extended release 24 hr	T2	
propranolol oral solution	T1	
propranolol oral tablet	T1	
QBRELIS	T5	
QUESTRAN LIGHT	T4	
QUESTRAN ORAL POWDER	T4	
quinapril	T1	
quinapril-hydrochlorothiazide	T1	
quinidine gluconate oral	T2	
quinidine sulfate oral tablet	T2	
ramipril	T1	
ranolazine	T3	QL (62 EA per 31 days)
REPATHA SURECLICK	T3	PA; QL (3 ML per 28 days)
REPATHA SYRINGE	T3	PA; QL (3 ML per 28 days)
rivaroxaban oral suspension for reconstitution	T4	QL (930 ML per 31 days)
rivaroxaban oral tablet	T4	QL (62 EA per 31 days)
rosuvastatin	T1	
sacubitril-valsartan oral tablet 24-26 mg	T2	QL (186 EA per 31 days)
sacubitril-valsartan oral tablet 49-51 mg	T2	QL (93 EA per 31 days)
sacubitril-valsartan oral tablet 97-103 mg	T2	QL (62 EA per 31 days)
SAVAYSA	T4	QL (31 EA per 31 days)
simvastatin	T1	
SOAANZ ORAL TABLET 40 MG	T4	ST
SOTALOL AF	T1	
sotalol oral	T1	
SOTYLIZE	T4	
spironolactone oral suspension	T4	
spironolactone oral tablet	T1	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
spironolacton-hydrochlorothiaz	T1	
SULAR ORAL TABLET EXTENDED RELEASE 24 HR 17 MG, 34 MG, 8.5 MG	T4	
TAVALISSE	T5	PA; QL (62 EA per 31 days)
TEKTURNA	T4	
telmisartan	T1	
telmisartan-amlodipine	T2	
telmisartan-hydrochlorothiazid	T1	
TENORETIC 100	T4	
TENORETIC 50	T4	
TENORMIN ORAL TABLET 25 MG	T4	
terazosin	T1	
TEZRULY	T4	PA; QL (620 ML per 31 days)
THALITONE	T4	
TIADYLT ER	T1	
TIAZAC	T4	
ticagrelor	T2	
TIKOSYN	T3	
timolol maleate oral	T1	
TOPROL XL	T4	
torsemide oral	T1	
trandolapril	T1	
trandolapril-verapamil	T2	
triamterene	T4	
triamterene-hydrochlorothiazid	T1	
TRIBENZOR	T4	
TRYNGOLZA	T5	PA; QL (0.8 ML per 28 days)
TRYVIO	T4	PA; QL (31 EA per 31 days)
UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 400 MCG, 600 MCG, 800 MCG	T5	PA; QL (62 EA per 31 days)
UPTRAVI ORAL TABLET 200 MCG	T5	PA; QL (224 EA per 28 days)
UPTRAVI ORAL TABLETS,DOSE PACK	T5	PA; QL (400 EA per 365 days)
valsartan oral solution	T5	QL (2480 ML per 31 days)
valsartan oral tablet 160 mg, 40 mg, 80 mg	T1	QL (62 EA per 31 days)
valsartan oral tablet 320 mg	T1	QL (31 EA per 31 days)
valsartan-hydrochlorothiazide	T1	QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
VANRAFIA	T5	PA; QL (31 EA per 31 days)
VASCEPA ORAL CAPSULE 0.5 GRAM	T4	QL (248 EA per 31 days)
VASCEPA ORAL CAPSULE 1 GRAM	T4	QL (124 EA per 31 days)
VASERETIC	T4	
VASOTEC ORAL TABLET 10 MG	T5	
VASOTEC ORAL TABLET 2.5 MG, 20 MG, 5 MG	T4	
VECAMYL	T5	
verapamil oral	T2	
VERQUVO	T4	PA; QL (31 EA per 31 days)
VYNDAMAX	T5	PA; QL (31 EA per 31 days)
VYNDAQEL	T5	PA; QL (124 EA per 31 days)
VYTORIN 10-10	T4	QL (31 EA per 31 days)
VYTORIN 10-20	T4	QL (31 EA per 31 days)
VYTORIN 10-40	T4	QL (31 EA per 31 days)
VYTORIN 10-80	T4	QL (31 EA per 31 days)
warfarin	T1	
WELCHOL	T4	
XARELTO DVT-PE TREAT 30D START	T3	QL (51 EA per 30 days)
XARELTO ORAL SUSPENSION FOR RECONSTITUTION	T3	QL (930 ML per 31 days)
XARELTO ORAL TABLET 10 MG, 20 MG	T3	QL (31 EA per 31 days)
XARELTO ORAL TABLET 15 MG	T3	QL (52 EA per 31 days)
XARELTO ORAL TABLET 2.5 MG	T3	QL (62 EA per 31 days)
ZESTORETIC	T4	
ZESTRIL	T4	
ZETIA	T4	
ZOCOR ORAL TABLET 10 MG, 20 MG, 40 MG	T4	
ZYPITAMAG	T4	
Dermatologicals/Topical Therapy		
ABSORICA	T5	
ABSORICA LD	T5	
ACANYA TOPICAL GEL WITH PUMP	T4	
ACCUTANE ORAL CAPSULE 10 MG, 20 MG, 40 MG	T2	
acitretin	T4	PA

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
acyclovir topical cream	T3	QL (5 GM per 28 days)
acyclovir topical ointment	T1	QL (30 GM per 30 days)
ACZONE	T4	QL (90 GM per 28 days)
adapalene topical cream	T2	PA
adapalene topical gel 0.3 %	T2	PA
adapalene topical swab	T2	PA
adapalene-benzoyl peroxide	T4	PA
ADBRY	T5	PA; QL (4 ML per 28 days)
AKLIEF	T4	PA
ALA-CORT TOPICAL CREAM 1 %	T1	
ALA-SCALP	T4	
alclometasone	T1	
ALTRENO	T4	PA; QL (45 GM per 28 days)
amcinonide topical cream	T2	
amcinonide topical ointment	T2	
ammonium lactate	T2	
AMNESTEEM	T2	
AMZEEQ	T4	QL (30 GM per 28 days)
ANALPRAM-HC TOPICAL	T4	
ANZUPGO	T5	PA; QL (60 GM per 30 days)
ARAZLO	T4	PA; QL (45 GM per 28 days)
ATRALIN	T4	PA; QL (45 GM per 28 days)
azelaic acid	T4	ST; QL (50 GM per 28 days)
AZELEX	T4	QL (50 GM per 28 days)
BENZAMYCIN	T4	
betamethasone dipropionate	T1	
betamethasone valerate topical cream	T2	
betamethasone valerate topical foam	T4	
betamethasone valerate topical lotion	T2	
betamethasone valerate topical ointment	T2	
betamethasone, augmented	T2	
BIMZELX AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 160 MG/ML	T5	PA; QL (1 ML per 28 days)
BIMZELX AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 320 MG/2 ML	T5	PA; QL (2 ML per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
BIMZELX SUBCUTANEOUS SYRINGE 160 MG/ML	T5	PA; QL (1 ML per 28 days)
BIMZELX SUBCUTANEOUS SYRINGE 320 MG/2 ML	T5	PA; QL (2 ML per 28 days)
brimonidine topical	T4	ST
BRYHALI	T4	QL (100 GM per 28 days)
CABTREO	T4	PA; QL (50 GM per 28 days)
calcipotriene scalp	T2	QL (60 ML per 28 days)
calcipotriene topical cream	T2	QL (60 GM per 28 days)
calcipotriene topical foam	T5	ST; QL (120 GM per 28 days)
calcipotriene topical ointment	T2	QL (60 GM per 28 days)
calcipotriene-betamethasone topical ointment	T4	ST; QL (400 GM per 28 days)
calcipotriene-betamethasone topical suspension	T5	ST; QL (400 GM per 28 days)
calcitriol topical	T3	ST
CIBINQO	T5	PA; QL (31 EA per 31 days)
ciclopirox topical cream	T2	QL (90 GM per 28 days)
ciclopirox topical gel	T2	QL (45 GM per 28 days)
ciclopirox topical shampoo	T2	QL (120 ML per 28 days)
ciclopirox topical solution	T2	
ciclopirox topical suspension	T3	QL (60 ML per 28 days)
CLARAVIS	T2	
CLEOCIN T TOPICAL LOTION	T4	QL (60 ML per 28 days)
CLINDACIN	T2	QL (100 GM per 28 days)
CLINDACIN ETZ TOPICAL SWAB	T4	
CLINDAGEL	T5	QL (75 ML per 28 days)
clindamycin phosphate topical foam	T2	QL (100 GM per 28 days)
clindamycin phosphate topical gel	T2	QL (60 GM per 28 days)
clindamycin phosphate topical gel, once daily	T4	QL (75 ML per 28 days)
clindamycin phosphate topical lotion	T2	QL (60 ML per 28 days)
clindamycin phosphate topical solution	T2	QL (60 ML per 28 days)
clindamycin phosphate topical swab	T2	
clindamycin-benzoyl peroxide topical gel	T2	
clindamycin-benzoyl peroxide topical gel with pump 1.2 %(1 % base) -3.75 %	T4	
clindamycin-benzoyl peroxide topical gel with pump 1.2-2.5 %	T2	
clindamycin-tretinoin	T2	PA; QL (60 GM per 28 days)
clobetasol scalp	T2	QL (50 ML per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
clobetasol topical cream 0.05 %	T3	QL (60 GM per 28 days)
clobetasol topical foam	T2	QL (100 GM per 28 days)
clobetasol topical gel	T2	QL (60 GM per 28 days)
clobetasol topical lotion	T2	QL (118 ML per 28 days)
clobetasol topical ointment	T3	QL (60 GM per 28 days)
clobetasol topical shampoo	T2	QL (118 ML per 28 days)
clobetasol topical spray,non-aerosol	T2	QL (125 ML per 28 days)
clobetasol-emollient topical cream	T3	QL (60 GM per 28 days)
clobetasol-emollient topical foam	T3	QL (100 GM per 28 days)
CLOBEX TOPICAL LOTION	T4	QL (118 ML per 28 days)
CLOBEX TOPICAL SHAMPOO	T4	QL (118 ML per 28 days)
CLOBEX TOPICAL SPRAY,NON-AEROSOL	T4	QL (125 ML per 28 days)
clocortolone pivalate	T4	
CLODAN	T2	QL (118 ML per 28 days)
clotrimazole topical cream	T2	QL (45 GM per 28 days)
clotrimazole topical solution	T2	QL (30 ML per 28 days)
clotrimazole-betamethasone topical cream	T2	QL (45 GM per 28 days)
clotrimazole-betamethasone topical lotion	T2	QL (60 ML per 28 days)
CONDYLOX TOPICAL GEL	T4	
CORDRAN TAPE LARGE ROLL	T4	
COSENTYX (2 SYRINGES)	T5	PA; QL (2 ML per 28 days)
COSENTYX PEN (2 PENS)	T5	PA; QL (2 ML per 28 days)
COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML	T5	PA; QL (0.5 ML per 28 days)
COSENTYX UNOREADY PEN	T5	PA; QL (2 ML per 28 days)
CROTAN	T4	
dapsone topical gel 5 %	T4	QL (90 GM per 28 days)
dapsone topical gel with pump	T4	QL (90 GM per 28 days)
DENAVIR	T4	QL (5 GM per 28 days)
DERMA-SMOOTHE/FS SCALP OIL	T4	QL (118.28 ML per 28 days)
desonide topical cream	T3	QL (60 GM per 28 days)
desonide topical gel	T3	QL (60 GM per 28 days)
desonide topical lotion	T3	QL (118 ML per 28 days)
desonide topical ointment	T3	QL (60 GM per 28 days)
desoximetasone topical cream	T2	QL (100 GM per 28 days)
desoximetasone topical gel	T2	QL (60 GM per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
desoximetasone topical ointment 0.05 %	T4	QL (100 GM per 28 days)
desoximetasone topical ointment 0.25 %	T2	QL (100 GM per 28 days)
desoximetasone topical spray,non-aerosol	T2	QL (100 ML per 28 days)
diclofenac sodium topical gel 3 %	T4	PA; QL (100 GM per 28 days)
DIFFERIN TOPICAL CREAM	T4	PA
DIFFERIN TOPICAL GEL WITH PUMP	T4	PA
diflorasone	T4	QL (60 GM per 28 days)
DIPROLENE (AUGMENTED) TOPICAL OINTMENT	T4	
doxepin topical	T4	PA; QL (45 GM per 28 days)
DUOBRII	T5	PA; QL (200 GM per 28 days)
DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML	T5	PA; QL (2.28 ML per 28 days)
DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 300 MG/2 ML	T5	PA; QL (8 ML per 28 days)
DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML	T5	PA; QL (2.28 ML per 28 days)
DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 300 MG/2 ML	T5	PA; QL (8 ML per 28 days)
EBGLYSS PEN	T5	PA; QL (2 ML per 28 days)
EBGLYSS SYRINGE	T5	PA; QL (2 ML per 28 days)
econazole nitrate topical cream	T2	QL (85 GM per 28 days)
ELIDEL	T4	QL (100 GM per 28 days)
ELIMITE	T4	
ENSTILAR	T5	ST; QL (60 GM per 28 days)
EPIDUO FORTE	T4	PA
EPIDUO TOPICAL GEL WITH PUMP	T4	PA
EPSOLAY	T4	ST; QL (30 GM per 28 days)
ERTACZO	T4	ST; QL (60 GM per 28 days)
ERY PADS	T2	
erythromycin with ethanol topical gel	T2	QL (60 GM per 28 days)
erythromycin with ethanol topical solution	T2	QL (60 ML per 28 days)
erythromycin-benzoyl peroxide	T2	
EUCRISA	T5	PA; QL (60 GM per 30 days)
EXELDERM TOPICAL CREAM	T4	ST; QL (60 GM per 28 days)
EXELDERM TOPICAL SOLUTION	T4	ST; QL (30 ML per 28 days)
FABIOR	T4	PA; QL (100 GM per 28 days)
FILSUVEZ	T5	PA

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
FINACEA TOPICAL FOAM	T4	ST; QL (50 GM per 28 days)
fluocinolone and shower cap	T2	QL (118.28 ML per 28 days)
fluocinolone topical cream 0.01 %	T2	QL (60 GM per 28 days)
fluocinolone topical cream 0.025 %	T2	QL (120 GM per 28 days)
fluocinolone topical ointment	T2	QL (120 GM per 28 days)
fluocinolone topical solution	T2	QL (90 ML per 28 days)
fluocinonide topical cream 0.05 %	T2	QL (60 GM per 28 days)
fluocinonide topical cream 0.1 %	T4	QL (120 GM per 28 days)
fluocinonide topical gel	T2	QL (60 GM per 28 days)
fluocinonide topical ointment	T2	QL (60 GM per 28 days)
fluocinonide topical solution	T2	QL (60 ML per 28 days)
fluocinonide-emollient	T2	QL (60 GM per 28 days)
fluorouracil topical cream 0.5 %	T5	PA-NS
fluorouracil topical cream 5 %	T2	
fluorouracil topical solution	T2	
flurandrenolide topical lotion	T3	QL (120 ML per 28 days)
fluticasone propionate topical cream	T2	
fluticasone propionate topical lotion	T4	QL (120 ML per 28 days)
fluticasone propionate topical ointment	T2	
gentamicin topical	T2	QL (60 GM per 28 days)
halcinonide topical cream	T4	QL (60 GM per 28 days)
halcinonide topical solution	T4	QL (120 ML per 28 days)
halobetasol propionate topical cream	T2	QL (50 GM per 28 days)
halobetasol propionate topical foam	T4	QL (200 GM per 28 days)
halobetasol propionate topical ointment	T2	QL (50 GM per 28 days)
HALOG TOPICAL CREAM	T4	QL (60 GM per 28 days)
hydrocortisone butyrate topical cream	T2	QL (45 GM per 28 days)
hydrocortisone butyrate topical lotion	T4	QL (118 ML per 28 days)
hydrocortisone butyrate topical ointment	T2	QL (45 GM per 28 days)
hydrocortisone butyrate topical solution	T2	QL (60 ML per 28 days)
hydrocortisone topical cream 1 %	T1	
hydrocortisone topical lotion 2 %	T4	QL (118.4 ML per 28 days)
hydrocortisone topical lotion 2.5 %	T1	QL (118 ML per 28 days)
hydrocortisone topical ointment 1 %, 2.5 %	T1	
hydrocortisone topical solution	T4	
hydrocortisone valerate	T2	QL (60 GM per 28 days)
HYFTOR	T5	PA; QL (30 GM per 30 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ILUMYA	T5	PA; QL (1 ML per 84 days)
imiquimod topical cream in metered-dose pump	T4	
imiquimod topical cream in packet 5 %	T2	
isotretinoin	T2	
ivermectin topical cream	T4	ST; QL (45 GM per 28 days)
JUBLIA	T5	QL (8 ML per 28 days)
ketoconazole topical cream	T2	QL (60 GM per 28 days)
ketoconazole topical foam	T4	QL (100 GM per 28 days)
ketoconazole topical shampoo	T2	QL (120 ML per 28 days)
KETODAN	T2	ST; QL (100 GM per 28 days)
KLARON	T4	
LEXETTE	T4	QL (200 GM per 28 days)
lidocaine hcl mucous membrane solution 4 % (40 mg/ml)	T2	PA; QL (50 ML per 28 days)
lidocaine topical adhesive patch,medicated 5 %	T2	PA; QL (93 EA per 31 days)
lidocaine topical ointment	T2	PA; QL (50 GM per 28 days)
LIDOCAINE VISCOUS	T2	
lidocaine-prilocaine topical cream	T2	PA; QL (30 GM per 28 days)
LIDOCAN III	T4	PA; QL (93 EA per 31 days)
luliconazole	T4	QL (60 GM per 28 days)
LUZU	T4	QL (60 GM per 28 days)
malathion	T2	
methoxsalen	T5	
METROCREAM	T4	ST
metronidazole topical cream	T2	
metronidazole topical gel 0.75 %	T2	
metronidazole topical gel 1 %	T1	
metronidazole topical lotion	T2	
MIRVASO	T4	ST
mometasone topical	T2	
mupirocin	T2	
mupirocin calcium	T4	ST
naftifine topical cream 1 %	T4	ST; QL (90 GM per 28 days)
naftifine topical cream 2 %	T4	ST; QL (60 GM per 28 days)
naftifine topical gel	T4	ST; QL (60 GM per 28 days)
NAFTIN TOPICAL GEL 2 %	T4	ST; QL (60 GM per 28 days)
NATROBA	T4	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
NEO-SYNALAR	T4	
NEUAC	T2	
NORITATE	T5	ST
NYAMYC	T2	QL (60 GM per 28 days)
nystatin topical cream	T2	QL (30 GM per 28 days)
nystatin topical ointment	T2	QL (30 GM per 28 days)
nystatin topical powder	T2	QL (60 GM per 28 days)
nystatin-triamcinolone	T3	QL (60 GM per 28 days)
NYSTOP	T2	QL (60 GM per 28 days)
ONEXTON TOPICAL GEL WITH PUMP	T4	
OPZELURA	T5	PA; QL (240 GM per 28 days)
OTULFI SUBCUTANEOUS SYRINGE 45 MG/0.5 ML	T4	PA; QL (0.5 ML per 84 days)
OTULFI SUBCUTANEOUS SYRINGE 90 MG/ML	T5	PA; QL (1 ML per 56 days)
OVIDE	T4	
oxiconazole	T4	ST; QL (90 GM per 28 days)
OXISTAT TOPICAL LOTION	T4	ST; QL (60 ML per 28 days)
PANRETIN	T5	PA-NS
penciclovir	T3	QL (5 GM per 28 days)
permethrin	T2	
pimecrolimus	T3	QL (100 GM per 28 days)
podofilox topical gel	T4	
podofilox topical solution	T2	
PRAMOSONE TOPICAL LOTION 2.5-1 %	T4	
PRUDOXIN	T4	PA; QL (45 GM per 28 days)
PRURADIK	T4	
PYZCHIVA SUBCUTANEOUS SOLUTION	T4	PA; QL (0.5 ML per 84 days)
PYZCHIVA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML	T4	PA; QL (0.5 ML per 84 days)
PYZCHIVA SUBCUTANEOUS SYRINGE 90 MG/ML	T5	PA; QL (1 ML per 56 days)
QBREXZA	T4	QL (30 EA per 30 days)
RETIN-A	T4	PA; QL (45 GM per 28 days)
RETIN-A MICRO	T4	PA; QL (45 GM per 28 days)
RETIN-A MICRO PUMP TOPICAL GEL WITH PUMP 0.06 %, 0.08 %	T4	PA; QL (50 GM per 28 days)
RHOFADE	T4	ST

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
SANTYL	T4	QL (180 GM per 30 days)
SELARSDI SUBCUTANEOUS SYRINGE 45 MG/0.5 ML	T4	PA; QL (0.5 ML per 84 days)
SELARSDI SUBCUTANEOUS SYRINGE 90 MG/ML	T5	PA; QL (1 ML per 56 days)
selenium sulfide topical lotion	T1	
SILIQ	T5	PA; QL (6 ML per 28 days)
SILVADENE	T4	
silver sulfadiazine	T1	
SKYRIZI SUBCUTANEOUS PEN INJECTOR	T5	PA; QL (1 ML per 84 days)
SKYRIZI SUBCUTANEOUS SYRINGE	T5	PA; QL (1 ML per 84 days)
SOOLANTRA	T4	ST; QL (45 GM per 28 days)
SORILUX	T5	ST; QL (120 GM per 28 days)
SOTYKTU	T5	PA; QL (31 EA per 31 days)
SPEVIGO SUBCUTANEOUS	T5	PA; QL (2 ML per 28 days)
spinosad	T4	
SSD	T4	
STELARA SUBCUTANEOUS SOLUTION	T5	PA; QL (0.5 ML per 84 days)
STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML	T5	PA; QL (0.5 ML per 84 days)
STELARA SUBCUTANEOUS SYRINGE 90 MG/ML	T5	PA; QL (1 ML per 56 days)
STEQEYMA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML	T3	PA; QL (0.5 ML per 84 days)
STEQEYMA SUBCUTANEOUS SYRINGE 90 MG/ML	T5	PA; QL (1 ML per 56 days)
sulfacetamide sodium (acne)	T1	
SULFAMYLON TOPICAL CREAM	T3	
SYNALAR TOPICAL CREAM	T4	QL (120 GM per 28 days)
SYNALAR TOPICAL OINTMENT	T4	QL (120 GM per 28 days)
TACLONEX TOPICAL SUSPENSION	T5	ST; QL (400 GM per 28 days)
tacrolimus topical	T2	QL (100 GM per 28 days)
TALTZ AUTOINJECTOR	T5	PA; QL (1 ML per 28 days)
TALTZ SYRINGE SUBCUTANEOUS SYRINGE 20 MG/0.25 ML	T5	PA; QL (0.25 ML per 28 days)
TALTZ SYRINGE SUBCUTANEOUS SYRINGE 40 MG/0.5 ML	T5	PA; QL (0.5 ML per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
TALTZ SYRINGE SUBCUTANEOUS SYRINGE 80 MG/ML	T5	PA; QL (1 ML per 28 days)
tavaborole	T4	QL (10 ML per 28 days)
tazarotene topical cream	T4	PA; QL (60 GM per 28 days)
tazarotene topical foam	T4	PA; QL (100 GM per 28 days)
tazarotene topical gel 0.05 %	T5	PA; QL (100 GM per 28 days)
tazarotene topical gel 0.1 %	T4	PA; QL (100 GM per 28 days)
TAZORAC TOPICAL CREAM	T4	PA; QL (60 GM per 28 days)
TAZORAC TOPICAL GEL	T4	PA; QL (100 GM per 28 days)
TEXACORT	T4	
TOPICORT TOPICAL OINTMENT 0.05 %	T4	QL (100 GM per 28 days)
TOPICORT TOPICAL SPRAY,NON-AEROSOL	T4	QL (100 ML per 28 days)
TOVET EMOLLIENT	T3	QL (100 GM per 28 days)
TREMFYA PEN INDUCTION PK-CROHN	T5	PA; QL (24 ML per 365 days)
TREMFYA PEN SUBCUTANEOUS PEN INJECTOR 200 MG/2 ML	T5	PA; QL (2 ML per 28 days)
TREMFYA SUBCUTANEOUS AUTO-INJECTOR	T5	PA; QL (1 ML per 56 days)
TREMFYA SUBCUTANEOUS SYRINGE 100 MG/ML	T5	PA; QL (1 ML per 56 days)
TREMFYA SUBCUTANEOUS SYRINGE 200 MG/2 ML	T5	PA; QL (2 ML per 28 days)
tretinoin microspheres topical gel	T4	PA; QL (50 GM per 28 days)
tretinoin microspheres topical gel with pump 0.08 %	T4	PA; QL (50 GM per 28 days)
tretinoin topical cream	T2	PA; QL (45 GM per 28 days)
tretinoin topical gel 0.01 %, 0.025 %	T2	PA; QL (45 GM per 28 days)
tretinoin topical gel 0.05 %	T3	PA; QL (45 GM per 28 days)
triamcinolone acetonide topical cream	T1	
triamcinolone acetonide topical lotion	T1	
triamcinolone acetonide topical ointment 0.025 %, 0.1 %, 0.5 %	T1	
triamcinolone acetonide topical ointment 0.05 %	T4	
TRIDACAINE II	T4	PA; QL (93 EA per 31 days)
TRIDERM TOPICAL CREAM 0.5 %	T1	
TWYNEO	T4	PA; QL (30 GM per 28 days)
ULTRAVATE TOPICAL LOTION	T4	QL (60 ML per 28 days)
ustekinumab subcutaneous solution	T5	PA; QL (0.5 ML per 84 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ustekinumab subcutaneous syringe 45 mg/0.5 ml	T5	PA; QL (0.5 ML per 84 days)
ustekinumab subcutaneous syringe 90 mg/ml	T5	PA; QL (1 ML per 56 days)
ustekinumab-aekn subcutaneous syringe 45 mg/0.5 ml	T4	PA; QL (0.5 ML per 84 days)
ustekinumab-aekn subcutaneous syringe 90 mg/ml	T5	PA; QL (1 ML per 56 days)
ustekinumab-ttwe subcutaneous syringe 45 mg/0.5 ml	T4	PA; QL (0.5 ML per 84 days)
ustekinumab-ttwe subcutaneous syringe 90 mg/ml	T5	PA; QL (1 ML per 56 days)
VALCHLOR	T5	PA-NS
VANOS	T5	QL (120 GM per 28 days)
VECTICAL	T4	ST
VEREGEN	T5	QL (30 GM per 28 days)
VTAMA	T5	PA; QL (60 GM per 28 days)
WEZLANA SUBCUTANEOUS SOLUTION	T5	PA; QL (0.5 ML per 84 days)
WEZLANA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML	T5	PA; QL (0.5 ML per 84 days)
WEZLANA SUBCUTANEOUS SYRINGE 90 MG/ML	T5	PA; QL (1 ML per 56 days)
WINLEVI	T4	PA; QL (60 GM per 28 days)
XERESE	T5	
YESINTEK SUBCUTANEOUS SOLUTION	T3	PA; QL (0.5 ML per 84 days)
YESINTEK SUBCUTANEOUS SYRINGE 45 MG/0.5 ML	T3	PA; QL (0.5 ML per 84 days)
YESINTEK SUBCUTANEOUS SYRINGE 90 MG/ML	T5	PA; QL (1 ML per 56 days)
ZELSUVMI	T5	PA; QL (31 GM per 28 days)
ZENATANE	T2	
ZIANA	T4	PA; QL (60 GM per 28 days)
ZILXI	T4	ST; QL (30 GM per 28 days)
ZONALON	T4	PA; QL (30 GM per 28 days)
ZORYVE TOPICAL CREAM 0.15 %, 0.3 %	T4	PA; QL (60 GM per 28 days)
ZORYVE TOPICAL FOAM	T4	PA; QL (60 GM per 28 days)
ZOVIRAX TOPICAL CREAM	T4	QL (5 GM per 28 days)
ZOVIRAX TOPICAL OINTMENT	T4	QL (30 GM per 30 days)
ZTLIDO	T4	PA; QL (93 EA per 31 days)
ZYCLARA TOPICAL CREAM IN METERED-DOSE PUMP	T5	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
Diagnostics / Miscellaneous Agents		
acamprosate	T2	
AGRYLIN	T5	
anagrelide	T2	
ARALAST NP INTRAVENOUS RECON SOLN 1,000 MG	T5	PA
BUPHENYL	T5	PA
bupropion hcl (smoking deter)	T2	QL (62 EA per 31 days)
CARBAGLU	T5	PA
carglumic acid	T5	PA
CARNITOR ORAL	T4	PA-BvD
cevimeline	T4	
CHEMET	T4	
CLINIMIX 4.25%/D5W SULFIT FREE	T4	PA-BvD
CLINIMIX E 2.75%/D5W SULF FREE	T4	PA-BvD
CUVRIOR	T5	PA; QL (310 EA per 31 days)
d10 %-0.45 % sodium chloride	T2	
d2.5 %-0.45 % sodium chloride	T2	
d5 % and 0.9 % sodium chloride	T2	
d5 %-0.45 % sodium chloride	T2	
deferasirox oral granules in packet	T5	PA
deferasirox oral tablet 180 mg, 360 mg	T5	PA
deferasirox oral tablet 90 mg	T3	PA
deferasirox oral tablet, dispersible 125 mg	T3	PA
deferasirox oral tablet, dispersible 250 mg, 500 mg	T5	PA
deferiprone	T5	PA
dextrose 10 % and 0.2 % nacl	T2	
dextrose 10 % in water (d10w)	T2	
dextrose 5 % in water (d5w) intravenous parenteral solution	T2	
dextrose 5%-0.2 % sod chloride	T2	
disulfiram	T2	
droxidopa oral capsule 100 mg	T5	PA; QL (465 EA per 31 days)
droxidopa oral capsule 200 mg, 300 mg	T5	PA; QL (186 EA per 31 days)
DUVYZAT	T5	PA; QL (420 ML per 35 days)
EMPAVELI	T5	PA; QL (160 ML per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ENDARI	T5	PA; QL (180 EA per 30 days)
EVOXAC	T4	
EXJADE	T5	PA
FABHALTA	T5	PA; QL (62 EA per 31 days)
FERRIPROX (2 TIMES A DAY)	T5	PA
FERRIPROX ORAL SOLUTION	T5	PA
FERRIPROX ORAL TABLET 1,000 MG	T5	PA
GLASSIA	T5	PA
glutamine (sickle cell)	T5	PA; QL (180 EA per 30 days)
INCRELEX	T5	PA
JADENU	T5	PA
JADENU SPRINKLE	T5	PA
JOENJA	T5	PA; QL (60 EA per 30 days)
KIONEX (WITH SORBITOL)	T2	
levocarnitine (with sugar)	T2	PA-BvD
levocarnitine oral tablet	T2	PA-BvD
LITFULO	T5	PA; QL (28 EA per 28 days)
LITHOSTAT	T4	
LOKELMA	T3	PA; QL (93 EA per 31 days)
midodrine	T2	
NICOTROL NS	T4	
nitisinone	T5	PA
NITYR	T5	PA
NORTHERA ORAL CAPSULE 100 MG	T5	PA; QL (465 EA per 31 days)
NORTHERA ORAL CAPSULE 200 MG, 300 MG	T5	PA; QL (186 EA per 31 days)
OLPRUVA ORAL PELLETS IN PACKET 2 GRAM, 3 GRAM	T5	PA; QL (186 EA per 31 days)
OLPRUVA ORAL PELLETS IN PACKET 4 GRAM	T5	PA; QL (155 EA per 31 days)
OLPRUVA ORAL PELLETS IN PACKET 5 GRAM	T5	PA; QL (124 EA per 31 days)
OLPRUVA ORAL PELLETS IN PACKET 6 GRAM	T5	PA; QL (93 EA per 31 days)
OLPRUVA ORAL PELLETS IN PACKET 6.67 GRAM	T5	PA; QL (62 EA per 31 days)
ORFADIN	T5	PA
PHEBURANE	T5	PA; QL (620 GM per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
pilocarpine hcl oral	T2	
PROLASTIN-C INTRAVENOUS SOLUTION	T5	PA
PYRUKYND ORAL TABLET 20 MG, 5 MG (4-WEEK PACK), 50 MG	T5	PA; QL (56 EA per 28 days)
PYRUKYND ORAL TABLET 5 MG	T5	PA; QL (14 EA per 365 days)
PYRUKYND ORAL TABLETS,DOSE PACK	T5	PA; QL (28 EA per 365 days)
RAVICTI	T5	PA
REVCOVI	T5	
REZDIFFRA	T5	PA; QL (31 EA per 31 days)
riluzole	T4	
risedronate oral tablet 30 mg	T5	
SALAGEN (PILOCARPINE)	T4	
sodium chloride 0.9 % intravenous parenteral solution	T2	
sodium chloride irrigation	T2	
sodium phenylbutyrate	T5	PA
sodium polystyrene sulfonate oral powder	T2	
SOHONOS ORAL CAPSULE 1 MG, 1.5 MG, 2.5 MG, 5 MG	T5	PA; QL (31 EA per 31 days)
SOHONOS ORAL CAPSULE 10 MG	T5	PA; QL (62 EA per 31 days)
SPS (WITH SORBITOL) ORAL	T2	
SYPRINE	T5	QL (248 EA per 31 days)
TAVNEOS	T5	PA; QL (186 EA per 31 days)
THIOLA	T5	PA
THIOLA EC	T5	PA
TIGLUTIK	T5	PA
tiopronin	T5	PA
trientine oral capsule 250 mg	T5	QL (248 EA per 31 days)
trientine oral capsule 500 mg	T5	PA; QL (124 EA per 31 days)
varenicline tartrate oral tablet	T4	QL (60 EA per 30 days)
varenicline tartrate oral tablets,dose pack	T4	QL (106 EA per 365 days)
VELTASSA ORAL POWDER IN PACKET 1 GRAM	T5	PA; QL (120 EA per 30 days)
VELTASSA ORAL POWDER IN PACKET 16.8 GRAM, 25.2 GRAM	T5	PA; QL (30 EA per 30 days)
VELTASSA ORAL POWDER IN PACKET 8.4 GRAM	T4	PA; QL (30 EA per 30 days)
VENXXIVA	T5	PA

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
VOYDEYA	T5	PA; QL (180 EA per 30 days)
VYKAT XR ORAL TABLET EXTENDED RELEASE 24 HR 150 MG	T5	PA; QL (93 EA per 31 days)
VYKAT XR ORAL TABLET EXTENDED RELEASE 24 HR 25 MG	T5	PA; QL (124 EA per 31 days)
VYKAT XR ORAL TABLET EXTENDED RELEASE 24 HR 75 MG	T5	PA; QL (217 EA per 31 days)
WEGOVY SUBCUTANEOUS PEN INJECTOR 0.25 MG/0.5 ML, 0.5 MG/0.5 ML, 1 MG/0.5 ML	T5	PA; QL (2 ML per 28 days)
WEGOVY SUBCUTANEOUS PEN INJECTOR 1.7 MG/0.75 ML, 2.4 MG/0.75 ML	T5	PA; QL (3 ML per 28 days)
ZEMAIRA INTRAVENOUS RECON SOLN 1,000 MG	T5	PA
ZEPBOUND SUBCUTANEOUS PEN INJECTOR 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 5 MG/0.5 ML	T4	PA; QL (2 ML per 28 days)
ZEPBOUND SUBCUTANEOUS PEN INJECTOR 2.5 MG/0.5 ML, 7.5 MG/0.5 ML	T5	PA; QL (2 ML per 28 days)
Ear, Nose / Throat Medications		
acetic acid otic (ear)	T2	
azelastine nasal spray,non-aerosol 137 mcg (0.1 %)	T2	QL (30 ML per 25 days)
chlorhexidine gluconate mucous membrane	T1	
CIPRO HC	T4	
ciprofloxacin hcl otic (ear)	T2	
ciprofloxacin-dexamethasone	T3	
DERMOTIC OIL	T4	
FLAC OTIC OIL	T2	
fluocinolone acetonide oil	T2	
hydrocortisone-acetic acid	T2	
ipratropium bromide nasal spray,non-aerosol 21 mcg (0.03 %)	T1	QL (30 ML per 28 days)
ipratropium bromide nasal spray,non-aerosol 42 mcg (0.06 %)	T1	QL (15 ML per 28 days)
KOURZEQ	T2	
neomycin-polymyxin-hc otic (ear)	T2	
ofloxacin otic (ear)	T2	
olopatadine nasal	T2	QL (30.5 GM per 30 days)
PERIOGARD	T1	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
triamcinolone acetonide dental	T2	
Endocrine/Diabetes		
acarbose	T1	QL (93 EA per 31 days)
ACTHAR	T5	PA
ACTHAR SELFJECT	T5	PA
ACTOPLUS MET	T4	QL (93 EA per 31 days)
ACTOS	T4	QL (31 EA per 31 days)
ADMELOG SOLOSTAR U-100 INSULIN	T4	ST
ADMELOG U-100 INSULIN LISPRO	T4	ST
AFREZZA INHALATION CARTRIDGE WITH INHALER 12 UNIT, 4 UNIT (90)/ 8 UNIT (90), 4 UNIT/8 UNIT/ 12 UNIT (60), 8 UNIT (90)/ 12 UNIT (90)	T5	ST
AFREZZA INHALATION CARTRIDGE WITH INHALER 4 UNIT, 8 UNIT	T4	ST
AGAMREE	T5	PA; QL (300 ML per 40 days)
ALCOHOL PADS	T2	PA
ALKINDI SPRINKLE ORAL CAPSULE, SPRINKLE 0.5 MG	T4	PA
ALKINDI SPRINKLE ORAL CAPSULE, SPRINKLE 1 MG, 2 MG, 5 MG	T5	PA
alogliptin	T4	PA; QL (31 EA per 31 days)
alogliptin-metformin	T4	PA; QL (62 EA per 31 days)
alogliptin-pioglitazone	T4	PA; QL (31 EA per 31 days)
APIDRA SOLOSTAR U-100 INSULIN	T4	ST
APIDRA U-100 INSULIN	T4	ST
AVEED	T4	PA
BAQSIMI	T4	
BASAGLAR KWIKPEN U-100 INSULIN	T4	
BASAGLAR TEMPO PEN(U-100)INSLN	T4	
cabergoline	T2	
calcitonin (salmon) nasal	T2	PA-BvD
calcitriol oral capsule	T2	PA-BvD
calcitriol oral solution	T3	PA-BvD
CERDELGA	T5	PA; QL (62 EA per 31 days)
cinacalcet oral tablet 30 mg, 60 mg	T3	PA-BvD; QL (62 EA per 31 days)
cinacalcet oral tablet 90 mg	T3	PA-BvD; QL (124 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
CORTEF	T4	
CORTROPHIN GEL	T5	PA
CRENESSITY ORAL CAPSULE 100 MG	T5	PA; QL (124 EA per 31 days)
CRENESSITY ORAL CAPSULE 25 MG, 50 MG	T5	PA; QL (62 EA per 31 days)
CRENESSITY ORAL SOLUTION	T5	PA; QL (124 ML per 31 days)
CYCLOSET	T4	
CYTOMEL	T4	
danazol	T2	
dapaglifloz propaned-metformin oral tablet, ir - er, biphasic 24hr 10-1,000 mg	T4	ST; QL (31 EA per 31 days)
dapaglifloz propaned-metformin oral tablet, ir - er, biphasic 24hr 5-1,000 mg	T4	ST; QL (62 EA per 31 days)
dapagliflozin propanediol	T3	QL (31 EA per 31 days)
DDAVP ORAL	T4	
deflazacort	T5	PA
DEPO-TESTOSTERONE	T4	PA
desmopressin nasal spray,non-aerosol 10 mcg/spray (0.1 ml)	T4	
desmopressin oral	T2	
dexamethasone oral solution	T1	
dexamethasone oral tablet	T1	
dexamethasone oral tablets,dose pack	T2	
diazoxide	T4	
doxercalciferol oral capsule 0.5 mcg, 2.5 mcg	T2	PA-BvD
doxercalciferol oral capsule 1 mcg	T4	PA-BvD
DUETACT	T4	QL (31 EA per 31 days)
EMFLAZA	T5	PA
ERMEZA	T4	
exenatide subcutaneous pen injector 10 mcg/dose(250 mcg/ml) 2.4 ml	T4	PA; QL (2.4 ML per 30 days)
exenatide subcutaneous pen injector 5 mcg/dose (250 mcg/ml) 1.2 ml	T4	PA; QL (1.2 ML per 30 days)
FARXIGA	T3	QL (31 EA per 31 days)
FIASP FLEXTOUCH U-100 INSULIN	T3	
FIASP PENFILL U-100 INSULIN	T3	
FIASP U-100 INSULIN	T3	
fludrocortisone	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
GALAFOLD	T5	PA; QL (14 EA per 28 days)
glimepiride oral tablet 1 mg, 2 mg, 4 mg	T1	
glimepiride oral tablet 3 mg	T4	
glipizide oral tablet 10 mg, 5 mg	T1	
glipizide oral tablet 2.5 mg	T3	
glipizide oral tablet extended release 24hr	T1	
glipizide-metformin	T1	
GLUCAGON EMERGENCY KIT (HUMAN)	T3	
GLUCOTROL XL ORAL TABLET EXTENDED RELEASE 24HR 10 MG, 5 MG	T4	
GLUMETZA ORAL TABLET,ER GAST.RETENTION 24 HR 1,000 MG	T5	ST; QL (62 EA per 31 days)
GLUMETZA ORAL TABLET,ER GAST.RETENTION 24 HR 500 MG	T5	ST; QL (31 EA per 31 days)
glyburide	T2	
glyburide micronized	T2	
glyburide-metformin	T2	
GLYXAMBI	T3	PA; QL (31 EA per 31 days)
GVOKE	T3	
GVOKE HYPOPEN 2-PACK	T3	
GVOKE PFS 1-PACK SYRINGE SUBCUTANEOUS SYRINGE 1 MG/0.2 ML	T3	
HEMADY	T4	PA-NS
HUMALOG JUNIOR KWIKPEN U-100	T3	
HUMALOG KWIKPEN INSULIN	T3	
HUMALOG MIX 50-50 KWIKPEN	T3	
HUMALOG MIX 75-25 KWIKPEN	T3	
HUMALOG MIX 75-25(U-100)INSULN	T3	
HUMALOG TEMPO PEN(U-100)INSULN	T3	
HUMALOG U-100 INSULIN	T3	
HUMULIN 70/30 U-100 INSULIN	T3	
HUMULIN 70/30 U-100 KWIKPEN	T3	
HUMULIN N NPH INSULIN KWIKPEN	T3	
HUMULIN N NPH U-100 INSULIN	T3	
HUMULIN R REGULAR U-100 INSULN	T3	
HUMULIN R U-500 (CONC) INSULIN	T3	
HUMULIN R U-500 (CONC) KWIKPEN	T3	
hydrocortisone oral	T1	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
INPEFA	T4	ST; QL (31 EA per 31 days)
insulin glargine u-300 conc subcutaneous insulin pen 300 unit/ml (1.5 ml)	T4	
insulin glargine u-300 conc subcutaneous insulin pen 300 unit/ml (3 ml)	T3	
insulin glargine-yfgn	T4	
insulin lispro	T3	
insulin lispro protamin-lispro	T3	
INVOKAMET	T4	ST; QL (62 EA per 31 days)
INVOKAMET XR	T4	ST; QL (62 EA per 31 days)
INVOKANA ORAL TABLET 100 MG	T4	ST; QL (62 EA per 31 days)
INVOKANA ORAL TABLET 300 MG	T4	ST; QL (31 EA per 31 days)
ISTURISA ORAL TABLET 1 MG	T5	PA; QL (558 EA per 31 days)
ISTURISA ORAL TABLET 5 MG	T5	PA; QL (372 EA per 31 days)
JANUMET	T4	PA; QL (62 EA per 31 days)
JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG, 50-500 MG	T4	PA; QL (31 EA per 31 days)
JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 50-1,000 MG	T4	PA; QL (62 EA per 31 days)
JANUVIA ORAL TABLET 100 MG, 50 MG	T3	PA; QL (31 EA per 31 days)
JANUVIA ORAL TABLET 25 MG	T3	PA; QL (93 EA per 31 days)
JARDIANCE ORAL TABLET 10 MG	T3	QL (62 EA per 31 days)
JARDIANCE ORAL TABLET 25 MG	T3	QL (31 EA per 31 days)
JATENZO ORAL CAPSULE 158 MG, 198 MG	T4	PA; QL (124 EA per 31 days)
JATENZO ORAL CAPSULE 237 MG	T4	PA; QL (62 EA per 31 days)
JAVYGTOR	T5	PA
JAYTHARI	T5	PA
JENTADUETO ORAL TABLET 2.5-1,000 MG, 2.5-500 MG	T3	PA; QL (62 EA per 31 days)
JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG	T3	PA; QL (62 EA per 31 days)
JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG	T3	PA; QL (31 EA per 31 days)
JYNARQUE ORAL TABLET	T5	PA; QL (112 EA per 28 days)
JYNARQUE ORAL TABLETS, SEQUENTIAL	T5	PA; QL (56 EA per 28 days)
KHINDIVI	T5	PA

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
KORLYM	T5	PA; QL (124 EA per 31 days)
KUVAN	T5	PA
LANTUS SOLOSTAR U-100 INSULIN	T3	
LANTUS U-100 INSULIN	T3	
levothyroxine oral capsule	T4	
levothyroxine oral tablet	T1	
LEVOXYL ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG	T3	
liothyronine oral	T2	
liraglutide	T4	PA; QL (9 ML per 30 days)
LYUMJEV KWIKPEN U-100 INSULIN	T4	ST
LYUMJEV KWIKPEN U-200 INSULIN	T4	ST
LYUMJEV TEMPO PEN(U-100)INSULN	T4	ST
LYUMJEV U-100 INSULIN	T4	ST
MEDROL (PAK)	T4	
MEDROL ORAL TABLET 16 MG, 2 MG, 4 MG, 8 MG	T4	
MERILOG	T4	ST
MERILOG SOLOSTAR	T4	ST
metformin oral solution	T4	ST; QL (791 ML per 31 days)
metformin oral tablet 1,000 mg, 500 mg, 850 mg	T1	
metformin oral tablet 625 mg	T4	ST; QL (124 EA per 31 days)
metformin oral tablet 750 mg	T5	ST; QL (93 EA per 31 days)
metformin oral tablet extended release 24 hr	T1	
metformin oral tablet extended release 24hr 1,000 mg	T4	ST; QL (62 EA per 31 days)
metformin oral tablet extended release 24hr 500 mg	T4	ST; QL (31 EA per 31 days)
metformin oral tablet,er gast.retention 24 hr 1,000 mg	T4	ST; QL (62 EA per 31 days)
metformin oral tablet,er gast.retention 24 hr 500 mg	T4	ST; QL (31 EA per 31 days)
methimazole oral tablet 10 mg, 5 mg	T2	
METHITEST	T5	PA
methylprednisolone	T2	
methyltestosterone oral capsule	T5	PA
mifepristone oral tablet 300 mg	T5	PA; QL (124 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
miglitol	T2	
miglustat	T5	PA; QL (93 EA per 31 days)
MOUNJARO	T3	PA; QL (2 ML per 28 days)
MYALEPT	T5	PA
nateglinide	T1	QL (93 EA per 31 days)
NOVOLIN 70/30 U-100 INSULIN	T3	
NOVOLIN 70-30 FLEXPEN U-100	T3	
NOVOLIN N FLEXPEN	T3	
NOVOLIN N NPH U-100 INSULIN	T3	
NOVOLIN R FLEXPEN	T3	
NOVOLIN R REGULAR U100 INSULIN	T3	
NOVOLOG FLEXPEN U-100 INSULIN	T3	
NOVOLOG MIX 70-30 U-100 INSULN	T3	
NOVOLOG MIX 70-30FLEXPEN U-100	T3	
NOVOLOG PENFILL U-100 INSULIN	T3	
NOVOLOG U-100 INSULIN ASPART	T3	
ORAPRED ODT	T4	
ORILISSA ORAL TABLET 150 MG	T5	PA; QL (31 EA per 31 days)
ORILISSA ORAL TABLET 200 MG	T5	PA; QL (62 EA per 31 days)
OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML)	T3	PA; QL (3 ML per 28 days)
PALYNZIQ SUBCUTANEOUS SYRINGE 10 MG/0.5 ML	T5	PA; QL (15 ML per 30 days)
PALYNZIQ SUBCUTANEOUS SYRINGE 2.5 MG/0.5 ML	T5	PA; QL (4 ML per 30 days)
PALYNZIQ SUBCUTANEOUS SYRINGE 20 MG/ML	T5	PA; QL (90 ML per 30 days)
paricalcitol oral	T2	PA-BvD
pioglitazone	T1	QL (31 EA per 31 days)
pioglitazone-glimepiride	T4	QL (31 EA per 31 days)
pioglitazone-metformin	T2	QL (93 EA per 31 days)
prednisolone	T2	
prednisolone sodium phosphate oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml), 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml)	T2	
PREDNISONE INTENSOL	T4	
prednisone oral solution	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
prednisone oral tablet	T1	
prednisone oral tablets,dose pack	T2	
PROGLYCEM	T4	
propylthiouracil	T2	
RAYALDEE	T5	QL (62 EA per 31 days)
RECORLEV	T5	PA; QL (248 EA per 31 days)
repaglinide oral tablet 0.5 mg	T1	QL (124 EA per 31 days)
repaglinide oral tablet 1 mg	T2	QL (124 EA per 31 days)
repaglinide oral tablet 2 mg	T2	QL (248 EA per 31 days)
REZVOGLAR KWIKPEN	T4	
ROCALTROL	T4	PA-BvD
RYBELSUS	T3	PA; QL (31 EA per 31 days)
SAMSCA	T5	PA
sapropterin	T5	PA
saxagliptin	T4	PA; QL (31 EA per 31 days)
saxagliptin-metformin oral tablet, er multiphase 24 hr 2.5-1,000 mg	T4	PA; QL (62 EA per 31 days)
saxagliptin-metformin oral tablet, er multiphase 24 hr 5-1,000 mg, 5-500 mg	T4	PA; QL (31 EA per 31 days)
SEGLUROMET	T4	ST; QL (62 EA per 31 days)
SEMGLEE(INSULIN GLARGINE-YFGN)	T4	
SEMGLEE(INSULIN GLARG-YFGN)PEN	T4	
sitagliptin oral tablet 100 mg, 50 mg	T4	PA; QL (31 EA per 31 days)
sitagliptin oral tablet 25 mg	T4	PA; QL (93 EA per 31 days)
sitagliptin-metformin oral tablet	T4	PA; QL (62 EA per 31 days)
sitagliptin-metformin oral tablet, er multiphase 24 hr 100-1,000 mg, 50-500 mg	T4	PA; QL (31 EA per 31 days)
sitagliptin-metformin oral tablet, er multiphase 24 hr 50-1,000 mg	T4	PA; QL (62 EA per 31 days)
SOLIQUA 100/33	T3	QL (18 ML per 30 days)
SOMAVERT	T5	PA
STEGLATRO	T4	ST; QL (31 EA per 31 days)
STEGLUJAN	T4	PA; QL (31 EA per 31 days)
SYMLINPEN 120	T5	QL (10.8 ML per 28 days)
SYMLINPEN 60	T5	QL (6 ML per 28 days)
SYNAREL	T5	PA
SYNJARDY	T3	QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 12.5-1,000 MG, 5-1,000 MG	T3	QL (62 EA per 31 days)
SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 25-1,000 MG	T3	QL (31 EA per 31 days)
SYNTHROID	T3	
TARPEYO	T5	PA; QL (124 EA per 31 days)
TESTIM	T4	PA
testosterone cypionate	T2	PA
testosterone enanthate	T2	PA
testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %), 20.25 mg/1.25 gram (1.62 %)	T4	PA
testosterone transdermal gel in packet	T4	PA
testosterone transdermal solution in metered pump w/app	T4	PA
THYQUIDITY	T4	
TIROSINT	T4	
TIROSINT-SOL	T4	
TLANDO	T4	PA; QL (124 EA per 31 days)
tolvaptan	T5	PA
tolvaptan (polycys kidney dis) oral tablet	T5	PA; QL (112 EA per 28 days)
tolvaptan (polycys kidney dis) oral tablets, sequential	T5	PA; QL (56 EA per 28 days)
TOUJEO MAX U-300 SOLOSTAR	T4	
TOUJEO SOLOSTAR U-300 INSULIN	T3	
TRADJENTA	T3	PA; QL (31 EA per 31 days)
TRESIBA FLEXTOUCH U-100	T3	
TRESIBA FLEXTOUCH U-200	T3	
TRESIBA U-100 INSULIN	T4	
TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 25-5-1,000 MG	T3	PA; QL (31 EA per 31 days)
TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-2.5-1,000 MG, 5-2.5-1,000 MG	T3	PA; QL (62 EA per 31 days)
TRULICITY	T3	PA; QL (2 ML per 28 days)
UNDECATREX	T4	PA; QL (124 EA per 31 days)
UNITHROID	T3	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
VICTOZA 3-PAK	T4	PA; QL (9 ML per 30 days)
VOGELXO TRANSDERMAL GEL	T4	PA
VOGELXO TRANSDERMAL GEL IN METERED-DOSE PUMP	T4	PA
VOXZOGO	T5	PA; QL (31 EA per 31 days)
XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 10-500 MG, 5-500 MG	T3	QL (31 EA per 31 days)
XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-1,000 MG	T3	QL (62 EA per 31 days)
XULTOPHY 100/3.6	T3	QL (15 ML per 30 days)
XYOSTED	T4	PA
YARGESA	T5	PA; QL (93 EA per 31 days)
YORVIPATH SUBCUTANEOUS PEN INJECTOR 168 MCG/0.56 ML	T5	PA; QL (1.12 ML per 28 days)
YORVIPATH SUBCUTANEOUS PEN INJECTOR 294 MCG/0.98 ML	T5	PA; QL (1.96 ML per 28 days)
YORVIPATH SUBCUTANEOUS PEN INJECTOR 420 MCG/1.4 ML	T5	PA; QL (2.8 ML per 28 days)
ZAVESCA	T5	PA; QL (93 EA per 31 days)
ZEGALOGUE AUTOINJECTOR	T4	
ZEGALOGUE SYRINGE	T4	
ZEMPLAR ORAL CAPSULE 1 MCG, 2 MCG	T4	PA-BvD
ZITUVIMET	T4	PA; QL (62 EA per 31 days)
ZITUVIMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG, 50-500 MG	T4	PA; QL (31 EA per 31 days)
ZITUVIMET XR ORAL TABLET, ER MULTIPHASE 24 HR 50-1,000 MG	T4	PA; QL (62 EA per 31 days)
ZITUVIO ORAL TABLET 100 MG, 50 MG	T4	PA; QL (31 EA per 31 days)
ZITUVIO ORAL TABLET 25 MG	T4	PA; QL (93 EA per 31 days)
Gastroenterology		
ACIPHEX	T4	QL (62 EA per 31 days)
alosetron oral tablet 0.5 mg	T4	PA; QL (93 EA per 31 days)
alosetron oral tablet 1 mg	T5	PA; QL (62 EA per 31 days)
AMITIZA	T4	PA; QL (62 EA per 31 days)
amoxicil-clarithromy-lansopraz	T2	
ANUSOL-HC TOPICAL	T4	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
aprepitant oral capsule 125 mg	T5	PA-BvD
aprepitant oral capsule 40 mg, 80 mg	T4	PA-BvD
aprepitant oral capsule,dose pack	T4	PA-BvD
APRISO	T4	PA; QL (124 EA per 31 days)
AZULFIDINE	T4	
AZULFIDINE EN-TABS	T4	
balsalazide	T2	
betaine	T5	
bismuth subcit k-metronidz-tcn	T4	
BONJESTA	T4	PA; QL (62 EA per 31 days)
budesonide oral capsule,delayed,extend.release	T4	
budesonide oral tablet,delayed and ext.release	T5	
budesonide rectal	T4	
BYLVAY ORAL CAPSULE 1,200 MCG	T5	PA; QL (186 EA per 31 days)
BYLVAY ORAL CAPSULE 400 MCG	T5	PA; QL (558 EA per 31 days)
BYLVAY ORAL PELLET 200 MCG	T5	PA; QL (1116 EA per 31 days)
BYLVAY ORAL PELLET 600 MCG	T5	PA; QL (372 EA per 31 days)
CANASA	T5	PA; QL (31 EA per 31 days)
CARAFATE ORAL SUSPENSION	T3	
CARAFATE ORAL TABLET	T4	
CHENODAL	T5	PA
chlordiazepoxide-clidinium	T2	
CHOLBAM	T5	PA
cimetidine	T2	
cimetidine hcl oral	T2	
CIMZIA POWDER FOR RECONST	T5	PA; QL (2 EA per 28 days)
CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2)	T5	PA; QL (2 EA per 28 days)
CLENPIQ ORAL SOLUTION 10 MG-3.5 GRAM- 12 GRAM/175 ML	T4	
COMPRO	T2	
CONSTULOSE	T2	
CREON	T3	
cromolyn oral	T4	
CTEXLI	T5	PA; QL (93 EA per 31 days)
CUVPOSA	T4	
CYSTADANE	T5	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
CYTOTEC	T4	
DEXILANT	T4	QL (31 EA per 31 days)
dexlansoprazole	T4	QL (31 EA per 31 days)
DICLEGIS	T4	PA; QL (124 EA per 31 days)
dicyclomine oral capsule	T2	
dicyclomine oral solution	T2	
dicyclomine oral tablet 20 mg	T2	
dicyclomine oral tablet 40 mg	T4	PA; QL (124 EA per 31 days)
DIPENTUM	T5	
diphenoxylate-atropine oral liquid	T3	
diphenoxylate-atropine oral tablet	T2	
doxylamine-pyridoxine (vit b6)	T4	PA; QL (124 EA per 31 days)
dronabinol oral capsule 10 mg	T4	PA-BvD
dronabinol oral capsule 2.5 mg, 5 mg	T2	PA-BvD
EMEND ORAL CAPSULE 80 MG	T4	PA-BvD
EMEND ORAL CAPSULE,DOSE PACK	T4	PA-BvD
EMEND ORAL SUSPENSION FOR RECONSTITUTION	T4	PA-BvD
ENTYVIO PEN	T5	PA; QL (1.36 ML per 28 days)
ENULOSE	T2	
esomeprazole magnesium oral capsule,delayed release(dr/ec)	T2	QL (31 EA per 31 days)
esomeprazole magnesium oral granules dr for susp in packet	T4	QL (31 EA per 31 days)
famotidine oral suspension for reconstitution	T1	
famotidine oral tablet 20 mg, 40 mg	T1	
GASTROCROM	T4	
GATTEX 30-VIAL	T5	PA
GAVILYTE-C	T1	
GAVILYTE-G	T1	
GAVILYTE-N	T1	
GENERLAC	T2	
GIMOTI	T5	PA; QL (9.8 ML per 28 days)
GLYCATE	T4	PA; QL (155 EA per 31 days)
glycopyrrolate oral solution	T4	
glycopyrrolate oral tablet 1 mg, 2 mg	T2	
glycopyrrolate oral tablet 1.5 mg	T4	PA; QL (155 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
GOLYTELY	T4	
granisetron hcl oral	T2	PA-BvD
hydrocortisone acetate topical cream with perineal applicator	T5	
hydrocortisone rectal	T3	
hydrocortisone topical cream with perineal applicator 2.5 %	T1	
hydrocortisone-pramoxine rectal cream 1-1 %	T4	
IBSRELA	T5	PA; QL (62 EA per 31 days)
IQIRVO	T5	PA; QL (31 EA per 31 days)
KONVOMEP	T4	
KRISTALOSE	T4	ST
lactulose oral packet 10 gram	T5	ST
lactulose oral packet 20 gram	T4	ST
lactulose oral solution	T1	
lansoprazole oral capsule,delayed release(dr/ec) 15 mg	T3	QL (31 EA per 31 days)
lansoprazole oral capsule,delayed release(dr/ec) 30 mg	T3	QL (62 EA per 31 days)
lansoprazole oral tablet,disintegrat, delay rel 15 mg	T4	QL (31 EA per 31 days)
lansoprazole oral tablet,disintegrat, delay rel 30 mg	T4	QL (62 EA per 31 days)
LIALDA	T5	PA; QL (124 EA per 31 days)
LIBRAX (WITH CLIDINIUM)	T5	
LINZESS	T3	QL (31 EA per 31 days)
LIVDELZI	T5	PA; QL (31 EA per 31 days)
LIVMARLI ORAL SOLUTION 19 MG/ML	T5	PA; QL (60 ML per 30 days)
LIVMARLI ORAL SOLUTION 9.5 MG/ML	T5	PA; QL (90 ML per 30 days)
LIVMARLI ORAL TABLET 10 MG, 15 MG, 20 MG	T5	PA; QL (62 EA per 31 days)
LIVMARLI ORAL TABLET 30 MG	T5	PA; QL (31 EA per 31 days)
LOMOTIL	T4	
loperamide oral capsule	T2	
LOTRONEX ORAL TABLET 0.5 MG	T5	PA; QL (93 EA per 31 days)
LOTRONEX ORAL TABLET 1 MG	T5	PA; QL (62 EA per 31 days)
lubiprostone	T4	QL (62 EA per 31 days)
MARINOL ORAL CAPSULE 2.5 MG	T4	PA-BvD

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
meclizine oral tablet 12.5 mg, 25 mg	T2	
mesalamine oral capsule (with del rel tablets)	T3	QL (186 EA per 31 days)
mesalamine oral capsule, extended release	T4	PA; QL (248 EA per 31 days)
mesalamine oral capsule,extended release 24hr	T4	QL (124 EA per 31 days)
mesalamine oral tablet,delayed release (dr/ec) 1.2 gram	T3	QL (124 EA per 31 days)
mesalamine oral tablet,delayed release (dr/ec) 800 mg	T4	PA; QL (186 EA per 31 days)
mesalamine rectal enema	T4	QL (1860 ML per 31 days)
mesalamine rectal suppository	T4	PA; QL (31 EA per 31 days)
methscopolamine	T2	
metoclopramide hcl oral	T2	
MICORT-HC	T4	
misoprostol	T2	
MOTEGRITY	T4	PA; QL (31 EA per 31 days)
MOVANTIK	T3	QL (31 EA per 31 days)
MOVIPREP	T4	
MYTESI	T5	QL (62 EA per 31 days)
NEXIUM	T4	QL (31 EA per 31 days)
NEXIUM PACKET	T4	QL (31 EA per 31 days)
nitroglycerin rectal	T4	
nizatidine oral capsule	T2	
OCALIVA	T5	PA; QL (31 EA per 31 days)
omeprazole oral capsule,delayed release(dr/ec)	T1	
omeprazole-sodium bicarbonate oral capsule	T2	
omeprazole-sodium bicarbonate oral packet	T5	
OMVOH PEN SUBCUTANEOUS PEN INJECTOR 100 MG/ML	T5	PA; QL (2 ML per 28 days)
OMVOH PEN SUBCUTANEOUS PEN INJECTOR 300MG/3ML(100MG /ML-200 MG/2ML)	T5	PA; QL (3 ML per 28 days)
OMVOH SUBCUTANEOUS SYRINGE 100 MG/ML	T5	PA; QL (2 ML per 28 days)
OMVOH SUBCUTANEOUS SYRINGE 300MG/3ML(100MG /ML-200 MG/2ML)	T5	PA; QL (3 ML per 28 days)
ondansetron hcl oral solution	T2	PA-BvD
ondansetron hcl oral tablet 4 mg, 8 mg	T2	PA-BvD
ondansetron oral tablet,disintegrating 4 mg, 8 mg	T2	PA-BvD

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
PANCREAZE ORAL CAPSULE,DELAYED RELEASE(DR/EC) 10,500-35,500- 61,500 UNIT, 16,800-56,800- 98,400 UNIT, 2,600-8,800- 15,200 UNIT, 4,200-14,200- 24,600 UNIT	T4	ST
PANCREAZE ORAL CAPSULE,DELAYED RELEASE(DR/EC) 21,000-54,700- 83,900 UNIT, 37,000-97,300- 149,900 UNIT	T5	ST
pantoprazole oral granules dr for susp in packet	T4	
pantoprazole oral tablet,delayed release (dr/ec)	T1	
peg 3350-electrolytes	T1	
peg3350-sod sul-nacl-kcl-asb-c	T4	
peg-electrolyte soln	T1	
PENTASA ORAL CAPSULE, EXTENDED RELEASE 250 MG	T3	QL (496 EA per 31 days)
PENTASA ORAL CAPSULE, EXTENDED RELEASE 500 MG	T5	PA; QL (248 EA per 31 days)
PEPCID ORAL TABLET	T4	
PERTZYE	T4	ST
PLENVU	T4	
PREVACID	T4	QL (62 EA per 31 days)
PREVACID SOLUTAB ORAL TABLET,DISINTEGRAT, DELAY REL 15 MG	T4	QL (31 EA per 31 days)
PREVACID SOLUTAB ORAL TABLET,DISINTEGRAT, DELAY REL 30 MG	T4	QL (62 EA per 31 days)
PRILOSEC ORAL SUSP,DELAYED RELEASE FOR RECON	T4	
prochlorperazine	T2	
prochlorperazine maleate	T2	
PROCTOFOAM HC	T4	
PROCTO-MED HC	T2	
PROCTOSOL HC TOPICAL	T2	
PROCTOZONE-HC	T2	
PROTONIX ORAL	T4	
prucalopride	T4	PA; QL (31 EA per 31 days)
PYLERA	T4	
rabeprazole oral tablet,delayed release (dr/ec)	T2	QL (62 EA per 31 days)
RECTIV	T4	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
REGLAN ORAL	T4	
RELISTOR ORAL	T5	PA; QL (93 EA per 31 days)
RELISTOR SUBCUTANEOUS SOLUTION	T5	PA; QL (18.6 ML per 31 days)
RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML	T5	PA; QL (18.6 ML per 31 days)
RELISTOR SUBCUTANEOUS SYRINGE 8 MG/0.4 ML	T5	PA; QL (12.4 ML per 31 days)
RELTONE	T5	ST
ROWASA RECTAL ENEMA KIT	T4	PA; QL (4 EA per 28 days)
SANCUSO	T5	
scopolamine base	T3	QL (10 EA per 30 days)
SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML)	T5	PA; QL (1.2 ML per 56 days)
SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 360 MG/2.4 ML (150 MG/ML)	T5	PA; QL (2.4 ML per 56 days)
sodium,potassium,mag sulfates	T4	
SUCRAID	T5	PA
sucralfate	T2	
SUFLAVE	T4	
sulfasalazine	T2	
SUPREP BOWEL PREP KIT	T4	
SUTAB	T4	
SYMPROIC	T4	PA; QL (31 EA per 31 days)
TALICIA	T4	PA
trimethobenzamide oral	T2	PA
TRULANCE	T4	PA; QL (31 EA per 31 days)
UCERIS ORAL	T5	
UCERIS RECTAL	T4	
ursodiol oral capsule 200 mg, 400 mg	T4	ST
ursodiol oral capsule 300 mg	T3	
ursodiol oral tablet	T3	
VARUBI	T5	PA-BvD
VELSIPITY	T5	PA; QL (31 EA per 31 days)
VIBERZI	T5	PA; QL (62 EA per 31 days)
VIOKACE	T4	
VOQUEZNA DUAL PAK	T4	PA; QL (112 EA per 14 days)
VOQUEZNA ORAL TABLET 10 MG	T4	PA; QL (31 EA per 31 days)
VOQUEZNA ORAL TABLET 20 MG	T4	PA; QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
VOQUEZNA TRIPLE PAK	T4	PA; QL (112 EA per 14 days)
VOWST	T5	PA; QL (12 EA per 14 days)
ZENPEP ORAL CAPSULE,DELAYED RELEASE(DR/EC) 10,000-32,000 -42,000 UNIT, 15,000-47,000 -63,000 UNIT, 20,000-63,000- 84,000 UNIT, 25,000-79,000- 105,000 UNIT, 3,000-10,000 -14,000-UNIT, 40,000-126,000- 168,000 UNIT, 5,000-17,000- 24,000 UNIT, 60,000-189,600- 252,600 UNIT	T3	
ZYMFENTRA	T5	PA; QL (1 EA per 28 days)
Immunology, Vaccines / Biotechnology		
ABRYSVO (PF)	T3	QL (1 EA per 365 days)
ACTHIB (PF)	T3	
ACTIMMUNE	T5	PA
ADACEL(TDAP ADOLESN/ADULT)(PF)	T3	
ARANESP (IN POLYSORBATE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 60 MCG/ML	T5	PA-BvD; ST
ARANESP (IN POLYSORBATE) INJECTION SOLUTION 25 MCG/ML, 40 MCG/ML	T4	PA-BvD; ST
ARANESP (IN POLYSORBATE) INJECTION SYRINGE 10 MCG/0.4 ML, 25 MCG/0.42 ML, 40 MCG/0.4 ML	T4	PA-BvD; ST
ARANESP (IN POLYSORBATE) INJECTION SYRINGE 100 MCG/0.5 ML, 150 MCG/0.3 ML, 200 MCG/0.4 ML, 300 MCG/0.6 ML, 500 MCG/ML, 60 MCG/0.3 ML	T5	PA-BvD; ST
ARCALYST	T5	PA
AREXVY (PF)	T3	QL (1 EA per 365 days)
AVONEX INTRAMUSCULAR PEN INJECTOR KIT	T5	PA; QL (1 EA per 28 days)
AVONEX INTRAMUSCULAR SYRINGE KIT	T5	PA; QL (1 EA per 28 days)
bcg vaccine, live (pf)	T3	
BESREMI	T5	PA-NS; QL (2 ML per 28 days)
BETASERON SUBCUTANEOUS KIT	T5	PA; QL (14 EA per 28 days)
BEXSERO	T3	
BIVIGAM	T5	PA
BOOSTRIX TDAP	T3	
DAPTACEL (DTAP PEDIATRIC) (PF)	T3	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
EGRIFTA SV	T5	PA
ENGERIX-B (PF)	T3	PA-BvD
ENGERIX-B PEDIATRIC (PF)	T3	PA-BvD
EPOGEN INJECTION SOLUTION 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML	T4	PA-BvD; ST
FULPHILA	T5	ST
FYLNETRA	T5	ST
GAMMAGARD LIQUID	T5	PA
GAMMAGARD S-D (IGA < 1 MCG/ML)	T5	PA
GAMMAKED INJECTION SOLUTION 1 GRAM/10 ML (10 %)	T5	PA
GAMMAPLEX	T5	PA
GAMMAPLEX (WITH SORBITOL)	T5	PA
GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %)	T5	PA
GARDASIL 9 (PF)	T3	
GENOTROPIN	T5	PA
GENOTROPIN MINIQUICK SUBCUTANEOUS SYRINGE 0.2 MG/0.25 ML	T4	PA
GENOTROPIN MINIQUICK SUBCUTANEOUS SYRINGE 0.4 MG/0.25 ML, 0.6 MG/0.25 ML, 0.8 MG/0.25 ML, 1 MG/0.25 ML, 1.2 MG/0.25 ML, 1.4 MG/0.25 ML, 1.6 MG/0.25 ML, 1.8 MG/0.25 ML, 2 MG/0.25 ML	T5	PA
GRANIX SUBCUTANEOUS SOLUTION 300 MCG/ML	T5	ST
GRANIX SUBCUTANEOUS SYRINGE	T5	ST
GRASTEK	T4	PA
HAVRIX (PF)	T3	
HEPLISAV-B (PF)	T3	PA-BvD
HIBERIX (PF)	T3	
HUMATROPE INJECTION CARTRIDGE	T5	PA
IMOVAX RABIES VACCINE (PF)	T3	PA-BvD
INFANRIX (DTAP) (PF)	T3	
IPOL	T3	
IXIARO (PF)	T3	
JYNNEOS (PF)	T3	PA-BvD

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
KINRIX (PF)	T3	
LEUKINE INJECTION RECON SOLN	T5	PA
MENQUADFI (PF)	T4	
MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR KIT	T3	
MIRCERA	T4	ST
M-M-R II (PF)	T3	
MRESVIA (PF)	T3	QL (1 ML per 365 days)
NEULASTA	T5	ST
NEUPOGEN	T5	ST
NGENLA	T5	PA
NIVESTYM	T5	
NORDITROPIN FLEXPRO	T5	PA
NUTROPIN AQ NUSPIN	T5	PA
NYVEPRIA	T5	ST
OCTAGAM	T5	PA
ODACTRA	T4	PA
OMNITROPE SUBCUTANEOUS CARTRIDGE 10 MG/1.5 ML (6.7 MG/ML)	T5	PA
OMNITROPE SUBCUTANEOUS CARTRIDGE 5 MG/1.5 ML (3.3 MG/ML)	T4	PA
OMNITROPE SUBCUTANEOUS RECON SOLN	T5	PA
PANZYGA	T5	PA
PEDIARIX (PF)	T3	
PEDVAX HIB (PF)	T3	
PEGASYS	T5	PA
PENBRAYA (PF)	T3	
PENMENVY MEN A-B-C-W-Y (PF)	T3	
PENTACEL (PF)	T3	
PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML	T5	PA; QL (1 ML per 28 days)
PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML	T5	PA; QL (1 ML per 28 days)
PRIORIX (PF)	T3	
PRIVIGEN	T5	PA
PROCRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML	T3	PA-BvD

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
PROCRIT INJECTION SOLUTION 20,000 UNIT/ML, 40,000 UNIT/ML	T5	PA-BvD
PROQUAD (PF)	T3	
QUADRACEL (PF)	T3	
RABAVERT (PF)	T3	PA-BvD
REBIF (WITH ALBUMIN)	T5	PA; QL (6 ML per 28 days)
REBIF REBIDOSE SUBCUTANEOUS PEN INJECTOR 22 MCG/0.5 ML, 44 MCG/0.5 ML	T5	PA; QL (6 ML per 28 days)
REBIF REBIDOSE SUBCUTANEOUS PEN INJECTOR 8.8MCG/0.2ML-22 MCG/0.5ML (6)	T5	PA; QL (4.2 ML per 365 days)
REBIF TITRATION PACK	T5	PA; QL (8.4 ML per 365 days)
RECOMBIVAX HB (PF)	T3	PA-BvD
RELEUKO SUBCUTANEOUS	T4	ST
RETACRIT	T3	PA-BvD
ROTARIX ORAL SUSPENSION	T3	
ROTATEQ VACCINE	T3	
SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG	T5	PA
SHINGRIX (PF)	T3	QL (2 EA per 999 days)
SKYTROFA SUBCUTANEOUS CARTRIDGE 11 MG, 13.3 MG, 3 MG, 3.6 MG, 4.3 MG, 5.2 MG, 6.3 MG, 7.6 MG, 9.1 MG	T5	PA
SOGROYA	T5	PA
STIMUFEND	T5	ST
TENIVAC (PF)	T3	
TICOVAC	T3	
TRUMENBA	T3	
TWINRIX (PF)	T3	
TYPHIM VI	T3	
UDENYCA	T5	ST
UDENYCA AUTOINJECTOR	T5	ST
VAQTA (PF)	T3	
VARIVAX (PF)	T3	
VAXCHORA VACCINE	T3	QL (200 ML per 365 days)
VIMKUNYA	T3	
VIVOTIF	T3	
XOLREMDI	T5	PA; QL (124 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
YF-VAX (PF)	T3	
ZARXIO	T5	
ZIEXTENZO	T5	ST
ZOMACTON	T4	PA
Miscellaneous Supplies		
ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2"	T4	PA
GAUZE PAD TOPICAL BANDAGE 2 X 2 "	T2	PA
insulin syringe-needle u-100 syringe 0.3 ml 29 gauge, 1 ml 29 gauge x 1/2", 1/2 ml 28 gauge	T3	
pen needle, diabetic needle 29 gauge x 1/2"	T4	PA
Musculoskeletal / Rheumatology		
ABRILADA(CF)	T5	PA; QL (2 EA per 28 days)
ABRILADA(CF) PEN	T5	PA; QL (2 EA per 28 days)
ACTEMRA ACTPEN	T5	PA; QL (3.6 ML per 28 days)
ACTEMRA SUBCUTANEOUS	T5	PA; QL (3.6 ML per 28 days)
ACTONEL ORAL TABLET 150 MG, 35 MG	T4	
adalimumab-aacf subcutaneous pen injector kit	T5	PA; QL (2 EA per 28 days)
adalimumab-aacf subcutaneous syringe kit	T5	PA; QL (2 EA per 28 days)
ADALIMUMAB-AACF(CF) PEN CROHNS	T5	PA; QL (12 EA per 365 days)
ADALIMUMAB-AACF(CF) PEN PS-UV	T5	PA; QL (8 EA per 365 days)
adalimumab-aaty	T5	PA; QL (2 EA per 28 days)
ADALIMUMAB-AATY(CF) AI CROHNS	T5	PA; QL (6 EA per 365 days)
adalimumab-adaz subcutaneous pen injector 40 mg/0.4 ml	T5	PA; QL (0.8 ML per 28 days)
adalimumab-adaz subcutaneous pen injector 80 mg/0.8 ml	T5	PA; QL (1.6 ML per 28 days)
adalimumab-adaz subcutaneous syringe 10 mg/0.1 ml	T5	PA; QL (0.2 ML per 28 days)
adalimumab-adaz subcutaneous syringe 20 mg/0.2 ml	T5	PA; QL (0.4 ML per 28 days)
adalimumab-adaz subcutaneous syringe 40 mg/0.4 ml	T5	PA; QL (0.8 ML per 28 days)
adalimumab-adbm	T5	PA; QL (2 EA per 28 days)
adalimumab-fkjp subcutaneous pen injector kit	T5	PA; QL (2 EA per 28 days)
adalimumab-fkjp subcutaneous syringe kit	T5	PA; QL (2 EA per 28 days)
adalimumab-ryvk subcutaneous auto-injector, kit 40 mg/0.4 ml	T5	PA; QL (2 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
adalimumab-ryvk subcutaneous syringe kit	T5	PA; QL (2 EA per 28 days)
alendronate oral solution	T1	
alendronate oral tablet 10 mg, 35 mg, 70 mg	T1	
allopurinol oral tablet 100 mg, 300 mg	T1	
allopurinol oral tablet 200 mg	T4	
AMJEVITA(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 40 MG/0.4 ML	T5	PA; QL (0.8 ML per 28 days)
AMJEVITA(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 40 MG/0.8 ML	T5	PA; QL (1.6 EA per 28 days)
AMJEVITA(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 80 MG/0.8 ML	T5	PA; QL (1.6 ML per 28 days)
AMJEVITA(CF) SUBCUTANEOUS SYRINGE 10 MG/0.2 ML, 20 MG/0.2 ML	T5	PA; QL (0.4 ML per 28 days)
AMJEVITA(CF) SUBCUTANEOUS SYRINGE 20 MG/0.4 ML	T5	PA; QL (0.8 EA per 28 days)
AMJEVITA(CF) SUBCUTANEOUS SYRINGE 40 MG/0.4 ML	T5	PA; QL (0.8 ML per 28 days)
AMJEVITA(CF) SUBCUTANEOUS SYRINGE 40 MG/0.8 ML	T5	PA; QL (1.6 EA per 28 days)
ARAVA	T5	
ATELVIA	T4	
BENLYSTA SUBCUTANEOUS	T5	PA; QL (4 ML per 28 days)
BINOSTO	T4	
BONSITY	T5	PA; QL (2.24 ML per 28 days)
colchicine oral capsule	T4	QL (62 EA per 31 days)
colchicine oral tablet	T2	QL (62 EA per 31 days)
CONEXXENCE	T4	PA; QL (1 ML per 180 days)
CUPRIMINE	T5	
CYLTEZO(CF)	T5	PA; QL (2 EA per 28 days)
CYLTEZO(CF) PEN	T5	PA; QL (2 EA per 28 days)
CYLTEZO(CF) PEN CROHN'S-UC-HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML	T5	PA; QL (12 EA per 365 days)
CYLTEZO(CF) PEN PSORIASIS-UV SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML	T5	PA; QL (8 EA per 365 days)
DEPEN TITRATABS	T5	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ENBREL MINI	T5	PA; QL (8 ML per 28 days)
ENBREL SUBCUTANEOUS SOLUTION	T5	PA; QL (4 ML per 28 days)
ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5)	T5	PA; QL (4 ML per 28 days)
ENBREL SUBCUTANEOUS SYRINGE 50 MG/ML (1 ML)	T5	PA; QL (8 ML per 28 days)
ENBREL SURECLICK	T5	PA; QL (8 ML per 28 days)
EVENITY SUBCUTANEOUS SYRINGE 210MG/2.34ML (105MG/1.17MLX2)	T5	PA; QL (2.34 ML per 28 days)
EVISTA	T3	
febuxostat	T4	PA
FORTEO	T5	PA; QL (2.4 ML per 28 days)
FOSAMAX ORAL TABLET 70 MG	T4	
FOSAMAX PLUS D	T4	
GLOPERBA	T4	QL (300 ML per 30 days)
HADLIMA	T5	PA; QL (1.6 ML per 28 days)
HADLIMA PUSHTOUCH	T5	PA; QL (1.6 ML per 28 days)
HADLIMA(CF)	T5	PA; QL (0.8 ML per 28 days)
HADLIMA(CF) PUSHTOUCH	T5	PA; QL (0.8 ML per 28 days)
HULIO(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT	T5	PA; QL (2 EA per 28 days)
HULIO(CF) SUBCUTANEOUS SYRINGE KIT	T5	PA; QL (2 EA per 28 days)
HUMIRA PEN	T5	PA; QL (2 EA per 28 days)
HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML	T5	PA; QL (2 EA per 28 days)
HUMIRA(CF)	T5	PA; QL (2 EA per 28 days)
HUMIRA(CF) PEN	T5	PA; QL (2 EA per 28 days)
HUMIRA(CF) PEN CROHNS-UC-HS	T5	PA; QL (6 EA per 365 days)
HUMIRA(CF) PEN PSOR-UV-ADOL HS	T5	PA; QL (6 EA per 365 days)
HYRIMOZ	T5	PA; QL (1.6 ML per 28 days)
HYRIMOZ PEN	T5	PA; QL (1.6 ML per 28 days)
HYRIMOZ PEN CROHN'S-UC STARTER	T5	PA; QL (4.8 ML per 365 days)
HYRIMOZ PEN PSORIASIS STARTER	T5	PA; QL (3.2 ML per 365 days)
HYRIMOZ(CF) PEDI CROHN STARTER SUBCUTANEOUS SYRINGE 80 MG/0.8 ML	T5	PA; QL (4.8 ML per 365 days)
HYRIMOZ(CF) PEDI CROHN STARTER SUBCUTANEOUS SYRINGE 80 MG/0.8 ML-40 MG/0.4 ML	T5	PA; QL (2.4 ML per 365 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
HYRIMOZ(CF) PEN SUBCUTANEOUS PEN INJECTOR 40 MG/0.4 ML	T5	PA; QL (0.8 ML per 28 days)
HYRIMOZ(CF) PEN SUBCUTANEOUS PEN INJECTOR 80 MG/0.8 ML	T5	PA; QL (1.6 ML per 28 days)
HYRIMOZ(CF) SUBCUTANEOUS SYRINGE 10 MG/0.1 ML	T5	PA; QL (0.2 ML per 28 days)
HYRIMOZ(CF) SUBCUTANEOUS SYRINGE 20 MG/0.2 ML	T5	PA; QL (0.4 ML per 28 days)
HYRIMOZ(CF) SUBCUTANEOUS SYRINGE 40 MG/0.4 ML	T5	PA; QL (0.8 ML per 28 days)
ibandronate oral	T2	
IDACIO(CF)	T5	PA; QL (2 EA per 28 days)
IDACIO(CF) PEN CROHN-UC STARTR	T5	PA; QL (12 EA per 365 days)
IDACIO(CF) PEN PSORIASIS START	T5	PA; QL (8 EA per 365 days)
IDACIO(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT	T5	PA; QL (2 EA per 28 days)
JUBBONTI	T4	PA; QL (1 ML per 180 days)
KEVZARA	T5	PA; QL (2.28 ML per 28 days)
KINERET	T5	PA; QL (18.76 ML per 28 days)
leflunomide	T2	
LEQSELVI	T5	PA; QL (62 EA per 31 days)
MITIGARE	T4	QL (62 EA per 31 days)
OLUMIANT	T5	PA; QL (31 EA per 31 days)
ORENCIA CLICKJECT	T5	PA; QL (4 ML per 28 days)
ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML	T5	PA; QL (4 ML per 28 days)
ORENCIA SUBCUTANEOUS SYRINGE 50 MG/0.4 ML	T5	PA; QL (1.6 ML per 28 days)
ORENCIA SUBCUTANEOUS SYRINGE 87.5 MG/0.7 ML	T5	PA; QL (2.8 ML per 28 days)
OTEZLA	T5	PA; QL (62 EA per 31 days)
OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)- 20 MG (51), 10 MG (4)-20 MG (4)-30 MG (47)	T5	PA; QL (110 EA per 365 days)
OTREXUP (PF)	T4	PA
penicillamine	T5	
probenecid	T2	
probenecid-colchicine	T2	
PROLIA	T4	PA; QL (1 ML per 180 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
raloxifene	T3	
RASUVO (PF)	T4	PA
RIDAURA	T5	
RINVOQ LQ	T5	PA; QL (372 ML per 31 days)
RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG	T5	PA; QL (31 EA per 31 days)
RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 45 MG	T5	PA; QL (168 EA per 365 days)
risedronate oral tablet 150 mg, 35 mg, 35 mg (12 pack), 35 mg (4 pack), 5 mg	T3	
risedronate oral tablet,delayed release (dr/ec)	T3	
SAVELLA	T4	PA
SIMLANDI(CF)	T5	PA; QL (2 EA per 28 days)
SIMLANDI(CF) AUTOINJECTOR	T5	PA; QL (2 EA per 28 days)
SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML	T5	PA; QL (1 ML per 28 days)
SIMPONI SUBCUTANEOUS PEN INJECTOR 50 MG/0.5 ML	T5	PA; QL (0.5 ML per 28 days)
SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML	T5	PA; QL (1 ML per 28 days)
SIMPONI SUBCUTANEOUS SYRINGE 50 MG/0.5 ML	T5	PA; QL (0.5 ML per 28 days)
STOBOCLO	T4	PA; QL (1 ML per 180 days)
teriparatide subcutaneous pen injector 20 mcg/dose (560mcg/2.24ml)	T5	PA; QL (2.48 ML per 28 days)
TYENNE AUTOINJECTOR	T5	PA; QL (3.6 ML per 28 days)
TYENNE SUBCUTANEOUS	T5	PA; QL (3.6 ML per 28 days)
TYMLOS	T5	PA; QL (1.56 ML per 30 days)
ULORIC	T4	PA
XELJANZ ORAL SOLUTION	T5	PA; QL (310 ML per 31 days)
XELJANZ ORAL TABLET	T5	PA; QL (62 EA per 31 days)
XELJANZ XR	T5	PA; QL (31 EA per 31 days)
YUFLYMA(CF)	T5	PA; QL (2 EA per 28 days)
YUFLYMA(CF) AI CROHN'S-UC-HS	T5	PA; QL (6 EA per 365 days)
YUFLYMA(CF) AUTOINJECTOR	T5	PA; QL (2 EA per 28 days)
YUSIMRY(CF) PEN	T5	PA; QL (1.6 ML per 28 days)
Obstetrics / Gynecology		
ABIGALE	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ABIGALE LO	T4	
ACTIVELLA	T4	
ALTAVERA (28)	T2	
ALYACEN 1/35 (28)	T2	
ANGELIQ	T4	
ANNOVERA	T4	
APRI	T2	
ARANELLE (28)	T2	
ASHLYNA	T2	
AUBRA EQ	T2	
AVIANE	T2	
AZURETTE (28)	T2	
BALCOLTRA	T4	
BALZIVA (28)	T2	
BEYAZ	T4	
BIJUVA	T4	
BLISOVI 24 FE	T2	
BLISOVI FE 1.5/30 (28)	T2	
BRIELLYN	T2	
CAMILA	T2	
CAMRESE LO	T2	
CLEOCIN VAGINAL	T4	
CLIMARA	T4	
CLIMARA PRO	T4	
clindamycin phosphate vaginal	T2	
CLINDESSE	T4	
COMBIPATCH	T4	
CRINONE	T4	PA
CRYSELLE (28)	T2	
CYRED EQ	T2	
DEBLITANE	T2	
DELESTROGEN INTRAMUSCULAR OIL 10 MG/ML, 20 MG/ML	T4	
DEPO-ESTRADIOL	T4	
DEPO-PROVERA INTRAMUSCULAR SUSPENSION 150 MG/ML	T4	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
DEPO-PROVERA INTRAMUSCULAR SYRINGE	T4	
DEPO-SUBQ PROVERA 104	T3	
DIVIGEL	T4	
DOLISHALE	T4	
DOTTI	T2	
drospirenone-e.estradiol-lm.fa oral tablet 3-0.02-0.451 mg (24) (4)	T2	
drospirenone-ethinyl estradiol	T2	
DUAVEE	T4	
ELESTRIN	T4	
ELURYNG	T3	
ENILLORING	T4	
ENSKYCE	T2	
ERRIN	T2	
ESTARYLLA	T2	
ESTRACE VAGINAL	T4	
estradiol oral	T1	
estradiol transdermal gel in metered-dose pump	T4	
estradiol transdermal gel in packet	T4	
estradiol transdermal patch semiweekly	T2	
estradiol transdermal patch weekly	T2	
estradiol vaginal	T4	
estradiol valerate	T2	
estradiol-norethindrone acet	T2	
ESTRING	T4	
etonogestrel-ethinyl estradiol	T3	
EVAMIST	T4	
FALMINA (28)	T2	
FEIRZA	T2	
FEMLYV	T4	
FEMRING	T4	
FINZALA	T2	
FYAVOLV	T2	
GALBRIELA	T4	
GALLIFREY	T2	
GEMMILY	T4	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
GYNAZOLE-1	T3	
HAILEY 24 FE	T2	
HALOETTE	T4	
HEATHER	T2	
ICLEVIA	T2	
IMVEXXY MAINTENANCE PACK	T3	
IMVEXXY STARTER PACK	T3	
INCASSIA	T2	
INTRAROSA	T4	PA; QL (28 EA per 28 days)
INTROVALE	T2	
ISIBLOOM	T2	
JAIMIESS	T2	
JASMIEL (28)	T2	
JINTELI	T2	
JOYEAUX	T4	
JULEBER	T2	
JUNEL 1.5/30 (21)	T2	
JUNEL 1/20 (21)	T2	
JUNEL FE 1.5/30 (28)	T2	
JUNEL FE 1/20 (28)	T2	
JUNEL FE 24	T2	
KAITLIB FE	T2	
KARIVA (28)	T2	
KELNOR 1/35 (28)	T2	
KURVELO (28)	T2	
KYLEENA	T4	
l norgest/e.estradiol-e.estrad oral tablets,dose pack,3 month 0.1 mg-20 mcg (84)/10 mcg (7)	T2	
LARIN 1.5/30 (21)	T2	
LARIN 1/20 (21)	T2	
LARIN FE 1.5/30 (28)	T2	
LARIN FE 1/20 (28)	T2	
LESSINA	T2	
LEVONEST (28)	T2	
levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg, 0.15-0.03 mg	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
levonorgestrel-ethinyl estrad oral tablet 90-20 mcg (28)	T4	
levonorgestrel-ethinyl estrad oral tablets,dose pack,3 month	T2	
levonorg-eth estrad triphasic	T2	
LEVORA-28	T2	
LILETTA	T3	
LO LOESTRIN FE	T4	
LOESTRIN 1.5/30 (21)	T4	
LOESTRIN 1/20 (21)	T4	
LOESTRIN FE 1.5/30 (28-DAY)	T4	
LOESTRIN FE 1/20 (28-DAY)	T4	
LOJAIMIESS	T2	
LORYNA (28)	T2	
LOW-OGESTREL (28)	T2	
LUTERA (28)	T2	
LYLEQ	T2	
LYLLANA	T2	
LYZA	T2	
MARLISSA (28)	T2	
medroxyprogesterone	T2	
MELEYA	T2	
MENOSTAR	T4	
MERZEE	T4	
metronidazole vaginal gel 0.75 % (37.5mg/5 gram)	T3	
MIBELAS 24 FE	T2	
MICONAZOLE-3 VAGINAL SUPPOSITORY	T2	
MICROGESTIN 1.5/30 (21)	T2	
MICROGESTIN 1/20 (21)	T2	
MICROGESTIN FE 1.5/30 (28)	T2	
MICROGESTIN FE 1/20 (28)	T2	
MILI	T2	
MIMVEY	T2	
MINIVELLE	T4	
MINZOYA	T4	
MIRENA	T4	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
MYFEMBREE	T5	PA; QL (31 EA per 31 days)
NATAZIA	T4	
NECON 0.5/35 (28)	T2	
NEXPLANON	T3	
NEXTSTELLIS	T4	
NIKKI (28)	T2	
NORA-BE	T2	
norelgestromin-ethin.estradiol	T2	
norethindrone (contraceptive)	T2	
norethindrone acetate	T2	
norethindrone ac-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-20 mg-mcg, 1-5 mg-mcg	T2	
norethindrone-e.estradiol-iron oral capsule	T4	
norethindrone-e.estradiol-iron oral tablet,chewable	T2	
norgestimate-ethinyl estradiol	T2	
NORTREL 0.5/35 (28)	T2	
NORTREL 1/35 (21)	T2	
NORTREL 1/35 (28)	T2	
NORTREL 7/7/7 (28)	T2	
NUVARING	T4	
NYLIA 1/35 (28)	T2	
NYLIA 7/7/7 (28)	T2	
OCELLA	T2	
ORIAHNN	T5	PA; QL (56 EA per 28 days)
ORQUIDEA	T2	
OSPHENA	T4	PA; QL (31 EA per 31 days)
PHEXXI	T4	
PIMTREA (28)	T2	
PORTIA 28	T2	
PREMARIN ORAL	T4	
PREMARIN VAGINAL	T3	
PREMPHASE	T4	
PREMPRO	T4	
progesterone micronized oral	T3	
PROMETRIUM	T4	
PROVERA	T4	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
RECLIPSEN (28)	T2	
RIVELSA	T4	
ROSYRAH	T4	
SAFYRAL	T4	
SETLAKIN	T2	
SHAROBEL	T2	
SKYLA	T4	
SPRINTEC (28)	T2	
SRONYX	T2	
SYEDA	T2	
TARINA 24 FE	T2	
TARINA FE 1-20 EQ (28)	T2	
terconazole	T2	
TILIA FE	T2	
tranexamic acid oral	T2	
TRI-ESTARYLLA	T2	
TRI-LEGEST FE	T2	
TRI-LO-ESTARYLLA	T2	
TRI-LO-SPRINTEC	T2	
TRI-MILI	T2	
TRI-SPRINTEC (28)	T2	
TRI-VYLIBRA	T2	
TRI-VYLIBRA LO	T2	
TURQOZ (28)	T2	
VAGIFEM	T4	
VALTYA ORAL TABLET 1-50 MG-MCG	T2	
VANDAZOLE	T3	
VELIVET TRIPHASIC REGIMEN (28)	T2	
VEOZAH	T4	PA; QL (31 EA per 31 days)
VESTURA (28)	T2	
VIENVA	T2	
VIVELLE-DOT	T4	
VYFEMLA (28)	T2	
VYLIBRA	T2	
WYMZYA FE	T2	
XACIATO	T4	
XARAH FE	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
XELRIA FE	T2	
XULANE	T2	
YASMIN (28)	T4	
YAZ (28)	T4	
YUVAFEM	T4	
ZAFEMY	T2	
ZOVIA 1-35 (28)	T2	
Ophthalmology		
acetazolamide	T2	
ACULAR	T4	
ACULAR LS	T4	
ACUVAIL (PF)	T4	
ALPHAGAN P OPHTHALMIC (EYE) DROPS 0.1 %	T3	
ALPHAGAN P OPHTHALMIC (EYE) DROPS 0.15 %	T4	
ALREX	T4	
apraclonidine	T2	
atropine ophthalmic (eye) drops 1 %	T2	
AZASITE	T4	
azelastine ophthalmic (eye)	T2	
AZOPT	T4	
bacitracin ophthalmic (eye)	T2	
bacitracin-polymyxin b	T2	
bepotastine besilate	T4	PA
BEPREVE	T4	PA
BESIVANCE	T4	
betaxolol ophthalmic (eye)	T2	
BETIMOL OPHTHALMIC (EYE) DROPS 0.5 %	T4	
bimatoprost ophthalmic (eye)	T2	
brimonidine ophthalmic (eye) drops 0.1 %	T3	
brimonidine ophthalmic (eye) drops 0.15 %, 0.2 %	T2	
brimonidine-timolol	T3	
brinzolamide	T4	
bromfenac ophthalmic (eye) drops 0.07 %, 0.075 %	T4	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
bromfenac ophthalmic (eye) drops 0.09 %	T2	
BROMSITE	T4	
carteolol	T2	
CEQUA	T4	ST; QL (60 EA per 30 days)
CILOXAN OPHTHALMIC (EYE) OINTMENT	T3	
ciprofloxacin hcl ophthalmic (eye)	T1	
COMBIGAN	T3	
COSOPT	T4	
COSOPT (PF)	T4	
cromolyn ophthalmic (eye)	T2	
cyclosporine ophthalmic (eye)	T3	QL (60 EA per 30 days)
CYSTADROPS	T5	PA; QL (20 ML per 28 days)
CYSTARAN	T5	PA; QL (60 ML per 28 days)
dexamethasone sodium phosphate ophthalmic (eye)	T2	
diclofenac sodium ophthalmic (eye)	T1	
difluprednate	T4	
dorzolamide	T2	
dorzolamide-timolol	T2	
dorzolamide-timolol (pf) ophthalmic (eye) dropperette	T4	
DUREZOL	T4	
epinastine	T2	
erythromycin ophthalmic (eye)	T2	
EYSUVIS	T3	QL (8.3 ML per 30 days)
FLAREX	T4	
fluorometholone	T2	
flurbiprofen sodium	T2	
FML FORTE	T4	
FML LIQUIFILM	T4	
gatifloxacin	T3	
gentamicin ophthalmic (eye) drops	T1	
ILEVRO	T3	
INVELTYS	T4	
IOPIDINE OPHTHALMIC (EYE) DROPPERETTE	T4	
ISTALOL	T4	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
IYUZEH (PF)	T4	ST; QL (30 EA per 30 days)
ketorolac ophthalmic (eye)	T2	
latanoprost	T1	
levobunolol ophthalmic (eye) drops 0.5 %	T1	
levofloxacin ophthalmic (eye) drops 0.5 %	T3	
LOTEMAX	T4	
LOTEMAX SM	T4	
loteprednol etabonate	T4	
LUMIGAN OPHTHALMIC (EYE) DROPS 0.01 %	T3	QL (5 ML per 31 days)
MAXIDEX	T4	
MAXITROL	T4	
methazolamide	T2	
MIEBO (PF)	T4	ST; QL (3 ML per 30 days)
moxifloxacin ophthalmic (eye) drops	T3	
neomycin-bacitracin-poly-hc	T2	
neomycin-bacitracin-polymyxin	T2	
neomycin-polymyxin b-dexameth	T2	
neomycin-polymyxin-gramicidin	T2	
neomycin-polymyxin-hc ophthalmic (eye)	T2	
NEO-POLYCIN	T2	
NEO-POLYCIN HC	T2	
NEVANAC	T4	
OCUFLOX	T4	
ofloxacin ophthalmic (eye)	T2	
OXERVATE	T5	PA; QL (112 ML per 56 days)
PHOSPHOLINE IODIDE	T5	PA; QL (5 ML per 25 days)
pilocarpine hcl ophthalmic (eye) drops 1 %, 2 %, 4 %	T2	
POLYCIN	T2	
polymyxin b sulf-trimethoprim	T1	
PRED FORTE	T4	
PRED MILD	T4	
prednisolone acetate	T1	
prednisolone sodium phosphate ophthalmic (eye)	T2	
PROLENSA	T3	
RESTASIS	T3	QL (60 EA per 30 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
RESTASIS MULTIDOSE	T3	QL (5.5 ML per 27 days)
RHOPRESSA	T3	ST
ROCKLATAN	T3	ST
SIMBRINZA	T4	
sulfacetamide sodium ophthalmic (eye) drops	T2	
sulfacetamide sodium ophthalmic (eye) ointment	T1	
sulfacetamide-prednisolone	T2	
tafluprost (pf)	T4	
timolol	T4	
timolol maleate (pf)	T4	
timolol maleate ophthalmic (eye) drops	T1	
timolol maleate ophthalmic (eye) drops, once daily	T2	
timolol maleate ophthalmic (eye) gel forming solution	T2	
TIMOPTIC OCUDOSE (PF)	T4	
TOBRADEX OPHTHALMIC (EYE) OINTMENT	T3	
TOBRADEX ST	T3	
tobramycin ophthalmic (eye)	T1	
tobramycin-dexamethasone	T2	
TOBREX OPHTHALMIC (EYE) OINTMENT	T3	
TRAVATAN Z	T4	
travoprost	T3	
trifluridine	T2	
TRYPTYR	T4	ST; QL (60 EA per 30 days)
TYRVAYA	T4	ST; QL (8.4 ML per 30 days)
VERKAZIA	T5	PA; QL (120 EA per 30 days)
VEVYE	T4	ST; QL (2 ML per 30 days)
VIGAMOX	T4	
VUITY	T4	PA; QL (5 ML per 25 days)
VYZULTA	T4	ST; QL (5 ML per 31 days)
XALATAN	T4	
XDEMVY	T5	PA; QL (10 ML per 42 days)
XIIDRA	T3	QL (60 EA per 30 days)
ZERVIATE	T4	PA
ZIOPTAN (PF)	T4	ST

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ZIRGAN	T4	ST
ZYLET	T4	
Respiratory And Allergy		
acetylcysteine	T2	PA-BvD
ADCIRCA	T5	PA; QL (62 EA per 31 days)
ADEMPAS	T5	PA; QL (93 EA per 31 days)
ADVAIR DISKUS	T4	ST; QL (60 EA per 30 days)
ADVAIR HFA	T3	QL (12 GM per 30 days)
AIRSUPRA	T4	PA; QL (32.1 GM per 30 days)
albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation	T3	QL (17 GM per 30 days)
albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020503)	T3	QL (13.4 GM per 30 days)
albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020983)	T4	ST; QL (36 GM per 30 days)
albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml	T2	PA-BvD
albuterol sulfate oral syrup	T1	
albuterol sulfate oral tablet	T1	
ALVESCO	T4	QL (12.2 GM per 30 days)
ALYFTREK ORAL TABLET 10-50-125 MG	T5	PA; QL (56 EA per 28 days)
ALYFTREK ORAL TABLET 4-20-50 MG	T5	PA; QL (84 EA per 28 days)
ALYQ	T5	PA; QL (62 EA per 31 days)
ambrisentan	T5	PA; QL (31 EA per 31 days)
ANDEMBRY AUTOINJECTOR	T5	PA; QL (1.2 ML per 28 days)
ANORO ELLIPTA	T3	QL (60 EA per 30 days)
arformoterol	T4	PA-BvD
ARNUITY ELLIPTA	T4	QL (30 EA per 30 days)
ASMANEX HFA	T3	QL (13 GM per 30 days)
ASMANEX TWISTHALER INHALATION AEROSOL POWDR BREATH ACTIVATED 110 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (120), 220 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (60)	T3	QL (1 EA per 30 days)
ATROVENT HFA	T3	QL (25.8 GM per 30 days)
AUVI-Q	T4	ST
azelastine-fluticasone	T4	QL (23 GM per 30 days)
BERINERT INTRAVENOUS KIT	T5	PA

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
BEVESPI AEROSPHERE	T4	QL (10.7 GM per 30 days)
bosentan oral tablet	T5	PA; QL (62 EA per 31 days)
BREO ELLIPTA	T3	QL (60 EA per 30 days)
BREYNA	T3	QL (10.3 GM per 30 days)
BREZTRI AEROSPHERE	T3	QL (10.7 GM per 30 days)
BRINSUPRI	T5	PA; QL (31 EA per 31 days)
BROVANA	T4	PA-BvD
budesonide inhalation	T4	PA-BvD
budesonide-formoterol	T3	QL (10.2 GM per 30 days)
carbinoxamine maleate oral liquid	T4	PA
carbinoxamine maleate oral tablet	T4	PA
cetirizine oral solution 1 mg/ml	T1	QL (310 ML per 31 days)
CINRYZE	T5	PA; QL (20 EA per 28 days)
CLARINEX ORAL TABLET	T4	QL (31 EA per 31 days)
CLARINEX-D 12 HOUR	T4	
clemastine oral syrup	T2	PA
clemastine oral tablet	T2	
COMBIVENT RESPIMAT	T3	QL (4 GM per 30 days)
cromolyn inhalation	T4	PA-BvD
cyproheptadine	T2	PA
DALIRESP	T4	QL (31 EA per 31 days)
desloratadine	T2	QL (31 EA per 31 days)
DUAKLIR PRESSAIR	T4	QL (1 EA per 30 days)
DULERA	T3	QL (13 GM per 30 days)
DYMISTA	T4	ST; QL (23 GM per 30 days)
EKTERLY	T5	PA; QL (8 EA per 31 days)
epinephrine injection auto-injector	T3	
EPIPEN 2-PAK	T4	ST
EPIPEN JR 2-PAK	T4	ST
ESBRIET ORAL CAPSULE	T5	PA; QL (279 EA per 31 days)
ESBRIET ORAL TABLET	T5	PA; QL (93 EA per 31 days)
FASENRA PEN	T5	PA; QL (1 ML per 28 days)
FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML	T5	PA; QL (0.5 ML per 56 days)
FASENRA SUBCUTANEOUS SYRINGE 30 MG/ML	T5	PA; QL (1 ML per 28 days)
FIRAZYR	T5	PA; QL (18 ML per 30 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
flunisolide	T2	QL (50 ML per 25 days)
fluticasone furoate	T4	QL (30 EA per 30 days)
fluticasone furoate-vilanterol	T4	ST; QL (60 EA per 30 days)
fluticasone propionate inhalation blister with device 100 mcg/actuation, 50 mcg/actuation	T4	ST; QL (60 EA per 30 days)
fluticasone propionate inhalation blister with device 250 mcg/actuation	T4	ST; QL (240 EA per 30 days)
fluticasone propionate inhalation hfa aerosol inhaler 110 mcg/actuation	T4	ST; QL (12 GM per 30 days)
fluticasone propionate inhalation hfa aerosol inhaler 220 mcg/actuation	T4	ST; QL (24 GM per 30 days)
fluticasone propionate inhalation hfa aerosol inhaler 44 mcg/actuation	T4	ST; QL (10.6 GM per 30 days)
fluticasone propionate nasal	T1	QL (16 GM per 30 days)
fluticasone propion-salmeterol inhalation aerosol powdr breath activated	T4	ST; QL (1 EA per 30 days)
fluticasone propion-salmeterol inhalation blister with device	T3	QL (60 EA per 30 days)
fluticasone propion-salmeterol inhalation hfa aerosol inhaler	T4	QL (12 GM per 30 days)
formoterol fumarate	T4	PA-BvD
HAEGARDA	T5	PA
hydroxyzine hcl oral solution 10 mg/5 ml	T2	PA
hydroxyzine hcl oral tablet	T2	PA
hydroxyzine pamoate	T2	PA
icatibant	T5	PA; QL (18 ML per 30 days)
INCRUSE ELLIPTA	T4	ST; QL (30 EA per 30 days)
ipratropium bromide inhalation	T1	PA-BvD
ipratropium-albuterol	T2	PA-BvD
KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 5.8 MG, 50 MG, 75 MG	T5	PA; QL (56 EA per 28 days)
KALYDECO ORAL GRANULES IN PACKET 25 MG	T5	PA; QL (62 EA per 31 days)
KALYDECO ORAL TABLET	T5	PA; QL (62 EA per 31 days)
LETAIRIS	T5	PA; QL (31 EA per 31 days)
levalbuterol hcl	T2	PA-BvD
levalbuterol tartrate	T3	QL (30 GM per 30 days)
levocetirizine oral solution	T4	QL (310 ML per 31 days)
levocetirizine oral tablet	T1	QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
mometasone nasal	T3	QL (34 GM per 30 days)
montelukast	T2	QL (31 EA per 31 days)
NEFFY	T4	ST
NUCALA SUBCUTANEOUS AUTO-INJECTOR	T5	PA; QL (3 ML per 28 days)
NUCALA SUBCUTANEOUS RECON SOLN	T5	PA; QL (3 EA per 28 days)
NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML	T5	PA; QL (3 ML per 28 days)
NUCALA SUBCUTANEOUS SYRINGE 40 MG/0.4 ML	T5	PA; QL (0.4 ML per 28 days)
OFEV	T5	PA; QL (62 EA per 31 days)
OHTUVAYRE	T5	PA; QL (150 ML per 30 days)
OMNARIS	T4	QL (12.5 GM per 30 days)
OPSUMIT	T5	PA; QL (31 EA per 31 days)
OPSYNVI	T5	PA; QL (31 EA per 31 days)
ORKAMBI ORAL GRANULES IN PACKET	T5	PA; QL (62 EA per 31 days)
ORKAMBI ORAL TABLET	T5	PA; QL (124 EA per 31 days)
ORLADEYO	T5	PA; QL (31 EA per 31 days)
PERFOROMIST	T4	PA-BvD
pirfenidone oral capsule	T5	PA; QL (279 EA per 31 days)
pirfenidone oral tablet	T5	PA; QL (93 EA per 31 days)
PROAIR RESPICLICK	T4	ST; QL (2 EA per 30 days)
promethazine oral	T2	PA
promethazine rectal suppository 12.5 mg, 25 mg	T2	
PROMETHEGAN RECTAL SUPPOSITORY 25 MG, 50 MG	T2	
PULMICORT	T4	PA-BvD
PULMICORT FLEXHALER	T4	QL (1 EA per 30 days)
PULMOZYME	T5	PA
QNASL NASAL HFA AEROSOL INHALER 40 MCG/ACTUATION	T4	QL (6.8 GM per 30 days)
QNASL NASAL HFA AEROSOL INHALER 80 MCG/ACTUATION	T4	QL (10.6 GM per 30 days)
QVAR REDIHALER INHALATION HFA AEROSOL BREATH ACTIVATED 40 MCG/ACTUATION	T3	QL (10.6 GM per 30 days)
QVAR REDIHALER INHALATION HFA AEROSOL BREATH ACTIVATED 80 MCG/ACTUATION	T3	QL (21.2 GM per 30 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
REVATIO ORAL TABLET	T5	PA; QL (372 EA per 31 days)
roflumilast oral tablet 250 mcg	T4	QL (31 EA per 31 days)
roflumilast oral tablet 500 mcg	T3	QL (31 EA per 31 days)
RUCONEST	T5	PA
RYALTRIS	T4	ST; QL (29 GM per 30 days)
RYCLORA	T4	
RYVENT	T4	PA
SAJAZIR	T5	PA; QL (18 ML per 30 days)
SEREVENT DISKUS	T3	QL (60 EA per 30 days)
sildenafil (pulm.hypertension) oral suspension for reconstitution	T5	PA; QL (784 ML per 31 days)
sildenafil (pulm.hypertension) oral tablet	T3	PA; QL (372 EA per 31 days)
SINGULAIR	T4	QL (31 EA per 31 days)
SPIRIVA RESPIMAT	T3	QL (4 GM per 30 days)
SPIRIVA WITH HANDIHALER	T4	ST; QL (30 EA per 30 days)
STIOLTO RESPIMAT	T3	QL (4 GM per 30 days)
STRIVERDI RESPIMAT	T3	QL (4 GM per 30 days)
SYMBICORT	T4	ST; QL (10.2 GM per 30 days)
SYMDEKO	T5	PA; QL (56 EA per 28 days)
tadalafil (pulm. hypertension)	T5	PA; QL (62 EA per 31 days)
TADLIQ	T5	PA; QL (310 ML per 31 days)
TAKHZYRO SUBCUTANEOUS SOLUTION	T5	PA; QL (4 ML per 28 days)
TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML	T5	PA; QL (2 ML per 28 days)
TAKHZYRO SUBCUTANEOUS SYRINGE 300 MG/2 ML (150 MG/ML)	T5	PA; QL (4 ML per 28 days)
terbutaline oral	T2	
THEO-24	T3	
theophylline oral solution	T2	
theophylline oral tablet extended release 12 hr	T2	
theophylline oral tablet extended release 24 hr	T2	
tiotropium bromide	T4	ST; QL (30 EA per 30 days)
TRACLEER ORAL TABLET	T5	PA; QL (62 EA per 31 days)
TRACLEER ORAL TABLET FOR SUSPENSION	T5	PA; QL (124 EA per 31 days)
TRELEGY ELLIPTA	T3	QL (60 EA per 30 days)
TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL	T5	PA; QL (56 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
TRIKAFTA ORAL TABLETS, SEQUENTIAL	T5	PA; QL (84 EA per 28 days)
TUDORZA PRESSAIR	T4	ST; QL (1 EA per 30 days)
TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16 MCG, 32 MCG, 48 MCG, 64 MCG	T5	PA
TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16(112)-32(112) -48(28) MCG	T5	PA; QL (504 EA per 365 days)
umeclidinium-vilanterol	T4	ST; QL (60 EA per 30 days)
VENTOLIN HFA	T3	QL (36 GM per 30 days)
WINREVAIR	T5	PA
WIXELA INHUB	T3	QL (60 EA per 30 days)
XHANCE	T4	PA; QL (32 ML per 30 days)
XOLAIR	T5	PA
XOPENEX HFA	T4	ST; QL (30 GM per 30 days)
YUPELRI	T5	PA-BvD
YUTREPIA INHALATION CAPSULE, W/INHALATION DEVICE 106 MCG	T5	PA; QL (224 EA per 28 days)
YUTREPIA INHALATION CAPSULE, W/INHALATION DEVICE 26.5 MCG, 53 MCG	T5	PA; QL (140 EA per 28 days)
YUTREPIA INHALATION CAPSULE, W/INHALATION DEVICE 79.5 MCG	T5	PA; QL (112 EA per 28 days)
zafirlukast oral tablet 10 mg	T4	QL (93 EA per 31 days)
zafirlukast oral tablet 20 mg	T4	QL (62 EA per 31 days)
zileuton	T5	PA; QL (124 EA per 31 days)
ZYFLO	T5	PA; QL (124 EA per 31 days)
Urologicals		
alfuzosin	T2	QL (31 EA per 31 days)
AVODART	T4	QL (31 EA per 31 days)
bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg	T2	
bethanechol chloride oral tablet 50 mg	T3	
CIALIS ORAL TABLET 5 MG	T4	PA; QL (31 EA per 31 days)
CYSTAGON	T3	
darifenacin	T3	QL (31 EA per 31 days)
dutasteride	T2	QL (31 EA per 31 days)
dutasteride-tamsulosin	T3	QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
ELMIRON	T4	
fesoterodine	T3	QL (31 EA per 31 days)
finasteride oral tablet 5 mg	T2	
flavoxate	T2	
GEMTESA	T4	QL (31 EA per 31 days)
JALYN	T5	QL (31 EA per 31 days)
mirabegron	T4	ST; QL (31 EA per 31 days)
MYRBETRIQ ORAL SUSPENSION,EXTENDED REL RECON	T3	QL (300 ML per 30 days)
MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HR	T3	QL (31 EA per 31 days)
oxybutynin chloride oral syrup	T2	
oxybutynin chloride oral tablet 5 mg	T2	
oxybutynin chloride oral tablet extended release 24hr 10 mg, 5 mg	T2	QL (31 EA per 31 days)
oxybutynin chloride oral tablet extended release 24hr 15 mg	T3	QL (62 EA per 31 days)
OXYTROL	T4	QL (8 EA per 28 days)
potassium citrate oral tablet extended release	T2	
PROCYSBI ORAL GRANULES DEL RELEASE IN PACKET	T5	PA
PROSCAR	T4	
RIVFLOZA SUBCUTANEOUS SOLUTION	T5	PA; QL (1 ML per 28 days)
RIVFLOZA SUBCUTANEOUS SYRINGE 128 MG/0.8 ML	T5	PA; QL (0.8 ML per 28 days)
RIVFLOZA SUBCUTANEOUS SYRINGE 160 MG/ML	T5	PA; QL (1 ML per 28 days)
silodosin	T4	
solifenacin	T3	QL (31 EA per 31 days)
tadalafil oral tablet 2.5 mg	T4	PA; QL (62 EA per 31 days)
tadalafil oral tablet 5 mg	T4	PA; QL (31 EA per 31 days)
tamsulosin	T1	
tolterodine oral capsule,extended release 24hr	T3	QL (31 EA per 31 days)
tolterodine oral tablet	T3	QL (62 EA per 31 days)
TOVIAZ	T4	QL (31 EA per 31 days)
trospium oral capsule,extended release 24hr	T4	QL (31 EA per 31 days)
trospium oral tablet	T2	QL (93 EA per 31 days)
UROCIT-K 10	T4	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
UROCIT-K 15	T4	
UROXATRAL	T4	QL (31 EA per 31 days)
VESICARE	T4	QL (31 EA per 31 days)
VESICARE LS	T4	QL (310 ML per 31 days)
Vitamins, Hematinics / Electrolytes		
AQNEURSA	T5	PA; QL (124 EA per 31 days)
CLINIMIX 5%/D15W SULFITE FREE	T4	PA-BvD
CLINIMIX 4.25%/D10W SULF FREE	T4	PA-BvD
CLINIMIX 5%-D20W(SULFITE-FREE)	T4	PA-BvD
CLINIMIX E 4.25%/D10W SUL FREE	T4	PA-BvD
CLINIMIX E 4.25%/D5W SULF FREE	T4	PA-BvD
CLINIMIX E 5%/D15W SULFIT FREE	T4	PA-BvD
CLINIMIX E 5%/D20W SULFIT FREE	T4	PA-BvD
CLINISOL SF 15 %	T4	PA-BvD
CLINOLIPID	T4	PA-BvD
DOJOLVI	T5	PA
electrolyte-a	T4	PA-BvD
fluoride (sodium) oral tablet	T2	
INTRALIPID INTRAVENOUS EMULSION 20 %, 30 %	T4	PA-BvD
ISOLYTE S PH 7.4	T3	PA-BvD
ISOLYTE-P IN 5 % DEXTROSE	T4	PA-BvD
KLOR-CON	T4	
KLOR-CON 10	T3	
KLOR-CON 8	T3	
KLOR-CON M10	T1	
KLOR-CON M15	T1	
KLOR-CON M20	T1	
magnesium sulfate injection	T2	
NUTRILIPID	T4	PA-BvD
PLASMA-LYTE A	T4	PA-BvD
PLENAMINE	T3	PA-BvD
potassium chlorid-d5-0.45%nacl	T2	
potassium chloride in 0.9%nacl intravenous parenteral solution 20 meq/l, 40 meq/l	T2	
potassium chloride in 5 % dex intravenous parenteral solution 20 meq/l	T2	

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Drug Name	Drug Tier	Requirements/Limits
potassium chloride in lr-d5 intravenous parenteral solution 20 meq/l	T2	
potassium chloride in water intravenous piggyback 10 meq/100 ml, 20 meq/100 ml, 40 meq/100 ml	T2	
potassium chloride intravenous	T2	
potassium chloride oral capsule, extended release	T1	
potassium chloride oral liquid	T2	
potassium chloride oral packet	T2	
potassium chloride oral tablet extended release 10 meq, 20 meq, 8 meq	T1	
potassium chloride oral tablet extended release 15 meq	T4	
potassium chloride oral tablet,er particles/crystals	T1	
potassium chloride-0.45 % nacl	T2	
potassium chloride-d5-0.2%nacl intravenous parenteral solution 20 meq/l	T2	
potassium chloride-d5-0.9%nacl	T2	
PREMASOL 10 %	T4	PA-BvD
PRENATAL VITAMIN PLUS LOW IRON	T2	PA
PROSOL 20 %	T4	PA-BvD
sodium chloride 0.45 % intravenous	T2	
sodium chloride 3 % hypertonic	T2	
sodium chloride 5 % hypertonic	T2	
TPN ELECTROLYTES	T4	
TRAVASOL 10 %	T4	PA-BvD
TROPHAMINE 10 %	T4	PA-BvD

You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table.

Index of Drugs

abacavir 3
abacavir-lamivudine 3
ABIGALE 107
ABIGALE LO 108
ABILIFY 26
ABILIFY ASIMTUFII 25, 26
ABILIFY MAINTENA 26
abiraterone 15
ABIRTEGA 15
ABRILADA(CF) 103
ABRILADA(CF) PEN 103
ABRYSVO (PF) 99
ABSORICA 69
ABSORICA LD 69
acamprosate 80
ACANYA 69
acarbose 84
ACCUTANE 69
acebutolol 58
acetaminophen-codeine 26
acetazolamide 114
acetic acid 83
acetylcysteine 118
ACIPHEX 92
acitretin 69
ACTEMRA 103
ACTEMRA ACTPEN 103
ACTHAR 84
ACTHAR SELFJECT 84
ACTHIB (PF) 99
ACTIMMUNE 99
ACTIVELLA 108
ACTONEL 103
ACTOPLUS MET 84
ACTOS 84
ACULAR 114
ACULAR LS 114
ACUVAIL (PF) 114
acyclovir 3, 70
acyclovir sodium 3
ACZONE 70
ADACEL(TDAP ADOLESN/ADULT)(PF) 99
adalimumab-aacf 103
ADALIMUMAB-AACF(CF) PEN CROHNS 103
ADALIMUMAB-AACF(CF) PEN PS-UV 103
adalimumab-aaty 103
ADALIMUMAB-AATY(CF) AI CROHNS 103
adalimumab-adaz 103
adalimumab-adbm 103
adalimumab-fkjp 103
adalimumab-ryvk 103, 104
adapalene 70
adapalene-benzoyl peroxide 70
ADBRY 70
ADCIRCA 118
ADDERALL 26
ADDERALL XR 26
adefovir 3
ADEMPAS 118
ADLARITY 26
ADMELOG SOLOSTAR U-100 INSULIN 84
ADMELOG U-100 INSULIN LISPRO 84
ADVAIR DISKUS 118
ADVAIR HFA 118
ADZENYS XR-ODT 26
AFINITOR 15
AFINITOR DISPERZ 15
AFREZZA 84
AGAMREE 84
AGRYLIN 80
AIMOVIG AUTOINJECTOR 26
AIRSUPRA 118
AJOVY AUTOINJECTOR 26
AJOVY SYRINGE 26
AKEEGA 15
AKLIEF 70
ALA-CORT 70
ALA-SCALP 70
albendazole 3
albuterol sulfate 118
alclometasone 70
ALCOHOL PADS 84
ALDACTONE 58
ALECENSA 15
alendronate 104
alfuzosin 123
aliskiren 58
ALKINDI SPRINKLE 84
allopurinol 104
ALLZITAL 26
almotriptan malate 26
alogliptin 84
alogliptin-metformin 84
alogliptin-pioglitazone 84
alosetron 92
ALPHAGAN P 114
alprazolam 26
ALPRAZOLAM INTENSOL 26
ALREX 114
ALTAVERA (28) 108
ALTRENO 70
ALUNBRIG 15
ALVAIZ 58
ALVESCO 118
ALYACEN 1/35 (28) 108
ALYFTREK 118
ALYQ 118
amantadine hcl 3
AMBIEN 26
AMBIEN CR 26
AMBISOME 3
ambrisentan 118
amcinonide 70
amikacin 3
amiloride 58
amiloride-hydrochlorothiazide 58
amiodarone 58
AMITIZA 92
amitriptyline 26
amitriptyline-chlordiazepoxide 27
AMJEVITA(CF) 104
AMJEVITA(CF) AUTOINJECTOR 104
amlodipine 58
amlodipine-atorvastatin 58
amlodipine-benazepril 58
amlodipine-olmesartan 58
amlodipine-valsartan 58
amlodipine-valsartan-hcthiazid 58
ammonium lactate 70
AMNESTEEM 70
amoxapine 27
amoxicil-clarithromy-lansopraz 92
amoxicillin 3
amoxicillin-pot clavulanate 3, 4
amphetamine sulfate 27
amphotericin b 4
amphotericin b liposome 4
ampicillin 4
ampicillin sodium 4
ampicillin-sulbactam 4
AMPYRA 27
AMRIX 27
AMZEEQ 70
ANAFRANIL 27
anagrelide 80
ANALPRAM-HC 70

anastrozole 16
ANCOBON 4
ANDEMBRY AUTOINJECTOR 118
ANGELIQ 108
ANNOVERA 108
ANORO ELLIPTA 118
ANUSOL-HC 92
ANZUPGO 70
APIDRA SOLOSTAR U-100 INSULIN 84
APIDRA U-100 INSULIN 84
APLENZIN 27
APOKYN 27
apomorphine 27
apraclonidine 114
aprepitant 93
APRI 108
APRISO 93
APTENSIO XR 27
APTIOM 27
APTIVUS 4
AQNEURSA 125
ARALAST NP 80
ARANELLE (28) 108
ARANESP (IN POLYSORBATE) 99
ARAVA 104
ARAZLO 70
ARBLI 58
ARCALYST 99
AREXVY (PF) 99
arformoterol 118
ARICEPT 27
ARIKAYCE 4
ARIMIDEX 16
aripiprazole 27
ARISTADA 27
ARISTADA INITIO 27
ARIXTRA 58
armodafinil 27
ARNUITY ELLIPTA 118
AROMASIN 16
ARTHROTEC 50 27
ARTHROTEC 75 27
ASCOMP WITH CODEINE 27
asenapine maleate 27
ASHLYNA 108
ASMANEX HFA 118
ASMANEX TWISTHALER 118
aspirin-dipyridamole 58
ASSURE ID INSULIN SAFETY 103
ASTAGRAF XL 16
ATACAND 58
ATACAND HCT 58
atazanavir 4
ATELVIA 104
atenolol 58
atenolol-chlorthalidone 58
ATIVAN 27
atomoxetine 28
ATORVALIQ 58
atorvastatin 58
atovaquone 4
atovaquone-proguanil 4
ATRALIN 70
atropine 114
ATROVENT HFA 118
ATTRUBY 59
AUBAGIO 28
AUBRA EQ 108
AUGMENTIN 4
AUGMENTIN ES-600 4
AUGTYRO 16
AUSTEDO 28
AUSTEDO XR 28
AUSTEDO XR TITRATION KT(WK1-4) 28
AUVELITY 28
AUVI-Q 118
AVALIDE 59
AVAPRO 59
AVEED 84
AVIANE 108
AVMAPKI-FAKZYNJA 16
AVODART 123
AVONEX 99
AVYCAZ 4
AYVAKIT 16
AZACTAM 4
AZASAN 16
AZASITE 114
azathioprine 16
azelaic acid 70
azelastine 83, 114
azelastine-fluticasone 118
AZELEX 70
AZILECT 28
azithromycin 4
AZOPT 114
AZOR 59
AZSTARYS 28
aztreonam 4
AZULFIDINE 93
AZULFIDINE EN-TABS 93
AZURETTE (28) 108
bacitracin 114
bacitracin-polymyxin b 114
baclofen 28
BACTRIM 4
BACTRIM DS 4
BAFIERTAM 28
BALCOLTRA 108
balsalazide 93
BALVERSA 16
BALZIVA (28) 108
BANZEL 28
BAQSIMI 84
BARACLUDE 4
BASAGLAR KWIKPEN U-100 INSULIN 84
BASAGLAR TEMPO PEN(U-100)INSLN 84
BAXDELA 4
bcg vaccine, live (pf) 99
BELBUCA 28
BELSOMRA 28
benazepril 59
benazepril-hydrochlorothiazide 59
BENICAR 59
BENICAR HCT 59
BENLYSTA 104
BENZAMYCIN 70
benztropine 28
bepotastine besilate 114
BEPREVE 114
BERINERT 118
BESIVANCE 114
BESREMI 99
betaine 93
betamethasone dipropionate 70
betamethasone valerate 70
betamethasone, augmented 70
BETAPACE AF 59
BETASERON 99
betaxolol 59, 114
bethanechol chloride 123
BETHKIS 4
BETIMOL 114
BEVESPI AEROSPHERE 119
bexarotene 16
BEXSERO 99
BEYAZ 108
bicalutamide 16

BICILLIN C-R 4
BICILLIN L-A 4
BIDIL 59
BIJUVA 108
BIKTARVY 4
bimatoprost 114
BIMZELX 71
BIMZELX AUTOINJECTOR 70
BINOSTO 104
bismuth subcit k-metronidz-tcn 93
bisoprolol fumarate 59
bisoprolol-hydrochlorothiazide 59
BIVIGAM 99
BLISOVI 24 FE 108
BLISOVI FE 1.5/30 (28) 108
BOMYNTRA 16
BONJESTA 93
BONSITY 104
BOOSTRIX TDAP 99
bosentan 119
BOSULIF 16
BRAFTOVI 16
BREO ELLIPTA 119
BREYNA 119
BREZTRI AEROSPHERE 119
BRIELLYN 108
BRILINTA 59
brimonidine 71, 114
brimonidine-timolol 114
BRINSUPRI 119
brinzolamide 114
BRIVIACT 28
bromfenac 114, 115
bromocriptine 28
BROMSITE 115
BROVANA 119
BRUKINSA 16
BRYHALI 71
BUCAPSOL 28
budesonide 93, 119
budesonide-formoterol 119
bumetanide 59
BUPHENYL 80
buprenorphine 28
buprenorphine hcl 28
buprenorphine-naloxone 28
bupropion hcl 28, 29
bupropion hcl (smoking deter) 80
buspirone 29
butalbital-acetaminop-caf-cod 29
butalbital-acetaminophen 29
butalbital-acetaminophen-caff 29
butalbital-aspirin-caffeine 29
butorphanol 29
BUTRANS 29
BYLVAY 93
BYSTOLIC 59
cabergoline 84
CABLIVI 59
CABOMETYX 16
CABTREO 71
CADUET 59
calcipotriene 71
calcipotriene-betamethasone 71
calcitonin (salmon) 84
calcitriol 71, 84
CALQUENCE (ACALABRUTINIB MAL) 16
CAMBIA 29
CAMILA 108
CAMRESE LO 108
CAMZYOS 59
CANASA 93
candesartan 59
candesartan-hydrochlorothiazid 59
CAPLYTA 29
CAPRELSA 16
captopril 59
CARAFATE 93
CARBAGLU 80
carbamazepine 29
CARBATROL 29
carbidopa 29
carbidopa-levodopa 29
carbidopa-levodopa-entacapone 29
carbinoxamine maleate 119
CARDIZEM 59
CARDIZEM CD 59
CARDIZEM LA 59
CARDURA 59
CARDURA XL 59
carglumic acid 80
carisoprodol 29
CARNITOR 80
CAROSPIR 59
carteolol 115
CARTIA XT 60
carvedilol 60
carvedilol phosphate 60
CASODEX 16
caspofungin 4
CAYSTON 4
cefaclor 4, 5
cefadroxil 5
cefazolin 5
cefdinir 5
cefepime 5
cefixime 5
cefotetan 5
cefoxitin 5
cefpodoxime 5
cefprozil 5
ceftazidime 5
ceftriaxone 5
cefuroxime axetil 5
cefuroxime sodium 5
CELEBREX 29
celecoxib 29
CELEXA 29
CELLCEPT 16
CELONTIN 29
cephalexin 5
CEQUA 115
CERDELGA 84
cetirizine 119
cevimeline 80
CHEMET 80
CHENODAL 93
chlordiazepoxide hcl 30
chlordiazepoxide-clidinium 93
chlorhexidine gluconate 83
chloroquine phosphate 5
chlorpromazine 30
chlorthalidone 60
chlorzoxazone 30
CHOLBAM 93
cholestyramine (with sugar) 60
CHOLESTYRAMINE LIGHT 60
CIALIS 123
CIBINQO 71
ciclopirox 71
cilostazol 60
CILOXAN 115
CIMDUO 5
cimetidine 93
cimetidine hcl 93
CIMZIA 93
CIMZIA POWDER FOR RECONST 93
cinacalcet 84
CINRYZE 119
CIPRO 5
CIPRO HC 83
ciprofloxacin hcl 5, 83, 115
ciprofloxacin in 5 % dextrose 5

ciprofloxacin-dexamethasone 83
citalopram 30
CLARAVIS 71
CLARINEX 119
CLARINEX-D 12 HOUR 119
clarithromycin 5
clemastine 119
CLENPIQ 93
CLEOCIN 5, 108
CLEOCIN HCL 5
CLEOCIN PEDIATRIC 5
CLEOCIN T 71
CLIMARA 108
CLIMARA PRO 108
CLINDACIN 71
CLINDACIN ETZ 71
CLINDAGEL 71
clindamycin hcl 5
clindamycin in 5 % dextrose 6
CLINDAMYCIN PEDIATRIC 6
clindamycin phosphate ... 6, 71, 108
clindamycin-benzoyl peroxide 71
clindamycin-tretinoin 71
CLINDESSE 108
CLINIMIX 5%/D15W SULFITE FREE 125
CLINIMIX 4.25%/D10W SULF FREE 125
CLINIMIX 4.25%/D5W SULFIT FREE 80
CLINIMIX 5%-D20W(SULFITE-FREE) 125
CLINIMIX E 2.75%/D5W SULF FREE 80
CLINIMIX E 4.25%/D10W SUL FREE 125
CLINIMIX E 4.25%/D5W SULF FREE 125
CLINIMIX E 5%/D15W SULFIT FREE 125
CLINIMIX E 5%/D20W SULFIT FREE 125
CLINISOL SF 15 % 125
CLINOLIPID 125
clobazam 30
clobetasol 71, 72
clobetasol-emollient 72
CLOBEX 72
clocortolone pivalate 72
CLODAN 72
clomipramine 30
clonazepam 30
clonidine 60
clonidine hcl 30, 60
clopidogrel 60
clorazepate dipotassium 30
clotrimazole 6, 72
clotrimazole-betamethasone 72
clozapine 30
CLOZARIL 30
COARTEM 6
COBENFY 30
COBENFY STARTER PACK . 30
codeine sulfate 30
codeine-butalbital-asa-caff 30
colchicine 104
colesevelam 60
COLESTID 60
colestipol 60
colistin (colistimethate na) 6
COMBIGAN 115
COMBIPATCH 108
COMBIVENT RESPIMAT ... 119
COMETRIQ 16, 17
COMPLERA 6
COMPRO 93
CONCERTA 30
CONDYLOX 72
CONEXXENCE 104
CONSTULOSE 93
CONZIP 30
COPAXONE 31
COPIKTRA 17
CORDRAN TAPE LARGE ROLL 72
COREG 60
COREG CR 60
CORLANOR 60
CORTEF 85
CORTROPHIN GEL 85
COSENTYX 72
COSENTYX (2 SYRINGES) ... 72
COSENTYX PEN (2 PENS) 72
COSENTYX UNOREADY PEN 72
COSOPT 115
COSOPT (PF) 115
COTELLIC 17
COTEMPLA XR-ODT 31
COZAAR 60
CRENESSITY 85
CREON 93
CRESEMBA 6
CRESTOR 60
CREXONT 31
CRINONE 108
cromolyn 93, 115, 119
CROTAN 72
CRYSELLE (28) 108
CTEXLI 93
CUPRIMINE 104
CUVPOSA 93
CUVRIOR 80
cyclobenzaprine 31
cyclophosphamide 17
cycloserine 6
CYCLOSET 85
cyclosporine 17, 115
cyclosporine modified 17
CYLTEZO(CF) 104
CYLTEZO(CF) PEN 104
CYLTEZO(CF) PEN CROHN'S-UC-HS 104
CYLTEZO(CF) PEN PSORIASIS-UV 104
cyproheptadine 119
CYRED EQ 108
CYSTADANE 93
CYSTADROPS 115
CYSTAGON 123
CYSTARAN 115
CYTOMEL 85
CYTOTEC 94
d10 %-0.45 % sodium chloride ... 80
d2.5 %-0.45 % sodium chloride .. 80
d5 % and 0.9 % sodium chloride 80
d5 %-0.45 % sodium chloride 80
dabigatran etexilate 60
dalfampridine 31
DALIRESP 119
DALVANCE 6
danazol 85
DANTRIUM 31
dantrolene 31
DANZITEN 17
dapaglifloz propaned-metformin 85
dapagliflozin propanediol 85
dapsone 6, 72
DAPTACEL (DTAP PEDIATRIC) (PF) 99
daptomycin 6
DARAPRIM 6
darifenacin 123
darunavir 6

dasatinib 17
DAURISMO 17
DAYBUE 31
DAYTRANA 31
DAYVIGO 31
DDAVP 85
DEBLITANE 108
deferasirox 80
deferiprone 80
deflazacort 85
DELESTROGEN 108
DELSTRIGO 6
demeclocycline 6
DEMEROL 31
DEMEROL (PF) 31
DEMSER 60
DENAVIR 72
DEPAKOTE 31
DEPAKOTE ER 31
DEPAKOTE SPRINKLES 31
DEPEN TITRATABS 104
DEPO-ESTRADIOL 108
DEPO-PROVERA 108, 109
DEPO-SUBQ PROVERA 104 109
DEPO-TESTOSTERONE 85
DERMA-SMOOTHE/FS SCALP OIL 72
DERMOTIC OIL 83
DESCOVY 6
desipramine 31
desloratadine 119
desmopressin 85
desonide 72
desoximetasone 72, 73
desvenlafaxine 31
desvenlafaxine succinate 31
dexamethasone 85
dexamethasone sodium phosphate 115
DEXEDRINE SPANSULE 31
DEXILANT 94
dexlansoprazole 94
dexmethylphenidate 31
dextroamphetamine sulfate ... 31, 32
dextroamphetamine-amphetamine 32
dextrose 10 % and 0.2 % nacl 80
dextrose 10 % in water (d10w) ... 80
dextrose 5 % in water (d5w) 80
dextrose 5%-0.2 % sod chloride . 80
DHIVY 32
DIACOMIT 32
diazepam 32
DIAZEPAM INTENSOL 32
diazoxide 85
DIBENZYLINE 60
DICLEGIS 94
diclofenac epolamine 32
diclofenac potassium 32
diclofenac sodium 32, 73, 115
diclofenac-misoprostol 33
dicloxacillin 6
dicyclomine 94
DIFFERIN 73
DIFICID 6
diflorasone 73
DIFLUCAN 6
diflunisal 33
difluprednate 115
digoxin 60
dihydroergotamine 33
DILANTIN 33
DILANTIN EXTENDED 33
DILANTIN INFATABS 33
DILANTIN-125 33
DILAUDID 33
diltiazem hcl 60, 61
DILT-XR 61
dimethyl fumarate 33
DIOVAN 61
DIOVAN HCT 61
DIPENTUM 94
diphenoxylate-atropine 94
DIPROLENE (AUGMENTED) 73
dipyridamole 61
disopyramide phosphate 61
disulfiram 80
DIURIL 61
divalproex 33
DIVIGEL 109
dofetilide 61
DOJOLVI 125
DOLISHALE 109
DOLOBID 33
donepezil 33
DOPTELET (10 TAB PACK) . 61
DOPTELET (15 TAB PACK) . 61
DOPTELET (30 TAB PACK) . 61
DORYX MPC 6
dorzolamide 115
dorzolamide-timolol 115
dorzolamide-timolol (pf) 115
DOTTI 109
DOVATO 6
doxazosin 61
doxepin 33, 73
doxercalciferol 85
DOXY-100 6
doxycycline hyclate 6, 7
doxycycline monohydrate 7
doxylamine-pyridoxine (vit b6) ... 94
DRIZALMA SPRINKLE 33
dronabinol 94
drospirenone-e.estradiol-lm.fa . 109
drospirenone-ethinyl estradiol .. 109
droxidopa 80
DUAKLIR PRESSAIR 119
DUAVEE 109
DUETACT 85
DULERA 119
duloxetine 33, 34
DUOBRII 73
DUOPA 34
DUPIXENT PEN 73
DUPIXENT SYRINGE 73
DUREZOL 115
dutasteride 123
dutasteride-tamsulosin 123
DUVYZAT 80
DYANAVEL XR 34
DYMISTA 119
DYRENIUM 61
E.E.S. 400 7
EBGLYSS PEN 73
EBGLYSS SYRINGE 73
econazole nitrate 73
EDARBI 61
EDARBYCLOR 61
EDECRIN 61
EDLUAR 34
EDURANT 7
EDURANT PED 7
efavirenz 7
efavirenz-emtricitabin-tenofov 7
efavirenz-lamivu-tenofov disop 7
EFFEXOR XR 34
EFFIENT 61
EGRIFTA SV 100
EKTERLY 119
electrolyte-a 125
ELESTRIN 109
eletriptan 34
ELIDEL 73
ELIGARD 17
ELIGARD (3 MONTH) 17

ELIGARD (4 MONTH) 17
ELIGARD (6 MONTH) 17
ELIMITE 73
ELIQUIS 61
ELIQUIS DVT-PE TREAT 30D START 61
ELMIRON 124
eltrombopag olamine 61
ELURYNG 109
ELYXYB 34
EMEND 94
EMFLAZA 85
EMGALITY PEN 34
EMGALITY SYRINGE 34
EMPAVELI 80
EMROSI 7
EMSAM 34
emtricitabine 7
emtricitabine-tenofovir (tdf) 7
emtricita-rilpivirine-tenof df 7
EMTRIVA 7
EMVERM 7
enalapril maleate 61
enalapril-hydrochlorothiazide 61
ENBREL 105
ENBREL MINI 105
ENBREL SURECLICK 105
ENDARI 81
ENDOCET 34
ENGERIX-B (PF) 100
ENGERIX-B PEDIATRIC (PF) 100
ENILLORING 109
enoxaparin 61
ENSKYCE 109
ENSPRYNG 17
ENSTILAR 73
entacapone 34
entecavir 7
ENTRESTO 62
ENTRESTO SPRINKLE 62
ENTYVIO PEN 94
ENULOSE 94
ENVARSUS XR 17
EPCLUSA 7
EPIDIOLEX 34
EPIDUO 73
EPIDUO FORTE 73
epinastine 115
epinephrine 119
EPIPEN 2-PAK 119
EPIPEN JR 2-PAK 119
EPIVIR 7
eplerenone 62
EPOGEN 100
EPRONTIA 34
EPSOLAY 73
EQUETRO 34
ERAXIS(WATER DILUENT) 8
ERGOMAR 34
ergotamine-caffeine 34
ERIVEDGE 17
ERLEADA 17
erlotinib 17
ERMEZA 85
ERRIN 109
ERTACZO 73
ertapenem 8
ERY PADS 73
ERYTHROCIN 8
erythromycin 8, 115
erythromycin ethylsuccinate 8
erythromycin with ethanol 73
erythromycin-benzoyl peroxide 73
ERZOFRI 34, 35
ESBRIET 119
escitalopram oxalate 35
eslicarbazepine 35
esomeprazole magnesium 94
ESTARYLLA 109
estazolam 35
ESTRACE 109
estradiol 109
estradiol valerate 109
estradiol-norethindrone acet 109
ESTRING 109
eszopiclone 35
ethacrynic acid 62
ethambutol 8
ethosuximide 35
etodolac 35
etonogestrel-ethinyl estradiol 109
etravirine 8
EUCRISA 73
EULEXIN 17
EVAMIST 109
EVEKEO 35
EVENITY 105
everolimus (antineoplastic) 17
everolimus (immunosuppressive) 17
EVISTA 105
EVOTAZ 8
EVOXAC 81
EVRYSDI 35
EXELDERM 73
EXELON PATCH 35
exemestane 17
exenatide 85
EXFORGE 62
EXFORGE HCT 62
EXJADE 81
EYSUVIS 115
ezetimibe 62
ezetimibe-simvastatin 62
FABHALTA 81
FABIOR 73
FALMINA (28) 109
famciclovir 8
famotidine 94
FANAPT 35
FANAPT TITRATION PACK A 35
FARXIGA 85
FASENRA 119
FASENRA PEN 119
febuxostat 105
FEIRZA 109
felbamate 35
FELBATOL 35
felodipine 62
FEMARA 17
FEMLYV 109
FEMRING 109
fenofibrate 62
fenofibrate micronized 62
fenofibrate nanocrystallized 62
fenofibric acid (choline) 62
fenoprofen 35
FENOPRON 35
fentanyl 35
FERRIPROX 81
FERRIPROX (2 TIMES A DAY) 81
fesoterodine 124
FETZIMA 35, 36
FIASP FLEXTOUCH U-100 INSULIN 85
FIASP PENFILL U-100 INSULIN 85
FIASP U-100 INSULIN 85
FILSPARI 62
FILSUVEZ 73
FINACEA 74
finasteride 124
fingolimod 36

FINTEPLA 36
FINZALA 109
FIORICET 36
FIORICET WITH CODEINE 36
FIRAZYR 119
FIRDAPSE 36
FIRMAGON KIT W DILUENT SYRINGE 18
FIRVANQ 8
FLAC OTIC OIL 83
FLAREX 115
flavoxate 124
flecainide 62
FLECTOR 36
FLEQSUVY 36
FLOLIPID 62
fluconazole 8
fluconazole in nacl (iso-osm) 8
flucytosine 8
fludrocortisone 85
flunisolide 120
fluocinolone 74
fluocinolone acetonide oil 83
fluocinolone and shower cap 74
fluocinonide 74
fluocinonide-emollient 74
fluoride (sodium) 125
fluorometholone 115
fluorouracil 74
fluoxetine 36
fluoxetine (pmdd) 36
fluphenazine decanoate 36
fluphenazine hcl 36
flurandrenolide 74
flurazepam 36
flurbiprofen 36
flurbiprofen sodium 115
fluticasone furoate 120
fluticasone furoate-vilanterol 120
fluticasone propionate 74, 120
fluticasone propion-salmeterol 120
fluvastatin 62
fluvoxamine 36
FML FORTE 115
FML LIQUIFILM 115
FOCALIN 36
FOCALIN XR 36
fondaparinux 62
formoterol fumarate 120
FORTEO 105
FOSAMAX 105
FOSAMAX PLUS D 105
fosamprenavir 8
fosfomycin tromethamine 8
fosinopril 62
fosinopril-hydrochlorothiazide 62
FOTIVDA 18
FRAGMIN 62
FROVA 36
frovatriptan 36
FRUZAQLA 18
FULPHILA 100
FUROSCIX 62
furosemide 63
FYAVOLV 109
FYCOMPA 36
FYLNETRA 100
gabapentin 36, 37
GABARONE 37
GALAFOLD 86
galantamine 37
GALBRIELA 109
GALLIFREY 109
GAMMAGARD LIQUID 100
GAMMAGARD S-D (IGA < 1 MCG/ML) 100
GAMMAKED 100
GAMMAPLEX 100
GAMMAPLEX (WITH SORBITOL) 100
GAMUNEX-C 100
GARDASIL 9 (PF) 100
GASTROCROM 94
gatifloxacin 115
GATTEX 30-VIAL 94
GAUZE PAD 103
GAVILYTE-C 94
GAVILYTE-G 94
GAVILYTE-N 94
GAVRETO 18
gefitinib 18
gemfibrozil 63
GEMMILY 109
GEMTESA 124
GENERLAC 94
GENGRAF 18
GENOTROPIN 100
GENOTROPIN MINIQUICK 100
gentamicin 8, 74, 115
gentamicin in nacl (iso-osm) 8
GENVOYA 8
GEODON 37
GILENYA 37
GILOTRIF 18
GIMOTI 94
GLASSIA 81
glatiramer 37
GLATOPA 37
GLEEVEC 18
GLEOSTINE 18
glimepiride 86
glipizide 86
glipizide-metformin 86
GLOPERBA 105
GLUCAGON EMERGENCY KIT (HUMAN) 86
GLUCOTROL XL 86
GLUMETZA 86
glutamine (sickle cell) 81
glyburide 86
glyburide micronized 86
glyburide-metformin 86
GLYCATE 94
glycopyrrolate 94
GLYXAMBI 86
GOCOVRI 37
GOLYTELY 95
GOMEKLI 18
GRALISE 37
granisetron hcl 95
GRANIX 100
GRASTEK 100
griseofulvin microsize 8
griseofulvin ultramicrosize 8
guanfacine 37, 63
GVOKE 86
GVOKE HYPOPEN 2-PACK 86
GVOKE PFS 1-PACK SYRINGE 86
GYNAZOLE-1 110
HADLIMA 105
HADLIMA PUSHTOUCH 105
HADLIMA(CF) 105
HADLIMA(CF) PUSHTOUCH 105
HAEGARDA 120
HAILEY 24 FE 110
halcinonide 74
HALCION 37
HALDOL DECANOATE 37
halobetasol propionate 74
HALOETTE 110
HALOG 74
haloperidol 37
haloperidol decanoate 37

haloperidol lactate 38
HARVONI 8
HAVRIX (PF) 100
HEATHER 110
HEMADY 86
HEMICLOR 63
heparin (porcine) 63
HEPLISAV-B (PF) 100
HERNEXEOS 18
HETLIOZ 38
HETLIOZ LQ 38
HIBERIX (PF) 100
HORIZANT 38
HULIO(CF) 105
HULIO(CF) PEN 105
HUMALOG JUNIOR KWIKPEN U-100 86
HUMALOG KWIKPEN INSULIN 86
HUMALOG MIX 50-50 KWIKPEN 86
HUMALOG MIX 75-25 KWIKPEN 86
HUMALOG MIX 75-25(U-100)INSULN 86
HUMALOG TEMPO PEN(U-100)INSULN 86
HUMALOG U-100 INSULIN .. 86
HUMATIN 8
HUMATROPE 100
HUMIRA 105
HUMIRA PEN 105
HUMIRA(CF) 105
HUMIRA(CF) PEN 105
HUMIRA(CF) PEN CROHNS-UC-HS 105
HUMIRA(CF) PEN PSOR-UV-ADOL HS 105
HUMULIN 70/30 U-100 INSULIN 86
HUMULIN 70/30 U-100 KWIKPEN 86
HUMULIN N NPH INSULIN KWIKPEN 86
HUMULIN N NPH U-100 INSULIN 86
HUMULIN R REGULAR U-100 INSULN 86
HUMULIN R U-500 (CONC) INSULIN 86
HUMULIN R U-500 (CONC) KWIKPEN 86
hydralazine 63
HYDREA 18
hydrochlorothiazide 63
hydrocodone bitartrate 38
hydrocodone-acetaminophen 38
hydrocodone-ibuprofen 38
hydrocortisone 74, 86, 95
hydrocortisone acetate 95
hydrocortisone butyrate 74
hydrocortisone valerate 74
hydrocortisone-acetic acid 83
hydrocortisone-pramoxine 95
hydromorphone 38
hydromorphone (pf) 38
hydroxychloroquine 8, 9
hydroxyurea 18
hydroxyzine hcl 120
hydroxyzine pamoate 120
HYFTOR 74
HYRIMOZ 105
HYRIMOZ PEN 105
HYRIMOZ PEN CROHN'S-UC STARTER 105
HYRIMOZ PEN PSORIASIS STARTER 105
HYRIMOZ(CF) 106
HYRIMOZ(CF) PEDI CROHN STARTER 105
HYRIMOZ(CF) PEN 106
HYSINGLA ER 38
HYZAAR 63
ibandronate 106
IBRANCE 18
IBSRELA 95
IBTROZI 18
IBU 38
ibuprofen 39
ibuprofen-famotidine 39
icatibant 120
ICLEVIA 110
ICLUSIG 18
icosapent ethyl 63
IDACIO(CF) 106
IDACIO(CF) PEN 106
IDACIO(CF) PEN CROHN-UC STARTR 106
IDACIO(CF) PEN PSORIASIS START 106
IDHIFA 18
ILEVRO 115
ILUMYA 75
imatinib 18
IMBRUVICA 18
imipenem-cilastatin 9
imipramine hcl 39
imipramine pamoate 39
imiquimod 75
IMITREX 39
IMITREX STATDOSE PEN ... 39
IMITREX STATDOSE REFILL 39
IMKELDI 18
IMOVAX RABIES VACCINE (PF) 100
IMPAVIDO 9
IMURAN 18
IMVEXXY MAINTENANCE PACK 110
IMVEXXY STARTER PACK 110
INBRIJA 39
INCASSIA 110
INCRELEX 81
INCRUSE ELLIPTA 120
indapamide 63
INDERAL LA 63
INDOCIN 39
indomethacin 39
INFANRIX (DTAP) (PF) 100
INGREZZA 39
INGREZZA INITIATION PK(TARDIV) 39
INGREZZA SPRINKLE 39
INLYTA 18
INNOPRAN XL 63
INPEFA 87
INQOVI 18
INREBIC 19
INSPRA 63
insulin glargine u-300 conc 87
insulin glargine-yfgn 87
insulin lispro 87
insulin lispro protamin-lispro 87
insulin syringe-needle u-100 103
INTELENCE 9
INTRALIPID 125
INTRAROSA 110
INTROVALE 110
INTUNIV ER 39
INVANZ 9
INVEGA 39
INVEGA HAFYERA 39
INVEGA SUSTENNA 39, 40
INVEGA TRINZA 40

INVELTYS 115
INVOKAMET 87
INVOKAMET XR 87
INVOKANA 87
INZIRQO 63
IOPIDINE 115
IPOL 100
ipratropium bromide 83, 120
ipratropium-albuterol 120
IQIRVO 95
irbesartan 63
irbesartan-hydrochlorothiazide 63
IRESSA 19
ISENTRESS 9
ISENTRESS HD 9
ISIBLOOM 110
ISOLYTE S PH 7.4 125
ISOLYTE-P IN 5 % DEXTROSE 125
isoniazid 9
ISORDIL 63
ISORDIL TITRADOSE 63
isosorbide dinitrate 63
isosorbide mononitrate 63
isosorbide-hydralazine 63
isotretinoin 75
isradipine 63
ISTALOL 115
ISTURISA 87
ITOVEBI 19
itraconazole 9
ivabradine 63
ivermectin 9, 75
IWILFIN 19
IXIARO (PF) 100
IYUZEH (PF) 116
JADENU 81
JADENU SPRINKLE 81
JAIMIESS 110
JAKAFI 19
JALYN 124
JANTOVEN 63
JANUMET 87
JANUMET XR 87
JANUVIA 87
JARDIANCE 87
JASMIEL (28) 110
JATENZO 87
JAVYGTOR 87
JAYPIRCA 19
JAYTHARI 87
JENTADUETO 87
JENTADUETO XR 87
JINTELI 110
JOENJA 81
JORNAY PM 40
JOURNAVX 40
JOYEAUX 110
JUBBONTI 106
JUBLIA 75
JULEBER 110
JULUCA 9
JUNEL 1.5/30 (21) 110
JUNEL 1/20 (21) 110
JUNEL FE 1.5/30 (28) 110
JUNEL FE 1/20 (28) 110
JUNEL FE 24 110
JUXTAPID 63
JYLAMVO 19
JYNARQUE 87
JYNNEOS (PF) 100
KAITLIB FE 110
KALETRA 9
KALYDECO 120
KARIVA (28) 110
KATERZIA 63
KELNOR 1/35 (28) 110
KEPPRA 40
KEPPRA XR 40
KERENDIA 64
KESIMPTA PEN 40
ketoconazole 9, 75
KETODAN 75
ketoprofen 40
ketorolac 40, 116
KEVEYIS 40
KEVZARA 106
KHINDIVI 87
KINERET 106
KINRIX (PF) 101
KIONEX (WITH SORBITOL) 81
KISQALI 19
KISQALI FEMARA CO-PACK 19
KITABIS PAK 9
KLARON 75
KLISYRI (250 MG) 19
KLONOPIN 40
KLOR-CON 125
KLOR-CON 10 125
KLOR-CON 8 125
KLOR-CON M10 125
KLOR-CON M15 125
KLOR-CON M20 125
KLOXXADO 40
KONVOMEP 95
KORLYM 88
KOSELUGO 19
KOURZEQ 83
KRAZATI 19
KRINTAFEL 9
KRISTALOSE 95
KURVELO (28) 110
KUVAN 88
KYLEENA 110
l norgest/e.estradiol-e.estrad 110
labetalol 64
lacosamide 40
lactulose 95
LAMICTAL 40, 41
LAMICTAL ODT 40
LAMICTAL STARTER (BLUE) KIT 41
LAMICTAL STARTER (GREEN) KIT 41
LAMICTAL STARTER (ORANGE) KIT 41
LAMICTAL XR 41
LAMICTAL XR STARTER (BLUE) 41
LAMICTAL XR STARTER (GREEN) 41
LAMICTAL XR STARTER (ORANGE) 41
lamivudine 9
lamivudine-zidovudine 9
lamotrigine 41
LAMPIT 9
LANOXIN 64
lansoprazole 95
LANTUS SOLOSTAR U-100 INSULIN 88
LANTUS U-100 INSULIN 88
lapatinib 19
LARIN 1.5/30 (21) 110
LARIN 1/20 (21) 110
LARIN FE 1.5/30 (28) 110
LARIN FE 1/20 (28) 110
LASIX 64
latanoprost 116
LATUDA 41
LAZCLUZE 19
ledipasvir-sofosbuvir 9
leflunomide 106
lenalidomide 19

LENVIMA 19
LEQSELVI 106
LESCOL XL 64
LESSINA 110
LETAIRIS 120
letrozole 19
leucovorin calcium 19
LEUKERAN 19
LEUKINE 101
leuprolide 19
leuprolide acetate (3 month) 19
levalbuterol hcl 120
levalbuterol tartrate 120
levetiracetam 41
levobunolol 116
levocarnitine 81
levocarnitine (with sugar) 81
levocetirizine 120
levofloxacin 9, 116
levofloxacin in d5w 9
LEVONEST (28) 110
levonorgestrel-ethinyl estrad 110, 111
levonorg-eth estrad triphasic 111
LEVORA-28 111
levorphanol tartrate 41
levothyroxine 88
LEVOXYL 88
LEXAPRO 41
LEXETTE 75
LIALDA 95
LIBRAX (WITH CLIDINIUM) 95
LICART 41
lidocaine 75
lidocaine hcl 75
LIDOCAINE VISCOUS 75
lidocaine-prilocaine 75
LIDOCAN III 75
LILETTA 111
linezolid 9
linezolid in dextrose 5% 9
LINZESS 95
liothyronine 88
LIPITOR 64
LIPOFEN 64
liraglutide 88
lisdexamfetamine 41
lisinopril 64
lisinopril-hydrochlorothiazide 64
LITFULO 81
lithium carbonate 41
lithium citrate 41
LITHOBID 41
LITHOSTAT 81
LIVALO 64
LIVDELZI 95
LIVMARLI 95
LIVTENCITY 9
LO LOESTRIN FE 111
LODINE 41
LODOCO 64
LODOSYN 41
LOESTRIN 1.5/30 (21) 111
LOESTRIN 1/20 (21) 111
LOESTRIN FE 1.5/30 (28-DAY) 111
LOESTRIN FE 1/20 (28-DAY) 111
LOFENA 41
lofexidine 41
LOJAIMIESS 111
LOKELMA 81
LOMOTIL 95
LONSURF 19
loperamide 95
LOPID 64
lopinavir-ritonavir 10
LOPRESSOR 64
lorazepam 42
LORAZEPAM INTENSOL 42
LORBRENA 19
LOREEV XR 42
LORYNA (28) 111
losartan 64
losartan-hydrochlorothiazide 64
LOTEMAX 116
LOTEMAX SM 116
LOTENSIN 64
loteprednol etabonate 116
LOTRONEX 95
lovastatin 64
LOVAZA 64
LOVENOX 64
LOW-OGESTREL (28) 111
loxapine succinate 42
lubiprostone 95
LUCEMYRA 42
luliconazole 75
LUMAKRAS 19, 20
LUMIGAN 116
LUMRYZ 42
LUMRYZ STARTER PACK 42
LUNESTA 42
LUPKYNIS 20
LUPRON DEPOT 20
LUPRON DEPOT (3 MONTH) 20
LUPRON DEPOT (4 MONTH) 20
LUPRON DEPOT (6 MONTH) 20
LUPRON DEPOT-PED 20
LUPRON DEPOT-PED (3 MONTH) 20
lurasidone 42
LUTERA (28) 111
LUTRATE DEPOT (3 MONTH) 20
LUZU 75
LYBALVI 42
LYLEQ 111
LYLLANA 111
LYNPARZA 20
LYRICA 42
LYRICA CR 42
LYSODREN 20
LYTGOBI 20
LYUMJEV KWIKPEN U-100 INSULIN 88
LYUMJEV KWIKPEN U-200 INSULIN 88
LYUMJEV TEMPO PEN(U-100)INSULN 88
LYUMJEV U-100 INSULIN 88
LYZA 111
MACROBID 10
MACRODANTIN 10
magnesium sulfate 125
MALARONE 10
MALARONE PEDIATRIC 10
malathion 75
maraviroc 10
MARINOL 95
MARLISSA (28) 111
MARPLAN 42
MATULANE 20
MATZIM LA 64
MAVENCLAD (10 TABLET PACK) 42
MAVENCLAD (4 TABLET PACK) 42
MAVENCLAD (5 TABLET PACK) 42
MAVENCLAD (6 TABLET PACK) 42

MAVENCLAD (7 TABLET PACK) 42
MAVENCLAD (8 TABLET PACK) 42
MAVENCLAD (9 TABLET PACK) 42
MAVYRET 10
MAXALT 42
MAXALT-MLT 42
MAXIDEX 116
MAXITROL 116
MAYZENT 42
MAYZENT STARTER(FOR 1MG MAINT) 43
MAYZENT STARTER(FOR 2MG MAINT) 43
meclizine 96
meclofenamate 43
MEDROL 88
MEDROL (PAK) 88
medroxyprogesterone 111
mefenamic acid 43
mefloquine 10
megestrol 20
MEKINIST 20
MEKTOVI 20
MELEYA 111
meloxicam 43
meloxicam submicronized 43
memantine 43
memantine-donepezil 43
MENOSTAR 111
MENQUADFI (PF) 101
MENVEO A-C-Y-W-135-DIP (PF) 101
meperidine 43
meperidine (pf) 43
meprobamate 43
MEPRON 10
mercaptopurine 20
MERILOG 88
MERILOG SOLOSTAR 88
meropenem 10
MERZEE 111
mesalamine 96
mesna 21
MESNEX 21
MESTINON 43
MESTINON TIMESPAN 43
METADATE CD 43
metaxalone 43
metformin 88
methadone 43
methamphetamine 43
methazolamide 116
methenamine hippurate 10
methimazole 88
METHITEST 88
methocarbamol 43
methotrexate sodium 21
methotrexate sodium (pf) 21
methoxsalen 75
methscopolamine 96
methsuximide 43
methyldopa 64
METHYLIN 43
methylphenidate 43
methylphenidate hcl 43, 44
methylprednisolone 88
methyltestosterone 88
metoclopramide hcl 96
metolazone 64
metoprolol succinate 64
metoprolol ta-hydrochlorothiaz 64
metoprolol tartrate 64
METROCREAM 75
metronidazole 10, 75, 111
metronidazole in nacl (iso-os) 10
metyrosine 65
mexiletine 65
MIBELAS 24 FE 111
micafungin 10
MICARDIS HCT 65
MICONAZOLE-3 111
MICORT-HC 96
MICROGESTIN 1.5/30 (21) 111
MICROGESTIN 1/20 (21) 111
MICROGESTIN FE 1.5/30 (28) 111
MICROGESTIN FE 1/20 (28) 111
midodrine 81
MIEBO (PF) 116
mifepristone 88
MIGERGOT 44
miglitol 89
miglustat 89
MILI 111
MIMVEY 111
MINIVELLE 111
minocycline 10
minoxidil 65
MINZOYA 111
MIPLYFFA 44
mirabegron 124
MIRCERA 101
MIRENA 111
mirtazapine 44
MIRVASO 75
misoprostol 96
MITIGARE 106
M-M-R II (PF) 101
modafinil 44
MODEYSO 21
moexipril 65
molindone 44
mometasone 75, 121
montelukast 121
morphine 44, 45
morphine concentrate 44
MOTEGRITY 96
MOTPOLY XR 45
MOUNJARO 89
MOVANTIK 96
MOVIPREP 96
moxifloxacin 10, 116
moxifloxacin-sod.chloride(iso) 10
MRESVIA (PF) 101
MS CONTIN 45
MULPLETA 65
MULTAQ 65
mupirocin 75
mupirocin calcium 75
MYALEPT 89
MYCAMINE 10
MYCAPSSA 21
mycophenolate mofetil 21
mycophenolate sodium 21
MYDAYIS 45
MYFEMBREE 112
MYFORTIC 21
MYHIBBIN 21
MYRBETRIQ 124
MYSOLINE 45
MYTESI 96
nabumetone 45
nadolol 65
nafcillin 10
naftifine 75
NAFTIN 75
NALOCET 45
naloxone 45
naltrexone 45
NAMZARIC 45
NAPRELAN CR 45
naproxen 45

naproxen sodium 45
naproxen-esomeprazole 45
naratriptan 45
NARDIL 45
NATAZIA 112
nateglinide 89
NATROBA 75
NAYZILAM 45
nebivolol 65
NEBUPENT 10
NECON 0.5/35 (28) 112
nefazodone 45
NEFFY 121
NEMLUVIO 21
neomycin 10
neomycin-bacitracin-poly-hc 116
neomycin-bacitracin-polymyxin 116
neomycin-polymyxin b-dexameth 116
neomycin-polymyxin-gramicidin 116
neomycin-polymyxin-hc 83, 116
NEO-POLYCIN 116
NEO-POLYCIN HC 116
NEORAL 21
NEO-SYNALAR 76
NERLYNX 21
NEUAC 76
NEULASTA 101
NEUPOGEN 101
NEUPRO 45
NEURONTIN 45
NEVANAC 116
nevirapine 10, 11
NEXAVAR 21
NEXICLON XR 65
NEXIUM 96
NEXIUM PACKET 96
NEXLETOL 65
NEXLIZET 65
NEXPLANON 112
NEXTSTELLIS 112
NGENLA 101
niacin 65
NIACOR 65
nicardipine 65
NICOTROL NS 81
nifedipine 65
NIKKI (28) 112
NILANDRON 21
nilotinib hcl 21
nilutamide 21
nimodipine 65
NINLARO 21
nisoldipine 65
nitazoxanide 11
nitisinone 81
NITRO-BID 65
NITRO-DUR 65
nitrofurantoin 11
nitrofurantoin macrocrystal 11
nitrofurantoin monohyd/m-cryst . 11
nitroglycerin 65, 96
NITROLINGUAL 65
NITROSTAT 65
NITYR 81
NIVESTYM 101
nizatidine 96
NORA-BE 112
NORDITROPIN FLEXPRO . 101
norelgestromin-ethin.estradiol . 112
norethindrone (contraceptive) .. 112
norethindrone acetate 112
norethindrone ac-eth estradiol . 112
norethindrone-e.estradiol-iron . 112
NORGESIC 46
NORGESIC FORTE 46
norgestimate-ethinyl estradiol .. 112
NORITATE 76
NORLIQVA 65
NORPACE 65
NORPACE CR 66
NORPRAMIN 46
NORTHERA 81
NORTREL 0.5/35 (28) 112
NORTREL 1/35 (21) 112
NORTREL 1/35 (28) 112
NORTREL 7/7/7 (28) 112
nortriptyline 46
NORVASC 66
NORVIR 11
NOURIANZ 46
NOVOLIN 70/30 U-100 INSULIN 89
NOVOLIN 70-30 FLEXPEN U-100 89
NOVOLIN N FLEXPEN 89
NOVOLIN N NPH U-100 INSULIN 89
NOVOLIN R FLEXPEN 89
NOVOLIN R REGULAR U100 INSULIN 89
NOVOLOG FLEXPEN U-100 INSULIN 89
NOVOLOG MIX 70-30 U-100 INSULN 89
NOVOLOG MIX 70-30FLEXPEN U-100 89
NOVOLOG PENFILL U-100 INSULIN 89
NOVOLOG U-100 INSULIN ASPART 89
NOXAFIL 11
NUBEQA 21
NUCALA 121
NUCYNTA 46
NUCYNTA ER 46
NUEDEXTA 46
NUPLAZID 46
NURTEC ODT 46
NUTRILIPID 125
NUTROPIN AQ NUSPIN 101
NUVARING 112
NUVIGIL 46
NUZYRA 11
NYAMYC 76
NYLIA 1/35 (28) 112
NYLIA 7/7/7 (28) 112
NYMALIZE 66
nystatin 11, 76
nystatin-triamcinolone 76
NYSTOP 76
NYVEPRIA 101
OCALIVA 96
OCELLA 112
OCTAGAM 101
octreotide acetate 21
OCUFLOX 116
ODACTRA 101
ODEFSEY 11
ODOMZO 21
OFEV 121
ofloxacin 11, 83, 116
OGSIVEO 21
OHTUVAYRE 121
OJEMDA 21, 22
OJJAARA 22
olanzapine 46
olanzapine-fluoxetine 46
olmesartan 66
olmesartan-amlodipin-hcthiazid . 66
olmesartan-hydrochlorothiazide . 66
olopatadine 83
OLPRUVA 81
OLUMIANT 106
omega-3 acid ethyl esters 66

omeprazole 96
omeprazole-sodium bicarbonate .96
OMNARIS 121
OMNITROPE 101
OMVOH 96
OMVOH PEN 96
ONAPGO 46
ondansetron 96
ondansetron hcl 96
ONEXTON 76
ONFI 46
ONGENTYS 46
ONUREG 22
ONYDA XR 46
ONZETRA XSAIL 46
OPIPZA 46
OPSUMIT 121
OPSYNVI 121
OPVEE 46
OPZELURA 76
ORACEA 11
ORAPRED ODT 89
ORENCIA 106
ORENCIA CLICKJECT 106
ORENITRAM 66
ORENITRAM MONTH 1 TITRATION KT 66
ORENITRAM MONTH 2 TITRATION KT 66
ORENITRAM MONTH 3 TITRATION KT 66
ORFADIN 81
ORGOVYX 22
ORIAHNN 112
ORILISSA 89
ORKAMBI 121
ORLADEYO 121
ORMALVI 46
orphenadrine citrate 46
orphenadrine-asa-caffeine 46
ORQUIDEA 112
ORSERDU 22
oseltamivir 11
OSENVELT 22
OSPHENA 112
OTEZLA 106
OTEZLA STARTER 106
OTREXUP (PF) 106
OTULFI 76
OVIDE 76
oxacillin 11
oxacillin in dextrose(iso-osm) 11
oxaprozin 46
oxazepam 46
oxcarbazepine 46, 47
OXERVATE 116
oxiconazole 76
OXISTAT 76
OXTELLAR XR 47
oxybutynin chloride 124
oxycodone 47
oxycodone-acetaminophen 47
OXYCONTIN 47
oxymorphone 47
OXYTROL 124
OZEMPIC 89
OZOBAX DS 47
PACERONE 66
paliperidone 48
PALYNZIQ 89
PANCREAZE 97
PANRETIN 76
pantoprazole 97
PANZYGA 101
paricalcitol 89
PARLODEL 48
PARNATE 48
paroxetine hcl 48
paroxetine mesylate(menop.sym) 48
PAXIL 48
PAXIL CR 48
PAXLOVID 11
pazopanib 22
PEDIARIX (PF) 101
PEDVAX HIB (PF) 101
peg 3350-electrolytes 97
peg3350-sod sul-nacl-kcl-asb-c .. 97
PEGASYS 101
peg-electrolyte soln 97
PEMAZYRE 22
pen needle, diabetic 103
PENBRAYA (PF) 101
penciclovir 76
penicillamine 106
penicillin g pot in dextrose 11
penicillin g potassium 11
penicillin g sodium 11
penicillin v potassium 11
PENMENVY MEN A-B-C-W-Y (PF) 101
PENTACEL (PF) 101
PENTAM 12
pentamidine 12
PENTASA 97
pentazocine-naloxone 48
pentoxifylline 66
PEPCID 97
perampanel 48
PERCOCET 48
PERFOROMIST 121
perindopril erbumine 66
PERIOGARD 83
permethrin 76
perphenazine 48
perphenazine-amitriptyline 48
PERSERIS 48
PERTZYE 97
PHEBURANE 81
phenelzine 48
phenobarbital 48
phenoxybenzamine 66
PHENYTEK 48
phenytoin 48
phenytoin sodium extended 48
PHEXXI 112
PHOSPHOLINE IODIDE 116
PIFELTRO 12
pilocarpine hcl 82, 116
pimecrolimus 76
pimozide 48
PIMTREA (28) 112
pindolol 66
pioglitazone 89
pioglitazone-glimepiride 89
pioglitazone-metformin 89
piperacillin-tazobactam 12
PIQRAY 22
pirfenidone 121
piroxicam 48
pitavastatin calcium 66
PLAQUENIL 12
PLASMA-LYTE A 125
PLAVIX 66
PLEGRIDY 101
PLENAMINE 125
PLENVU 97
podofilox 76
POLYCIN 116
polymyxin b sulfate 12
polymyxin b sulf-trimethoprim .. 116
POMALYST 22
PONVORY 48
PONVORY 14-DAY STARTER PACK 48
PORTIA 28 112

posaconazole 12
potassium chlorid-d5-0.45%nacl 125
potassium chloride 126
potassium chloride in 0.9%nacl 125
potassium chloride in 5 % dex .. 125
potassium chloride in lr-d5 126
potassium chloride in water 126
potassium chloride-0.45 % nacl 126
potassium chloride-d5-0.2%nacl 126
potassium chloride-d5-0.9%nacl 126
potassium citrate 124
PRADAXA 66
PRALUENT PEN 66
pramipexole 48
PRAMOSONE 76
prasugrel hcl 66
pravastatin 66
praziquantel 12
prazosin 66
PRED FORTE 116
PRED MILD 116
prednisolone 89
prednisolone acetate 116
prednisolone sodium phosphate 89, 116
prednisone 89, 90
PREDNISONE INTENSOL 89
pregabalin 48, 49
PREMARIN 112
PREMASOL 10 % 126
PREMPHASE 112
PREMPRO 112
PRENATAL VITAMIN PLUS LOW IRON 126
pretomanid 12
PREVACID 97
PREVACID SOLUTAB 97
PREVALITE 66
PREVYMIS 12
PREZCOBIX 12
PREZISTA 12
PRIFTIN 12
PRILOSEC 97
primaquine 12
PRIMAXIN IV 12
primidone 49
PRIORIX (PF) 101
PRISTIQ 49
PRIVIGEN 101
PROAIR RESPICLICK 121
probenecid 106
probenecid-colchicine 106
PROCARDIA XL 67
PROCENTRA 49
prochlorperazine 97
prochlorperazine maleate 97
PROCRIT 101, 102
PROCTOFOAM HC 97
PROCTO-MED HC 97
PROCTOSOL HC 97
PROCTOZONE-HC 97
PROCYSBI 124
progesterone micronized 112
PROGLYCEM 90
PROGRAF 22
PROLASTIN-C 82
PROLATE 49
PROLENSA 116
PROLIA 106
PROMACTA 67
promethazine 121
PROMETHEGAN 121
PROMETRIUM 112
propafenone 67
propranolol 67
propylthiouracil 90
PROQUAD (PF) 102
PROSCAR 124
PROSOL 20 % 126
PROTONIX 97
protriptyline 49
PROVERA 112
PROVIGIL 49
PROZAC 49
prucalopride 97
PRUDOXIN 76
PRURADIK 76
PULMICORT 121
PULMICORT FLEXHALER 121
PULMOZYME 121
PURIXAN 22
PYLERA 97
pyrazinamide 12
pyridostigmine bromide 49
pyrimethamine 12
PYRUKYND 82
PYZCHIVA 76
QBRELIS 67
QBREXZA 76
QELBREE 49
QINLOCK 22
QNASL 121
QUADRACEL (PF) 102
QUESTRAN 67
QUESTRAN LIGHT 67
quetiapine 49
QUILLICHEW ER 49
QUILLIVANT XR 49
quinapril 67
quinapril-hydrochlorothiazide 67
quinidine gluconate 67
quinidine sulfate 67
quinine sulfate 12
QULIPTA 49
QUVIVIQ 49
QVAR REDIHALER 121
RABAVERT (PF) 102
rabeprazole 97
RADICAVA ORS STARTER KIT SUSP 49
RALDESY 49
raloxifene 107
ramelteon 50
ramipril 67
ranolazine 67
rasagiline 50
RASUVO (PF) 107
RAVICTI 82
RAYALDEE 90
REBIF (WITH ALBUMIN) ... 102
REBIF REBIDOSE 102
REBIF TITRATION PACK .. 102
RECLIPSEN (28) 113
RECOMBIVAX HB (PF) 102
RECORLEV 90
RECTIV 97
REGLAN 98
RELAFEN DS 50
RELENZA DISKHALER 12
RELEUKO 102
RELEXXII 50
RELISTOR 98
RELPAX 50
RELTONE 98
REMERON 50
REMERON SOLTAB 50
repaglinide 90
REPATHA SURECLICK 67
REPATHA SYRINGE 67
RESTASIS 116
RESTASIS MULTIDOSE 117
RESTORIL 50
RETACRIT 102

RETEVMO 22
RETIN-A 76
RETIN-A MICRO 76
RETIN-A MICRO PUMP 76
RETROVIR 12
REVATIO 122
REVCOVI 82
REVLIMID 22
REVUFORJ 22
REXULTI 50
REYATAZ 12
REYVOW 50
REZDIFFRA 82
REZLIDHIA 22
REZUROCK 22
REZVOGLAR KWIKPEN 90
RHOFADE 76
RHOPRESSA 117
ribavirin 12
RIDAURA 107
rifabutin 12
rifampin 12
riluzole 82
rimantadine 12
RINVOQ 107
RINVOQ LQ 107
risedronate 82, 107
RISPERDAL 50
RISPERDAL CONSTA 50
risperidone 50
risperidone microspheres 50
RITALIN 51
RITALIN LA 51
ritonavir 13
rivaroxaban 67
rivastigmine 51
rivastigmine tartrate 51
RIVELSA 113
RIVFLOZA 124
rizatriptan 51
ROCALTROL 90
ROCKLATAN 117
roflumilast 122
ROMVIMZA 22
ropinirole 51
rosuvastatin 67
ROSYRAH 113
ROTARIX 102
ROTATEQ VACCINE 102
ROWASA 98
ROWEEPRA 51
ROXICODONE 51
ROXYBOND 51
ROZEREM 51
ROZLYTREK 22
RUBRACA 23
RUCONEST 122
rufinamide 51
RUKOBIA 13
RYALTRIS 122
RYBELSUS 90
RYCLORA 122
RYDAPT 23
RYTARY 51
RYVENT 122
SABRIL 51
sacubitril-valsartan 67
SAFYRAL 113
SAJAZIR 122
SALAGEN (PILOCARPINE) 82
SAMSCA 90
SANCUSO 98
SANDIMMUNE 23
SANDOSTATIN 23
SANTYL 77
SAPHRIS 51
sapropterin 90
SAVAYSA 67
SAVELLA 107
saxagliptin 90
saxagliptin-metformin 90
SCEMBLIX 23
scopolamine base 98
SECUADO 51
SEGLUROMET 90
SELARSDI 77
selegiline hcl 51
selenium sulfide 77
SELZENTRY 13
SEMGLEE(INSULIN GLARGINE-YFGN) 90
SEMGLEE(INSULIN GLARG-YFGN)PEN 90
SEREVENT DISKUS 122
SEROQUEL 51
SEROQUEL XR 51
SEROSTIM 102
sertraline 51
SETLAKIN 113
SEYSARA 13
SHAROBEL 113
SHINGRIX (PF) 102
SIGNIFOR 23
SIKLOS 23
sildenafil (pulm.hypertension) 122
SILENOR 52
SILIQ 77
silodosin 124
SILVADENE 77
silver sulfadiazine 77
SIMBRINZA 117
SIMLANDI(CF) 107
SIMLANDI(CF) AUTOINJECTOR 107
SIMPONI 107
simvastatin 67
SINEMET 52
SINGULAIR 122
sirolimus 23
SIRTURO 13
sitagliptin 90
sitagliptin-metformin 90
SIVEXTRO 13
SKYCLARYS 52
SKYLA 113
SKYRIZI 77, 98
SKYTROFA 102
SOAANZ 67
sodium chloride 82
sodium chloride 0.45 % 126
sodium chloride 0.9 % 82
sodium chloride 3 % hypertonic 126
sodium chloride 5 % hypertonic 126
sodium oxybate 52
sodium phenylbutyrate 82
sodium polystyrene sulfonate 82
sodium,potassium,mag sulfates 98
sofosbuvir-velpatasvir 13
SOGROYA 102
SOHONOS 82
solifenacin 124
SOLIQUA 100/33 90
SOLOSEC 13
SOLTAMOX 23
SOMA 52
SOMAVERT 90
SOOLANTRA 77
sorafenib 23
SORILUX 77
sotalol 67
SOTALOL AF 67
SOTYKTU 77
SOTYLIZE 67
SOVALDI 13

SOVUNA ... 13
SPEVIGO ... 77
spinosad ... 77
SPIRIVA RESPIMAT ... 122
SPIRIVA WITH HANDIHALER ... 122
spironolactone ... 67
spironolacton-hydrochlorothiaz ... 68
SPORANOX ... 13
SPRINTEC (28) ... 113
SPRITAM ... 52
SPRIX ... 52
SPRYCEL ... 23
SPS (WITH SORBITOL) ... 82
SRONYX ... 113
SSD ... 77
STEGLATRO ... 90
STEGLUJAN ... 90
STELARA ... 77
STEQEYMA ... 77
STIMUFEND ... 102
STIOLTO RESPIMAT ... 122
STIVARGA ... 23
STOBOCLO ... 107
streptomycin ... 13
STRIBILD ... 13
STRIVERDI RESPIMAT ... 122
STROMECTOL ... 13
SUBOXONE ... 52
SUBVENITE ... 52
SUBVENITE STARTER (BLUE) KIT ... 52
SUBVENITE STARTER (GREEN) KIT ... 52
SUBVENITE STARTER (ORANGE) KIT ... 52
SUCRAID ... 98
sucralfate ... 98
SUFLAVE ... 98
SULAR ... 68
sulfacetamide sodium ... 117
sulfacetamide sodium (acne) ... 77
sulfacetamide-prednisolone ... 117
sulfadiazine ... 13
sulfamethoxazole-trimethoprim ... 13
SULFAMYLON ... 77
sulfasalazine ... 98
sulindac ... 52
sumatriptan ... 52
sumatriptan succinate ... 52
sumatriptan-naproxen ... 52
sunitinib malate ... 23
SUNLENCA ... 13
SUNOSI ... 52
SUPREP BOWEL PREP KIT ... 98
SUTAB ... 98
SUTENT ... 23
SYEDA ... 113
SYMBICORT ... 122
SYMBRAVO ... 52
SYMDEKO ... 122
SYMFI ... 13
SYMLINPEN 120 ... 90
SYMLINPEN 60 ... 90
SYMPAZAN ... 52
SYMPROIC ... 98
SYMTUZA ... 13
SYNALAR ... 77
SYNAREL ... 90
SYNJARDY ... 90
SYNJARDY XR ... 91
SYNTHROID ... 91
SYPRINE ... 82
TABLOID ... 23
TABRECTA ... 23
TACLONEX ... 77
tacrolimus ... 23, 77
tadalafil ... 124
tadalafil (pulm. hypertension) ... 122
TADLIQ ... 122
TAFINLAR ... 23
tafluprost (pf) ... 117
TAGRISSO ... 23
TAKHZYRO ... 122
TALICIA ... 98
TALTZ AUTOINJECTOR ... 77
TALTZ SYRINGE ... 77, 78
TALZENNA ... 23
TAMIFLU ... 13
tamoxifen ... 23
tamsulosin ... 124
TANLOR ... 52
TARGADOX ... 13
TARGRETIN ... 23
TARINA 24 FE ... 113
TARINA FE 1-20 EQ (28) ... 113
TARPEYO ... 91
TASCENSO ODT ... 52
TASIGNA ... 23
tasimelteon ... 52
TASMAR ... 53
tavaborole ... 78
TAVALISSE ... 68
TAVNEOS ... 82
tazarotene ... 78
TAZICEF ... 13
TAZORAC ... 78
TAZVERIK ... 23
TECFIDERA ... 53
TEFLARO ... 13
TEGRETOL ... 53
TEGRETOL XR ... 53
TEKTURNA ... 68
telmisartan ... 68
telmisartan-amlodipine ... 68
telmisartan-hydrochlorothiazid ... 68
temazepam ... 53
TENCON ... 53
TENIVAC (PF) ... 102
tenofovir disoproxil fumarate ... 13
TENORETIC 100 ... 68
TENORETIC 50 ... 68
TENORMIN ... 68
TEPMETKO ... 23
terazosin ... 68
terbinafine hcl ... 13
terbutaline ... 122
terconazole ... 113
teriflunomide ... 53
teriparatide ... 107
TESTIM ... 91
testosterone ... 91
testosterone cypionate ... 91
testosterone enanthate ... 91
tetrabenazine ... 53
tetracycline ... 13
TEXACORT ... 78
TEZRULY ... 68
THALITONE ... 68
THALOMID ... 23
THEO-24 ... 122
theophylline ... 122
THIOLA ... 82
THIOLA EC ... 82
thioridazine ... 53
thiothixene ... 53
THYQUIDITY ... 91
TIADYLT ER ... 68
tiagabine ... 53
TIAZAC ... 68
TIBSOVO ... 24
ticagrelor ... 68
TICOVAC ... 102
tigecycline ... 13
TIGLUTIK ... 82
TIKOSYN ... 68

TILIA FE 113
timolol 117
timolol maleate 68, 117
timolol maleate (pf) 117
TIMOPTIC OCUDOSE (PF) 117
tinidazole 13
tiopronin 82
tiotropium bromide 122
TIROSINT 91
TIROSINT-SOL 91
TIVICAY 13
TIVICAY PD 13
tizanidine 53
TLANDO 91
TOBI 14
TOBI PODHALER 14
TOBRADEX 117
TOBRADEX ST 117
tobramycin 14, 117
tobramycin in 0.225 % nacl 14
tobramycin sulfate 14
tobramycin-dexamethasone 117
TOBREX 117
tolcapone 53
TOLECTIN 600 53
tolmetin 53
TOLSURA 14
tolterodine 124
tolvaptan 91
tolvaptan (polycys kidney dis) 91
TOPAMAX 53
TOPICORT 78
topiramate 53
TOPROL XL 68
toremifene 24
TORPENZ 24
torsemide 68
TOSYMRA 53
TOUJEO MAX U-300 SOLOSTAR 91
TOUJEO SOLOSTAR U-300 INSULIN 91
TOVET EMOLLIENT 78
TOVIAZ 124
TPN ELECTROLYTES 126
TRACLEER 122
TRADJENTA 91
tramadol 53, 54
tramadol-acetaminophen 54
trandolapril 68
trandolapril-verapamil 68
tranexamic acid 113
tranylcypromine 54
TRAVASOL 10 % 126
TRAVATAN Z 117
travoprost 117
trazodone 54
TRELEGY ELLIPTA 122
TRELSTAR 24
TREMFYA 78
TREMFYA PEN 78
TREMFYA PEN INDUCTION PK-CROHN 78
TRESIBA FLEXTOUCH U-100 91
TRESIBA FLEXTOUCH U-200 91
TRESIBA U-100 INSULIN 91
tretinoin 78
tretinoin (antineoplastic) 24
tretinoin microspheres 78
TREXALL 24
TREXIMET 54
triamcinolone acetonide 78, 84
triamterene 68
triamterene-hydrochlorothiazid 68
triazolam 54
TRIBENZOR 68
TRIDACAINE II 78
TRIDERM 78
trientine 82
TRI-ESTARYLLA 113
trifluoperazine 54
trifluridine 117
trihexyphenidyl 54
TRIJARDY XR 91
TRIKAFTA 122, 123
TRI-LEGEST FE 113
TRILEPTAL 54
TRI-LO-ESTARYLLA 113
TRI-LO-SPRINTEC 113
trimethobenzamide 98
trimethoprim 14
TRI-MILI 113
trimipramine 54
TRINTELLIX 54
TRI-SPRINTEC (28) 113
TRIUMEQ 14
TRIUMEQ PD 14
TRI-VYLIBRA 113
TRI-VYLIBRA LO 113
TROKENDI XR 54
TROPHAMINE 10 % 126
trospium 124
TRUDHESA 54
TRULANCE 98
TRULICITY 91
TRUMENBA 102
TRUQAP 24
TRUVADA 14
TRYNGOLZA 68
TRYPTYR 117
TRYVIO 68
TUDORZA PRESSAIR 123
TUKYSA 24
TURALIO 24
TURQOZ (28) 113
TWINRIX (PF) 102
TWYNEO 78
TYBOST 14
TYENNE 107
TYENNE AUTOINJECTOR 107
TYGACIL 14
TYKERB 24
TYMLOS 107
TYPHIM VI 102
TYRVAYA 117
TYVASO DPI 123
UBRELVY 54
UCERIS 98
UDENYCA 102
UDENYCA AUTOINJECTOR 102
ULORIC 107
ULTRAVATE 78
umeclidinium-vilanterol 123
UNASYN 14
UNDECATREX 91
UNITHROID 91
UPTRAVI 68
UROCIT-K 10 124
UROCIT-K 15 125
UROXATRAL 125
ursodiol 98
ustekinumab 78, 79
ustekinumab-aekn 79
ustekinumab-ttwe 79
UZEDY 54, 55
VABOMERE 14
VAGIFEM 113
valacyclovir 14
VALCHLOR 79
VALCYTE 14
valganciclovir 14
VALIUM 55
valproic acid 55

valproic acid (as sodium salt) 55
valsartan 68
valsartan-hydrochlorothiazide ... 68
VALTOCO 55
VALTREX 14
VALTYA 113
VANCOCIN 14
vancomycin 14
VANDAZOLE 113
VANFLYTA 24
VANOS 79
VANRAFIA 69
VAQTA (PF) 102
varenicline tartrate 82
VARIVAX (PF) 102
VARUBI 98
VASCEPA 69
VASERETIC 69
VASOTEC 69
VAXCHORA VACCINE 102
VECAMYL 69
VECTICAL 79
VELIVET TRIPHASIC REGIMEN (28) 113
VELSIPITY 98
VELTASSA 82
VEMLIDY 14
VENCLEXTA 24
VENCLEXTA STARTING PACK 24
venlafaxine 55
venlafaxine besylate 55
VENTOLIN HFA 123
VENXXIVA 82
VEOZAH 113
verapamil 69
VEREGEN 79
VERKAZIA 117
VERQUVO 69
VERSACLOZ 55
VERZENIO 24
VESICARE 125
VESICARE LS 125
VESTURA (28) 113
VEVYE 117
VFEND 14
VFEND IV 14
VIBERZI 98
VICTOZA 3-PAK 92
VIENVA 113
vigabatrin 55
VIGADRONE 55
VIGAFYDE 55
VIGAMOX 117
VIGPODER 55
VIIBRYD 55
VIJOICE 24
vilazodone 55
VIMKUNYA 102
VIMPAT 55
VIOKACE 98
VIRACEPT 14
VIREAD 14
VITRAKVI 24
VIVELLE-DOT 113
VIVITROL 55
VIVJOA 14
VIVOTIF 102
VIZIMPRO 24
VOGELXO 92
VONJO 24
VOQUEZNA 98
VOQUEZNA DUAL PAK 98
VOQUEZNA TRIPLE PAK 99
VORANIGO 24
voriconazole 14
VOSEVI 14
VOTRIENT 24
VOWST 99
VOXZOGO 92
VOYDEYA 83
VRAYLAR 55
VTAMA 79
VUITY 117
VUMERITY 55
VYFEMLA (28) 113
VYKAT XR 83
VYLIBRA 113
VYNDAMAX 69
VYNDAQEL 69
VYTORIN 10-10 69
VYTORIN 10-20 69
VYTORIN 10-40 69
VYTORIN 10-80 69
VYVANSE 55
VYVGART HYTRULO 56
VYZULTA 117
WAINUA 56
WAKIX 56
warfarin 69
WEGOVY 83
WELCHOL 69
WELIREG 24
WELLBUTRIN SR 56
WELLBUTRIN XL 56
WEZLANA 79
WINLEVI 79
WINREVAIR 123
WIXELA INHUB 123
WYMZYA FE 113
WYOST 25
XACIATO 113
XALATAN 117
XALKORI 25
XANAX 56
XANAX XR 56
XARAH FE 113
XARELTO 69
XARELTO DVT-PE TREAT 30D START 69
XATMEP 25
XCOPRI 56
XCOPRI MAINTENANCE PACK 56
XCOPRI TITRATION PACK 56
XDEMVY 117
XELJANZ 107
XELJANZ XR 107
XELRIA FE 114
XELSTRYM 56
XENAZINE 56
XERESE 79
XERMELO 25
XGEVA 25
XHANCE 123
XIFAXAN 15
XIGDUO XR 92
XIIDRA 117
XOFLUZA 15
XOLAIR 123
XOLREMDI 102
XOPENEX HFA 123
XOSPATA 25
XPOVIO 25
XROMI 25
XTAMPZA ER 56
XTANDI 25
XULANE 114
XULTOPHY 100/3.6 92
XYOSTED 92
XYREM 56
XYWAV 56
YARGESA 92
YASMIN (28) 114
YAZ (28) 114
YESINTEK 79

YF-VAX (PF).....103
YONSA..... 25
YORVIPATH.....92
YUFLYMA(CF).....107
YUFLYMA(CF) AI CROHN'S-UC-HS..... 107
YUFLYMA(CF) AUTOINJECTOR..... 107
YUPELRI..... 123
YUSIMRY(CF) PEN..... 107
YUTREPIA..... 123
YUVAFEM.....114
ZAFEMY..... 114
zafirlukast..... 123
zaleplon.....56
ZANAFLEX..... 56
ZARONTIN.....56
ZARXIO..... 103
ZAVESCA..... 92
ZAVZPRET.....57
ZEGALOGUE AUTOINJECTOR..... 92
ZEGALOGUE SYRINGE..... 92
ZEJULA.....25
ZELAPAR..... 57
ZELBORAF..... 25
ZELSUVMI.....79
ZEMAIRA.....83
ZEMBRACE SYMTOUCH.....57
ZEMDRI.....15
ZEMPLAR..... 92
ZENATANE..... 79
ZENPEP.....99
ZENZEDI..... 57
ZEPATIER.....15
ZEPBOUND..... 83
ZEPOSIA.....57
ZEPOSIA STARTER KIT (28-DAY).....57
ZEPOSIA STARTER PACK (7-DAY).....57
ZERBAXA.....15
ZERVIATE..... 117
ZESTORETIC..... 69
ZESTRIL.....69
ZETIA.....69
ZEVTERA.....15
ZIAGEN.....15
ZIANA..... 79
zidovudine..... 15
ZIEXTENZO.....103
ZILBRYSQ.....57
zileuton.....123
ZILXI..... 79
ZIOPTAN (PF).....117
ziprasidone hcl.....57
ziprasidone mesylate.....57
ZIPSOR..... 57
ZIRGAN..... 118
ZITHROMAX.....15
ZITHROMAX TRI-PAK.....15
ZITHROMAX Z-PAK..... 15
ZITUVIMET.....92
ZITUVIMET XR..... 92
ZITUVIO.....92
ZOCOR.....69
ZOLINZA.....25
zolmitriptan.....57
ZOLOFT.....57
zolpidem.....57
ZOMACTON..... 103
ZOMIG..... 57
ZONALON..... 79
ZONEGRAN..... 57
ZONISADE..... 57
zonisamide..... 57
ZORTRESS.....25
ZORYVE..... 79
ZOSYN IN DEXTROSE (ISO-OSM)..... 15
ZOVIA 1-35 (28)..... 114
ZOVIRAX..... 79
ZTALMY.....58
ZTLIDO.....79
ZUBSOLV..... 58
ZUNVEYL.....58
ZURZUVAE.....58
ZYCLARA.....79
ZYDELIG.....25
ZYFLO.....123
ZYKADIA..... 25
ZYLET.....118
ZYMFENTRA.....99
ZYPITAMAG..... 69
ZYPREXA.....58
ZYTIGA.....25
ZYVOX.....15

Section:
Prior Authorization

Acitretin

Products Affected

- *acitretin*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Acthar H.P.

Products Affected

- **ACTHAR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Covered for the following indications: 1. Infantile spasms (West syndrome) in children less than 2 years of age 2. Acute exacerbations of multiple sclerosis (MS) for patients receiving concurrent immunomodulator therapy (e.g., interferon beta, glatiramer acetate, dimethyl fumarate, fingolimod, teriflunomide) 3. Rheumatic disorders for patients receiving maintenance therapy with at least one NSAID, DMARD (e.g. leflunomide) or biologic (e.g. adalimumab) 4. Collagen diseases for members receiving maintenance therapy with at least one antimalarial (e.g. hydroxychloroquine) or immunosuppressant (e.g. azathioprine) 5. Dermatologic diseases 6. Allergic states (i.e. serum sickness and transfusion reaction due to serum protein reaction 7. Ophthalmic diseases 8. Respiratory diseases 9. Gout 10. Pediatric acquired epileptic aphasia. 11. Proteinuria in nephrotic syndrome and trial/failure or contraindication to two therapies from any of the following different classes: corticosteroids (e.g., cortisone or dexamethasone), calcineurin inhibitors (e.g., cyclosporine or tacrolimus, per DRUGDEX). For covered indications 2 through 10, limited/unsatisfactory response or intolerance (i.e. severe anaphylaxis) to two corticosteroids (i.e. IV methylprednisolone, IV dexamethasone, or high dose oral steroids) must be documented.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	RA, JRA, and Collagen Diseases: 1 month initial, 6 month reauth. All other indications: 1 month

PA Criteria	Criteria Details
Other Criteria	For reauthorization, the following (1. 2. and 3.) must be met. 1) Prescriber attestation that the member cannot use corticosteroids (e.g. IV methylprednisolone, high dose oral corticosteroids) due to unsatisfactory response, intolerance (e.g. severe anaphylaxis) or experienced a severe adverse event to corticosteroids (e.g. psychosis). 2) If the reauthorization is for the treatment of multiple sclerosis, a rheumatic disorder, dermatologic disease, or nephrotic syndrome, the prescriber attests that H.P. Acthar is being used for a new acute exacerbation and not on a routine basis to prevent an exacerbation as supported by Compendia. 3) If the reauthorization is for treatment of multiple sclerosis, a rheumatic disorder, or collagen disease, the member continues to receive maintenance therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Gout, Epileptic Aphasia
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Acthar SelfJect

Products Affected

- **ACTHAR SELFJECT**

PA Criteria	Criteria Details
Exclusion Criteria	Treatment of infantile spasms
Required Medical Information	Covered for the following indications: 1. Acute exacerbations of multiple sclerosis (MS) for patients receiving concurrent immunomodulator therapy (e.g., interferon beta, glatiramer acetate, dimethyl fumarate, fingolimod, teriflunomide) 2. Rheumatic disorders for patients receiving maintenance therapy with at least one NSAID, DMARD (e.g. leflunomide) or biologic (e.g. adalimumab) 3. Collagen diseases for members receiving maintenance therapy with at least one antimalarial (e.g. hydroxychloroquine) or immunosuppressant (e.g. azathioprine) 4. Dermatologic diseases 5. Allergic states (i.e. serum sickness and transfusion reaction due to serum protein reaction 6. Ophthalmic diseases 7. Respiratory diseases 8. Gout 9. Pediatric acquired epileptic aphasia. 10. Proteinuria in nephrotic syndrome and trial/failure or contraindication to two therapies from any of the following different classes: corticosteroids (e.g., cortisone or dexamethasone), calcineurin inhibitors (e.g., cyclosporine or tacrolimus, per DRUGDEX). For covered indications 1 through 9, limited/unsatisfactory response or intolerance (i.e. severe anaphylaxis) to two corticosteroids (i.e. IV methylprednisolone, IV dexamethasone, or high dose oral steroids) must be documented.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	RA, JRA, and Collagen Diseases: 1 month initial, 6 month reauth. All other indications: 1 month

PA Criteria	Criteria Details
Other Criteria	For reauthorization, the following (1. 2. and 3.) must be met. 1) Prescriber attestation that the member cannot use corticosteroids (e.g. IV methylprednisolone, high dose oral corticosteroids) due to unsatisfactory response, intolerance (e.g. severe anaphylaxis) or experienced a severe adverse event to corticosteroids (e.g. psychosis). 2) If the reauthorization is for the treatment of multiple sclerosis, a rheumatic disorder, dermatologic disease, or nephrotic syndrome, the prescriber attests that H.P. Acthar is being used for a new acute exacerbation and not on a routine basis to prevent an exacerbation as supported by Compendia. 3) If the reauthorization is for treatment of multiple sclerosis, a rheumatic disorder, or collagen disease, the member continues to receive maintenance therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Gout, Epileptic Aphasia
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Actimmune

Products Affected

- **ACTIMMUNE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Adalimumab

Products Affected

- **ABRILADA(CF)**
- **ABRILADA(CF) PEN**
- *adalimumab-aacf subcutaneous pen injector kit*
- *adalimumab-aacf subcutaneous syringe kit*
- **ADALIMUMAB-AACF(CF) PEN CROHNS**
- **ADALIMUMAB-AACF(CF) PEN PS-UV**
- *adalimumab-aaty*
- **ADALIMUMAB-AATY(CF) AI CROHNS**
- *adalimumab-adaz subcutaneous pen injector 40 mg/0.4 ml, 80 mg/0.8 ml*
- *adalimumab-adaz subcutaneous syringe 10 mg/0.1 ml, 20 mg/0.2 ml, 40 mg/0.4 ml*
- *adalimumab-adbm*
- *adalimumab-fkjp subcutaneous pen injector kit*
- *adalimumab-fkjp subcutaneous syringe kit*
- *adalimumab-ryvk subcutaneous auto-injector, kit 40 mg/0.4 ml*
- *adalimumab-ryvk subcutaneous syringe kit*
- **AMJEVITA(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 40 MG/0.4 ML, 40 MG/0.8 ML, 80 MG/0.8 ML**
- **AMJEVITA(CF) SUBCUTANEOUS SYRINGE 10 MG/0.2 ML, 20 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.4 ML, 40 MG/0.8 ML**
- **CYLTEZO(CF)**
- **CYLTEZO(CF) PEN**
- **CYLTEZO(CF) PEN CROHN'S-UC-HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML**
- **CYLTEZO(CF) PEN PSORIASIS-UV SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML**
- **HULIO(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT**
- **HULIO(CF) SUBCUTANEOUS SYRINGE KIT**
- **HUMIRA PEN**
- **HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML**
- **HUMIRA(CF)**
- **HUMIRA(CF) PEN**
- **HUMIRA(CF) PEN CROHNS-UC-HS**
- **HUMIRA(CF) PEN PSOR-UV-ADOL HS**
- **HYRIMOZ**
- **HYRIMOZ PEN**
- **HYRIMOZ PEN CROHN'S-UC STARTER**
- **HYRIMOZ PEN PSORIASIS STARTER**
- **HYRIMOZ(CF) PEDI CROHN STARTER SUBCUTANEOUS SYRINGE 80 MG/0.8 ML, 80 MG/0.8 ML- 40 MG/0.4 ML**
- **HYRIMOZ(CF) PEN SUBCUTANEOUS PEN INJECTOR 40 MG/0.4 ML, 80 MG/0.8 ML**
- **HYRIMOZ(CF) SUBCUTANEOUS SYRINGE 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML**
- **IDACIO(CF)**
- **IDACIO(CF) PEN CROHN-UC STARTR**
- **IDACIO(CF) PEN PSORIASIS START**
- **IDACIO(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT**
- **YUSIMRY(CF) PEN**

PA Criteria	Criteria Details
Exclusion Criteria	

PA Criteria	Criteria Details
Required Medical Information	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID). For moderate to severe polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For uveitis, inadequate response or intolerance to 1 immunosuppressant or corticosteroid, or all are contraindicated.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, and Ankylosing Spondylitis or less than 12 years of age for Hidradenitis Suppurative or Less than 6 years of age for Crohn's disease or Less than 5 years of age for Ulcerative Colitis or less than 2 years of age for Polyarticular Juvenile Idiopathic Arthritis and Uveitis
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	Intolerance to 2 of the following preferred adalimumab products is required: Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. For plaque psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For rheumatoid arthritis therapy without concomitant methotrexate, doses above plan quantity limit will be approved aligned with recommended weekly dosing regimen. For pediatric ulcerative colitis and hidradenitis suppurativa, doses above plan quantity limit will be approved to align with recommended dosing regimen. Induction therapy or treatment regimens for other indications are aligned with plan quantity limit on Humira starter kit.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Adbry

Products Affected

- **ADBRY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe atopic dermatitis, documentation of one of the following (1 or 2): 1) trial & failure or intolerance to at least one topical corticosteroid or one topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus) -OR- 2) severe atopic dermatitis and the member is incapable of applying topical therapies due to the extent of body surface area involvement or severe atopic dermatitis and topical therapies are contraindicated due to severely damaged skin.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Atopic Dermatitis, patients must have a trial/failure, intolerance, or contraindication to both preferred products: Dupixent and Rinvoq. For induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ADHD Drugs

Products Affected

- *clonidine hcl oral tablet extended release 12 hr*
- *guanfacine oral tablet extended release 24 hr*
- **INTUNIV ER**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of ADHD -AND- trial/failure, intolerance or contraindication to a stimulant
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Adlarity

Products Affected

- **ADLARITY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- one of the following (1 or 2): 1) therapeutic failure or intolerance to donepezil tablets, 2) Unable to take daily oral donepezil due to impaired memory.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Afinitor

Products Affected

- **AFINITOR**
- **AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG, 3 MG, 5 MG**
- *everolimus (antineoplastic) oral tablet*
- *everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Agamree

Products Affected

- **AGAMREE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Duchenne muscular dystrophy (DMD) with mutation of dystrophin gene -AND- One of the following: 1) Therapeutic failure, intolerance, or contraindication to prednisone, or 2) Growth delay or decline while on prednisone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Aimovig

Products Affected

- **AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML, 70 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Airsupra

Products Affected

- **AIRSUPRA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following: 1) therapeutic failure or intolerance to inhaled corticosteroid/formoterol combination product, 2) therapeutic failure or intolerance to inhaled corticosteroid used in combination with albuterol.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ajovy

Products Affected

- **AJOVY AUTOINJECTOR**
- **AJOVY SYRINGE**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Akeega

Products Affected

- **AKEEGA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- All of the following: 1) BRCA mutations, 2) Comcomitant therapy with prednisone, 3) Concomitant therapy with a gonadotropin-releasing hormone analog or a bilateral orchiectomy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Alecensa

Products Affected

- **ALECENSA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive -AND- One of the following (1-2): 1) metastatic disease, 2) will be used as adjuvant treatment following tumor resection of node positive or greater than or equal to 4 cm tumor(s).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Alkindi

Products Affected

- **ALKINDI SPRINKLE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of adrenocortical insufficiency -AND- Therapeutic failure or intolerance to oral generic hydrocortisone tablets.
Age Restrictions	Deny if greater than 17 years old
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Alpha1-Proteinase Inhibitors

Products Affected

- **ARALAST NP INTRAVENOUS RECON SOLN 1,000 MG**
- **GLASSIA**
- **PROLASTIN-C INTRAVENOUS SOLUTION**
- **ZEMAIRA INTRAVENOUS RECON SOLN 1,000 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of panacinar emphysema AND documentation of a decline in forced expiratory volume in 1 second (fev1) despite medical therapy (bronchodilators, corticosteroids) AND documentation of phenotype (pi*zz, pi*znull or pi*nullnull) associated with causing serum alpha 1-antitrypsin of less than 80 mg/dl AND documentation of an alpha 1-antitrypsin serum level below the value of 35% of normal (less than 80 mg/dl).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Covered under Part B when furnished incident to a physician service and is not self-administered.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Alunbrig

Products Affected

- **ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG**
- **ALUNBRIG ORAL TABLETS,DOSE PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Alyftrek

Products Affected

- **ALYFTREK ORAL TABLET 10-50-125 MG, 4-20-50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystic fibrosis (CF) in patients who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to vanzacaftor/tezacaftor/deutivacaftor based on clinical and/or in vitro assay.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Amitiza

Products Affected

- **AMITIZA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Amlodipine Liquid

Products Affected

- **KATERZIA**
- **NORLIQVA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- Inability to swallow amlodipine tablets
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ampyra

Products Affected

- **AMPYRA**
- *dalfampridine*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Anabolic Steroids

Products Affected

- **METHITEST**
- *methyltestosterone oral capsule*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ancobon

Products Affected

- **ANCOBON**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Andembry

Products Affected

- **ANDEMBRY AUTOINJECTOR**

PA Criteria	Criteria Details
Exclusion Criteria	Member should not be on two prophylactic therapies simultaneously.
Required Medical Information	For the prophylactic treatment of attacks of hereditary angioedema (HAE) due to deficiency of C1INH (type I & II) with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the prophylactic treatment of attacks of hereditary angioedema (HAE) with normal C1INH (type III) with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE, FXII mutation, angiopoietin-1 mutation, plasminogen mutation, kininogen-1 mutation, myoferlin mutation, or heparin sulfate-glucosamine 3-O-sulfotransferas 6 mutation. 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	For initial and induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended initial and induction therapy dosing regimens per indication.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Anticholinergic Meds

Products Affected

- *paroxetine hcl*
- **PAXIL CR**
- **PAXIL ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- Attestation of counseling on risk-benefit profile and potential anticholinergic adverse effects -AND- Therapeutic failure, contraindication, or intolerance to 2 other antidepressants (i.e., SSRI, SNRI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Anzupgo

Products Affected

- **ANZUPGO**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Apokyn

Products Affected

- **APOKYN**
- *apomorphine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of advanced Parkinson's disease -AND- for use in acute, intermittent treatment of hypomobility off episodes -AND- experiencing off episodes despite the use of oral carbidopa/levodopa -AND- Therapeutic failure, intolerance, or contraindication to one of the following generic products: pramipexole, ropinirole, entacapone, selegiline or rasagiline
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Aqneursa

Products Affected

- **AQNEURSA**

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use of Aqneursa (levacetylleucine) -AND- Miplyffa (arimoclomal)
Required Medical Information	Documentation of diagnosis -AND- neurological symptoms of Niemann-Pick Disease Type C (e.g., ataxia, dysarthria, dysphagia, cognitive impairment, seizures) -AND- weight at least 15 kg
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of positive clinical response
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Arikayce

Products Affected

- **ARIKAYCE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Mycobacterium avium complex lung disease -AND- Attestation of not achieving negative sputum cultures despite at least 6 months with a multidrug background regimen containing 2 of the following: 1) macrolide 2) rifamycin or 3) ethambutal -AND- Arikayce will be used in conjunction with a background multidrug regimen.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of positive sputum cultures -OR- negative sputum cultures for insufficient period of time (e.g. less than 12 months).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ATTR-CM drugs

Products Affected

- **ATTRUBY**
- **VYNDAMAX**
- **VYNDAQEL**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitantly with transthyretin-lowering agents
Required Medical Information	Documentation of cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) with amyloid deposits on cardiac biopsy or scintigraphy with heart contralateral greater than 1.5 (Grade III) or visual grade 2 to 3 -AND- Cardiac involvement supported by cardiac magnetic resonance, echocardiography or serum cardiac biomarker (e.g. B-type natriuretic peptide, cardiac troponin) -AND- For Attruby (acoramidis), ATTR-CM type is wild-type or variant -AND- For Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis), ATTR-CM type is wild-type or hereditary.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of improvement or delayed disease progression from baseline demonstrated by 6-minute walk test, cardiac function (e.g. LVEF, NYHA class), Kansas City Cardiomyopathy Questionnaire-Overall Summary, number of cardiovascular-related hospitalizations or serum cardiac biomarkers (e.g. B-type natriuretic peptide, cardiac troponin)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Atypical Antipsychotics

Products Affected

- **ABILIFY ORAL TABLET**
- *aripiprazole oral solution*
- *aripiprazole oral tablet,disintegrating*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. If medication is being used for major depressive disorder, documentation of adjunctive therapy and therapeutic failure, contraindication or intolerance to one other generic antidepressant in addition to the antidepressant currently being used for the treatment of MDD (e.g. SSRI, SNRI, NDRIs, TCA, MAOI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Aubagio

Products Affected

- **AUBAGIO**
- *teriflunomide*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Augtyro

Products Affected

- **AUGTYRO ORAL CAPSULE 160 MG, 40 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ROS1-positive. Documentation of solid tumors -AND- disease harbors a NTRK gene fusion -AND- one of the following (1-2): 1) disease is locally advanced or metastatic, or 2) surgical resection is likely to result in severe morbidity -AND- one of the following (3-4): 3) disease has progressed following treatment, or 4) the member has no satisfactory alternative therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Austedo

Products Affected

- **AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG**
- **AUSTEDO XR**
- **AUSTEDO XR TITRATION KT(WK1-4)**
- **ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-3) 1) Chorea associated with Huntington's disease 2) In patients with comorbid depression, attestation of adequate treatment for depression is required. 3) Attestation that patient is not actively suicidal. -OR- 4) Tardive Dyskinesia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Auvelity

Products Affected

- **AUVELITY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of major depressive disorder (MDD) -AND- Therapeutic failure or intolerance to generic bupropion hydrochloride tablets -AND- Therapeutic failure, intolerance or contraindication to one other generic antidepressant (e.g. SNRI, SSRI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Avmapki-Fakzynja

Products Affected

- **AVMAPKI-FAKZYNJA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ayvakit

Products Affected

- **AYVAKIT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of unresectable or metastatic gastrointestinal stromal tumor -AND- tumors harbor a PDGFRA exon 18 mutation. Documentation of agressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, mast cell leukemia, or indolent systemic mastocytosis -AND- platelet count greater than or equal to 50 x 10*9/L.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Baclofen Solution

Products Affected

- *baclofen oral solution 10 mg/5 ml (2 mg/ml), 5 mg/5 ml*
- *baclofen oral suspension*
- **FLEQSUVY**
- **OZOBAX DS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- the member has an inability to swallow generic baclofen tablets.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Bafiertam

Products Affected

- **BAFIERTAM**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Therapeutic failure or intolerance to generic dimethyl fumarate
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Balversa

Products Affected

- **BALVERSA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following: 1) FGFR3 mutation status as detected by an FDA approved test 2) disease progression on or after at least on prior line of systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Banzel

Products Affected

- **BANZEL**
- *rufinamide*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Benlysta

Products Affected

- **BENLYSTA SUBCUTANEOUS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For diagnosis of active systemic lupus erythematosus (SLE), both of the following (1-2): 1) Documentation of positive anti-nuclear antibody (ANA) titer (greater than or equal to 1:80) or anti-double-stranded DNA antibody (anti-dsDNA) greater than or equal to 30IU/mL, 2) member will continue to receive concomitant standard of care treatment with use of at least one of the following (alone or in combination) (a-c): a) corticosteroids (e.g. prednisone), b) antimalarials (e.g. hydroxychloroquine), c) immunosuppressants (e.g. azathioprine, mycophenolate mofetil, or methotrexate). For diagnosis of active lupus nephritis (LN), one of the following (3 or 4): 3) Diagnosis confirmed by renal biopsy, 4) Contraindication to renal biopsy, laboratory findings specific to LN (e.g., elevated serum creatinine, abnormal urine analysis, decreased eGFR). -AND- Member will continue to receive concomitant standard of care treatment which includes corticosteroids (e.g. prednisone) with at least one of the following (d or e): d) mycophenolate for induction followed by mycophenolate for maintenance, e) cyclophosphamide for induction followed by azathioprine for maintenance.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	For SLE reauthorization, attestation of disease stability or improvement -AND- attestation the member will continue to receive standard of care therapy with corticosteroids, antimalarials, or immunosuppressives. For active LN reauthorization, attestation of disease stability or improvement -AND- attestation the member will continue to receive standard of care therapy with mycophenolate or azathioprine. For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Berinert

Products Affected

- **BERINERT INTRAVENOUS KIT**

PA Criteria	Criteria Details
Exclusion Criteria	Member should not be on two acute therapies simultaneously and acute therapy should not be used as prophylactic therapy
Required Medical Information	For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) due to deficiency of C1INH (type I & II) with the following (1-4): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. 4) Documentation of member's weight. For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) with normal C1INH (type III) with the following (5-9): 5) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 6) Documentation of family history of HAE, FXII mutation, angiopoietin-1 mutation, plasminogen mutation, kininogen-1 mutation, myoferlin mutation, or heparin sulfate-glucosamine 3-O-sulfotransferas 6 mutation. 7) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 8) Medications known to cause angioedema have been evaluated and discontinued. 9) Documentation of member's weight.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	For 18 years of age or older, therapeutic failure, intolerance or contraindication to icatibant.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Besremi

Products Affected

- **BESREMI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of polycythemia vera
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Bimzelx

Products Affected

- **BIMZELX AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 160 MG/ML, 320 MG/2 ML** **160 MG/ML, 320 MG/2 ML**
- **BIMZELX SUBCUTANEOUS SYRINGE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- documentation of member weight and prescribed dose. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For non-radiographic axial spondyloarthritis, inadequate response or intolerance to 2 nonsteroidal anti-inflammatory drugs (NSAIDs) or all are contraindicated. For ankylosing spondylitis, inadequate response or intolerance to 1 NSAID or all are contraindicated.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year

PA Criteria	Criteria Details
Other Criteria	Must follow recommended dosing guidelines based upon weight. Induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For plaque psoriasis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla, and Skyrizi SC. For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla, Skyrizi SC, Rinvoq, and Xeljanz/Xeljanz XR. For non-radiographic axial spondyloarthritis patients must have therapeutic failure or intolerance to 2 of the following preferred products: Cimzia, Rinvoq, Cosentyx. For ankylosing spondylitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Cosentyx, Rinvoq, and Xeljanz/Xeljanz XR. For hidradenitis suppurativa, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Cosentyx. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Bonjesta

Products Affected

- **BONJESTA**
- **DICLEGIS**
- *doxylamine-pyridoxine (vit b6)*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	9 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Bosulif

Products Affected

- **BOSULIF ORAL CAPSULE 100 MG, 50 MG**
- **BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For members 18 years of age and older, one of the following (1, 2): 1) newly diagnosed Philadelphia chromosome (PH) -positive CML in the chronic phase 2) diagnosis of Ph-positive CML in the chronic, accelerated, or blast phase and no longer responding to or intolerant to at least 1 prior therapy. For pediatric patients 1 year of age and older, one of the following (3, 4): 3) newly diagnosed PH-positive CML in the chronic phase 4) diagnosis of Ph-positive CML in the chronic phase and no longer responding to or intolerant to at least 1 prior therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Bosutinib capsules and 18 years of age or older, inability to swallow tablets is required. For Bosutinib 100mg capsules and pediatric 1 year of age or older, inability to swallow tablets is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Braftovi

Products Affected

- **BRAFTOVI**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Brinsupri

Products Affected

- **BRINSUPRI**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Brukinsa

Products Affected

- **BRUKINSA ORAL CAPSULE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For mantle cell lymphoma (MCL), previous treatment with at least 1 prior therapy. For marginal zone lymphoma (MZL), previous treatment with at least 1 anti-CD20-based regimen. For follicular lymphoma (FL), using in combination with obinutuzumab and previous treatment with at least 2 prior lines of systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Bucapsol

Products Affected

- **BUCAPSOL ORAL CAPSULE 15 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Buphenyl

Products Affected

- **BUPHENYL**
- *sodium phenylbutyrate*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Bylvay

Products Affected

- **BYLVAY ORAL CAPSULE 1,200 MCG, 400 MCG**
- **BYLVAY ORAL PELLET 200 MCG, 600 MCG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of pruritis with progressive familial intrahepatic cholestasis or cholestatic pruritus with Alagille syndrome -AND- The member does not have cirrhosis, portal hypertension, or history of hepatic decompensation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial, 12 months reauthorization
Other Criteria	For reauthorization, attestation of improvement in pruritis -AND- attestation that the member has not progressed to any of the following (1-3): 1) portal hypertension, 2) cirrhosis, or 3) experienced a hepatic decompensation event.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Cablivi

Products Affected

- **CABLIVI INJECTION KIT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of acquired thrombocytopenic purpura (aTTP) -AND- Used in conjunction with plasma exchange and immunosuppressive therapy (i.e. systemic corticosteroids or rituximab)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	75 days initial authorization, 60 days reauthorization
Other Criteria	For reauthorization, the request is for a new episode requiring the re-initiation of plasma exchange for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) -AND- no more than 2 recurrences of aTTP have occurred following initial course of therapy. Total treatment duration will be limited to 58 days beyond the last therapeutic plasma exchange. No more than three courses of Cablivi will be approved per lifetime.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Cabometyx

Products Affected

- **CABOMETYX**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Calquence

Products Affected

- **CALQUENCE (ACALABRUTINIB MAL)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For mantle cell lymphoma, member has received at least one prior therapy -OR- all of the following (1-3): 1) member has not received prior therapy for MCL, 2) member is ineligible for autologous hematopoietic stem cell transplantation (HSCT), and 3) using in combination with bendamustine and rituximab.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Camzyos

Products Affected

- **CAMZYOS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy -AND- Left ventricular ejection fraction of greater than or equal to 55% -AND- Valsalva left ventricular outflow tract peak gradient of greater than or equal to 50 mmHg at rest or after provocation -AND- Therapeutic failure or intolerance to one of the following (1 or 2) or contraindication to all: 1) Non-vasodilating beta blocker (e.g. metoprolol) 2) non-dihydropyridine calcium channel blocker (e.g. diltiazem) -AND- Not currently treated with and attestation Camzyos will not be used concomitantly with disopyramide, ranolazine, or combination therapy of beta-blocker and calcium channel blocker
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, prescriber attestation of no NYHA class worsening -AND- Not currently treated with and attestation Camzyos will not be used concomitantly with disopyramide, ranolazine, or combination therapy of beta-blocker and calcium channel blocker
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Caplyta

Products Affected

- **CAPLYTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- therapeutic failure, intolerance, or contraindication to one other generic atypical antipsychotic (e.g. quetiapine).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Caprelsa

Products Affected

- **CAPRELSA ORAL TABLET 100 MG, 300 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Carac

Products Affected

- *fluorouracil topical cream 0.5 %*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Carbaglu

Products Affected

- **CARBAGLU**
- *carglumic acid*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Carbinoxamine

Products Affected

- *carbinoxamine maleate oral liquid*
- *carbinoxamine maleate oral tablet*
- **RYVENT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- Failure, contraindication or intolerance to 2 antihistamines indicated for diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Cayston

Products Affected

- **CAYSTON**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of cystic fibrosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of decrease in sputum density of pseudomonas aeruginosa, increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Cerdelga

Products Affected

- **CERDELGA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of type 1 Gaucher disease confirmed by the following A. or B. A) With one of the following symptoms (1, 2, 3, 4, or, 5): 1)Hepatomegaly. 2)Splenomegaly. 3)Bone disease (i.e. osteonecrosis, osteopenia, secondary pathologic fractures, bone infarct). 4)Bone marrow complications as defined by anemia with hemoglobin less than or equal to 11.5 g/dL for females or 12.5 g/dL for males or thrombocytopenia with platelet count less than or equal to 120,000/mm*3. 5)Symptomatic disease (e.g. bone pain, exertional limitation, cachexia). -OR- B) Attestation of deficiency in glucocerebrosidase activity in peripheral leukocytes or genetic testing confirms mutant alleles -AND- Documentation of CYP2D6 metabolizer status (e.g. intermediate metabolizer).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

CF drugs

Products Affected

- **BETHKIS**
- **KITABIS PAK**
- **TOBI**
- **TOBI PODHALER**
- *tobramycin in 0.225 % nacl*
- *tobramycin inhalation*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Chenodal

Products Affected

- **CHENODAL**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Cholbam

Products Affected

- **CHOLBAM**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of bile acid synthesis disorders due to single enzyme defects (e.g. AKR1D1, CTX, CYP7A1) -OR- documentation of use as adjunctive therapy for peroxisomal disorders (PDs), including Zellweger spectrum disorders, in patients who exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Cialis

Products Affected

- **CIALIS ORAL TABLET 5 MG**
- *tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Cibinqo

Products Affected

- **CIBINQO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe atopic dermatitis, documentation of one of the following (1 or 2): 1) trial & failure or intolerance to at least one topical corticosteroid or one topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus) -OR- 2) severe atopic dermatitis and the member is incapable of applying topical therapies due to the extent of body surface area involvement or severe atopic dermatitis and topical therapies are contraindicated due to severely damaged skin.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Atopic Dermatitis, patients must have a trial/failure, intolerance, or contraindication to both preferred products: Dupixent and Rinvoq.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Cimzia

Products Affected

- **CIMZIA POWDER FOR RECONST**
- **CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. leflunomide) or all nonbiologic DMARDs are contraindicated. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID) or all are contraindicated. For non-radiographic axial spondyloarthritis, inadequate response or intolerance to two nonsteroidal anti-inflammatory drugs (NSAIDs) or all are contraindicated. For moderate to severe psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- all nonbiologic DMARDs are contraindicated -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity, or at high risk of disabling joint damage.
Age Restrictions	Deny if less than 2 years of age for polyarticular juvenile idiopathic arthritis or less than 18 years of age for all other indications.
Prescriber Restrictions	
Coverage Duration	Plan Year

PA Criteria	Criteria Details
Other Criteria	For initial and induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended initial and induction therapy dosing regimens per indication. For Crohn's disease, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, and Rinvoq. For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Rinvoq and Xeljanz/Xeljanz XR. For plaque psoriasis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla, and Skyrizi SC. For ankylosing spondylitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Cosentyx, Rinvoq, and Xeljanz/Xeljanz XR. For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla, Skyrizi SC, Rinvoq, and Xeljanz/Xeljanz XR. For polyarticular juvenile idiopathic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Rinvoq/Rinvoq LQ, and Xeljanx/Xeljanz solution. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Cinryze

Products Affected

- **CINRYZE**

PA Criteria	Criteria Details
Exclusion Criteria	Member should not be on two prophylactic therapies simultaneously.
Required Medical Information	For the prophylactic treatment of abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) due to deficiency of C1INH (type I & II) with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the prophylactic treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) with normal C1INH (type III) with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE, FXII mutation, angiopoietin-1 mutation, plasminogen mutation, kininogen-1 mutation, myoferlin mutation, or heparin sulfate-glucosamine 3-O-sulfotransferas 6 mutation. 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Citalopram Capsule

Products Affected

- *citalopram oral capsule*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Clemastine Syrup

Products Affected

- *clemastine oral syrup*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of allergic rhinitis or mild, uncomplicated allergic skin manifestations of urticaria and angioedema -AND- Therapeutic failure, contraindication or intolerance to one generic antihistamine product -AND- Therapeutic failure or intolerance to generic clemastine fumarate tablets or an inability to swallow tablets.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Cobenfy

Products Affected

- **COBENFY**
- **COBENFY STARTER PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- therapeutic failure, intolerance, or contraindication to one other generic atypical antipsychotic (e.g. quetiapine).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Cometriq

Products Affected

- **COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of progressive, metastatic medullary thyroid cancer
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Copiktra

Products Affected

- **COPIKTRA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Corlanor

Products Affected

- **CORLANOR ORAL SOLUTION**
- **CORLANOR ORAL TABLET 5 MG, 7.5 MG**
- *ivabradine oral tablet 5 mg, 7.5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- All of the following: 1) Normal sinus rhythm, 2) Resting heart rate greater than or equal to 70 beats per minute, 3) For adults, left ventricular ejection fraction less than or equal to 35 percent, 4) For adults, concurrent use of 1 beta-blocker used for treatment of heart failure (i.e. bisoprolol, carvedilol, metoprolol succinate) or therapeutic failure, intolerance, or contraindication to the maximum tolerated dose of 2 beta-blockers used for treatment of heart failure.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For oral solution, attestation of inability to swallow tablets is required. For brand Corlanor tablets, when being utilized for the same medically accepted indication, trial and failure of generic ivabradine tablets is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Cosentyx

Products Affected

- **COSENTYX (2 SYRINGES)**
- **COSENTYX PEN (2 PENS)**
- **COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML**
- **COSENTYX UNOREADY PEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID) or all are contraindicated. For non-radiographic axial spondyloarthritis, inadequate response or intolerance to 2 NSAIDs or all are contraindicated.
Age Restrictions	Deny if less than 6 years of age for moderate to severe plaque psoriasis -OR- less than 2 years of age for psoriatic arthritis -OR- less than 4 years of age for enthesitis-related arthritis -OR- less than 18 years of age for all other indications
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication. For hidradenitis suppurativa, doses above plan quantity limit will be approved to align with recommended dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

Cotellic

Products Affected

- **COTELLIC**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following for unresectable or metastatic melanoma (1-2): 1) BRAF V600E or V600K mutation status 2) Concomitant therapy with vemurafenib. For cobimetinib monotherapy, documentation of histiocytic neoplasms.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Crenessity

Products Affected

- **CRENESSITY ORAL CAPSULE 100 MG, 25 MG, 50 MG**
- **CRENESSITY ORAL SOLUTION**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Cresemba

Products Affected

- **CRESEMBA ORAL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of invasive aspergillosis infection -AND- therapeutic failure, contraindication, or intolerance to voriconazole -OR- Documentation of invasive mucormycosis infection.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For reauthorization, attestation of presence of continued indicators of active disease (e.g. histopathology, fungal culture).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Crinone

Products Affected

- **CRINONE**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ctexli

Products Affected

- **CTEXLI**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Cuvrior

Products Affected

- **CUVRIOR**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Cysteamine Ophthalmic Drops

Products Affected

- **CYSTADROPS**
- **CYSTARAN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystinosis -AND- Attestation of accumulation of corneal cystine crystals
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Danziten

Products Affected

- **DANZITEN**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Daraprim

Products Affected

- **DARAPRIM**
- *pyrimethamine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For primary prophylaxis of toxoplasmosis gondii infection, CD4 count less than 100 cells/mm*3 -AND- Toxoplasma IgG positive -AND- failure, intolerance or contraindication to trimethoprim-sulfamethoxazole. For secondary prophylaxis of toxoplasmosis gondii infection, CD4 count less than 200 cells/mm*3. For secondary prophylaxis of cystoisosporiasis with CD4 count less than 200 cells/mm*3 or acute cystoisosporiasis infection: failure, intolerance or contraindication to trimethoprim-sulfamethoxazole. For primary prophylaxis of Pneumocystis jirovecii pneumonia: diagnosis of HIV -AND- CD4 count less than 200 cells/mm*3 -AND- failure, intolerance or contraindication to trimethoprim-sulfamethoxazole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Daraprim, trial and failure of generic pyrimethamine is required.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Daurismo

Products Affected

- **DAURISMO ORAL TABLET 100 MG, 25 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of newly diagnosed Acute Myeloid Leukemia -AND- Used in combination with cytarabine -AND- At least one comorbidity that preclude use of intensive induction chemotherapy defined as one of the following: 1) Age greater than or equal to 75 2) Severe cardiac or pulmonary comorbidity 3) Reduced renal function 4) Hepatic impairment 5.) Physician attests patient is not a candidate for intensive induction therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Daybue

Products Affected

- **DAYBUE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Rett syndrome confirmed by all of the following (1 thru 4): 1) Partial or complete loss of acquired purposeful hand skills, 2) Partial or complete loss of acquired spoken language, 3) Gait abnormalities: impaired or absence of ability, 4) Stereotypic hand movements such as hand wringing/squeezing, clapping/tapping, mouthing, and washing/rubbing automatisms
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Daytrana

Products Affected

- **DAYTRANA**
- *methylphenidate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- trial/failure or intolerance to 2 of the following generic medications: methylphenidate, atomoxetine, or dextroamphetamine/amphetamine.
Age Restrictions	Deny if less than 6 years of age or greater than 17 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Daytrana, trial/failure of generic methylphenidate patch is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Deferasirox

Products Affected

- *deferasirox*
- **EXJADE**
- **JADENU**
- **JADENU SPRINKLE**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Denosumab (Onco)

Products Affected

- **BOMYNTRA**
- **OSENVELT**
- **WYOST**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For hypercalcemia of malignancy, refractory to bisphosphonates. For giant cell tumor of bone, unresectable or surgical resection is likely to result in severe morbidity -AND- one of the following (1. or 2.)- 1.) the member is 18 years old or older -OR- 2.) the member is a skeletally mature adolescent (e.g. has at least one mature long bone)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Intolerance to Xgeva is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Denosumab (Osteo)

Products Affected

- **CONEXXENCE**
- **JUBBONTI**
- **STOBOCLO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -And- For osteoporosis at high risk for fracture, meeting one of the following (1. thru 4.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 (i.e. osteopenia) -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent. 4) Age 40 years or older with T-score between -1.0 and -2.5 -AND- History of glucocorticoid use for at least 3 months at a dose of 5mg per day or more of prednisone (or equivalent).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For osteoporosis and osteopenia, documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Covered under Part B for patients eligible for home health services when provider certifies that patient sustained bone fracture related to post-menopausal osteoporosis and is unable to learn the skills needed to self-administer the drug or is otherwise physically or mentally incapable of administering the drug or family/caregivers are unable or unwilling to administer the drug. Intolerance to Prolia is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Diacomit

Products Affected

- **DIACOMIT ORAL CAPSULE 250 MG, 500 MG**
- **DIACOMIT ORAL POWDER IN PACKET 250 MG, 500 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Dravets syndrome - AND- Used in combination with clobazam
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation supporting reduction in seizure frequency
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Dicyclomine

Products Affected

- *dicyclomine oral tablet 40 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Dihydroergotamine

Products Affected

- *dihydroergotamine nasal*
- **TRUDHESA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of acute migraine headaches with or without aura -AND- requires non-oral route of administration -AND- therapeutic failure or intolerance to generic sumatriptan nasal spray.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Dojolvi

Products Affected

- **DOJOLVI**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitantly with another medium chain triglyceride product
Required Medical Information	Documentation of molecularly confirmed long-chain fatty acid oxidation disorders
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Doptelet

Products Affected

- **DOPTELET (10 TAB PACK)**
- **DOPTELET (15 TAB PACK)**
- **DOPTELET (30 TAB PACK)**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Doxepin Cream

Products Affected

- *doxepin topical*
- **PRUDOXIN**
- **ZONALON**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- course of therapy will not exceed 8 days -AND- experienced therapeutic failure, intolerance, or contraindication to one of the following (1 or 2): 1) at least 2 generic formulary topical corticosteroids. 2) generic topical tacrolimus or pimecrolimus for topic dermatitis with the facial or anogenital involvement.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	1 month
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

DPP4 Agents

Products Affected

- *alogliptin*
- *alogliptin-metformin*
- *alogliptin-pioglitazone*
- **JANUMET**
- **JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG, 50-1,000 MG, 50-500 MG**
- **JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG**
- **JENTADUETO ORAL TABLET 2.5-1,000 MG, 2.5-500 MG**
- **JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-1,000 MG**
- *saxagliptin*
- *saxagliptin-metformin oral tablet, er multiphase 24 hr 2.5-1,000 mg, 5-1,000 mg, 5-500 mg*
- *sitagliptin oral tablet 100 mg, 25 mg, 50 mg*
- *sitagliptin-metformin oral tablet*
- *sitagliptin-metformin oral tablet, er multiphase 24 hr 100-1,000 mg, 50-1,000 mg, 50-500 mg*
- **TRADJENTA**
- **ZITUVIMET**
- **ZITUVIMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG, 50-1,000 MG, 50-500 MG**
- **ZITUVIO ORAL TABLET 100 MG, 25 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

DPP4-SGLT2 Combo

Products Affected

- **GLYXAMBI**
- **STEGLUJAN**
- **TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 12.5-2.5-1,000 MG, 25-5-1,000 MG, 5-2.5-1,000 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Drizalma

Products Affected

- **DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG, 30 MG, 40 MG, 60 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- inability to swallow tablets/capsules. For fibromyalgia, members must also have widespread bilateral pain above and below the waist for greater than 3 months duration -AND- At least 1 fibromyalgia-related symptom (e.g., cognitive impairment, fatigue, sleep disturbance, neurologic symptoms, exercise intolerance).
Age Restrictions	Deny if less than 18 years of age in the treatment of fibromyalgia, major depressive disorder, diabetic peripheral neuropathy and chronic musculoskeletal pain -OR- if less than 7 years of age in generalized anxiety disorder
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Duexis2

Products Affected

- *ibuprofen-famotidine*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Duobrii

Products Affected

- **DUOBRII**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of plaque psoriasis -AND- therapeutic failure or intolerance to generic tazarotene cream -AND- therapeutic failure or intolerance to 1 high-potency topical corticosteroid (e.g. betamethasone dipropionate 0.05%, halobetasol propionate 0.05%)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Dupixent

Products Affected

- **DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML**
- **DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML, 300 MG/2 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Moderate to severe atopic dermatitis: trial/failure or intolerance to 1 topical corticosteroid or, if 2 yrs or older, topical calcineurin inhibitor (e.g. tacrolimus, pimecrolimus) -OR- severe atopic dermatitis and incapable of applying topical therapies due to the extent of body surface area involvement or topical therapies are contraindicated due to severely damaged skin. Moderate-to-severe asthma: history of at least 2 asthma exacerbations requiring oral or injectable corticosteroids in past 12mos or at least 1 asthma exacerbation requiring hospitalization in past 12mos -AND- blood eosinophils of at least 150cells/uL or current daily or alternate-day oral corticosteroid (OCS) therapy -AND- inadequate symptom control despite regular treatment w/ medium- or high-dose inhaled corticosteroids (ICS) and at least 1 add'l asthma controller medication (e.g. long-acting beta2-agonist [LABA], leukotriene receptor antagonist [LTRA], theophylline) w/ or w/o OCS, unless intolerant or contraindicated to all -AND- will continue treatment with a medium- or high-dose ICS and at least 1 add'l asthma controller medication w/ or w/o OCS. Chronic rhinosinusitis with nasal polyposis: trial/ failure, intolerance or contraindication to intra-nasal corticosteroid and 14 day course of OCS. Eosinophilic esophagitis: esophageal eosinophil count of at least 15eos/hpf on esophageal biopsy -AND- clinical symptoms of esophageal dysfunction. Prurigo nodularis. COPD: blood eosinophils of at least 300cells/uL or current daily or alternate-day OCS therapy -AND- inadequate symptom control despite regular treatment for at least 3 months with LAMA, LABA, and ICS, unless intolerant or contraindicated to all. Chronic Spontaneous Urticaria: trial/failure, contraindication or intolerance to 1 second-generation non-sedating H1 antihistamine at the maximum recommended dose (e.g. cetirizine, fexofenadine, loratadine, desloratadine, levocetirizine).
Age Restrictions	

PA Criteria	Criteria Details
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For atopic dermatitis reauthorization, attestation of positive clinical response to therapy. For asthma reauthorization, attestation of one of the following is required (1-4): 1) decreased rescue medication or oral corticosteroid use, 2) decreased frequency of severe asthma exacerbations, 3) increased pulmonary function from baseline (e.g. FEV1), or 4) reduction in reported asthma related symptoms. For CRSwNP reauthorization, attestation of decrease in nasal polyp score or reduction in nasal congestion/obstruction severity score. For EoE reauthorization, attestation of histological remission (less than 15 eos/hpf) on esophageal biopsy or reduced severity or frequency of clinical symptoms of esophageal dysfunction. For prurigo nodularis reauthorization, attestation of reduction in itch or number of nodules or lesions from baseline. For COPD reauthorization, attestation of one of the following is required (1-4): 1) reduction in COPD symptoms, 2) improvement in exercise tolerance, 3) delayed disease progression, or 4) reduction in the number of COPD exacerbations. For CSU reauthorization, improved CSU symptoms.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Duvyzat

Products Affected

- **DUVYZAT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Duchenne muscular dystrophy with pathogenic mutation in the dystrophin gene.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ebglyss

Products Affected

- **EBGLYSS PEN**
- **EBGLYSS SYRINGE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe atopic dermatitis, documentation of one of the following (1 or 2): 1) trial & failure, or intolerance to at least one generic topical corticosteroid -OR- generic topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus) 2) The member has severe atopic dermatitis and is incapable of applying topical therapies due to the extent of body surface area involvement or topical therapies are contraindicated due to severely damaged skin.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Atopic Dermatitis, patients must have a trial/failure, intolerance, or contraindication to both preferred products: Dupixent and Rinvoq. For induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen for 16 weeks and once for an additional 8 weeks if clinical response is not achieved by 16 weeks.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EGFR Tyrosine Kinase Inhibitors

Products Affected

- *erlotinib*
- **GILOTRIF**

PA Criteria	Criteria Details
Exclusion Criteria	Afatinib products: tumors with resistant EGFR mutations. Erlotinib products: use in NSCLC tumors with mutations other than those in FDA-approved indications. Use in combination with platinum based chemotherapy.
Required Medical Information	For afatinib, documentation of metastatic non-small cell lung cancer (NSCLC) -AND- one of the following, as detected by an FDA-approved test (1-3): 1) disease harbors EGFR exon 19 deletions 2) disease harbors EGFR exon 21 (L858R) substitution mutation 3) disease harbors non-resistant EGFR mutation (i.e., S768I, L861Q, G719X) -OR- documentation of squamous metastatic NSCLC and member has experienced progression on platinum-based chemotherapy. For erlotinib, documentation of metastatic NSCLC -AND- one of the following, as detected by an FDA-approved test (1-2): 1) disease harbors EGFR exon 19 deletions 2) disease harbors EGFR exon 21 (L858R) substitution mutations -OR- documentation of locally advanced, unresectable or metastatic pancreatic cancer -AND- all of the following (1-2): 1) using erlotinib as first-line therapy 2) using in combination with gemcitabine.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Egrifta

Products Affected

- **EGRIFTA SV**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documented diagnosis of HIV and lipodystrophy, member must actively be receiving antiretroviral therapy including protease inhibitors, nucleoside reverse transcriptase inhibitors, or non-nucleoside reverse transcriptase inhibitors
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, continued antiretroviral therapy for HIV infection -AND- reduction in visceral adipose tissue from baseline (e.g. reduction of minimum waist circumference, waist to hip ratio, or BMI) are required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ekterly

Products Affected

- **EKTERLY**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Elyxyb

Products Affected

- **ELYXYB**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of migraine diagnosis -AND- trial/failure or intolerance to 2 generic NSAIDs.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of reduction in migraine symptoms.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Emflaza

Products Affected

- *deflazacort*
- **EMFLAZA**
- **JAYTHARI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Duchenne muscular dystrophy (DMD) with mutation of dystrophin gene -AND- onset of weakness or history of DMD starting before age 5 -AND- One of the following (1, 2, or 3). 1) Documented trial/failure, intolerance or contraindication to prednisone. 2) Documented trial of prednisone has resulted in intolerable adverse events (e.g. diabetes, hypertension that is difficult to manage, Cushingoid features, truncal obesity, greater than or equal to 10 percent increase in body weight over a 6 month period). 3) Documented severe behavioral adverse event while on prednisone that warrants prednisone dose reduction impacting efficacy for management of DMD (i.e. abnormal behavior, aggression, irritability, disturbance in mood)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Emflaza tablets and 5 years of age or older, therapeutic failure or intolerance to generic deflazacort tablets is required. For brand Emflaza suspension and 5 years of age or older, therapeutic failure or intolerance to generic deflazacort tablets or inability to swallow tablets is required, and therapeutic failure or intolerance to generic deflazacort suspension. For generic deflazacort suspension and 5 years of age or older, therapeutic failure or intolerance to generic deflazacort tablets or inability to swallow tablets is required.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Emgality

Products Affected

- **EMGALITY PEN**
- **EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML, 300 MG/3 ML (100 MG/ML X 3)**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Empaveli

Products Affected

- **EMPAVELI**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Endari

Products Affected

- **ENDARI**
- *glutamine (sickle cell)*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Enspryng

Products Affected

- **ENSPRYNG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of neuromyelitis optica spectrum disorder (NMOSD) -AND- Attestation of anti-aquaporin-4 (AQP4) antibody positive -AND- Not used in combination with another monoclonal antibody used for the treatment of NMOSD -AND- One core clinical characteristic of NMOSD (1-6): 1) Optic neuritis 2) Acute myelitis 3) Area postrema syndrome 4) Acute brainstem syndrome 5) Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions 6) Symptomatic cerebral syndrome with NMOSD-typical brain lesions
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of decrease in number of NMOSD relapses. For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Entresto Sprinkle

Products Affected

- **ENTRESTO SPRINKLE**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Entyvio

Products Affected

- **ENTYVIO PEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- attestation of receiving or currently undergoing at least 2 doses of IV Entyvio within 6 weeks of initiating therapy with Entyvio SC.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For moderate to severe ulcerative colitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, Rinvoq, and Xeljanz/Xeljanz XR. For moderate to severe active Crohn's disease, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, and Rinvoq. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Epclusa

Products Affected

- **EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG, 200-50 MG**
- **EPCLUSA ORAL TABLET**
- *sofosbuvir-velpatasvir*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guidance. For Brand Epclusa, the member has a contraindication to or is otherwise not a candidate for one of the following regimens recommended by the AASLD/IDSA guidelines containing the following agents: sofosbuvir/velpatasvir (i.e. Epclusa authorized generic), Mavyret.
Age Restrictions	Deny if less than 3 years of age
Prescriber Restrictions	
Coverage Duration	Criteria/duration applied consistent with current AASLD-IDSA guidance
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Epidiolex

Products Affected

- **EPIDIOLEX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Lennox-Gastaut, Dravet syndromes or Tuberous Sclerosis Complex. For Lennox-Gastaut, trial and failure or intolerance of at least two standard of care treatments (e.g. lamotrigine, clobazam). For Lennox-Gastaut and Dravet syndromes, treatment is in combination with other conventional agents.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Eprontia

Products Affected

- **EPRONTIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- inability to swallow pills or food. For migraine, therapeutic failure, intolerance, or contraindication to two generic preventive migraine therapies. For partial onset seizures, primary generalized tonic-clonic seizures, or adjunctive treatment of Lennox-Gastaut Syndrome, therapeutic failure, contraindication, or intolerance to two generic anti-epileptic drugs.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ergotamine

Products Affected

- **ERGOMAR**
- *ergotamine-caffeine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of use to abort a vascular headache -AND- therapeutic failure, intolerance, or contraindication to a generic triptan -OR- documentation of use to prevent a vascular headache -AND- therapeutic failure, intolerance, or contraindication to generic prophylactic migraine medication (e.g., topiramate, propanolol, timolol).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Erivedge

Products Affected

- **ERIVEDGE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- if disease is locally advanced all of the following: 1) disease has recurred following surgery, or is not a candidate for surgery, 2) is not a candidate for radiation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Erleada

Products Affected

- **ERLEADA ORAL TABLET 240 MG, 60 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- the member meets one of the following (1 or 2) 1. Documentation of use in combination with a GnRH analog -OR- 2. The member has had a bilateral orchiectomy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Etanercept

Products Affected

- **ENBREL MINI**
- **ENBREL SUBCUTANEOUS SOLUTION**
- **ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML)**
- **ENBREL SURECLICK**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Eucrisa

Products Affected

- **EUCRISA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1 and 2): 1) mild to moderate atopic dermatitis 2) trial & failure, intolerance, or contraindication to at least one topical corticosteroid -OR- documentation of facial or anogenital involvement
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	If 2 years of age or older, therapeutic failure of one of the following is required: topical tacrolimus -OR- topical pimecrolimus. Reauthorization or continuation of therapy will be approved when documentation of improvement or response to therapy is provided.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Evekeo

Products Affected

- *amphetamine sulfate*
- **EVEKEO**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Evenity

Products Affected

- **EVENITY SUBCUTANEOUS SYRINGE 210MG/2.34ML (105MG/1.17MLX2)**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Evrysdi

Products Affected

- **EVRYSDI ORAL RECON SOLN**
- **EVRYSDI ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Fabhalta

Products Affected

- **FABHALTA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Fanapt

Products Affected

- **FANAPT**
- **FANAPT TITRATION PACK A**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis - AND - trial and failure of one of the following: olanzapine, quetiapine, or risperidone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Fasenra

Products Affected

- **FASENRA PEN**
- **FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 30 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Fecal Microbiota Products

Products Affected

- **VOWST**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of a recent diagnosis of Clostridioides difficile infection (CDI) confirmed by a positive stool test -AND- Classified as recurrent (e.g., at least 2 CDI episodes) -AND- Will be used for prophylaxis and not treatment of recurrent CDI -AND- Attestation that antibiotic treatment for the most recent recurrent CDI is complete or will be completed.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month
Other Criteria	For reauthorization, attestation of recurrent CDI episodes after administration of the initial fecal microbiota product -AND- Will be used for prophylaxis and not treatment of recurrent CDI -AND- Attestation that antibiotic treatment for the most recent recurrent CDI is complete or will be completed.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ferriprox

Products Affected

- *deferiprone*
- **FERRIPROX (2 TIMES A DAY)**
- **FERRIPROX ORAL SOLUTION**
- **FERRIPROX ORAL TABLET 1,000 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Fetzima

Products Affected

- **FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26)**
- **FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of major depressive disorder and trial and failure of two other generic antidepressants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Filspari

Products Affected

- **FILSPARI**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with renin-angiotensin system inhibitors (i.e., ACE inhibitors, ARBs, aliskiren) or endothelin receptor antagonists (e.g., Letairis, Opsumit, Tracleer)
Required Medical Information	Documentation of primary immunoglobulin A nephropathy confirmed by biopsy -AND- Risk for rapid disease progression, evidenced by proteinuria greater than or equal to 0.5 g/day -AND- Therapeutic failure, contraindication, or intolerance to an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, reduction in proteinuria from baseline is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Filsuvez

Products Affected

- **FILSUVEZ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of dystrophic epidermolysis bullosa (DEB) or junctional epidermolysis bullosa (JEB) -AND- at least one open wound.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of improvement in targeted wound(s) -AND- member requires additional courses of treatment.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Fintepla

Products Affected

- **FINTEPLA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Dravet syndrome or Lennox-Gastaut syndrome. For Lennox-Gastaut syndrome, therapeutic failure, contraindication, or intolerance to at least 2 standard of care treatments (e.g. lamotrigine, clobazam).
Age Restrictions	Deny if less than 2 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Firazyr

Products Affected

- **FIRAZYR**
- *icatibant*
- **SAJAZIR**

PA Criteria	Criteria Details
Exclusion Criteria	Member should not be on two acute therapies simultaneously and acute therapy should not be used as prophylactic therapy
Required Medical Information	For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) due to deficiency of C1INH (type I & II) with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) with normal C1INH (type III) with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE, FXII mutation, angiopoietin-1 mutation, plasminogen mutation, kininogen-1 mutation, myoferlin mutation, or heparin sulfate-glucosamine 3-O-sulfotransferas 6 mutation. 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Firazyr, therapeutic failure, intolerance or contraindication to icatibant.

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Firdapse

Products Affected

- **FIRDAPSE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of positive clinical response to therapy.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Firmagon

Products Affected

- **FIRMAGON KIT W DILUENT SYRINGE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of advanced prostate cancer.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Flector

Products Affected

- *diclofenac epolamine*
- **FLECTOR**
- **LICART**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis AND one of the following (1,2 or 3): 1) trial/failure, intolerance, or contraindication to 2 oral generic NSAIDs one of which must be diclofenac 2) hypersensitivity to oral NSAIDs 3) history or high risk for adverse gastrointestinal effects associated with oral NSAID use.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Forteo

Products Affected

- **BONSITY**
- **FORTEO**
- *teriparatide subcutaneous pen injector 20 mcg/dose (560mcg/2.24ml)*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Fotivda

Products Affected

- **FOTIVDA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Fruzaqla

Products Affected

- **FRUZAQLA ORAL CAPSULE 1 MG, 5 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- member has received previous threatment with a fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy -AND- member has received previous treatment with an anti-VEGF therapy -AND- one of the following, if member is RAS wild-type (1-2): 1) member has received previous therapy with an anti-EGFR therapy 2) prescriber attests that treatment with an anti-EGFR therapy would not be medically appropriate.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Fulvicin PG

Products Affected

- *griseofulvin ultramicrosize oral tablet 165 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	onychomycosis: 12mos, tinea capitis: 12wks, tinea pedis: 8wks, tinea barbae/corporis/cruris: 6wks
Other Criteria	Therapeutic failure or intolerance to one of the following generic griseofulvin products is required: griseofulvin suspension, griseofulvin microsize tablets, griseofulvin ultramicrosize 125mg tablets, or griseofulvin ultramicrosize 150mg tablets.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Furoscix

Products Affected

- **FUROSCIX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- medication regimen includes an oral loop diuretic (e.g. furosemide, bumetanide, torsemide) -AND- treatment with oral diuretics will replace the use of Furoscix as soon as practical.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Gabapentin

Products Affected

- **NEURONTIN ORAL CAPSULE 100 MG, 800 MG 300 MG, 400 MG**
- **NEURONTIN ORAL SOLUTION**
- **NEURONTIN ORAL TABLET 600 MG,**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. When using concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Gabarone

Products Affected

- **GABARONE ORAL TABLET 100 MG, 400 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. When using concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Intolerance to generic immediate release gabapentin tablets or capsules is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Galafold

Products Affected

- **GALAFOLD**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Fabry disease confirmed by biochemical or genetic test -AND- Presence of an amenable GLA variant causing Fabry disease in the clinical context of the patient -AND- Will not be used concomitantly with enzyme replacement therapy (ERT) e.g. Fabrazyme.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of positive clinical response to therapy -AND- Will not be used concomitantly with enzyme replacement therapy (ERT) e.g. Fabrazyme.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Gattex

Products Affected

- **GATTEX 30-VIAL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of short bowel syndrome (SBS) having less than 200 cm of functional small bowel -AND- Dependence on parenteral/intravenous nutrition -AND- weight of at least 10 kg.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of increase in weight from baseline or decrease in intravenous parenteral nutrition requirements from baseline -AND- 1 of the following (1-2): 1) continued dependence on parenteral nutrition/intravenous nutritional support, 2) not receiving parenteral nutrition/intravenous support and experienced therapeutic failure upon trial of discontinuation of parenteral nutrition/intravenous support.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Gavreto

Products Affected

- **GAVRETO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For metastatic non-small cell lung cancer, disease is RET fusion-positive as detected by an FDA approved test. For advanced or metastatic thyroid cancer, all of the following (1-2): 1) disease is RET fusion-positive 2) if radioactive iodine is appropriate, the member is radioactive iodine-refractory.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Gilenya

Products Affected

- *fingolimod*
- **GILENYA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Gimoti

Products Affected

- **GIMOTI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of acute or recurrent diabetic gastroparesis -AND- Attestation of no signs or symptoms of tardive dyskinesia -AND- Therapeutic failure or intolerance to generic metoclopramide (tablets, orally disintegrating tablets, or solution) or not a candidate for oral dosage forms -AND- If over 65 years of age, member was titrated to a stable does of metoclopramide tablets or solution at 10mg four times a day before switching to Gimoti therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 weeks
Other Criteria	For reauthorization, treatment is for a new episode of diabetic gastroparesis -AND- There has been a 2 week drug holiday without Gimoti since its last administration -AND- Attestation of no signs or symptoms of tardive dyskinesia -AND- Attestation that extended therapy with Gimoti outweighs risk of developing tardive dyskinesia.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Glatiramer

Products Affected

- **COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML, 40 MG/ML**
- *glatiramer subcutaneous syringe 20 mg/ml, 40 mg/ml*
- **GLATOPA SUBCUTANEOUS SYRINGE 20 MG/ML, 40 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Gleevec

Products Affected

- **GLEEVEC ORAL TABLET 100 MG, 400 MG**
- *imatinib oral tablet 100 mg, 400 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Ph+ chronic myeloid leukemia -AND- one of the following: 1) member is newly diagnosed in chronic phase 2) member is in blast crisis, the accelerated phase or the chronic phase after failure of interferon-alpha therapy. Documentation of Ph+ acute lymphocytic leukemia -AND- one of the following: 1) for adults, member has relapsed or refractory disease 2) for pediatric patients, member is newly diagnosed and will be using imatinib in combination with a chemotherapy regimen. Documentation of adult agressive systemic mastocytosis -AND- one of the following: 1) documentation that the member does not have D816V c-KIT status 2) member's c-KIT status is unknown. For gastrointestinal stromal tumors (GIST) one of the following: 1) member has diagnosis of KIT (CD117)-positive unresectable and/or metastatic malignant GIST 2) imatinib will be used as adjuvent treatment following resection of KIT (CD117)-positive GIST. Documentation of unresectable, recurrent or metastatic dermatofibrosarcoma protuberans. Documentation of Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia. Documentation of myeloproliferative disease -AND- disease is associated with PDGFR gene rearrangements. Documentation of myelodysplastic syndrome -AND- disease is associated with PDGFR gene rearrangements.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Gleevec, documentation of trial and failure of generic imatinib is required.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Gleostine

Products Affected

- **GLEOSTINE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of primary or metastatic brain tumor(s) -AND- member has previously received surgical and/or radiotherapeutic procedure(s). Documentation of Hodgkin's lymphoma -AND- all of the following (1-2): 1) using lomustine in combination with other chemotherapies 2) member has experienced disease progression with initial chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

GLP1

Products Affected

- *exenatide subcutaneous pen injector 10 mcg/dose(250 mcg/ml) 2.4 ml, 5 mcg/dose (250 mcg/ml) 1.2 ml*
- *liraglutide*
- **MOUNJARO**
- **OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML)**
- **RYBELSUS**
- **TRULICITY**
- **VICTOZA 3-PAK**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Glycate

Products Affected

- **GLYCATE**
- *glycopyrrolate oral tablet 1.5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- using as an adjunctive treatment for peptic ulcer disease -AND- Therapeutic failure or intolerance to both generic glycopyrrolate 1mg tablet AND 2 mg tablet
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Gocovri

Products Affected

- **GOCOVRI ORAL CAPSULE,EXTENDED RELEASE 24HR 137 MG, 68.5 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For dyskinesia associated with Parkinson's disease, documentation of concurrent levodopa-based therapy -AND- trial and failure, contraindication, or intolerance to immediate-release amantadine. For off-episodes of Parkinson's disease, documentation of concurrent carbidopa/levodopa therapy -AND- trial and failure, contraindication, or intolerance to immediate-release amantadine -AND- trial and failure, contraindication, or intolerance to one (1) of the following agents: entacapone, pramipexole, rasagiline, ropinirole, or selegiline.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Gomekli

Products Affected

- **GOMEKLI ORAL CAPSULE 1 MG, 2 MG**
- **GOMEKLI ORAL TABLET FOR SUSPENSION**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of neurofibromatosis type 1 (NF1) -AND- presence of symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Gralise

Products Affected

- *gabapentin oral tablet extended release 24 hr 300 mg, 600 mg*
- **GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 300 MG, 450 MG, 600 MG, 750 MG, 900 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Grastek

Products Affected

- **GRASTEK**

PA Criteria	Criteria Details
Exclusion Criteria	Asthma (severe, unstable or uncontrolled), concomitant sublingual or subcutaneous immunotherapy, therapy initiation during active allergy season
Required Medical Information	Documentation of allergic rhinitis and use for Timothy grass pollen or cross reactive grass pollens (Sweet Vernal, Orchard, Perennial Rye, Timothy, Kentucky Blue Grass pollen, Redtop, or meadow fescue) -AND- allergic rhinitis with or without conjunctivitis has been confirmed by a pollen specific positive skin test or in vitro testing for pollen-specific IgE antibodies -AND- trial and failure or intolerance to an intranasal steroid and an oral non-sedating antihistamine, intranasal antihistamine or intranasal anticholinergic agent
Age Restrictions	Deny if less than 5 years of age or greater than 65 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Member must also be prescribed an epinephrine auto injector. For reauthorization, attestation of improved allergy symptoms is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Growth Hormone

Products Affected

- **GENOTROPIN**
- **GENOTROPIN MINIQUICK**
- **HUMATROPE INJECTION CARTRIDGE**
- **NGENLA**
- **NORDITROPIN FLEXPRO**
- **NUTROPIN AQ NUSPIN**
- **OMNITROPE**
- **SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG**
- **ZOMACTON**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis, growth chart, member has open epiphyses, growth velocity, response to stimulation test, when applicable to meet standard diagnostic criteria. Additionally for growth failure due to chronic kidney disease, glomerular filtration rate is less than 89ml/min per 1.73m*2. For HIV wasting and cachexia, Concurrent use of antiretroviral therapy -AND- weight loss of at least 10 percent from baseline. For short bowel syndrome, receiving management for short bowel syndrome, including specialized nutritional support -AND- less than 200 cm of functional small bowel.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of growth velocity and member has open epiphyses, as applicable to meet standard continuation of therapy guidelines. For reauthorization of HIV wasting and cachexia, attestation of increase in weight from start of therapy. For reauthorization of short bowel syndrome, continued dependence on parenteral nutrition/intravenous nutritional support -AND- attestation of increase in weight from baseline or decrease in intravenous parenteral nutrition requirements from baseline.
Indications	All Medically-accepted Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

Haegarda

Products Affected

- **HAEGARDA**

PA Criteria	Criteria Details
Exclusion Criteria	Member should not be on two prophylactic therapies simultaneously.
Required Medical Information	For the prophylactic treatment of abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) due to deficiency of C1INH (type I & II) with the following (1-4): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. 4) Documentation of member's weight. For the prophylactic treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) with normal C1INH (type III) with the following (5-9): 5) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 6) Documentation of family history of HAE, FXII mutation, angiopoietin-1 mutation, plasminogen mutation, kininogen-1 mutation, myoferlin mutation, or heparin sulfate-glucosamine 3-O-sulfotransferas 6 mutation. 7) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 8) Medications known to cause angioedema have been evaluated and discontinued. 9) Documentation of member's weight.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Harvoni

Products Affected

- **HARVONI**
- *ledipasvir-sofosbuvir*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guidance -AND- the member has a contraindication to or is otherwise not a candidate for one of the following regimens recommended by the AASLD/IDSA guidelines containing the following agents: sofosbuvir/velpatasvir (i.e. Epclusa authorized generic), Mavyret.
Age Restrictions	Deny if less than 3 years of age
Prescriber Restrictions	
Coverage Duration	Criteria/duration applied consistent with current AASLD-IDSA guidance
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Hemady

Products Affected

- **HEMADY**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Hernexeos

Products Affected

- **HERNEXEOS**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Hetlioz

Products Affected

- **HETLIOZ**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Hetlioz LQ

Products Affected

- **HETLIOZ LQ**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

High-risk meds

Products Affected

- *amitriptyline*
- *amitriptyline-chlordiazepoxide*
- **ANAFRANIL**
- *benztropine oral*
- *carisoprodol*
- *chlorzoxazone*
- *clomipramine*
- *cyproheptadine*
- *doxepin oral capsule*
- *doxepin oral concentrate*
- *doxepin oral tablet*
- *hydroxyzine hcl oral solution 10 mg/5 ml*
- *hydroxyzine hcl oral tablet*
- *hydroxyzine pamoate*
- *imipramine hcl*
- *imipramine pamoate*
- *metaxalone oral tablet 400 mg, 800 mg*
- **NORGESIC**
- **NORGESIC FORTE**
- *orphenadrine citrate oral*
- *orphenadrine-asa-caffeine oral tablet 25-385-30 mg*
- *perphenazine-amitriptyline*
- *promethazine oral*
- **SILENOR**
- **SOMA**
- *trimipramine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For all medications subject to this PA group, the following information (1 through 3) is required: 1. Documentation of diagnosis 2. Explanation of risk-benefit profile favoring use of the high-risk medication 3. Attestation of an intent to monitor and address treatment-related adverse events. For target tricyclic antidepressants (TCAs), in addition to criteria 1 through 3 above, trial and failure or documentation of intolerance or contraindication to at least 2 non-high risk alternative drugs for the same indication, if available, is required (e.g. SSRIs and SNRIs). If using a TCA for a medically-accepted indication not shared by the safer alternatives listed, then no trial of alternatives is required.
Age Restrictions	Automatic approval if less than 65 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Doxepin doses less than or equal to 6 mg per day will receive automatic approval.
Indications	All Medically-accepted Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

High-risk meds phenobarbital

Products Affected

- *phenobarbital*

PA Criteria	Criteria Details
Exclusion Criteria	Coverage is not provided for use in sedation/insomnia
Required Medical Information	For use in seizures the following are required: 1. Explanation of risk-benefit profile favoring use of the high-risk medication 2. Attestation of an intent to monitor and address treatment-related adverse events. 3. For new starts, the trial and failure or documentation of intolerance or contraindication to at least 2 non-high risk alternative drugs used for seizures (e.g. carbamazepine, lamotrigine) is required.
Age Restrictions	Automatic approval if less than 65 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Seizure disorders
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Homozygous FH

Products Affected

- **JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of homozygous familial hypercholesterolemia (HoFH) supported by genetic confirmation of two mutant alleles at LDLR, APOB, PCSK9, or LDLRAP1 gene -OR- untreated LDL-C greater than 400mg/dL or TC greater than 500mg/dl with cutaneous or tendon xanthoma before age 10 yrs or HeFH in both parents -AND- The member has a current LDL-C greater than 70 mg/dL or greater than 55 mg/dL if ASCVD or major ASCVD risk factors despite use of maximally tolerated statin OR statin intolerance -AND- The member will continue to receive concurrent lipid-lowering therapies for the treatment of HoFH
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	Patients must have a trial/failure or contraindication to the preferred product Repatha. For reauthorization, documentation showing an LDL-C reduction on Juxtapid therapy from baseline must be provided. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statins which resolved upon discontinuation of statin or attestation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Horizant

Products Affected

- **HORIZANT ORAL TABLET EXTENDED RELEASE 300 MG, 600 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Hyftor

Products Affected

- **HYFTOR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of tuberous sclerosis complex with facial angiofibromas.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of positive clinical response to therapy (e.g. decrease in size of facial angiofibromas, decrease in redness of facial angiofibromas)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ibrance

Products Affected

- **IBRANCE**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ibsrela

Products Affected

- **IBSRELA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of irritable bowel syndrome with constipation (IBS-C) -AND- Therapeutic failure, contraindication, or intolerance to Linzess -AND- If member is female, therapeutic failure, contraindication, or intolerance to lubiprostone -AND- If the member is male, therapeutic failure, contraindication, or intolerance to Trulance.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ibtrozi

Products Affected

- **IBTROZI**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Iclusig

Products Affected

- **ICLUSIG**

PA Criteria	Criteria Details
Exclusion Criteria	Treatment of newly-diagnosed chronic phase CML
Required Medical Information	Documentation of T3151+ chronic myeloid leukemia (CML) -OR- documentation of chronic phase CML and member has experienced resistance or intolerance to at least two prior kinase inhibitors -OR- documentation of accelerated phase or blast phase CML and no other kinase inhibitor is indicated -OR- member is using Iclusig as monotherapy and meets one of the following (1-2): 1) documentation of T3151+ acute lymphoblastic leukemia (ALL) 2) documentation of Ph+ ALL and no other tyrosine kinase inhibitor therapy is indicated -OR- member has newly diagnosed Ph+ ALL and is using Iclusig in combination with chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Idhifa

Products Affected

- **IDHIFA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

IG

Products Affected

- **BIVIGAM**
- **GAMMAGARD LIQUID**
- **GAMMAGARD S-D (IGA**
- **GAMMAKED INJECTION SOLUTION 1 GRAM/10 ML (10 %)**
- **GAMMAPLEX**
- **GAMMAPLEX (WITH SORBITOL)**
- **GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %)**
- **OCTAGAM**
- **PANZYGA**
- **PRIVIGEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For select diagnoses the following apply 1) For Myasthenia Gravis Syndrome, documentation that the patient is refractory to other standard therapies (e.g., cholinesterase inhibitors, corticosteroids, azathioprine) given in therapeutic doses over at least 3 months OR is intolerant/contraindication to those standard therapies. 2) For Multiple Sclerosis, patient is refractory to other standard therapies (e.g., interferons) given in therapeutic doses over at least 3 months OR is intolerant/contraindication to those standard therapies. 3) For B-cell CLL, associated with recurrent bacterial infections OR with Associated Hypogammaglobulinemia defined as IgG level less than 600mg/dL or evidence of a specific antibody deficiency. 4) For Bone Marrow Transplantation, the member is 20 years of age or older and within the first 100 days after transplantation. 5) For Dermatomyositis/Polymyositis, trial and failure, intolerance, or contraindication to standard fist line therapy (i.e. corticosteroids or immunosuppressants). 6) For Pediatric HIV, the patient is less than 13 y.o. who have entry CD4 lymphocyte count greater than or equal to 200/mcl and IgG less than 400mg/dL OR recurrent bacterial infections. 7) For Guillain-Barre syndrome, impaired function by objective assessment and/or objective findings on physical exam at the time of initial therapy and IVIG therapy must be initiated within 2 weeks of symptom onset. 8) For Autoimmune Mucocutaneous Blistering Diseases (e.g. Stevens-Johnson Syndrome), trial and failure, intolerance, or contraindication to conventional therapy (e.g. corticosteroids) or the patient has rapidly progressive disease in which a clinical response could not be affected quickly enough using conventional agents.
Age Restrictions	

PA Criteria	Criteria Details
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Covered under Part B when administered in the home to a member with a diagnosis of primary immunodeficiency disease. For non-preferred IG products, patients must have a trial/failure, intolerance, or contraindication to both preferred products: Gammagard and Privigen.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Myasthenia Gravis syndrome, Multiple Sclerosis, Polymyositis, Bone Marrow Transplant, Pediatric HIV, Guillain-Barre syndrome, Autoimmune Mucocutaneous Blistering Diseases
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ilumya

Products Affected

- **ILUMYA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For psoriasis induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen. For psoriasis, patients must have therapeutic failure or intolerance to 2 preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla, and Skyrizi SC. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Imbruvica

Products Affected

- **IMBRUVICA ORAL CAPSULE 140 MG, 280 MG, 420 MG 70 MG**
- **IMBRUVICA ORAL SUSPENSION**
- **IMBRUVICA ORAL TABLET 140 MG,**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Imkeldi

Products Affected

- **IMKELDI**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Inbrija

Products Affected

- **INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of use for the treatment of intermittent off episodes of Parkinson's disease while on carbidopa/levodopa
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of positive clinical response
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Increlex

Products Affected

- **INCRELEX**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ingrezza

Products Affected

- **INGREZZA INITIATION PK(TARDIV)**
- **INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG**
- **INGREZZA SPRINKLE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of tardive dyskinesia -OR- documentation of chorea associated with Huntington's disease.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Inlyta

Products Affected

- **INLYTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of advanced renal cell carcinoma -AND- one of the following (1-2): 1) if using axitinib as first line therapy, member is using axitinib in combination with avelumab or pembrolizumab 2) if using axitinib as a single-agent, member has been treated with at least one prior systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Inqovi

Products Affected

- **INQOVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation chronic myelomonocytic leukemia. Documentation of myelodysplastic syndrome -AND- One of the following (1 or 2): 1) French American-British MDS subtypes of refractory anemia, refractory anemia with ringed sideroblasts or refractory anemia with excess blasts. 2) International Prognostic Scoring System group of intermediate-1, intermediate-2 or high-risk.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Inrebic

Products Affected

- **INREBIC**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of intermediate-2 or high-risk myelofibrosis per an accepted risk stratification tool for myelofibrosis (e.g., International Prognostic Scoring System [IPSS]) -AND- If a new start, baseline platelet count of greater than or equal to 50x10*9/L
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Baseline platelet count to be provided.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Insulin Supplies

Products Affected

- **ALCOHOL PADS**
- **GAUZE PAD TOPICAL BANDAGE 2 X 2 "**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation the product is being used for the delivery of insulin into the body.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Interferon Alfa

Products Affected

- **PEGASYS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Interferon Beta

Products Affected

- **AVONEX INTRAMUSCULAR PEN INJECTOR KIT**
- **AVONEX INTRAMUSCULAR SYRINGE KIT**
- **BETASERON SUBCUTANEOUS KIT**
- **PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML**
- **PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML**
- **REBIF (WITH ALBUMIN)**
- **REBIF REBIDOSE SUBCUTANEOUS PEN INJECTOR 22 MCG/0.5 ML, 44 MCG/0.5 ML, 8.8MCG/0.2ML-22 MCG/0.5ML (6)**
- **REBIF TITRATION PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Interleukin-1b Blockers

Products Affected

- **ARCALYST**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For Deficiency of Interleukin-1 Receptor Antagonist (DIRA), documentation of need for maintenance of remission. For Recurrent Pericarditis (RP), documentation of trial/failure or intolerance to one, or contraindication to all of the following: oral nonsteroidal anti-inflammatory drug (NSAID), systemic corticosteroid, or colchicine.
Age Restrictions	Deny if less than 12 years of age for Recurrent Pericarditis and Cryopyrin-Associated Periodic Syndromes
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For DIRA: patient must weigh 10kg or more
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Intrarosa

Products Affected

- **INTRAROSA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

IPF Agents

Products Affected

- **ESBRIET ORAL CAPSULE**
- **ESBRIET ORAL TABLET**
- **OFEV**
- *pirfenidone oral capsule*
- *pirfenidone oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of idiopathic pulmonary fibrosis -AND- baseline forced vital capacity (FVC) of at least 50% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30%. For Ofev only, documentation of systemic sclerosis-associated interstitial lung disease -AND- baseline forced vital capacity (FVC) of at least 40% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30% -AND- documentation of a high-resolution chest computed tomography (CT) scan demonstrating greater than or equal to 10% pulmonary fibrosis. For Ofev only, documentation of chronic fibrosing interstitial lung disease with progressive phenotype -AND- high resolution chest computing tomography (HRCT) scan demonstrating greater than 10% fibrosing disease -AND- baseline forced vital capacity (FVC) of at least 45% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30% -AND- disease progression in previous 24 months shown by one of the following : 1. Relative decline in FVC greater than or equal to 10% predicted 2. Relative decline in FVC greater than or equal to 5% but less than 10% predicted and either worsening of respiratory symptoms or increased extent of fibrotic changes on HRCT 3. Worsening of respiratory symptoms and increasing extent of fibrotic changes on HRCT
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Esbriet, documentation of failure on generic pirfenidone tablets is required.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Iqirvo

Products Affected

- **IQIRVO**

PA Criteria	Criteria Details
Exclusion Criteria	Decompensated cirrhosis
Required Medical Information	Documentation of primary biliary cholangitis -AND- trial and failure, contraindication, or intolerance to ursodiol monotherapy -AND- will use concomitantly with ursodiol unless contraindicated or intolerant.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Iressa

Products Affected

- *gefitinib*
- **IRESSA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Itovebi

Products Affected

- **ITOVEBI ORAL TABLET 3 MG, 9 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of endocrine-resistant, locally advanced or metastatic breast cancer -AND- all of the following (1-4): 1) disease is HR-positive, HER2-negative 2) disease is PIK3CA-mutated, as detected by an FDA-approved test 3) the member is using in combination with palbociclib and fulvestrant 4) the member has experienced recurrence on or after completing adjuvant endocrine therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Itraconazole

Products Affected

- *itraconazole*
- **SPORANOX ORAL CAPSULE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. If using for diagnosis of onychomycosis, confirmation through positive laboratory testing (e.g. KOH preparation, fungal culture, or nail biopsy) is required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Onychomycosis: 3 months. All other indications: 3 months initial, 12 months reauth
Other Criteria	Documentation of trial/failure or intolerance of amphotericin b must be provided for approval in patients with aspergillosis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ivermectin Oral

Products Affected

- *ivermectin oral*
- **STROMECTOL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of strongyloidiasis of the intestinal tract (non-disseminated disease) or onchocerciasis -AND- Member weighs greater than or equal to 15kg.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Iwilfin

Products Affected

- **IWILFIN**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Jakafi

Products Affected

- **JAKAFI**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Jaypirca

Products Affected

- **JAYPIRCA ORAL TABLET 100 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Joenja

Products Affected

- **JOENJA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of activated phosphoinositide 3-kinase delta syndrome (APDS) with genetic confirmation of variant in PIK3CD or PIK3R1 gene.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Journavx

Products Affected

- **JOURNAVX**

PA Criteria	Criteria Details
Exclusion Criteria	Treatment duration beyond 14 days for a single episode of acute pain
Required Medical Information	Documentation of moderate to severe acute pain -AND- The episode of acute pain is anticipated to last less than 1 month -AND- Attestation that alternative therapies have been explored (e.g. NSAIDs).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	14 days
Other Criteria	For reauthorization, all of the following are required (1-3): 1) treatment is for a new episode of moderate to severe pain, separate and distinct from the previous episode of moderate to severe pain, 2) the new episode of acute pain is anticipated to last less than 1 month, 3) Attestation that, for the new episode of acute pain alternative therapies have been explored (e.g. NSAIDs).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Jynarque

Products Affected

- **JYNARQUE ORAL TABLET**
- **JYNARQUE ORAL TABLETS, SEQUENTIAL**
- *tolvaptan (polycys kidney dis) oral tablet*
- *tolvaptan (polycys kidney dis) oral tablets, sequential*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Kalydeco

Products Affected

- **KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 25 MG, 5.8 MG, 50 MG, 75 MG**
- **KALYDECO ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystic fibrosis (CF) in patients who have one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to ivacaftor based on clinical and or in vitro assay (e.g. G551D, G1244E, G1349D)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Kerendia

Products Affected

- **KERENDIA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Kesimpta

Products Affected

- **KESIMPTA PEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Keveyis

Products Affected

- **KEVEYIS**
- **ORMALVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of one of the following: 1. Primary hyperkalemic periodic paralysis 2. Primary hypokalemic periodic paralysis 3. Related variants of primary periodic paralysis
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	2 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation the number of muscle weakness attacks per week has decreased from baseline
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Kevzara

Products Affected

- **KEVZARA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For polymyalgia rheumatica (PMR), one of the following (1-3): 1) inadequate response to corticosteroids, 2) intolerance to corticosteroid taper, or 3) used in combination with corticosteroid tapering course. For polyarticular juvenile idiopathic arthritis, weight greater than or equal to 63 kg -AND- one of the following (4-5): 4) inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide), or 5) requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage.
Age Restrictions	Deny if less than 18 years of age for rheumatoid arthritis and polymyalgia rheumatica.
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Rinvoq and Xeljanz/Xeljanz XR. For polyarticular juvenile idiopathic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Rinvoq/Rinvoq LQ, and Xeljanx/Xeljanz solution. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Khindivi

Products Affected

- **KHINDIVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of adrenocortical insufficiency -AND- Attestation that the member is not experiencing a period of adrenal stress or acute events -AND- Intolerance to oral generic hydrocortisone tablets.
Age Restrictions	Deny if less than 5 years of age or greater than 17 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Kineret

Products Affected

- **KINERET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For Deficiency of Interleukin-1 Receptor Antagonist (DIRA), therapeutic failure or intolerance to at least one (1) corticosteroid, or all corticosteroids are contraindicated.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Rinvoq and Xeljanz/Xeljanz XR. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Kisqali

Products Affected

- **KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- disease is classified as HR-positive, HER2-negative -AND- one of the following (1-3): 1) member is using ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy 2) member is using ribociclib in combination with fulvestrant and member is using fulvestrant as initial endocrine-based therapy or member has experienced disease progression on endocrine therapy. 3) disease is classified as stage II or stage III early breast cancer at high risk of recurrence, ribociclib is being used in combination with an aromatase inhibitor as adjuvant treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Kisqali Femara

Products Affected

- **KISQALI FEMARA CO-PACK ORAL TABLET 400 MG/DAY(200 MG X 2)-2.5 MG, 600 MG/DAY(200 MG X 3)-2.5 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- disease is classified as HR-positive, HER2-negative - AND- one of the following (1-2): 1) disease is classified as stage II or stage III early breast cancer at high risk of recurrence and used as adjuvant treatment 2) used as initial endocrine-based therapy for advanced or metastatic breast cancer.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Klisyri

Products Affected

- **KLISYRI (250 MG)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of actinic keratosis of the face or scalp -AND- Therapeutic failure or intolerance to 1 of the following 1) generic topical imiquimod 5% cream 2) generic fluorouracil 5% topical cream 3) generic fluorouracil topical solution
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For reauthorization, attestation that the member has previously experienced complete or partial clearance of actinic keratosis lesions with Klisyri -AND- additional course of therapy is required for recurrence of actinic keratosis -AND- member is restarting therapy at least 60 days after cessation of an initial Klisyri 5-day course.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Korlym

Products Affected

- **KORLYM**
- *mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Koselugo

Products Affected

- **KOSELUGO ORAL CAPSULE 10 MG, 25 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- for neurofibromatosis type 1 (NF1), documentation of symptomatic, inoperable plexiform neurofibromas (PN)
Age Restrictions	Deny if less than 2 years of age or older than 17 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Krazati

Products Affected

- **KRAZATI**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Kuvan

Products Affected

- **JAVYGTOR**
- **KUVAN**
- *sapropterin*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lampit

Products Affected

- **LAMPIT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	2 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Latuda

Products Affected

- **LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG, 80 MG**
- *lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lazcluze

Products Affected

- **LAZCLUZE ORAL TABLET 240 MG, 80 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of non-small cell lung cancer (NSCLC) -AND- all of the following (1-4): 1) disease harbors EGFR exon 19 deletions or EGFR exon 21 (L858R) substitution mutation, as detected by an FDA-approved test 2) disease is locally advanced or metastatic, 3) member is treatment naive for advanced disease, 4) using in combination with amivantinib.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Lenvima

Products Affected

- **LENVIMA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of differentiated thyroid cancer -AND- meets all of the following (1-3): 1) disease is locally recurrent or metastatic 2) disease is progressive 3) disease is radioactive iodine refractory. Documentation of advanced renal cell carcinoma -AND- one of the following (4-5): 4) member is using lenvatinib in combination with pembrolizumab and is using lenvatinib and pembrolizumab as first-line treatment 5) member is using lenvatinib in combination with everolimus and has experienced therapeutic failure or intolerance to one prior anti-angiogenic therapy. Documentation of unresectable hepatocellular carcinoma -AND- member is using lenvatinib as first-line treatment. Documentation of endometrial cancer -AND- meets all of the following (6-10): 6) member is using lenvatinib in combination with pembrolizumab 7) disease is advanced 8) disease is not classified as microsatellite instability-high or disease is classified as mismatch repair proficient as determined by an FDA-approved test 9) member has experienced disease progression following prior systemic therapy 10) member is not a candidate for curative surgery or radiation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Leqselvi

Products Affected

- **LEQSELVI**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Leukine

Products Affected

- **LEUKINE INJECTION RECON SOLN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis: following induction chemotherapy in patients who are 55 years or older with acute myelogenous leukemia (AML) -OR- mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation -OR- acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation -OR- acceleration of myeloid reconstitution following allogeneic BMT -OR- treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic BMT -OR- following acute exposure to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Leukotriene Modifiers

Products Affected

- *zileuton*
- **ZYFLO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of asthma -AND- trial/failure of generic montelukast and generic zafirlukast
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lidoderm

Products Affected

- *lidocaine topical adhesive patch,medicated 5 %*
- **LIDOCAN III**
- **TRIDACAINE II**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of postherpetic neuralgia (PHN) or diabetic peripheral neuropathy (DPN) -AND- One of the following (1-3): 1) trial and failure of 1 other agent used to treat diagnosis (e.g. gabapentin for PHN, duloxetine for DPN), 2) inability to swallow oral medication, 3) unable to take an oral medication due to potential adverse events (e.g. sedation).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Diabetic peripheral neuropathy
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Litfulo

Products Affected

- **LITFULO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For severe alopecia areata, therapeutic failure/intolerance to an intralesional corticosteroid or high potency topical corticosteroid, or contraindication to all.
Age Restrictions	Deny if less than 12 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Livdelzi

Products Affected

- **LIVDELZI**

PA Criteria	Criteria Details
Exclusion Criteria	Decompensated cirrhosis
Required Medical Information	Documentation of primary biliary cholangitis -AND- trial and failure, contraindication, or intolerance to ursodiol monotherapy -AND- will use concomitantly with ursodiol unless contraindicated or intolerant.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Livmarli

Products Affected

- **LIVMARLI ORAL SOLUTION 19 MG/ML, 9.5 MG/ML**
- **LIVMARLI ORAL TABLET 10 MG, 15 MG, 20 MG, 30 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Livtencity

Products Affected

- **LIVTENCITY**

PA Criteria	Criteria Details
Exclusion Criteria	Diagnosis of CMV prophylaxis.
Required Medical Information	Documentation of refractory cytomegalovirus infection or disease as evidenced by antigenemia or polymerase chain reaction (PCR) test -AND- all of the following (1-3): 1) member weighs at least 35 kg, 2) member is a recipient of hematopoietic stem cell transplant -OR- solid organ transplant. 3) member has experienced therapeutic failure to one of the following: ganciclovir, valganciclovir, cidofovir, or foscarnet.
Age Restrictions	Deny if less than 12 years of age
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For reauthorization, attestation of a previous reduction in CMV DNA level -AND- documentation of one of the following (1-3): 1) new onset symptomatic CMV infection, 2) virologic relapse with treatment-emergent maribavir resistance or 3) continued antiviral treatment is required to achieve virologic clearance.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lodoco

Products Affected

- **LODOCO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of established atherosclerotic disease (e.g., ASCVD, experienced CV event) or multiple risk factors for cardiovascular disease (e.g., high cholesterol, high blood pressure, obesity, diabetes, smoking) -AND- being used to reduce the risk of myocardial infarction, stroke, coronary revascularization, or cardiovascular death -AND- trial and failure of maximally tolerated statin or documentation of statin intolerance.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statins which resolved upon discontinuation of statin or attestation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lokelma

Products Affected

- **LOKELMA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of hyperkalemia as defined by serum potassium level between 5.1 and 7.4 mmol/L on at least two (2) screenings -AND- Modification of medications to reduce serum potassium levels were not successful, when applicable
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of reduction in serum potassium levels following Lokelma administration and continued treatment for hyperkalemia is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Lonsurf

Products Affected

- **LONSURF**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Lorbrena

Products Affected

- **LORBRENA ORAL TABLET 100 MG, 25 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of ALK-positive metastatic non-small cell lung cancer (NSCLC)
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Lotronex

Products Affected

- *alosetron oral tablet 0.5 mg, 1 mg*
- **LOTRONEX ORAL TABLET 0.5 MG, 1 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lovaza

Products Affected

- **LOVAZA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For hypertriglyceridemia, triglycerides greater than or equal to 500mg/dL indicating severe hypertriglyceridemia -AND- Therapeutic failure or intolerance to a prescription, generic omega 3 acid ethyl ester capsules
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, reduction in triglyceride levels from baseline for hypertriglyceridemia
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lumakras

Products Affected

- **LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of locally advanced or metastatic non-small cell lung cancer -AND- disease is KRAS G12C-mutated as determined by an FDA approved test -AND- member has received at least one prior systemic therapy -AND- using as a single agent. Documentation of metastatic colorectal cancer -AND- disease is KRAS G12C-mutated as determined by an FDA approved test -AND- using in combination with panitumumab -AND- prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lumryz

Products Affected

- **LUMRYZ**
- **LUMRYZ STARTER PACK**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Lupkynis

Products Affected

- **LUPKYNIS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of active lupus nephritis (LN) -AND- One of the following (1 or 2): 1) Diagnosis confirmed by renal biopsy, 2) Contraindication to renal biopsy, laboratory findings specific to LN (e.g., elevated serum creatinine, abnormal urine analysis, decreased eGFR) -AND- Member will continue to receive concomitant standard of care treatment with corticosteroids (e.g. prednisone) and mycophenolic acid analog (e.g. mycophenolate mofetil).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 weeks initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of disease stability or disease improvement -AND- Member will continue to receive concomitant standard of care treatment with corticosteroids (e.g. prednisone) and one of the following (1 or 2): 1) mycophenolic acid analog (e.g. mycophenolate mofetil), 2) azathioprine.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Lupron Depot Ped

Products Affected

- **LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG**
- **LUPRON DEPOT-PED INTRAMUSCULAR KIT 7.5 MG (PED)**
- **LUPRON DEPOT-PED INTRAMUSCULAR SYRINGE KIT**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Lybalvi

Products Affected

- **LYBALVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of schizophrenia or bipolar I disorder -AND- One of the following (1 or 2): 1) Therapeutic failure, intolerance or contraindication to generic risperidone and generic quetiapine 2) Currently stable and responding to olanzapine but experiencing weight gain from the medication
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lynparza

Products Affected

- **LYNPARZA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Lyrica

Products Affected

- **LYRICA ORAL CAPSULE 100 MG, 150 MG, 200 MG, 225 MG, 25 MG, 300 MG, 50 MG, 75 MG**
- **LYRICA ORAL SOLUTION**
- *pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg*
- *pregabalin oral solution*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. When using pregabalin products concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Lyrica, intolerance to generic pregabalin is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lyrica CR

Products Affected

- **LYRICA CR**
- *pregabalin oral tablet extended release 24 hr*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lytgobi

Products Affected

- **LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following (1-2): 1) disease harbors FGFR2 fusions or other rearrangements 2) member has experienced therapeutic failure or intolerance to at least one prior therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Mavenclad

Products Affected

- **MAVENCLAD (10 TABLET PACK)**
- **MAVENCLAD (4 TABLET PACK)**
- **MAVENCLAD (5 TABLET PACK)**
- **MAVENCLAD (6 TABLET PACK)**
- **MAVENCLAD (7 TABLET PACK)**
- **MAVENCLAD (8 TABLET PACK)**
- **MAVENCLAD (9 TABLET PACK)**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of Mavenclad and other disease modifying agents such as interferons, Copaxone, Tysabri. Treatment duration greater than 24 months.
Required Medical Information	Documentation of diagnosis of relapse-remitting multiples sclerosis or active secondary progressive disease -AND- therapeutic failure or intolerance to one other disease modifying therapy (e.g. Avonex, Gilenya, Copaxone)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	Coverage beyond 24 months will not be approved.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Mavyret

Products Affected

- **MAVYRET ORAL PELLETS IN PACKET**
- **MAVYRET ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guidance
Age Restrictions	Deny if less than 3 years of age
Prescriber Restrictions	
Coverage Duration	Criteria/duration applied consistent with current AASLD-IDSA guidance
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Mayzent

Products Affected

- **MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG**
- **MAYZENT STARTER(FOR 1MG MAINT)**
- **MAYZENT STARTER(FOR 2MG MAINT)**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of Mayzent and other disease modifying agents such as interferons, Copaxone, Tysabri.
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Testing for CYP2C9 variants has confirmed member does not have CYP2C9*3/*3 genotype
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Megace

Products Affected

- *megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)*
- *megestrol oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Mekinist

Products Affected

- **MEKINIST ORAL RECON SOLN**
- **MEKINIST ORAL TABLET 0.5 MG, 2 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Mektovi

Products Affected

- **MEKTOVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For unresectable or metastatic melanoma, all of the following (1-2): 1) BRAF V600E or V600K mutation status 2) using in combination with encorafenib. For metastatic non-small cell lung cancer, all of the following (1-2): 1) BRAF V600E mutation status 2) using in combination with encorafenib.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Mesalamine Active

Products Affected

- **CANASA**
- *mesalamine oral tablet,delayed release (dr/ec) 800 mg*
- *mesalamine rectal suppository*
- **ROWASA RECTAL ENEMA KIT**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Mesalamine Remission

Products Affected

- **APRISO**
- **LIALDA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Methamphetamine

Products Affected

- *methamphetamine*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Metronidazole

Products Affected

- *metronidazole oral tablet 125 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- intolerance to either generic metronidazole 250mg tablet or generic metronidazole 500mg tablet.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For reauthorization, the following attestations are required (1-2): 1) treatment is for a repeat episode of infection, 2) for recurrent trochomoniasis infection, first course of treatment completed at least 4 weeks prior to reauthorization.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Metyrosine

Products Affected

- **DEMSER**
- *metyrosine*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Miplyffa

Products Affected

- **MIPLYFFA**

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use of Aqneursa (levacetylleucine) -AND- Miplyffa (arimoclomal)
Required Medical Information	Documentation of diagnosis -AND- neurological symptoms of Niemann-Pick Disease Type C (e.g., ataxia, dysarthria, dysphagia, cognitive impairment, seizures) -AND- concurrent use with miglustat.
Age Restrictions	Deny if less than 2 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of positive clinical response
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Modeyso

Products Affected

- **MODEYSO**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Motegrity

Products Affected

- **MOTEGRITY**
- *prucalopride*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of chronic idiopathic constipation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Therapeutic failure, contraindication or intolerance to Linzess and lubiprostone are required. For brand Motegrity, therapeutic failure or intolerance to generic prucalopride is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Motpoly XR

Products Affected

- **MOTPOLY XR ORAL CAPSULE,EXTENDED RELEASE 24HR 100 MG, 150 MG, 200 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

MTX Injection

Products Affected

- **OTREXUP (PF)**
- **RASUVO (PF)**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Mulpleta

Products Affected

- **MULPLETA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of thrombocytopenia and chronic liver disease - AND- beneficiary is scheduled to undergo a procedure -AND- trial and failure or intolerance to Doptelet
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Myalept

Products Affected

- **MYALEPT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of congenital or acquired generalized lipodystrophy -AND- Leptin levels less than 8 ng/mL for males or less than 12 ng/mL for females -AND- the member has a diagnosis of diabetes or fasting insulin levels greater than 30uU/mL or fasting hypertriglyceridemia greater than 200mg/dL -AND- Therapeutic failure to one previous diabetes therapy (e.g. metformin, insulin) or hypertriglyceridemia therapy (e.g. statin, fibrate)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, decrease in HbA1c from baseline, decrease in fasting plasma glucose from baseline or decrease in fasting triglycerides from baseline
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Myasthenia Gravis

Products Affected

- **ZILBRYSQ SUBCUTANEOUS SYRINGE 16.6 MG/0.416 ML, 23 MG/0.574 ML, 32.4 MG/0.81 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of generalized myasthenia gravis (gMG) -AND- Anti-acetylcholine receptor (AChR) antibody-positive -AND- Therapeutic failure, contraindication, or intolerance to generic pyridostigmine.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of gMG signs/symptoms improvement (e.g., speech, swallowing, mobility, and/or respiratory function) -OR- decreased gMG exacerbations.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Mycapssa

Products Affected

- **MYCAPSSA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Myfembree

Products Affected

- **MYFEMBREE**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Namzaric

Products Affected

- *memantine-donepezil*
- **NAMZARIC ORAL CAPSULE,SPRINKLE,ER 24HR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis and intolerance to generic memantine and generic donepezil
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nayzilam

Products Affected

- **NAYZILAM**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizure clusters or acute repetitive seizures -AND- the member is currently receiving antiepileptic maintenance therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Nemluvio

Products Affected

- **NEMLUVIO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of prurigo nodularis -OR- Documentation of moderate to severe atopic dermatitis and one of the following (1-3): 1) trial and failure or intolerance to at least one topical corticosteroid or one topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus), 2) severe atopic dermatitis and the member is incapable of applying topical therapies due to the extent of body surface area involvement, or 3) severe atopic dermatitis and topical therapies are contraindicated due to severely damaged skin.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For prurigo nodularis, must follow recommended dosing guidelines based upon weight. For atopic dermatitis, must follow recommended dosing based on FDA approved dosing guidelines. For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For prurigo nodularis reauthorization, attestation of reduction in itch or number of nodules or lesions from baseline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Nerlynx

Products Affected

- **NERLYNX**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Nexavar

Products Affected

- **NEXAVAR**
- *sorafenib*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For locally recurrent or metastatic, progressive, differentiated thyroid carcinoma, refractory to radioactive iodine treatment
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Nexavar, documentation of trial and failure of generic sorafenib is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nexletol

Products Affected

- **NEXLETOL**
- **NEXLIZET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	1. HeFH supported by presence of causal mutation of FH by genetic testing OR untreated LDL-C at least 190mg/dL or untreated LDL-C at least 160mg/dL before 20 yrs of age with physical signs of FH (e.g. xanthomas, xanthelasma) OR diagnosis based on WHO criteria/Dutch Lipid Clinical Network criteria with score greater than 8 points, or definite Simon Broome register criteria, or definite on the Make Early Diagnosis to Prevent Early Deaths tool -AND- LDL-C at least 70mg OR non-HDL at least 100mg/dL or less than 50% reduction in baseline LDL-C despite use with maximally tolerated statin therapy or if very high risk, LDL-C at least 55mg/dL or non-HDL at least 85mg/dL -AND- Attestation of combination use with other LDL-C lowering therapies or concomitant LDL-C lowering therapy is not possible -AND- Therapeutic failure to a maximally tolerated statin or documented statin intolerance -AND- Therapeutic failure/intolerance/contraindication to ezetimibe 2. Hyperlipidemia w/ASCVD or Hyperlipidemia with attestation of high risk for CVD, LDL-C at least 70mg OR non-HDL at least 100mg/dL or less than 50% reduction in baseline LDL-C despite use with maximally tolerated statin therapy or if very high risk, LDL-C at least 55mg/dL or non-HDL at least 85mg/dL -AND- Therapeutic failure to a maximally tolerated statin or documented statin intolerance -AND- Therapeutic failure/intolerance/contraindication to ezetimibe. 3. Primary Hyperlipidemia not associated w/ ASCVD or HeFH, LDL-C at least 70mg/dL or non-HDL-C at least 100mg/dL or less than 50% reduction in baseline LDL-C despite use with maximally tolerated statin therapy -AND- Attestation of combination use with other LDL-C lowering therapies or concomitant LDL-C lowering therapy is not possible -AND- Therapeutic failure to a maximally tolerated statin or documented statin intolerance -AND- Therapeutic failure/intolerance/contraindication to ezetimibe.
Age Restrictions	

PA Criteria	Criteria Details
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, documentation showing an LDL-C reduction from baseline -AND- for HeFH and Primary Hyperlipidemia (not associated with ASCVD or HeFH), attestation of continued use in combination with other LDL-C lowering therapies or concomitant LDL-C lowering therapy is not possible. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statin which resolved upon discontinuation of statin or documentation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ninlaro

Products Affected

- **NINLARO**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Nitisinone

Products Affected

- *nitisinone*
- **NITYR**
- **ORFADIN**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Northera

Products Affected

- *droxidopa oral capsule 100 mg, 200 mg, 300 mg*
- **NORTHERA ORAL CAPSULE 100 MG, 200 MG, 300 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of neurogenic orthostatic hypotension caused by primary autonomic failure (e.g., Parkinson's disease, multiple system atrophy, or pure autonomic failure), dopamine beta-hydroxylase deficiency or non-diabetic autonomic neuropathy -AND- documentation of inadequate response, intolerance or contraindication to preferred generic alternative midodrine.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For brand Northera, initial authorization requires documentation of trial and failure of generic droxidopa and reauthorization requires failure of generic droxidopa if not previously trialed. For reauthorization, attestation of increase from baseline of systolic or diastolic blood pressure upon standing -OR- attestation of decrease from baseline of neurogenic orthostatic hypotension symptoms upon standing (e.g., dizziness, feeling faint, etc.).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nourianz

Products Affected

- **NOURIANZ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Parkinson's disease experiencing off episodes -AND- Used as adjunct to levodopa/carbidopa -AND- trial/failure, contraindication or intolerance to one of the following generic products: ropinirole, pramipexole, entacapone, selegiline, or rasagiline
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nubeqa

Products Affected

- **NUBEQA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Nucala

Products Affected

- **NUCALA SUBCUTANEOUS AUTO-INJECTOR**
- **NUCALA SUBCUTANEOUS RECON SOLN**
- **NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML, 40 MG/0.4 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of severe asthma and all of the following (1-4): 1) history of at least 2 asthma exacerbations requiring oral or injectable corticosteroid treatment in past 12 mos or at least 1 asthma exacerbation requiring hospitalization in past 12 mos 2) Blood eosinophils greater than or equal to 150cells/uL within past 6 wks or greater than or equal to 300cells/uL within past 12 mos without other potential causes of eosinophilia (e.g. hypereosinophilic syndromes, neoplastic disease, known suspected parasitic infection) 3) inadequate symptom control despite regular treatment with medium or high dose inhaled corticosteroid (ICS) and at least 1 add'l asthma controller medication (e.g. long-acting beta2-agonist [LABA], leukotriene receptor antagonist [LTRA], theophylline), with or without oral corticosteroids (OCS) 4) will continue treatment with medium or high dose ICS and at least 1 add'l asthma controller medication, with or without OCS -OR- Documentation of eosinophilic granulomatosis with polyangiitis (EGPA) with history of relapsing or refractory disease and will be receiving concomitant glucocorticoid treatment with or without immunosuppressive therapy -OR- Diagnosis of hypereosinophilic syndrome (HES) without identifiable non-hematologic secondary cause for greater than or equal to 6 mos and both of the following (5-6): 5) At least 2 HES flares (HES-related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy) within past 12 mos 6) Stable on HES therapy for at least 4 wks (chronic or episodic OCS, immunosuppressive or cytotoxic therapy) -OR- Diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) and trial/failure, contraindication, or intolerance to intranasal corticosteroid.
Age Restrictions	
Prescriber Restrictions	

PA Criteria	Criteria Details
Coverage Duration	12 months
Other Criteria	For Severe Asthma reauthorization, attestation of one of the following is required (1-4): 1) decreased rescue medication or oral corticosteroid use, 2) decreased frequency of severe asthma exacerbation, 3) increased pulmonary function from baseline (e.g. FEV1), or 4) reduction in reported asthma related symptoms. For EGPA reauthorization, attestation of one of the following is required (5-8): 5) reduction in frequency and/or severity of relapses, 6) reduction or discontinuation of corticosteroids and/or immunosuppressant, 7) disease remission, or 8) reduction in severity or frequency of EGPA-related symptoms. For HES reauthorization, attestation of one of the following is required (9-10): 9) reduction in frequency of HES flares, or 10) maintenance or reduction in background HES therapy requirements. For CRSwNP reauthorization, attestation of one of the following is required (11-12): 11) decrease in nasal polyp score, or 12) reduction in nasal congestion/obstruction severity score.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nuedexta

Products Affected

- **NUEDEXTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation supporting improvement in symptoms is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Nuplazid

Products Affected

- **NUPLAZID**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of hallucinations and delusions associated with Parkinson's disease psychosis
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Nurtec

Products Affected

- **NURTEC ODT**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nuvigil

Products Affected

- *armodafinil*
- **NUVIGIL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of shift work sleep disorder (SWSD) substantiated by excessive sleepiness or insomnia that is temporarily associated with a recurring work schedule that overlaps the usual time for sleep -AND- Symptoms are accompanied by a reduction of total sleep time -AND- Symptoms experienced for at least 3 months -AND- Sleep log or actigraphy monitoring for at least 14 days including both work and free days -AND- Sleep disturbance is not better explained by another current sleep disorder, medical or neurological disorder, mental disorder, medication use, or substance use disorder. Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than or equal to 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than or equal to 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. Diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by objective polysomnography as established in accordance with ICSD or DSM V criteria acceptable for all indications
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	For reauthorization, provider attestation of improvement in daytime sleepiness is required. For brand Nuvigil, documentation of failure on modafinil (generic Provigil).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ocaliva

Products Affected

- **OCALIVA**

PA Criteria	Criteria Details
Exclusion Criteria	Compensated cirrhosis with evidence of portal hypertension
Required Medical Information	Documentation of primary biliary cholangitis -AND- trial and failure, contraindication, or intolerance to ursodiol monotherapy -AND- will use concomitantly with ursodiol unless contraindicated or intolerant.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Octreotide

Products Affected

- *octreotide acetate injection solution*
- **SANDOSTATIN INJECTION SOLUTION 100 MCG/ML, 50 MCG/ML, 500 MCG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For acromegaly, high pretreatment insulin-like growth factor-1 (IGF-1) based on laboratory reference range -AND- therapeutic failure or cannot be treated with surgical resection, pituitary irradiation or bromocriptine mesylate.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization of acromegaly, decreased or normalized IGF-1 from baseline
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Odactra

Products Affected

- **ODACTRA**

PA Criteria	Criteria Details
Exclusion Criteria	Asthma (severe, unstable or uncontrolled), concomitant sublingual or subcutaneous immunotherapy
Required Medical Information	Documentation of allergic rhinitis due to house dust mites -AND- allergic rhinitis with or without conjunctivitis has been confirmed by skin testing for licensed house dust mite allergen extracts or in vitro testing for IgE antibodies to D. pteronyssinus or D. Farina -AND- trial and failure or intolerance to an intranasal steroid and an oral non-sedating antihistamine, intranasal antihistamine or intranasal anticholinergic agent
Age Restrictions	Deny if less than 5 years of age or greater than 65 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Member must also be prescribed an epinephrine auto injector. For reauthorization, attestation of improved allergy symptoms is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Odomzo

Products Affected

- **ODOMZO**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ogsiveo

Products Affected

- **OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of progressing desmoid tumor(s) requiring systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ohtuvayre

Products Affected

- **OHTUVAYRE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of chronic obstructive pulmonary disease (COPD) -AND- Inadequate symptom control despite regular treatment for at least 3 months of at least two maintenance COPD controllers (e.g. LABA/LAMA, LAMA/LABA/ICS), or intolerance/contraindication to these agents.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Ohtuvayre covered under Part B when using via nebulizer in the home setting.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ojemda

Products Affected

- **OJEMDA ORAL SUSPENSION FOR RECONSTITUTION**
- **OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4), 500 MG/WEEK (100 MG X 5), 600 MG/WEEK (100 MG X 6)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of relapsed or refractory pediatric low-grade glioma -AND- one of the following (1-2): 1) BRAF fusion or rearrangement, or 2) BRAF V600K mutation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ojjaara

Products Affected

- **OJJAARA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of intermediate or high-risk myelofibrosis -AND- attestation of anemia.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Olpruva

Products Affected

- **OLPRUVA ORAL PELLETS IN PACKET 2 GRAM, 3 GRAM, 4 GRAM, 5 GRAM, 6 GRAM, 6.67 GRAM**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Olumiant

Products Affected

- **OLUMIANT**

PA Criteria	Criteria Details
Exclusion Criteria	Part A covered for Covid-19 in hospitalized patients
Required Medical Information	Documentation of diagnosis. For moderate to severely active rheumatoid arthritis an inadequate response or intolerance to at least one non-biologic DMARD (e.g., methotrexate, leflunomide). For severe alopecia areata, inadequate response or intolerance to an intralesional corticosteroid or high potency topical corticosteroid, or contraindication to all.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis and Alopecia Areata
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Rinvoq and Xeljanz/Xeljanz XR, with at least 1 being a tumor necrosis factor blocker. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Omvoh

Products Affected

- **OMVOH PEN SUBCUTANEOUS PEN INJECTOR 100 MG/ML, 300MG/3ML(100MG /ML-200 MG/2ML)**
- **OMVOH SUBCUTANEOUS SYRINGE 100 MG/ML, 300MG/3ML(100MG /ML-200 MG/2ML)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- attestation of receiving or currently undergoing 3 doses of IV Omvoh within 3 months of initiating therapy with Omvoh SC.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For moderate to severe ulcerative colitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, Rinvoq, and Xeljanz/Xeljanz XR. For moderate to severe active Crohn's disease, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, and Rinvoq. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Onapgo

Products Affected

- **ONAPGO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of advanced Parkinson's disease -AND- being used to treat motor fluctuations -AND- experiencing motor fluctuations despite the use of oral carbidopa/levodopa -AND- Therapeutic failure, intolerance, or contraindication to one of the following generic products: pramipexole, ropinirole, entacapone, selegiline or rasagiline
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Onfi

Products Affected

- *clobazam oral suspension*
- *clobazam oral tablet*
- **ONFI ORAL SUSPENSION**
- **ONFI ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ongentys

Products Affected

- **ONGENTYS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Parkinson's disease experiencing off episodes -AND- Used as adjunct to levodopa/carbidopa -AND- trial/failure, contraindication or intolerance to the following (1. and 2.): 1) entacapone 2) one of the following generic products: rasagiline, pramipexole, ropinirole, selegiline
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Onureg

Products Affected

- **ONUREG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Onyda XR

Products Affected

- **ONYDA XR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of ADHD -AND- trial/failure, intolerance or contraindication to a stimulant
Age Restrictions	Deny if less than 6 years of age or greater than 17 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Inability to swallow tablets or capsules is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ophthalmic Antihistamines

Products Affected

- *bepotastine besilate*
- **BEPREVE**
- **ZERVIATE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of ocular itching associated with allergic conjunctivitis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Therapeutic failure, intolerance, or contraindication to generic azelastine ophthalmic drops is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Opipza

Products Affected

- **OPIPZA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- 1 of the following (1-2): 1) intolerance to generic aripiprazole tablets, 2) inability to swallow oral tablets. If medication is being used for major depressive disorder, documentation of adjunctive therapy and therapeutic failure, contraindication or intolerance to one other generic antidepressant in addition to the antidepressant currently being used for the treatment of MDD (e.g. SSRI, SNRI, NDRIs, TCA, MAOI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Opzelura

Products Affected

- **OPZELURA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-4): 1) mild to moderate atopic dermatitis (AD), 2) attestation of up to 20 percent of body surface area (excluding scalp) with AD involvement, 3) trial & failure, intolerance, or contraindication to at least one topical corticosteroid -OR- documentation of facial or anogenital involvement, 4) trial & failure, intolerance, or contraindication to topical generic tacrolimus or topical generic pimecrolimus -OR- Documentation of all of the following (5-7): 5) Nonsegmental vitiligo, 6) body surface area with vitiligo involvement does not exceed 10%, 7) trial & failure or intolerance to at least 1 generic, formulary high or ultrahigh potency topical corticosteroid -OR- vitiligo with facial or anogenital involvement
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initial authorization: 8 weeks for AD, 24 weeks for vitiligo. Reauthorization: 12 months
Other Criteria	For reauthorization, attestation of positive clinical response to therapy for atopic dermatitis -OR- meaningful repigmentation of affected areas for vitiligo
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Oral Rosacea

Products Affected

- **EMROSI**
- **ORACEA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Orencia

Products Affected

- **ORENCIA CLICKJECT**
- **ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis or less than 2 years of age for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Rinvoq and Xeljanz/Xeljanz XR. For psoriatic arthritis, patients over 18 years of age must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla, Skyrizi SC, Rinvoq, and Xeljanz/Xeljanz XR. For polyarticular juvenile idiopathic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Rinvoq/Rinvoq LQ, and Xeljanx/Xeljanz solution. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Orgovyx

Products Affected

- **ORGOVYX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of advanced prostate cancer
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Oriahnn

Products Affected

- **ORIAHNN**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Orilissa

Products Affected

- **ORILISSA ORAL TABLET 150 MG, 200 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Diagnosis of severe hepatic impairment or osteoporosis.
Required Medical Information	Documentation of premenopausal woman with diagnosis of endometriosis with moderate to severe pain -AND- For women of childbearing age, attestation of not pregnant -AND- Inadequate response, failure or contraindication to 2 standard of care treatments (e.g. NSAIDS, combined hormonal contraceptives, progestin, GnRH agonist, Danazol) -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist with or with out estrogen and progestin does not exceed 24 months.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 18 months reauthorization
Other Criteria	For reauthorization, Orilissa is continued to be used for pain associated with endometriosis -AND- attestation of reduction in pain -AND- For women of childbearing age, attestation of not pregnant -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist with or without estrogen and progestin does not exceed 24 months.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Orkambi

Products Affected

- **ORKAMBI ORAL GRANULES IN PACKET**
- **ORKAMBI ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystic fibrosis and homozygous F508del mutation
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Orladeyo

Products Affected

- **ORLADEYO**

PA Criteria	Criteria Details
Exclusion Criteria	Member should not be on two prophylactic therapies simultaneously.
Required Medical Information	For the prophylactic treatment of attacks of hereditary angioedema (HAE) due to deficiency of C1INH (type I & II) with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the prophylactic treatment of attacks of hereditary angioedema (HAE) with normal C1INH (type III) with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE, FXII mutation, angiopoietin-1 mutation, plasminogen mutation, kininogen-1 mutation, myoferlin mutation, or heparin sulfate-glucosamine 3-O-sulfotransferas 6 mutation. 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Orserdu

Products Affected

- **ORSERDU ORAL TABLET 345 MG, 86 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Osphena

Products Affected

- **OSPHENA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Otezla

Products Affected

- **OTEZLA** **(47)**
- **OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)- 20 MG (51), 10 MG (4)-20 MG (4)-30 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For plaque psoriasis, all of the following (1-2): 1) if the member is greater than or equal to 6 years of age and less than 18 years, weight is greater than or equal to 20 kg and member has moderate-to-severe disease -AND- 2) inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For oral ulcers associated with Behcet's Disease, inadequate response or intolerance to one systemic therapy for prevention of recurrent oral ulcers
Age Restrictions	Deny if less than 6 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Oxervate

Products Affected

- **OXERVATE**

PA Criteria	Criteria Details
Exclusion Criteria	Treatment duration greater than 8 weeks per eye
Required Medical Information	Documentation of diagnosis -AND- affected eye (e.g. right eye, both eyes).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 weeks
Other Criteria	Coverage beyond 8 weeks per eye will not be approved
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Palynziq

Products Affected

- **PALYNZIQ SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 2.5 MG/0.5 ML, 20 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of phenylketonuria -AND- all of the following criteria (1-3): 1) Baseline Phe level greater than 600 micromoles/L, 2) Failure or intolerance to existing management (i.e. sapropterin dihydrochloride)
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of reduction in baseline pretreatment Phe levels -OR- blood Phe levels are less than or equal to 600 micromoles/L -OR- attestation that additional therapy with Palynziq is needed to allow adequate trial of maximum dose of 60mg per day for 16 weeks or member is not currently on 60mg per day dose.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Panretin

Products Affected

- **PANRETIN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cutaneous lesions in patients with AIDS-related Kaposi Sarcoma (KS) who are not receiving systemic therapy for KS.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Paroxetine Capsule

Products Affected

- *paroxetine mesylate(menop.sym)*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- Attestation of counseling on risk-benefit profile and potential anticholinergic adverse effects
Age Restrictions	Automatic approval if less than 65 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Pemazyre

Products Affected

- **PEMAZYRE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of unresectable locally advanced cholangiocarcinoma or metastatic cholangiocarcinoma -AND- all of the following (1-2): 1) disease harbors FGFR2 fusion or other rearrangement as detected by an FDA-approved test 2) member has experienced therapeutic failure or intolerance to at least on prior therapy. Documentation of relapsed or refractory myeloid/lymphoid neoplasms -AND- disease harbors an FGFR1 rearrangement.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Pen Needles

Products Affected

- *pen needle, diabetic needle 29 gauge x 1/2"*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For non-preferred pen needle products, trial/failure or contraindication to preferred Embecta pen needles with NDC starting with 83017 is required. Embecta pen needles with NDC starting with 83017 will receive automatic approval.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Pentasa

Products Affected

- *mesalamine oral capsule, extended release*
- **PENTASA ORAL CAPSULE, EXTENDED RELEASE 500 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Pheburane

Products Affected

- **PHEBURANE**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Phenoxybenzamine

Products Affected

- **DIBENZYLINE**
- *phenoxybenzamine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of excessive sweating and hypertension associated with pheochromocytoma supported by one of the following (1. or 2.): 1. Elevated metanephrines in plasma or urine. 2. Tumor evidence from CT scan or MRI
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Phospholine Iodide

Products Affected

- **PHOSPHOLINE IODIDE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For diagnosis of elevated intraocular pressure (IOP), the following criteria apply (1 and 2): therapeutic failure or intolerance to generic latanoprost, 2) therapeutic failure, contraindication, or intolerance to one generic ophthalmic alternative that lowers IOP (a. through f.): a) prostaglandin analog, b) ophthalmic beta-blocker, c) alpha-adrenergic agonist, d) carbonic anhydrase inhibitor, e) ophthalmic cholinergic agonist, f) combination products of these classes
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Piqray

Products Affected

- **PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following: 1) HR-positive, HER2-negative tumor status, 2) PIK3CA mutation positive as detected by an FDA-approved test, 3) disease progression on or after an endocrine-based regimen, 4) Concomitant therapy with fulvestrant
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Pomalyst

Products Affected

- **POMALYST**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of multiple myeloma, and combination use with dexamethasone, and previous trial of at least 2 therapies including lenalidomide and a proteasome inhibitor, and disease progression on or within 60 days of completion of the last therapy -OR- Documentation of AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV negative
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ponvory

Products Affected

- **PONVORY**
- **PONVORY 14-DAY STARTER PACK**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Posaconazole Powder Packet

Products Affected

- **NOXAFIL ORAL SUSP,DELAYED RELEASE FOR RECON**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For aspergillus or candida infection prophylaxis, high risk of developing invasive Aspergillosis or Candidiasis infection due to being severely immunocompromised (e.g., hematopoietic stem cell transplant recipients with graft versus host disease, those with hematologic malignancies with prolonged neutropenia from chemotherapy) -AND- weight less than or equal to 40 kg.
Age Restrictions	Deny if less than 2 years of age or greater than 17 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Posaconazole Suspension

Products Affected

- **NOXAFIL ORAL SUSPENSION**
- *posaconazole oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For aspergillus or candida infection prophylaxis, high risk of developing invasive Aspergillosis or Candidiasis infection due to being severely immunocompromised (e.g., hematopoietic stem cell transplant recipients with graft versus host disease, those with hematologic malignancies with prolonged neutropenia from chemotherapy). For oropharyngeal candidiasis treatment, trial/failure or intolerance to generic fluconazole or generic itraconazole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Documentation of failure on generic posaconazole delayed-release tablets or an inability to swallow tablets is required when being utilized for the same FDA approved indication. For brand Noxafil oral suspension, therapeutic failure or intolerance to generic posaconazole oral suspension is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Posaconazole Tablet

Products Affected

- *posaconazole oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For aspergillus or candida infection prophylaxis, high risk of developing invasive Aspergillosis or Candidiasis infection due to being severely immunocompromised (e.g., hematopoietic stem cell transplant recipients with graft versus host disease, those with hematologic malignancies with prolonged neutropenia from chemotherapy) -AND- weight greater than 40 kg. For invasive aspergillosis infection, trial/failure or contraindication to voriconazole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Praluent

Products Affected

- **PRALUENT PEN**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with another PCSK9 inhibitor or siRNA directed to PCSK9.
Required Medical Information	1.HoFH supported by genetic confirmation of two mutant alleles at LDLR, APOB, PCSK9, or LDLRAP1 gene OR untreated LDL-C greater than 400mg/dL or TC greater than 500mg/dl with cutaneous or tendon xanthoma before age 10 yrs or HeFH in both parents AND current LDL-C of greater than 115mg/dL (if 17 yrs or younger) or greater than 70mg/dL (if 18 yrs or older) or greater than 55mg/dL (if 18 yrs or older with ASCVD or major ASCVD risk factors) despite use of maximally tolerated statin or statin intolerance AND will continue to receive concurrent lipid-lowering therapies for the treatment of HoFH. 2.HeFH supported by presence of genetic confirmation of one mutant allele at the LDLR, APOB, or PCSK9 gene locus OR untreated LDL-C at least 190mg/dL or untreated LDL-C at least 160mg/dL before 20 yrs of age with physical signs of FH (e.g. xanthomas, xanthelasma) OR diagnosis based on WHO criteria/Dutch Lipid Clinical Network criteria with score greater than 8 points, or definite on Simon Broome register, or definite on the Make Early Diagnosis to Prevent Early Deaths tool AND LDL-C at least 70mg/dL or non-HDL-C at least 100mg/dL or less than 50% reduction in baseline LDL-C or if very high risk, LDL-C at least 55mg/dL or non-HDL-C at least 85mg/dL, despite use of maximally tolerated statin or statin intolerance. If 17 and younger will continue to receive concurrent lipid-lowering therapies. 3.Hypercholesterolemia ASCVD, LDL-C at least 70mg/dL or non-HDL-C at least 100mg/dL or less than 50% reduction in baseline LDL-C or if very high risk, LDL-C at least 55mg/dL or non-HDL-C at least 85mg/dL, despite use of maximally tolerated statin or statin intolerance. 4. Primary Hyperlipidemia, LDL-C at least 70mg/dL or non-HDL-C at least 100mg/dL or less than 50% reduction in baseline LDL-C despite use of maximally tolerated statin or statin intolerance
Age Restrictions	
Prescriber Restrictions	

PA Criteria	Criteria Details
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For Primary Hyperlipidemia, HoFH, and Hypercholesterolemia with ASCVD, patients must have a trial/failure or contraindication to the preferred product Repatha . For HeFH and 10 years and older, patients must have a trial/failure or contraindication to the preferred product Repatha. For reauthorization, documentation showing an LDL-C reduction on Praluent therapy from baseline must be provided. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statins which resolved upon discontinuation of statin or attestation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Preferred Adalimumab

Products Affected

- **HADLIMA**
- **HADLIMA PUSHTOUCH**
- **HADLIMA(CF)**
- **HADLIMA(CF) PUSHTOUCH**
- **SIMLANDI(CF)**
- **SIMLANDI(CF) AUTOINJECTOR**
- **YUFLYMA(CF)**
- **YUFLYMA(CF) AI CROHN'S-UC-HS**
- **YUFLYMA(CF) AUTOINJECTOR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID). For moderate to severe polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For uveitis, inadequate response or intolerance to 1 immunosuppressant or corticosteroid, or all are contraindicated.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, and Ankylosing Spondylitis or less than 12 years of age for Hidradenitis Suppurative or Less than 6 years of age for Crohn's disease or Less than 5 years of age for Ulcerative Colitis or less than 2 years of age for Polyarticular Juvenile Idiopathic Arthritis and Uveitis
Prescriber Restrictions	
Coverage Duration	Plan Year

PA Criteria	Criteria Details
Other Criteria	For plaque psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For rheumatoid arthritis therapy without concomitant methotrexate, doses above plan quantity limit will be approved aligned with recommended weekly dosing regimen. For pediatric ulcerative colitis and hidradenitis suppurativa, doses above plan quantity limit will be approved to align with recommended dosing regimen. Induction therapy or treatment regimens for other indications are aligned with plan quantity limit on Humira starter kit. These criteria are applicable to Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Preferred Ustekinumab

Products Affected

- **STEQEYMA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML**
- **YESINTEK SUBCUTANEOUS SOLUTION**
- **YESINTEK SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Prenatal Vitamins

Products Affected

- **PRENATAL VITAMIN PLUS LOW IRON**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of nutritional supplementation required in a female of child-bearing potential during pre-conception, pregnancy, or lactation
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Prescription Drug Combo

Products Affected

- *acetaminophen-codeine oral solution 120-12 mg/5 ml*
- *acetaminophen-codeine oral tablet*
- **ALPRAZOLAM INTENSOL**
- *alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg*
- *alprazolam oral tablet extended release 24 hr 0.5 mg, 1 mg, 2 mg, 3 mg*
- *alprazolam oral tablet,disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg*
- **AMBIEN**
- **AMBIEN CR**
- **ASCOMP WITH CODEINE**
- **ATIVAN ORAL TABLET 0.5 MG, 1 MG, 2 MG**
- **BELBUCA**
- *buprenorphine*
- *butalbital-acetaminop-caf-cod oral capsule 50-300-40-30 mg, 50-325-40-30 mg*
- **BUTRANS**
- *chlordiazepoxide hcl*
- *clonazepam oral tablet 0.5 mg, 1 mg, 2 mg*
- *clonazepam oral tablet,disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg*
- *clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg*
- *codeine sulfate*
- *codeine-butalbital-asa-caff*
- **CONZIP**
- **DEMEROL (PF) INJECTION SYRINGE 25 MG/ML**
- **DEMEROL INJECTION**
- **DIAZEPAM INTENSOL**
- *diazepam oral solution 5 mg/5 ml (1 mg/ml)*
- *diazepam oral tablet*
- **DILAUDID ORAL LIQUID**
- **DILAUDID ORAL TABLET 2 MG, 4 MG, 8 MG**
- **EDLUAR**
- **ENDOCET**
- *estazolam*
- *eszopiclone*
- *fentanyl*
- **FIORICET WITH CODEINE**
- *flurazepam*
- **HALCION ORAL TABLET 0.25 MG**
- *hydrocodone bitartrate oral capsule, oral only, er 12hr*
- *hydrocodone bitartrate oral tablet,oral only,ext.rel.24 hr*
- *hydrocodone-acetaminophen oral solution 10-300 mg/15 ml, 10-325 mg/15 ml, 7.5-325 mg/15 ml*
- *hydrocodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 2.5-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg*
- *hydrocodone-ibuprofen*
- *hydromorphone (pf) injection solution 10 (mg/ml) (5 ml), 10 mg/ml*
- *hydromorphone oral liquid*
- *hydromorphone oral tablet 2 mg, 4 mg, 8 mg*
- *hydromorphone oral tablet extended release 24 hr 12 mg, 16 mg, 32 mg, 8 mg*
- **HYSINGLA ER ORAL TABLET,ORAL ONLY,EXT.REL.24 HR 100 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG**
- **KLONOPIN ORAL TABLET 0.5 MG, 1 MG, 2 MG**
- *levorphanol tartrate*
- **LORAZEPAM INTENSOL**
- *lorazepam oral tablet 0.5 mg, 1 mg, 2 mg*
- **LOREEV XR ORAL CAPSULE,EXTENDED RELEASE 24HR 1 MG, 1.5 MG, 2 MG, 3 MG**
- **LUNESTA**
- *meperidine (pf) injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml*
- *meperidine oral solution*
- *meperidine oral tablet 50 mg*
- *methadone oral solution 10 mg/5 ml, 5 mg/5 ml*
- *methadone oral tablet 10 mg, 5 mg*
- *morphine concentrate oral solution*
- *morphine oral capsule, er multiphase 24 hr 120 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg*
- *morphine oral capsule,extend.release pellets*

- *morphine oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml)*
- *morphine oral tablet*
- *morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg*
- **MS CONTIN ORAL TABLET EXTENDED RELEASE 15 MG, 30 MG, 60 MG**
- **NALOCET**
- **NUCYNTA**
- **NUCYNTA ER**
- *oxazepam*
- *oxycodone oral capsule*
- *oxycodone oral concentrate*
- *oxycodone oral solution*
- *oxycodone oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg*
- *oxycodone oral tablet, oral only*
- *oxycodone-acetaminophen oral solution 5-325 mg/5 ml*
- *oxycodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 2.5-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg*
- **OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG**
- *oxymorphone oral tablet*
- *oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg*
- **PERCOCET ORAL TABLET 10-325 MG, 5-325 MG, 7.5-325 MG**
- **PROLATE ORAL SOLUTION**
- **PROLATE ORAL TABLET**
- **RESTORIL**
- **ROXICODONE ORAL TABLET 15 MG, 30 MG**
- **ROXYBOND**
- *temazepam*
- *tramadol oral capsule,er biphase 24 hr 17-83*
- *tramadol oral capsule,er biphase 24 hr 25-75 100 mg, 200 mg*
- *tramadol oral tablet 100 mg, 25 mg, 50 mg, 75 mg*
- *tramadol oral tablet extended release 24 hr*
- *tramadol-acetaminophen*
- *triazolam*
- **VALIUM**
- **XANAX ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG**
- **XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 0.5 MG, 1 MG, 2 MG, 3 MG**
- **XTAMPZA ER**
- *zaleplon oral capsule 10 mg, 5 mg*
- *zolpidem*

PA Criteria	Criteria Details
Exclusion Criteria	

PA Criteria	Criteria Details
Required Medical Information	For concomitant use of opiate agonist and substance abuse therapy, documentation of acute pain condition (eg, acute traumatic injury) in which treatment with other agents would cause insufficient pain control or treatment for terminal illness related pain. For concomitant use of an opiate agonist, benzodiazepine, and centrally acting skeletal muscle relaxant, trial/failure of at least 2 other skeletal muscle relaxants (eg, methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients, attestations that non-opiate (eg, NSAIDs) and non-benzodiazepine therapies (eg, SSRI, SNRI) have been considered, and attestation of intent to monitor & address concomitant drug-drug interaction adverse events. For concomitant use of opiate agonist and other opiate potentiators (eg, gabapentinoids, sedative-hypnotics), attestation of intent to monitor & address concomitant drug-drug interaction adverse events. For long acting opioid medications, the following apply (1-3): 1)Severe pain requiring daily, around-the-clock, long-term opioid treatment. 2)Not opioid naive. 3)Attestations that non-opiate alternative therapies have been explored (eg, NSAIDs), controlled substance history was reviewed in the state Prescription Drug Monitoring Program (PDMP), counseling on potential adverse effects of opioid analgesics, including risk of misuse, abuse, addiction. For greater than 7 days of opioid analgesics, 1 of the following (4-7): 4)Not opioid naive. 5)Patient is in hospice /palliative/end-of-life care, has sickle cell disease, or is being treated for cancer-related pain. 6)Attestation that clinical circumstances require more than 7 days of opioids to manage severe pain. 7)Attestations that non-opiate alternative therapies have been explored (eg, NSAIDs), controlled substance history was reviewed in the state PDMP, and counseling on potential adverse effects of opioid analgesics, including risk of misuse, abuse, addiction.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Opiate tx for pain+subs. abuse, approve opiate x 1mo. All other combos and dx approve x 12mo.

PA Criteria	Criteria Details
Other Criteria	Opiate agonists will receive automatic approval if no recent claims for a substance abuse therapy (e.g. buprenorphine-naloxone) OR a benzodiazepine with a centrally acting skeletal muscle relaxant (e.g., carisoprodol) OR a gabapentinoid OR a sedative-hypnotic. Benzodiazepines (e.g. triazolam, alprazolam) will receive automatic approval if no recent claims for an opiate agonist with a centrally acting skeletal muscle relaxant (e.g. carisoprodol). Sedative-hypnotics (e.g. zolpidem) will receive automatic approval if no recent claims for an opiate agonist. Opioid analgesics will receive automatic approval if less than or equal to 7 day supply OR opioid history within 90 days. Infusible opiate agonists will be covered under Part B when administered via infusion pump.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Pretomanid

Products Affected

- *pretomanid*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. Criteria will be applied consistent with the current ATS/CDC/ERS/IDSA Clinical Practice Guideline for the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of disease improvement -AND- member requires additional antimicrobial therapy.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Prevymis Oral Pellets

Products Affected

- **PREVYMIS ORAL PELLETS IN PACKET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	Deny if less than 6 months of age with HSCT. Deny if less than 12 years of age with kidney transplant.
Prescriber Restrictions	
Coverage Duration	7 months
Other Criteria	One of the following is required (1-2): 1) inability to swallow tablets, 2) unable to use Prevymis (letermovir) tablets due to body weight dosing limitations.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Procysbi

Products Affected

- **PROCYSBI ORAL GRANULES DEL RELEASE IN PACKET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- previous trial and failure, intolerance, or contraindication to Cystagon (cysteamine bitartrate immediate-release)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Prolia

Products Affected

- **PROLIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -And- For osteoporosis at high risk for fracture, meeting one of the following (1. thru 4.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 (i.e. osteopenia) -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent. 4) Age 40 years or older with T-score between -1.0 and -2.5 -AND- History of glucocorticoid use for at least 3 months at a dose of 5mg per day or more of prednisone (or equivalent).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For osteoporosis and osteopenia, documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Covered under Part B for patients eligible for home health services when provider certifies that patient sustained bone fracture related to post-menopausal osteoporosis and is unable to learn the skills needed to self-administer the drug or is otherwise physically or mentally incapable of administering the drug or family/caregivers are unable or unwilling to administer the drug.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Provigil

Products Affected

- *modafinil*
- **PROVIGIL ORAL TABLET 200 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of shift work sleep disorder (SWSD) substantiated by excessive sleepiness or insomnia that is temporarily associated with a recurring work schedule that overlaps the usual time for sleep -AND- Symptoms are accompanied by a reduction of total sleep time -AND- Symptoms experienced for at least 3 months -AND- Sleep log or actigraphy monitoring for at least 14 days including both work and free days -AND- Sleep disturbance is not better explained by another current sleep disorder, medical or neurological disorder, mental disorder, medication use, or substance use disorder. Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than or equal to 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than or equal to 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. Diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by objective polysomnography as established in accordance with ICSD or DSM V criteria acceptable for all indications. Diagnosis of fatigue associated with Multiple Sclerosis (MS)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	For reauthorization, provider attestation of improvement in daytime sleepiness is required. For brand Provigil, documentation of failure on generic modafinil.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Fatigue associated with Multiple Sclerosis (MS)
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Pulmonary Arterial Hypertension

Products Affected

- **ADCIRCA**
- **ADEMPAS**
- **ALYQ**
- *ambrisentan*
- *bosentan oral tablet*
- **LETAIRIS**
- **OPSUMIT**
- **OPSYNVI**
- **ORENITRAM MONTH 1 TITRATION KT**
- **ORENITRAM MONTH 2 TITRATION KT**
- **ORENITRAM MONTH 3 TITRATION KT**
- **ORENITRAM ORAL TABLET EXTENDED RELEASE 0.125 MG, 0.25 MG, 1 MG, 2.5 MG, 5 MG**
- **REVATIO ORAL TABLET**
- *sildenafil (pulm.hypertension) oral suspension for reconstitution*
- *sildenafil (pulm.hypertension) oral tablet*
- *tadalafil (pulm. hypertension)*
- **TADLIQ**
- **TRACLEER ORAL TABLET**
- **TRACLEER ORAL TABLET FOR SUSPENSION**
- **TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16 MCG, 16(112)-32(112) -48(28) MCG, 32 MCG, 48 MCG, 64 MCG**
- **YUTREPIA INHALATION CAPSULE, W/INHALATION DEVICE 106 MCG, 26.5 MCG, 53 MCG, 79.5 MCG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Pulmozyme

Products Affected

- **PULMOZYME**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of cystic fibrosis -AND- Used in conjunction with standard therapies for management of cystic fibrosis to improve pulmonary function.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Inhalation solutions covered under Part B when administered in the home setting using a covered nebulizer (i.e. DME). For reauthorization, attestation of increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Purified Cortrophin Gel

Products Affected

- **CORTROPHIN GEL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Covered for the following indications: 1. Acute exacerbations of multiple sclerosis (MS) for patients receiving concurrent immunomodulator therapy 2. Rheumatic disorders for patients receiving maintenance therapy 3. Collagen diseases for members receiving maintenance therapy 4. Dermatologic diseases, if using for severe psoriasis, then the member is concurrently receiving maintenance therapy 5. Allergic states (i.e. serum sickness and transfusion reaction due to serum protein reaction), if using for atopic dermatitis, then the member is concurrently receiving maintenance therapy 6. Ophthalmic diseases 7. Respiratory diseases 8. Gout 9. Pediatric acquired epileptic aphasia. 10. Proteinuria in nephrotic syndrome and trial/failure or contraindication to two therapies from any of the following different classes: corticosteroids (e.g., cortisone or dexamethasone), calcineurin inhibitors (e.g., cyclosporine or tacrolimus, per DRUGDEX). For covered indications 1 through 9, limited/unsatisfactory response or intolerance (i.e. severe anaphylaxis) to two corticosteroids (i.e. IV methylprednisolone, IV dexamethasone, or high dose oral steroids) must be documented.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	RA, JRA, and Collagen Diseases: 1 month initial, 6 month reauth. All other indications: 1 month

PA Criteria	Criteria Details
Other Criteria	For reauthorization, the following (1. 2. and 3.) must be met. 1) Prescriber attestation that the member cannot use corticosteroids (e.g. IV methylprednisolone, high dose oral corticosteroids) due to unsatisfactory response, intolerance (e.g. severe anaphylaxis) or experienced a severe adverse event to corticosteroids (e.g. psychosis). 2) If the reauthorization is for the treatment of multiple sclerosis, a rheumatic disorder, dermatologic disease, or nephrotic syndrome, the prescriber attests that Cortrophin is being used for a new acute exacerbation and not on a routine basis to prevent an exacerbation as supported by Compendia. 3) If the reauthorization is for treatment of multiple sclerosis, a rheumatic disorder, or collagen disease, the member continues to receive maintenance therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Epileptic Aphasia
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Pyrukynd

Products Affected

- **PYRUKYND ORAL TABLET 20 MG, 5 MG, 5 MG (4-WEEK PACK), 50 MG**
- **PYRUKYND ORAL TABLETS,DOSE PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of hemolytic anemia with pyruvate kinase deficiency, as supported by one of the following (1-2): 1) mutations in the PKLR gene, 2) reduced activity of the pyruvate kinase enzyme.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 weeks initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of increase in hemoglobin level from baseline -OR- decrease in transfusion burden from baseline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Qelbree

Products Affected

- **QELBREE ORAL CAPSULE,EXTENDED RELEASE 24HR 100 MG, 150 MG, 200 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of ADHD -AND- trial/failure, intolerance or contraindication to a stimulant and generic atomoxetine
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Qinlock

Products Affected

- **QINLOCK**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Quinine

Products Affected

- *quinine sulfate*

PA Criteria	Criteria Details
Exclusion Criteria	Treatment or prevention of leg cramps
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	10 days
Other Criteria	Doses for duration greater than 10 days will not be approved
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Qulipta

Products Affected

- **QULIPTA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Radicava ORS

Products Affected

- **RADICAVA ORS STARTER KIT SUSP**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of amyotrophic lateral sclerosis (ALS) -AND- Therapeutic failure, intolerance, or contraindication to riluzole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of experiencing stability or improvement of symptoms.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ravicti

Products Affected

- **RAVICTI**

PA Criteria	Criteria Details
Exclusion Criteria	Urea cycle disorders due to N-acetylglutamate synthetase deficiency, Treatment of acute hyperammonemia in urea cycle disorders
Required Medical Information	Documentation of chronic management of a urea cycle disorders (UCDs)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Relistor

Products Affected

- **RELISTOR ORAL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of opioid induced constipation (OIC) due to any of the following (1-2): 1) chronic non-cancer pain, or 2) chronic pain related to prior cancer or its treatment who do not require frequent (e.g. weekly) opioid dosage escalation -AND- documentation of opioid medication use -AND- trial and failure, contraindication, or intolerance to 2 of the following (3-5): 3) Laxatives, 4) lubiprostone, 5) Movantik
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Relistor SC

Products Affected

- **RELISTOR SUBCUTANEOUS SOLUTION**
- **RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML, 8 MG/0.4 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of opioid induced constipation (OIC) due to any of the following (1-3): 1) chronic non-cancer pain, 2) advanced illness or active cancer in palliative care or 3) chronic pain related to prior cancer or its treatments who do not require frequent (e.g., weekly) opioid dosage escalation -AND- documentation of opioid medication use -AND- trial and failure, contraindication, or intolerance to 2 of the following (4 to 6): 4) Laxatives 5) lubiprostone 6) Movantik.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Repatha

Products Affected

- **REPATHA SURECLICK**
- **REPATHA SYRINGE**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with another PCSK9 inhibitor or siRNA directed to PCSK9.
Required Medical Information	1.HoFH supported by genetic confirmation of two mutant alleles at LDLR, APOB, PCSK9, or LDLRAP1 gene OR untreated LDL-C greater than 400mg/dL or TC greater than 500mg/dl with cutaneous or tendon xanthoma before age 10 yrs or HeFH in both parents AND current LDL-C of greater than 115mg/dL (if 17 yrs or younger) or greater than 70mg/dL (if 18 yrs or older) or greater than 55mg/dL (if 18 yrs or older with ASCVD or major ASCVD risk factors) despite use of maximally tolerated statin or statin intolerance AND will continue to receive concurrent lipid-lowering therapies for the treatment of HoFH. 2.HeFH supported by presence of genetic confirmation of one mutant allele at the LDLR, APOB, or PCSK9 gene locus OR untreated LDL-C at least 190mg/dL or untreated LDL-C at least 160mg/dL before 20 yrs of age with physical signs of FH (e.g. xanthomas, xanthelasma) OR diagnosis based on WHO criteria/Dutch Lipid Clinical Network criteria with score greater than 8 points, or definite on Simon Broome register, or definite on the Make Early Diagnosis to Prevent Early Deaths tool AND LDL-C at least 70mg/dL or non-HDL-C at least 100mg/dL or less than 50% reduction in baseline LDL-C or if very high risk, LDL-C at least 55mg/dL or non-HDL-C at least 85mg/dL, despite use of maximally tolerated statin or statin intolerance. If 17 and younger will continue to receive concurrent lipid-lowering therapies. 3.Hypercholesterolemia ASCVD, LDL-C at least 70mg/dL or non-HDL-C at least 100mg/dL or less than 50% reduction in baseline LDL-C or if very high risk, LDL-C at least 55mg/dL or non-HDL-C at least 85mg/dL, despite use of maximally tolerated statin or statin intolerance. 4. Primary Hyperlipidemia, LDL-C at least 70mg/dL or non-HDL-C at least 100mg/dL or less than 50% reduction in baseline LDL-C despite use of maximally tolerated statin or statin intolerance
Age Restrictions	
Prescriber Restrictions	

PA Criteria	Criteria Details
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, documentation showing an LDL-C reduction on Repatha therapy from baseline must be provided. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statins which resolved upon discontinuation of statin or attestation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Retevmo

Products Affected

- **RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Revlimid

Products Affected

- *lenalidomide*
- **REVLIMID**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Revuforj

Products Affected

- **REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Rexulti

Products Affected

- **REXULTI ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For major depressive disorder, documentation of adjunctive therapy and therapeutic failure, contraindication or intolerance to one other generic antidepressant in addition to the antidepressant currently being used for the treatment of MDD (e.g. SSRI, SNRI, NDRIs, TCA, MAOI). For schizophrenia, therapeutic failure, intolerance, or contraindication to one other generic atypical antipsychotic (e.g. quetiapine).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Reyvow

Products Affected

- **REYVOW ORAL TABLET 100 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of acute migraine headaches with or without aura -AND- Therapeutic failure, contraindication or intolerance to one generic triptan
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of reduction in migraine symptoms.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Rezdiffra

Products Affected

- **REZDIFFRA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in conjunction with diet and exercise. Liver biopsy (within the past 3 years) or noninvasive tests (NITs) (performed within the past 6 months) indicating stage F2 or F3 fibrosis -AND- attestation of 1 cardiometabolic risk factor (e.g. obesity, hyperglycemia, hypertriglyceridemia, hyperlipidemia, hypertension) -AND- attestation that member does not have evidence of cirrhosis, hepatic decompensation, or hepatocellular carcinoma -AND- attestation that member's alcohol consumption is not defined as excess alcohol use (greater than 20g/day in females or greater than 30g/day in males)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of continued use in conjunction with diet and exercise -AND- member has experienced improvement or stabilization of fibrosis as demonstrated by NIT -AND- member has not progressed to stage F4 fibrosis -AND- attestation that member does not have evidence of cirrhosis, hepatic decompensation, or hepatocellular carcinoma -AND- attestation that member's alcohol consumption is not defined as excess alcohol use (greater than 20g/day in females or greater than 30g/day in males)
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

Rezlidhia

Products Affected

- **REZLIDHIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Rezurock

Products Affected

- **REZUROCK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of chronic graft-versus-host disease (cGVHD) -AND- therapeutic failure or intolerance to 2 lines of systemic therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Riluzole

Products Affected

- **TIGLUTIK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of amyotrophic lateral sclerosis (ALS) -AND- Inability to swallow tablets.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Rinvoq

Products Affected

- **RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe active rheumatoid arthritis, an inadequate response or intolerance to at least one non-biologic DMARD (e.g., leflunomide, methotrexate) or all non-biologic DMARDs are contraindicated. For moderate to severe refractory atopic dermatitis whose disease is not adequately controlled with other systemic drug products, documentation of one of the following (1 or 2): 1) trial & failure, or intolerance to at least one topical corticosteroid -OR- topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus) 2) The member has severe atopic dermatitis and is incapable of applying topical therapies due to the extent of body surface area involvement or topical therapies are contraindicated due to severely damaged skin. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For Non-radiographic Axial Spondyloarthritis, trial & failure or intolerance to two nonsteroidal anti-inflammatory drugs (NSAIDs) or contraindication to all. For polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) or all non-biologic DMARDs are contraindicated or requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For diagnoses in which tumor necrosis factor (TNF) blockers are also indicated (e.g., Rheumatoid Arthritis, Psoriatic Arthritis), the member has experienced therapeutic failure or intolerance to at least 1 TNF blocker.

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Rinvoq LQ

Products Affected

- **RINVOQ LQ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) or all non-biologic DMARDs are contraindicated or requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage.
Age Restrictions	For PsA, deny if 18 years of age or older
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	The member has experienced therapeutic failure or intolerance to at least 1 tumor necrosis factor (TNF) blocker.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Rivfloza

Products Affected

- **RIVFLOZA SUBCUTANEOUS SOLUTION**
- **RIVFLOZA SUBCUTANEOUS SYRINGE 128 MG/0.8 ML, 160 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-4): 1) diagnosis of primary hyperoxaluria type 1 (PH1) confirmed by one of the following (a or b): a) Genetic testing (i.e., AGXT gene mutation), b) Liver biopsy (i.e., absence or significantly reduced AGT activity), 2) relatively preserved kidney function (e.g., eGFR greater than or equal to 30 mL/min/1.73 m2), 3) at least two elevated urinary oxalate levels greater than 1.5 times the upper reference limit, and 4) The member has not received a liver transplant.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, continued preserved kidney function (e.g., eGFR greater than or equal to 30 mL/min/1.73 m2) -AND- reduction in urinary oxalate levels from baseline -AND- has not received a liver transplant.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Romvimza

Products Affected

- **ROMVIMZA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of symptomatic tenosynovial giant cell tumor -AND- attestation that surgical resection may cause one of the following (1-2): 1) worsening functional limitation, 2) severe morbidity
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Rozlytrek

Products Affected

- **ROZLYTREK ORAL CAPSULE 100 MG, 200 MG**
- **ROZLYTREK ORAL PELLETS IN PACKET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For metastatic non-small cell lung cancer, the tumor status is ROS1-positive. For solid tumors with NTRK gene fusion without a known acquired resistance mutation, the tumors are metastatic or surgical resection is likely to result in severe morbidity -AND- There are no satisfactory alternative treatments or the tumors have progressed following treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Rubraca

Products Affected

- **RUBRACA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ruconest

Products Affected

- **RUCONEST**

PA Criteria	Criteria Details
Exclusion Criteria	Member should not be on two acute therapies simultaneously and acute therapy should not be used as prophylactic therapy
Required Medical Information	For the treatment of attacks of hereditary angioedema (HAE) due to deficiency of C1INH (type I & II) with the following (1-4): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. 4) Documentation of member's weight. For the treatment of attacks of hereditary angioedema (HAE) with normal C1INH (type III) with the following (5-9): 5) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 6) Documentation of family history of HAE, FXII mutation, angiopoietin-1 mutation, plasminogen mutation, kininogen-1 mutation, myoferlin mutation, or heparin sulfate-glucosamine 3-O-sulfotransferas 6 mutation. 7) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 8) Medications known to cause angioedema have been evaluated and discontinued. 9) Documentation of member's weight.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	For 18 years of age or older, therapeutic failure, intolerance or contraindication to icatibant.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Rydapt

Products Affected

- **RYDAPT**

PA Criteria	Criteria Details
Exclusion Criteria	Use as single agent induction therapy for AML
Required Medical Information	Documentation of diagnosis. For a new diagnosis of acute myeloid leukemia, member is using in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy regimens and member is FLT3 mutation positive as detected by an FDA-approved test.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Sabril

Products Affected

- **SABRIL**
- *vigabatrin*
- **VIGADRONE**
- **VIGPODER**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Safety Pen Needles

Products Affected

- **ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2"**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For non-preferred safety pen needle products, trial/failure or contraindication to preferred Embecta safety pen needles with NDC starting with 83017 is required. Embecta safety pen needles with NDC starting with 83017 will receive automatic approval.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Samsca

Products Affected

- **SAMSCA**
- *tolvaptan*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Saphris

Products Affected

- *asenapine maleate*
- **SAPHRIS**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Savella

Products Affected

- **SAVELLA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation to support a diagnosis of fibromyalgia and trial/failure or intolerance to both duloxetine and pregabalin
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Scemblix

Products Affected

- **SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Secuado

Products Affected

- **SECUADO**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Sertraline Capsule

Products Affected

- *sertraline oral capsule*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Seysara

Products Affected

- **SEYSARA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of inflammatory lesions of non-nodular moderate to severe acne -AND- trial and failure or intolerance of at least 1 generic topical acne medication (e.g. adapalene, clindamycin, sulfacetamide, erythromycin) -AND- trial and failure or intolerance of at least 1 generic oral acne antibiotic (e.g. minocycline, azithromycin, trimethoprim)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 weeks
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Siliq

Products Affected

- **SILIQ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For psoriasis, patients must have therapeutic failure or intolerance to 2 preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla, and Skyrizi SC. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Simponi

Products Affected

- **SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML, 50 MG/0.5 ML**
- **SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML, 50 MG/0.5 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. Simponi 50mg: For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. leflunomide) and Simponi will be used in combination with methotrexate. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). Diagnosis of psoriatic arthritis Simponi 100mg: Diagnosis of moderate to severe ulcerative colitis.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year

PA Criteria	Criteria Details
Other Criteria	For ulcerative colitis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Rinvoq and Xeljanz/Xeljanz XR. For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla, Skyrizi SC, Rinvoq, and Xeljanz/Xeljanz XR. For ankylosing spondylitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Cosentyx, Rinvoq, and Xeljanz/Xeljanz XR. For ulcerative colitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, Rinvoq, and Xeljanz/Xeljanz XR. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Sirturo

Products Affected

- **SIRTURO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. Criteria will be applied consistent with the current ATS/CDC/ERS/IDSA Clinical Practice Guideline for the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of disease improvement -AND- member requires additional antimicrobial therapy.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Skyclarys

Products Affected

- **SKYCLARYS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Friedreichs ataxia confirmed by genetic testing (i.e., FXN gene mutation).
Age Restrictions	Deny if less than 16 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Skyrizi

Products Affected

- **SKYRIZI SUBCUTANEOUS PEN INJECTOR**
- **SKYRIZI SUBCUTANEOUS SYRINGE**
- **SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For Crohns disease, attestation of receiving or currently undergoing IV administration of Skyrizi within 3 months of initiating therapy with Skyrizi SC. For moderate to severe ulcerative colitis, attestation of receiving or currently undergoing IV administration of Skyrizi within 3 months of initiating therapy with Skyrizi SC.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Skytrofa

Products Affected

- **SKYTROFA SUBCUTANEOUS CARTRIDGE 11 MG, 13.3 MG, 3 MG, 3.6 MG, 4.3 MG, 5.2 MG, 6.3 MG, 7.6 MG, 9.1 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Sogroya

Products Affected

- **SOGROYA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Sohonos

Products Affected

- **SOHONOS ORAL CAPSULE 1 MG, 1.5 MG, 10 MG, 2.5 MG, 5 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	Deny if female and less than 8 years of age -OR- if male and less than 10 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of reduction in volume of new heterotopic ossification from baseline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Solaraze

Products Affected

- *diclofenac sodium topical gel 3 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- trial and failure, intolerance, or contraindication to one of the following (1 or 2): 1) topical fluorouracil solution or fluorouracil 5% cream 2) topical imiquimod 5% cream
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For reauthorization, attestation of 30 day washout period since optimal therapeutic effect may not be evident until 30 days following cessation of therapy AND attestation of previous response to diclofenac sodium 3% topical gel therapy
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Somavert

Products Affected

- **SOMAVERT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For acromegaly, high pretreatment insulin-like growth factor-1 (IGF-1) based on laboratory reference range -AND- inadequate or partial response to surgery or radiotherapy or not a candidate for surgery or radiotherapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization of acromegaly, decreased or normalized IGF-1 from baseline
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Sotyktu

Products Affected

- **SOTYKTU**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	Patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab product, Cosentyx, Otezla, and Skyrizi. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Sovaldi

Products Affected

- **SOVALDI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guidance -AND- the member has a contraindication to or is otherwise not a candidate for one of the following regimens recommended by the AASLD/IDSA guidelines containing the following agents: sofosbuvir/velpatasvir (i.e. Epclusa authorized generic), Mavyret.
Age Restrictions	Deny if less than 3 years of age
Prescriber Restrictions	
Coverage Duration	Criteria/duration applied consistent with current AASLD-IDSA guidance
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Spevigo SC

Products Affected

- **SPEVIGO SUBCUTANEOUS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of generalized pustular psoriasis (GPP) -AND- Previous GPP flares have been experienced -AND- A flare is not currently being experienced -AND- Prevetion for future GPP flares is required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Sprycel

Products Affected

- *dasatinib*
- **SPRYCEL**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Statin Liquid

Products Affected

- **ATORVALIQ**
- **FLOLIPID**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- Inability to swallow tablets.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Steroidogenesis Inhibitors

Products Affected

- **ISTURISA ORAL TABLET 1 MG, 5 MG**
- **RECORLEV**
- **SIGNIFOR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- patient is not a candidate for pituitary surgery or surgery has not been curative
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of decrease in urinary free cortisol levels from baseline
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Stivarga

Products Affected

- **STIVARGA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic colorectal cancer and trial of a fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy, AND an anti-VEGF therapy AND if RAS wild-type, an anti-EGFR therapy -OR- documentation of locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) after treatment with both imatinib and sunitinib -OR- documentation of hepatocellular cancer AND previous treatment with sorafenib
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Sucraid

Products Affected

- **SUCRAID**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of congenital-sucrase-isomaltase deficiency (CSID) supported by one of the following (1, 2, or 3): 1) small bowel biopsy with disaccharidase assay showing absent or reduced sucrase activity, reduced or normal isomaltase activity, reduced maltase activity, and reduced or normal lactase activity. 2) genetic testing indicates a mutation in the sucrase-isomaltase gene. 3) sucrase deficiency evidenced by sucrose breath hydrogen test or carbon-sucrose breath test.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Sunosi

Products Affected

- **SUNOSI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B) A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL, or B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range, 2) Multiple sleep latency test (MSLT) documenting MSL less than or equal to 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP), or 3) MSLT documenting MSL less than or equal to 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. Diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by objective polysomnography as established in accordance with ICSD or DSM V criteria acceptable for all indications.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For narcolepsy and OSAHS, documentation of trial and failure, contraindication or intolerance to modafinil and armodafinil. For reauthorization, provider attestation of improvement in daytime sleepiness is required.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Sutent

Products Affected

- *sunitinib malate*
- **SUTENT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For gastrointestinal stromal tumor (GIST), the member has experienced therapeutic failure, intolerance, or contraindication to imatinib. For a high risk of recurrent renal cell carcinoma, member has had a nephrectomy and sunitinib is to be used as adjuvant treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Sutent, documentation of trial and failure of generic sunitinib is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Symdeko

Products Affected

- **SYMDEKO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystic fibrosis (CF) in patients who have either the homozygous F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to tezacaftor/ivacaftor based on clinical and/or in vitro assay (e.g. E56K, R117C, A455E)
Age Restrictions	Deny if less than 6 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Sympazan

Products Affected

- **SYMPAZAN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance of a previous antiepileptic therapy -AND- unable to tolerate generic clobazam
Age Restrictions	Deny if less than 2 years old
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Symproic

Products Affected

- **SYMPROIC**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of opioid induced constipation (OIC) due to any of the following (1-2): 1) chronic non-cancer pain, or 2) chronic pain related to prior cancer or its treatments who do not require frequent (e.g., weekly) opioid dosage escalation -AND- documentation of opioid medication use -AND- trial and failure, contraindication, or intolerance to at least 2 of the following (3-5): 3) Laxatives, 4) lubiprostone, 5) Movantik
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Synarel

Products Affected

- **SYNAREL**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tabrecta

Products Affected

- **TABRECTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic non-small cell lung cancer with MET exon 14 skipping mutation as detected by an FDA approved test.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tafinlar

Products Affected

- **TAFINLAR ORAL CAPSULE**
- **TAFINLAR ORAL TABLET FOR SUSPENSION**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For dabrafenib monotherapy, documentation of unresectable or metastatic melanoma -AND- documentation of a BRAF V600E mutation. For use in combination with trametinib, documentation of unresectable or metastatic melanoma or melanoma with lymph node(s) involvement following complete resection and member is using trametinib and dabrafenib as adjuvant therapy -AND- member has a BRAF V600E or V600K mutation. For use in combination with trametinib, documentation of metastatic non-small cell lung cancer, locally advanced or metastatic anaplastic thyroid cancer, or low-grade glioma -AND- member has a BRAF V600E mutation, as detected by an FDA-approved test when FDA indicated. For use in combination with trametinib, documentation of unresectable or metastatic solid tumors -AND- all of the following (1-3): 1) BRAF V600E mutation 2) disease has progressed following prior treatment 3) member has no satisfactory alternative treatment options.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Tafinlar tablets for oral suspension, attestation of inability to swallow Tafinlar (dabrafenib) capsules is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

Tagrisso

Products Affected

- **TAGRISSO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of non-small cell lung cancer (NSCLC) and one of the following (1-5): 1) Adjuvant therapy after tumor resection -AND- disease harbors EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test 2) Locally advanced disease -AND- using as first-line therapy -AND- disease harbors EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test -AND- used in combination with pemetrexed and platinum-based chemotherapy, 3) Metastatic disease -AND- using as first-line therapy -AND- disease harbors EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test -AND- used with or without combination therapy of pemetrexed and platinum-based chemotherapy, 4) Metastatic disease -AND- disease harbors EGFR T790M mutations, as detected by an FDA-approved test -AND- has progressed on or after EGFR TKI therapy, 5) Locally advanced, unresectable (stage III) disease -AND- disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy -AND- disease harbors EGFR exon 19 deletions or EGFR exon 21 L858R mutations, as detected by an FDA-approved test.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Takhzyro

Products Affected

- **TAKHZYRO SUBCUTANEOUS SOLUTION (150 MG/ML)**
- **TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML**

PA Criteria	Criteria Details
Exclusion Criteria	Member should not be on two prophylactic therapies simultaneously.
Required Medical Information	For the prophylactic treatment of attacks of hereditary angioedema (HAE) due to deficiency of C1INH (type I & II) with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the prophylactic treatment of attacks of hereditary angioedema (HAE) with normal C1INH (type III) with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE, FXII mutation, angiopoietin-1 mutation, plasminogen mutation, kininogen-1 mutation, myoferlin mutation, or heparin sulfate-glucosamine 3-O-sulfotransferas 6 mutation. 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Talicia

Products Affected

- **TALICIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of H. Pylori infection confirmed by invasive techniques (e.g. endoscopic) or non-invasive techniques (e.g. urea breath test, stool antigen) -AND- One of the following (1-2): 1) previous treatment using all the components of a first line therapy (e.g. Pylera and a proton pump inhibitor) failed to eradicate the H. Pylori infection, 2) allergy, intolerance, or contraindication to any component of Pylera.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	14 days
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Taltz

Products Affected

- **TALTZ AUTOINJECTOR**
- **TALTZ SYRINGE SUBCUTANEOUS SYRINGE 20 MG/0.25 ML, 40 MG/0.5 ML, 80 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For non-radiographic axial spondyloarthritis, inadequate response or intolerance to 2 NSAIDs.
Age Restrictions	Deny if less than 18 years of age for Psoriatic Arthritis, Ankylosing Spondylitis and non-radiographic axial spondyloarthritis or less than 6 years of age for Plaque Psoriasis
Prescriber Restrictions	
Coverage Duration	Plan Year

PA Criteria	Criteria Details
Other Criteria	For induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen. For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla, Skyrizi SC, Rinvoq, and Xeljanz/Xeljanz XR. For plaque psoriasis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla, and Skyrizi SC. For ankylosing spondylitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Cosentyx, Rinvoq, and Xeljanz/Xeljanz XR. For non-radiographic axial spondyloarthritis patients must have therapeutic failure or intolerance to 2 of the following preferred products: Cimzia, Rinvoq, Cosentyx. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Talzenna

Products Affected

- **TALZENNA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of deleterious or suspected deleterious gBRCAm, HER2-negative locally advanced or metastatic breast cancer as a single agent -OR- Documentation of HRR gene-mutated metastatic castration-resistant prostate cancer in combination with enzalutamide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Targretin

Products Affected

- *bexarotene oral*
- **TARGRETIN ORAL**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Targretin Gel

Products Affected

- *bexarotene topical*
- **TARGRETIN TOPICAL**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tarpeyo

Products Affected

- **TARPEYO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of primary immunoglobulin A nephropathy (IgAN) confirmed by biopsy -AND- At risk of disease progression as evidenced by proteinuria greater than or equal to 0.5 g/day -AND- One of the following (1 or 2): 1) Used in combination with an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB) or Filspari (sparsentan), or 2) Intolerance to at least one ACE-I and at least one ARB or contraindication all.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	10 months
Other Criteria	For reauthorizations, documentation of primary immunoglobulin A nephropathy (IgAN) -AND- member requires re-continuation of therapy with Tarpeyo -AND- One of the following (1 or 2): 1) Used in combination with an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB) or Filspari (sparsentan), or 2) Intolerance to at least one ACE-I and at least one ARB or contraindication all.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tascenso ODT

Products Affected

- **TASCENSO ODT**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying agents such as teriflunomide, interferons, Copaxone, Tysabri
Required Medical Information	Documentation of a relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Inability to swallow capsules
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tasigna

Products Affected

- *nilotinib hcl*
- **TASIGNA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For adult patients with Ph+ chronic myeloid leukemia (CML), member's CML is in the chronic or accelerated phase and the member is no longer responding to or is intolerant to imatinib -OR- member is newly diagnosed in the chronic phase. For pediatric patients, one of the following (1-2): 1) member has chronic phase or accelerated phase Ph+ CML and is is resistant or intolerant to prior tyrosine kinase inhibitor therapy 2) member is newly diagnosed with Ph+ CML in the chronic phase.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Tasigna, documentation of intolerance to generic nilotinib is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tasimelteon

Products Affected

- *tasimelteon*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tavalisse

Products Affected

- **TAVALISSE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For diagnosis of ITP, the following criteria apply (1 and 2): 1) insufficient response to a corticosteroid, immunoglobulin, or splenectomy. 2) One of the following (A or B): A) Platelet count less than or equal to 50 x 10*9/L and has significant mucous member bleeding or at least one risk factor for bleeding (e.g. hypertension, peptic ulcer disease). B) Platelet count of less than or equal to 30 x 10*9/L.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tavneos

Products Affected

- **TAVNEOS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of severe active granulomatosis with polyangiitis or severe active microscopic polyangiitis -AND- Prescriber attests to positive test for anti-PR3 or positive test for anti-MPO -AND- Member will continue to receive concomitant standard of care treatment with immunosuppressives (e.g. mycophenolate mofetil, azathioprine).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of therapeutic response defined by disease stability or disease improvement -AND- Member will continue to receive concomitant standard of care treatment with immunosuppressives (e.g. mycophenolate mofetil, azathioprine).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tazarotene

Products Affected

- **ARAZLO**
- **FABIOR**
- *tazarotene topical foam*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of acne vulgaris -AND- trial and failure or intolerance of at least two topical acne medications (e.g. adapalene, clindamycin, sulfacetamide, erythromycin) one of which must be generic topical tretinoin
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tazorac

Products Affected

- *tazarotene topical cream*
- *tazarotene topical gel*
- **TAZORAC TOPICAL CREAM**
- **TAZORAC TOPICAL GEL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of 1 of the following (A or B). A) Documentation of plaque psoriasis -AND- trial and failure or intolerance to at least one topical corticosteroid (e.g. fluocinonide, mometasone, triamcinolone, betamethasone). B) Documentation of acne vulgaris -AND- trial and failure or intolerance of at least two topical acne medications (e.g. adapalene, clindamycin, sulfacetamide, erythromycin) one of which must be generic topical tretinoin
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Tazorac cream, therapeutic failure or intolerance to generic tazarotene cream is required. For brand Tazorac gel, therapeutic failure or intolerance to generic tazarotene gel is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tazverik

Products Affected

- **TAZVERIK**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tecfidera

Products Affected

- *dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg*
- **TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 120 MG, 120 MG (14)- 240 MG (46), 240 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tepmetko

Products Affected

- **TEPMETKO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic non-small cell lung cancer with a MET exon 14 skipping alteration
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Testosterone (androgens)

Products Affected

- **AVEED**
- **DEPO-TESTOSTERONE**
- **JATENZO ORAL CAPSULE 158 MG, 198 MG, 237 MG**
- **TESTIM**
- *testosterone cypionate*
- *testosterone enanthate*
- *testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %), 20.25 mg/1.25 gram (1.62 %)*
- *testosterone transdermal gel in packet*
- *testosterone transdermal solution in metered pump w/app*
- **TLANDO**
- **UNDECATREX**
- **VOGELXO TRANSDERMAL GEL**
- **VOGELXO TRANSDERMAL GEL IN METERED-DOSE PUMP**
- **XYOSTED**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of primary or secondary hypogonadism in males with testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, radiation or toxic damage -OR- documentation of primary or secondary hypogonadism in males with multiple symptoms of hypogonadism including at least one of the following specific symptoms: height loss due to vertebral fractures, low trauma fractures, low bone density, incomplete or delayed sexual development, breast discomfort, loss of axillar and/or pubic body hair, hot flushes -OR- documentation of HIV infection in men with weight loss -OR- documentation of chronic steroid treatment in men. In all previously noted indications, members must also have documented low total testosterone level below the normal range for the laboratory -OR- a total testosterone level near the lower limit of the normal range with a low free testosterone level which is less than normal based upon the laboratory reference range -OR- the member is not producing any testosterone. Additional approvable indications include female patients with metastatic breast cancer (testosterone enanthate only), primary or secondary hypogonadism in males with testicular failure due to double orchidectomy, and delayed puberty in males (testosterone enanthate only).
Age Restrictions	
Prescriber Restrictions	

PA Criteria	Criteria Details
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	HIV Wasting
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tezruly

Products Affected

- **TEZRULY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis benign prostatic hyperplasia or hypertension -AND- Therapeutic failure to generic doxazosin, intolerance to generic doxazosin, or intolerance to generic terazosin -AND- Inability to swallow tablets and capsules
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Thalomid

Products Affected

- **THALOMID ORAL CAPSULE 100 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Use as monotherapy for ENL treatment in the presence of moderate to severe neuritis
Required Medical Information	Documentation of multiple myeloma in combination with dexamethasone -OR- documentation for use in the treatment of cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) -OR- documentation of therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Thiola

Products Affected

- **THIOLA**
- **THIOLA EC**
- *tiopronin*
- **VENXXIVA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- Confirmation of cystinuria by at least one 24-hour urine collection with measurement of urinary cysteine levels greater than 400 mg/day -AND- Attestation of failure of urine alkalization with potassium citrate (to achieve pH of 7.0).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For brand Thiola, brand Thiola EC, or Venxxiva, intolerance to generic tiopronin. For reauthorization, attestation of urine cystine concentration decreased from baseline -OR- decrease in production of cystine stones is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Thrombopoiesis Stimulating Agents

Products Affected

- **ALVAIZ ORAL TABLET 18 MG, 36 MG, 54 MG, 9 MG**
- *eltrombopag olamine oral powder in packet 12.5 mg, 25 mg*
- *eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg*
- **PROMACTA ORAL POWDER IN PACKET 12.5 MG, 25 MG**
- **PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of persistent or chronic immune idiopathic thrombocytopenia purpura and trial and failure of corticosteroid or immunoglobulin therapy or splenectomy -OR- documentation of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy -OR- severe aplastic anemia who have had an insufficient response to immunosuppressive therapy -OR- For eltrombopag olamine only, documentation of first line treatment for severe aplastic anemia and used in combination with at least two immunosuppressive therapies.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Platelet count to be provided. For Alvaiz (eltrombopag choline), therapeutic failure, contraindication, or intolerance to Promacta (eltrombopag olamine) is required. For brand Promacta, intolerance to generic eltrombopag olamine is required.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tibsovo

Products Affected

- **TIBSOVO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- disease is IDH1 mutation positive as detected by an FDA-approved test. For newly-diagnosed acute myeloid leukemia, member is using as monotherapy or in combination with azacitidine -AND- member meets one of the following (1-5): 1) age is greater than or equal to 75 years of age 2) severe cardiac or pulmonary comorbidity 3) reduced renal function 4) hepatic impairment 5) or prescriber attestation that member is not a candidate for intensive induction therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tigan

Products Affected

- *trimethobenzamide oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tocilizumab

Products Affected

- **ACTEMRA ACTPEN**
- **ACTEMRA SUBCUTANEOUS**
- **TYENNE AUTOINJECTOR**
- **TYENNE SUBCUTANEOUS**

PA Criteria	Criteria Details
Exclusion Criteria	Part A covered for Covid-19 in hospitalized patients
Required Medical Information	Documentation of diagnosis. For rheumatoid arthritis, patients must have an inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide). For giant cell arteritis, patients must have therapeutic failure or intolerance to one systemic corticosteroid (e.g., prednisone). For polyarticular juvenile idiopathic arthritis, patients must have an inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For systemic sclerosis-associated interstitial lung disease (SSc-ILD), patients must have therapeutic failure or intolerance to one immunosuppressant (e.g., mycophenolate mofetil, corticosteroids, cyclophosphamide). Documentation of systemic juvenile idiopathic arthritis.
Age Restrictions	Deny if less than 18 years of age for systemic sclerosis-associated interstitial lung disease (SSc-ILD), Rheumatoid Arthritis, and Giant Cell Arteritis or less than 2 years of age for Polyarticular Juvenile Idiopathic Arthritis and Systemic Juvenile Idiopathic Arthritis
Prescriber Restrictions	
Coverage Duration	Plan Year

PA Criteria	Criteria Details
Other Criteria	For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Rinvoq and Xeljanz/Xeljanz XR. For polyarticular juvenile idiopathic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Rinvoq/Rinvoq LQ, and Xeljanz/Xeljanz solution. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tolsura

Products Affected

- **TOLSURA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- Unable to tolerate generic itraconazole capsules
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation the member is still unable to tolerate generic itraconazole capsules
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Topical Lidocaine

Products Affected

- *lidocaine hcl mucous membrane solution 4 % (40 mg/ml)*
- *lidocaine topical ointment*
- *lidocaine-prilocaine topical cream*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Torpenz

Products Affected

- **TORPENZ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of advanced, hormone receptor-positive, HER2-negative breast cancer -AND- member is a postmenopausal woman -AND- member is using Torpenz in combination with exemestane -AND- member has experienced therapeutic failure or intolerance to prior treatment with letrozole or anastrozole. Documentation of renal angiomyolipoma and tuberous sclerosis complex (TSC) -AND- the member does not require immediate surgery. Documentation of TSC with subependymal giant cell astrocytoma -AND- the member is not a candidate for curative surgical resection.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Torpenz, documentation of failure on generic everolimus tablets is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tremfya

Products Affected

- **TREMFYA PEN INDUCTION PK-CROHN**
- **TREMFYA PEN SUBCUTANEOUS PEN INJECTOR 200 MG/2 ML**
- **TREMFYA SUBCUTANEOUS AUTO-INJECTOR**
- **TREMFYA SUBCUTANEOUS SYRINGE 100 MG/ML, 200 MG/2 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For moderate to severe ulcerative colitis, attestation of receiving or currently undergoing 3 doses of IV Tremfya within 3 to 4 months of initiating therapy with Tremfya SC. For moderate to severe Crohn's disease, attestation of receiving or currently undergoing 3 doses of IV Tremfya within 3 to 4 months of initiating maintenance therapy with Tremfya SC or Tremfya SC is used for induction dosing.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year

PA Criteria	Criteria Details
Other Criteria	For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For UC and CD, documentation that the maintenance dose is the lowest effective dose to maintain therapeutic response -AND- requests for the maintenance dose of 200mg every 4 weeks require attestation that the maintenance dose of 100mg every 8 weeks is unable to maintain therapeutic response. For psoriasis, patients must have therapeutic failure or intolerance to 2 preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla, and Skyrizi SC. For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla, Skyrizi SC, Rinvoq, and Xeljanz/Xeljanz XR. For ulcerative colitis (UC), patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, Rinvoq, and Xeljanz/Xeljanz XR. For moderate to severe active Crohn's disease (CD), patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, and Rinvoq. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tretinoin

Products Affected

- *adapalene topical cream*
- *adapalene topical gel 0.3 %*
- *adapalene topical swab*
- *adapalene-benzoyl peroxide*
- **AKLIEF**
- **ALTRENO**
- **ATRALIN**
- **CABTREO**
- *clindamycin-tretinoin*
- **DIFFERIN TOPICAL CREAM**
- **DIFFERIN TOPICAL GEL WITH PUMP**
- **EPIDUO FORTE**
- **EPIDUO TOPICAL GEL WITH PUMP**
- **RETIN-A**
- **RETIN-A MICRO**
- **RETIN-A MICRO PUMP TOPICAL GEL WITH PUMP 0.06 %, 0.08 %**
- *tretinoin*
- *tretinoin microspheres topical gel*
- *tretinoin microspheres topical gel with pump 0.08 %*
- **TWYNEO**
- **WINLEVI**
- **ZIANA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Trientine

Products Affected

- *trientine oral capsule 500 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Trikafta

Products Affected

- **TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL**
- **TRIKAFTA ORAL TABLETS, SEQUENTIAL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystic fibrosis (CF) in patients who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to elexacaftor/tezacaftor/ivacaftor based on in vitro assay (e.g. E56K, R117C, A455E)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Trintellix

Products Affected

- **TRINTELLIX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of major depressive disorder -AND- Therapeutic failure, intolerance or contraindication to one generic antidepressant (e.g. SSRI, TCA, MAOI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Trulance

Products Affected

- **TRULANCE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For chronic idiopathic constipation, therapeutic failure, contraindication or intolerance to Linzess and lubiprostone. For irritable bowel syndrome with constipation, therapeutic failure, contraindication or intolerance to Linzess -AND- if member is female, therapeutic failure, contraindication or intolerance to lubiprostone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Truqap

Products Affected

- **TRUQAP**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tryngolza

Products Affected

- **TRYNGOLZA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tryvio

Products Affected

- **TRYVIO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of Resistant Hypertension -AND- Therapeutic failure, intolerance, or contraindication to maximally tolerated doses of all of the following (1-3): 1) thiazide diuretic, 2) ACE-I or ARB, 3) mineralocorticoid receptor antagonist.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of a reduction in blood pressure from baseline is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tukysa

Products Affected

- **TUKYSA ORAL TABLET 150 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Turalio

Products Affected

- **TURALIO ORAL CAPSULE 125 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of symptomatic tenosynovial giant cell tumor associated with severe morbidity and functional limitations -AND- patient is not amenable to improvement with surgery or not a candidate for surgery
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tykerb

Products Affected

- *lapatinib*
- **TYKERB**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For advanced HER2-positive, or metastatic HER2-positive breast cancer, the member has received prior therapy with an anthracycline, a taxane, and trastuzumab -AND- will be using in combination with capecitabine. For HR+, metastatic breast cancer, the member is post-menopausal -AND- the member's cancer over expresses the HER2 receptor -AND- the member will be using lapatinib in combination with letrozole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Tykerb, trial and failure of generic lapatinib is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tymlos

Products Affected

- **TYMLOS**

PA Criteria	Criteria Details
Exclusion Criteria	Treatment duration greater than 24 months.
Required Medical Information	Documentation of diagnosis -AND- at high risk for fracture, meeting one of the following (1. thru 3.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	Documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Additional documentation of trial/failure, intolerance or contraindication to preferred parathyroid hormone analog teriparatide. Coverage of human parathyroid hormone related peptide analogs beyond 24 months will not be approved. A cumulative lifetime approval of Tymlos will be limited to a coverage duration of 24 months.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ubrelvy

Products Affected

- **UBRELVY ORAL TABLET 100 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Uloric

Products Affected

- *febuxostat*
- **ULORIC**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of chronic management of hyperuricemia due to gout -And- trial/failure, intolerance or contraindication to allopurinol.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Uptravi

Products Affected

- **UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG** **PACK**
- **UPTRAVI ORAL TABLETS,DOSE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of pulmonary arterial hypertension, substantiated by results from right heart catheterization (RHC), defined as a mean pulmonary arterial pressure (mPAP) of greater than 20 mmHg at rest, with a pulmonary capillary wedge pressure (PWP) of less than or equal to 15 mmHg, and a PVR greater than or equal to 3 Wood units -AND- WHO Group.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Trial and failure of Opsumit is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ustekinumab

Products Affected

- **OTULFI SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML**
- **PYZCHIVA SUBCUTANEOUS SOLUTION**
- **PYZCHIVA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML**
- **SELARSDI SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML**
- **STELARA SUBCUTANEOUS SOLUTION**
- **STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML**
- *ustekinumab subcutaneous solution*
- *ustekinumab subcutaneous syringe 45 mg/0.5 ml, 90 mg/ml*
- *ustekinumab-aekn subcutaneous syringe 45 mg/0.5 ml, 90 mg/ml*
- *ustekinumab-ttwe subcutaneous syringe 45 mg/0.5 ml, 90 mg/ml*
- **WEZLANA SUBCUTANEOUS SOLUTION**
- **WEZLANA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- documentation of member weight and prescribed dose. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For Crohn's Disease or Ulcerative Colitis, attestation of receiving or currently undergoing a single induction dose of IV ustekinumab within 2 months of initiating therapy with ustekinumab SC.
Age Restrictions	Deny if less than 18 years of age for Crohn's Disease and Ulcerative Colitis. Deny if less than 6 years of age for Plaque Psoriasis and Psoriatic Arthritis.
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	Intolerance to both preferred ustekinumab products is required: Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257. Must follow recommended dosing guidelines based upon weight. For PsA and PsO induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen.

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Valchlor

Products Affected

- **VALCHLOR**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Valtoco

Products Affected

- **VALTOCO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizure clusters or acute repetitive seizures -AND- the member is currently receiving antiepileptic maintenance therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Vanflyta

Products Affected

- **VANFLYTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- disease is FLT3-ITD-positive as detected by an FDA-approved test -AND- one of the following (1-3): 1) member is receiving induction therapy and is using Vanflyta in combination with standard cytarabine and anthracycline induction therapy 2) member is receiving consolidation therapy and is using Vanflyta in combination with standard cytarabine consolidation therapy 3) member is receiving maintenance therapy and is using Vanflyta as monotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Vanrafia

Products Affected

- **VANRAFIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of primary immunoglobulin A nephropathy (IgAN) confirmed by biopsy -AND- At risk of disease progression as evidenced by proteinuria greater than or equal to 0.5 g/day -AND- One of the following (1 or 2): 1) Used in combination with an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB), or 2) Contraindication or intolerance to a maximally tolerated dose of an ACE-I or ARB.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, reduction in proteinuria from baseline is required -AND- One of the following (1 or 2): 1) Used in combination with an ACE-I or ARB, or 2) Contraindication or intolerance to an ACE-I or ARB.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Velsipity

Products Affected

- **VELSIPITY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	Patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, Rinvoq, and Xeljanz/Xeljanz XR. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Veltassa

Products Affected

- **VELTASSA ORAL POWDER IN PACKET 1 GRAM, 16.8 GRAM, 25.2 GRAM, 8.4 GRAM**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of hyperkalemia as defined by serum potassium level between 5.1 and 6.4 mmol/L on at least two (2) screenings -AND- Modification of medications to reduce serum potassium levels were not successful, when applicable.
Age Restrictions	Deny if less than 12 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of reduction in serum potassium levels following Veltassa administration and continued treatment for hyperkalemia is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Venbysi XR

Products Affected

- *venlafaxine besylate*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Venclexta

Products Affected

- **VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG**
- **VENCLEXTA STARTING PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For newly-diagnosed AML, member is using in combination with azacitidine, decitabine, or cytarabine -AND- age greater than or equal to 75 years or presence of at least one comorbidity that precludes use of intensive induction chemotherapy (i.e. severe cardiac or pulmonary comorbidity, reduced renal function, hepatic impairment, or physician attestation) is required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Veozah

Products Affected

- **VEOZAH**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documenation of moderate to severe vasomotor symptoms due to menopause -AND- one of the following (1 or 2): 1) therapeutic failure, contraindication, or intolerance to a generic hormone therapy product, or 2) attestation that hormone therapy is not clinically appropriate
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Verkazia

Products Affected

- **VERKAZIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- therapeutic failure or intolerance to 2 of the following medication classes or all are contraindicated: 1) generic ophthalmic antihistamines (e.g., olopatadine), 2) generic ophthalmic mast cell stabilizers (e.g., cromolyn sodium), 3) Generic ophthalmic corticosteroids (e.g., dexamethasone, prednisolone, fluorometholone).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Verquvo

Products Affected

- **VERQUVO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of heart failure (NYHA Class II to IV) -AND- Left ventricular ejection fraction less than 45% -AND- Hospitalization for heart failure or received outpatient IV diuretics for heart failure -AND- Used in combination with a angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker or Entresto -AND- Used in combination with bisoprolol, carvedilol IR/ER or metoprolol succinate ER.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Verzenio

Products Affected

- **VERZENIO**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Viberzi

Products Affected

- **VIBERZI**

PA Criteria	Criteria Details
Exclusion Criteria	Severe (Child-Pugh C) hepatic impairment
Required Medical Information	Documentation of diarrhea predominant, irritable bowel syndrome (IBS-D) -AND- trial/failure or intolerance to one of the following medications for IBS-D or documentation of contraindication to all: antidiarrheal (e.g., loperamide), antispasmodic (e.g., dicyclomine, hyoscyamine), tricyclic antidepressant (e.g., amitriptyline, nortriptyline).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vigafyde

Products Affected

- **VIGAFYDE**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Viibryd

Products Affected

- **VIIBRYD ORAL TABLET**
- *vilazodone*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vijoice

Products Affected

- **VIJOICE ORAL GRANULES IN MG PACKET**
- **VIJOICE ORAL TABLET 125 MG, 250 MG/DAY (200 MG X1-50 MG X1), 50**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of severe manifestations of PIK3CA Related Overgrowth Spectrum (PROS)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Vimovo2

Products Affected

- *naproxen-esomeprazole*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vitrakvi

Products Affected

- **VITRAKVI ORAL CAPSULE 100 MG, 25 MG**
- **VITRAKVI ORAL SOLUTION**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation -AND- Tumors are metastatic or surgical resection is likely to result in severe morbidity -AND- There are no satisfactory alternative treatments or tumors have progressed following treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Vivjoa

Products Affected

- **VIVJOA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of recurrent vulvovaginal candidiasis defined as at least 3 episodes of vulvovaginal candidiasis in less than one year -AND Documentation the member is NOT of reproductive potential defined as postmenopausal or another reason for permanent infertility (e.g., tubal ligation, hysterectomy, salpingo-oophorectomy) -AND- the member has experienced therapeutic failure, contraindication, or intolerance to a six-month maintenance course of oral fluconazole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	14 weeks
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vivlodex

Products Affected

- *meloxicam submicronized*

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vizimpro

Products Affected

- **VIZIMPRO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic non-small cell lung cancer -AND- one of the following, as detected by an FDA-approved test (1 or 2): 1) Epidermal growth factor (EGFR) exon 19 deletions, 2) Epidermal growth factor receptor (EGFR) exon 21 L858R substitution mutations.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Vonjo

Products Affected

- **VONJO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of intermediate or high-risk myelofibrosis -AND- attestation of a platelet count of less than 50 x 10*9/L.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Voquezna

Products Affected

- **VOQUEZNA ORAL TABLET 10 MG, 20 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For healing of erosive esophagitis (EE) and relief of heartburn associated with EE, therapeutic failure, contraindication, or intolerance to omeprazole and pantoprazole. For relief of heartburn associated with non-erosive gasteroesophageal reflux disease (GERD), therapeutic failure, contraindication, or intolerance to omeprazole and pantoprazole. For treatment of H. pylori infection, used in combination with amoxicillin -OR- amoxicillin and clarithromycin.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	H.pylori tx: 14days. EE Initial-8wks, Reauth-6mo. Non-erosive GERD Initial-4wks, Reauth-20wks
Other Criteria	For Erosive Esophagitis (EE) reauthorization, all of the following are required (1-3): 1) using for maintenance of EE healing and relief of heartburn associated with EE, 2) positive clinical response to an initial treatment course, 3) EE continues to require treatment for maintenance. For Non-erosive GERD reauthorization, all of the following are required (4-5): 4) non-erosive GERD requires additional therapy, 5) experienced symptom improvement or control during the initial 4-week treatment course.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Voquezna Combo Pak

Products Affected

- **VOQUEZNA DUAL PAK**
- **VOQUEZNA TRIPLE PAK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	14 days
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Voranigo

Products Affected

- **VORANIGO ORAL TABLET 10 MG, 40 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following (1-3): 1) grade 2 astrocytoma or grade 2 oligodendroglioma, 2) disease harbors a susceptible isocitrate dehydrogenase (IDH)-1 or IDH-2 mutation, as detected by an FDA-approved test, 3) will be used following surgery including biopsy, sub-total resection, or gross total resection.
Age Restrictions	Deny if less than 12 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Voriconazole

Products Affected

- **VFEND IV**
- *voriconazole intravenous*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- attestation that the beneficiary cannot take oral voriconazole
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For reauthorization, attestation of continued indicators of active disease (e.g. histopathology, positive cultures) is required
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Vosevi

Products Affected

- **VOSEVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guidance -AND- the member has a contraindication to or is otherwise not a candidate for one of the following regimens recommended by the AASLD/IDSA guidelines containing the following agents: sofosbuvir/velpatasvir (i.e. Epclusa authorized generic), Mavyret.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Criteria/duration applied consistent with current AASLD-IDSA guidance
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Votrient

Products Affected

- *pazopanib*
- **VOTRIENT**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Voxzogo

Products Affected

- **VOXZOGO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of achondroplasia as evidenced by an FGFR3 gene mutation detected by genetic testing -AND- all of the following (1-2): 1) baseline annualized growth velocity (AGV), 2) attestation that the member's epiphyses have not closed.
Age Restrictions	Deny if greater than 17 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of increase in annualized growth velocity (AGV) from baseline and attestation that the member's epiphyses have not closed are required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Voydeya

Products Affected

- **VOYDEYA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Vraylar

Products Affected

- **VRAYLAR ORAL CAPSULE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For a diagnosis of schizophrenia and bipolar I disorder, therapeutic failure, intolerance, or contraindication to one other generic atypical antipsychotic (e.g. quetiapine). For major depressive disorder, documentation of adjunctive therapy and therapeutic failure, contraindication or intolerance to one other generic antidepressant in addition to the antidepressant currently being used for the treatment of MDD (e.g. SSRI, SNRI, NDRIs, TCA, MAOI).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vtama

Products Affected

- **VTAMA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-3). 1) Documentation of plaque psoriasis -AND- 2) trial and failure or intolerance to at least one generic, formulary medium, high, or ultrahigh potency topical corticosteroid (e.g. fluocinonide, triamcinolone, betamethasone) -OR- psoriasis on facial or intertriginous areas -AND- 3) trial and failure, contraindication, or intolerance to one generic, formulary vitamin D analog (e.g., calcipotriene, calcitriol) -OR- the member has psoriasis on the face -OR- Documentation of all of the following (4-6). 4) Atopic dermatitis, 5) trial and failure, intolerance, or contraindication to at least one generic formulary topical corticosteroid or documentation of facial or anogenital involvement, 6) trial and failure, intolerance, or contraindication to topical generic tacrolimus or topical generic pimecrolimus
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vuity

Products Affected

- **VUITY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	Deny if less than 18 years of age.
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Vumerity

Products Affected

- **VUMERITY**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Therapeutic failure or intolerance to generic dimethyl fumarate
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vykat XR

Products Affected

- **VYKAT XR ORAL TABLET EXTENDED RELEASE 24 HR 150 MG, 25 MG, 75 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of Prader-Willi Syndrome (PWS) confirmed by documentation of genetic analysis with identification of abnormal DNA methylation of chromosome 15q11.2-q13 -AND- Experiencing hyperphagia due to PWS diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of a decrease in hyperphagic and food-related behaviors is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Vyvgart Hytrulo

Products Affected

- **VYVGART HYTRULO SUBCUTANEOUS SYRINGE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For generalized myasthenia gravis (gMG), anti-acetylcholine receptor (AChR) antibody-positive -AND- therapeutic failure, contraindication, or intolerance to generic pyridostigmine. For chronic inflammatory demyelinating polyneuropathy (CIDP), 1 of the following (1-7): 1) motor distal latency prolongation in at least 2 nerves, 2) reduction of motor conduction velocity in at least 2 nerves, 3) prolongation of F-wave latency in at least 2 nerves, 4) absence of F-waves in at least 2 nerves, 5) motor conduction block in at least 1 nerve, 6) abnormal temporal dispersion in at least 2 nerves or, 7) distal CMAP duration prolongation in at least 1 nerve -AND- all of the following (8-12): 8) progressive symptoms occurring for at least 2 months, 9) progressive or relapsing motor sensory dysfunction of more than 1 limb or a peripheral nerve nature, developing over at least 2 months, 10) hypo- or areflexia, 11) nerve conduction studies strongly supportive of demyelination, 12) therapeutic failure or intolerance to 1 of the following or contraindication to all (a or b): a) systemic corticosteroids, b) an immune globulin (i.e., IVIG or subcutaneous immunoglobulin).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	gMG: 6 months initial, 12 months reauth. CIPD: 12 months
Other Criteria	For gMG reauthorization, improvement of gMG signs/symptoms (e.g., speech, swallowing, mobility, and/or respiratory function) -OR- decreased gMG exacerbations. For CIDP reauthorization, improvement of functional ability or strength from baseline.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Wainua

Products Affected

- **WAINUA**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitantly with transthyretin-lowering agents
Required Medical Information	Documentation of polyneuropathy associated with hereditary TTR (hATTR) amyloidosis with mutation in TTR gene confirmed by genetic testing -AND- Neurologic examination shows clinical signs and symptoms of the disease (e.g. peripheral/autonomic neuropathy, motor disability, carpel tunnel, etc.) -AND- Attestation of peripheral neuropathy impairment score (NIS) of 5 or greater
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of improvement of polyneuropathy from baseline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Wakix

Products Affected

- **WAKIX**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Wegovy

Products Affected

- **WEGOVY SUBCUTANEOUS PEN INJECTOR 0.25 MG/0.5 ML, 0.5 MG/0.5 ML, 1 MG/0.5 ML, 1.7 MG/0.75 ML, 2.4 MG/0.75 ML**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Welireg

Products Affected

- **WELIREG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For von Hippel Lindau (VHL) syndrome, one of the following diagnoses not requiring immediate surgery (1, 2, or 3): 1) Renal cell carcinoma (RCC) 2) CNS hemangioblastoma 3) Pancreatic neuroendocrine tumor. For advanced RCC with a clear cell component, prior treatment with a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI) -AND- a programmed death receptor-1 (PD-1) or a programmed death-ligand (PD-L1) inhibitor.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Winrevair

Products Affected

- **WINREVAIR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of pulmonary arterial hypertension, substantiated by results from right heart catheterization (RHC), defined as a mean pulmonary arterial pressure (mPAP) of greater than 20 mmHg at rest, with a pulmonary capillary wedge pressure (PWP) of less than or equal to 15 mmHg, and a PVR greater than or equal to 3 Wood units -AND- WHO Group -AND- Concomitant use of at least one of the following (1-4): 1) generic endothelin-1 receptor antagonist, 2) phosphodiesterase type 5 inhibitor, 3) soluble guanylate cyclase stimulator, 4) generic prostacyclin agent -AND- Background therapy with PAH-specific therapies will be continued while being treated with Winrevair.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xalkori

Products Affected

- **XALKORI ORAL CAPSULE**
- **XALKORI ORAL PELLET 150 MG, 20 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For metastatic non-small cell lung cancer (NSCLC), disease is ALK-positive or ROS1-positive. For relapsed or refractory anaplastic large cell lymphoma (ALCL), disease is ALK-positive. For unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT), disease is ALK-positive.
Age Restrictions	Deny if less than 18 years of age for NSCLC. Deny if less than 1 year of age or greater than 21 years of age for ALCL.
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For crizotinib oral pellets and NSCLC, inability to swallow capsules is required. For crizotinib oral pellets and ALCL / IMT, inability to swallow oral capsules -OR- body surface area less than 1.34 m2 is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xcopri

Products Affected

- **XCOPRI**
- **XCOPRI MAINTENANCE PACK**
- **XCOPRI TITRATION PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of partial-onset seizures -AND- Therapeutic failure, intolerance or contraindication to 1 other anti-epileptic drug (e.g. carbamazepine, levetiracetam)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xdemvy

Products Affected

- **XDEMVY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis confirmed by identification of Demodex infection via microscopic examination of pulled eyelashes -OR- identification of collarettes via slit-lamp evaluation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 weeks
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xeljanz

Products Affected

- **XELJANZ ORAL TABLET**
- **XELJANZ XR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe active rheumatoid arthritis, an inadequate response or intolerance to at least one non-biologic DMARD (e.g., leflunomide, methotrexate). Xeljanz immediate release for polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID).
Age Restrictions	Deny if less than 18 years of age for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis. For Xeljanz regular release tablet, deny if less than 2 years of age for polyarticular juvenile idiopathic arthritis
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	The member has experienced inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker. Doses greater than 10 mg per day for Xeljanz and 11 mg per day for Xeljanz XR will not be approved for rheumatoid arthritis and psoriatic arthritis. Doses greater than 20mg per day for Xeljanz and 22 mg per day for Xeljanz XR will not be approved for ulcerative colitis.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xeljanz Solution

Products Affected

- **XELJANZ ORAL SOLUTION**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of polyarticular juvenile idiopathic arthritis -AND- Inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) or requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage.
Age Restrictions	Deny if less than 2 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	The member has experienced therapeutic failure or intolerance to at least 1 tumor necrosis factor (TNF) blocker.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xenazine

Products Affected

- *tetrabenazine oral tablet 12.5 mg, 25 mg*
- **XENAZINE ORAL TABLET 12.5 MG, 25 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- attestation that the beneficiary is not actively suicidal
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Xenazine, trial and failure of generic tetrabenazine is required. In patients with comorbid depression, attestation of adequate treatment for depression is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xermelo

Products Affected

- **XERMELO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of carcinoid syndrome diarrhea AND used in combination with a somatostatin analog AND trial and failure of somatostatin analog monotherapy
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	3 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of reduction in average number of daily bowel movements -AND- the member will continue to use in combination with a somatostatin analog.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xgeva

Products Affected

- **XGEVA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xhance

Products Affected

- **XHANCE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of chronic rhinosinusitis with nasal polyps or chronic rhinosinusitis without nasal polyps -AND- Therapeutic failure, intolerance or contraindication 1 corticosteroid nasal sprays.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xifaxan

Products Affected

- **XIFAXAN ORAL TABLET 550 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of 1 or 2. 1) Diagnosis of hepatic encephalopathy AND trial/failure, intolerance, or contraindication to lactulose. 2) Diagnosis of Irritable Bowel Syndrome with Diarrhea (IBS-D) AND trial/failure, intolerance to one of the following medications for IBS-D or documentation of contraindication to all: antidiarrheal (e.g., loperamide), antispasmodic (e.g., dicyclomine, hyoscyamine), tricyclic antidepressant (e.g., amitriptyline, nortriptyline).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Hepatic encephalopathy: 1 year. IBS-D: 14 days.
Other Criteria	No more than three courses of rifaximin for the treatment of IBS-D will be approved per lifetime.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xolair

Products Affected

- **XOLAIR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of the following (1-2): 1) Chronic Spontaneous Urticaria, 2) trial/failure or intolerance of a second-generation non-sedating H1 antihistamine at the maximum recommended doses (e.g. cetirizine, fexofenadine, loratadine, desloratadine, levocetirizine). -OR- Documentation of the following (3-9): 3) moderate to severe persistent asthma, 4) a positive skin test or in vitro reactivity to a perennial aeroallergen, 5) Baseline IgE titer greater than or equal to 30 IU/mL, 6) documented pretreatment FEV1 less than 80% predicted in adults or less than 90% predicted in children and adolescents or FEV1 reversibility of at least 12% and 200mL after albuterol administration, 7) history of at least 2 asthma exacerbations requiring oral or injectable corticosteroid treatment in past 12mos or at least 1 asthma exacerbation requiring hospitalization in past 12mos, 8) inadequate symptom control despite regular treatment w/ medium- or high-dose inhaled corticosteroids (ICS) and at least 1 add'l asthma controller medication (e.g. long-acting beta2-agonist [LABA], leukotriene receptor antagonist [LTRA], theophylline) w/ or w/o OCS, unless intolerant or contraindicated to all, 9) will continue treatment with a medium- or high-dose ICS and at least 1 add'l asthma controller medication w/ or w/o OCS -OR- Documentation of the following (10-11): 10) chronic rhinosinusitis with nasal polyps (CRSwNP), 11) will use concomitantly with nasal corticosteroid maintenance treatment, -OR- Documentation of the following (12-17): 12) IgE mediated food allergy, 13) diagnosis confirmed by skin prick test or food-specific antibodies, 14) previous allergic reaction to food, 15) using for the reduction of allergic reactions (type 1), including anaphylaxis, 16) will be used in conjunction with food allergen avoidance, 17) member has a documented prescription for epinephrine.
Age Restrictions	
Prescriber Restrictions	

PA Criteria	Criteria Details
Coverage Duration	12 months
Other Criteria	For asthma reauthorization, attestation of one of the following is required (1-4): 1) decreased rescue medication or oral corticosteroid use, 2) decreased frequency of asthma exacerbations, 3) increased pulmonary function from baseline (e.g. FEV1), or 4) reduction in reported asthma related symptoms. For CSU reauthorization, improved CSU symptoms. For CRSwNP reauthorization, attestation of decrease in nasal polyp score or reduction in nasal congestion/obstruction severity score. For IgE-mediated food allergy reauthorization, member requires continuation of therapy and will continue food allergen avoidance.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xolremdi

Products Affected

- **XOLREMDI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of WHIM syndrome (warts, hypogammaglobulinemia, infections, myelokathexis).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of reduction in incidence of infections is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xospata

Products Affected

- **XOSPATA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- member is FLT3 mutation-positive.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xpovio

Products Affected

- **XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (10 MG X 4), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of use in combination with dexamethasone for relapse or refractory multiple myeloma with failure, intolerance or contraindication to 5 therapies (e.g. bortezomib, carfilzomib, lenalidomide, pomalidomide and daratumumab) -OR- Documentation of use in combination with both bortezomib and dexamethasone for multiple myeloma after receiving 1 prior multiple myeloma therapy -OR- Documentation of relapsing or refractory diffuse large B-cell lymphoma with failure, intolerance or contraindication to at least 2 lines of systemic therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xtandi

Products Affected

- **XTANDI ORAL CAPSULE**
- **XTANDI ORAL TABLET 40 MG, 80 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For castration-resistant prostate cancer and metastatic castration sensitive-prostate cancer, the member is using in combination with a GnRH analog or the member has had a bilateral orchiectomy. For non-metastatic castration-sensitive prostate cancer, the member has biochemical recurrence at high risk for metastasis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xyrem

Products Affected

- *sodium oxybate*
- **XYREM**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) - AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. If the member has a diagnosis of cataplexy provision of baseline number of cataplexy episodes is required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	If 18 years or older and no diagnosis of cataplexy, trial and failure, intolerance, or contraindication to generic modafinil -AND- a generic CNS stimulant indicated for use in narcolepsy (e.g. methylphenidate, amphetamine salts) is required. For reauthorization, attestation supporting improvement in symptoms of narcolepsy and cataplexy (if applicable) is required.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xywav

Products Affected

- **XYWAV**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) - AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP -AND- Sensitivity to sodium intake due to heart failure, hypertension or impaired renal function. If the member has a diagnosis of cataplexy, provision of baseline number of cataplexy episodes is required. -OR- (II) Diagnosis of idiopathic hypersomnia -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- documentation the member does not have cataplexy -AND- documentation of less than 2 SOREMPs -AND- documentation of the following (1, 2, or 3): 1) MSLT documenting MSL less than or equal to 8 minutes -OR- 2) polysomnography demonstrating total sleep time greater than or equal to 660 minutes per 24 hours -OR- 3) wrist actigraphy demonstrating total sleep time greater than or equal to 660 minutes per 24 hours.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	If 18 years or older and diagnosis of narcolepsy without cataplexy, trial and failure, intolerance, or contraindication to generic modafinil -AND- a generic CNS stimulant indicated for use in narcolepsy (e.g. methylphenidate, amphetamine salts) is required. For reauthorization, attestation supporting improvement in symptoms of narcolepsy, idiopathic hypersomnia and cataplexy (if applicable) is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Yonsa

Products Affected

- **YONSA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- using in combination with methylprednisolone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Yorvipath

Products Affected

- **YORVIPATH SUBCUTANEOUS PEN INJECTOR 168 MCG/0.56 ML, 294 MCG/0.98 ML, 420 MCG/1.4 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of hypoparathyroidism -AND- albumin-corrected serum calcium greater than or equal to 7.8 mg/dL -AND- trial and failure of calcium -AND- trial and failure of an active form of vitamin D (e.g. calcitriol, alfacalcidol).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of an improvement in total serum calcium from baseline is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zavesca

Products Affected

- *miglustat*
- **YARGESA**
- **ZAVESCA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zavzpret

Products Affected

- **ZAVZPRET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of acute migraine headaches with or without aura -AND- Therapeutic failure, contraindication or intolerance to one generic triptan -AND- Inability to swallow capsules/tablets
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of reduction in migraine symptoms.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zejula

Products Affected

- **ZEJULA ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zelboraf

Products Affected

- **ZELBORAF**

PA Criteria	Criteria Details
Exclusion Criteria	Wild-type BRAF melanoma
Required Medical Information	Documentation of diagnosis. For unresectable or metastatic melanoma, member has a BRAF V600E mutation. For Erdheim-Chester Disease, member has a BRAF V600 mutation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zelsuvmi

Products Affected

- **ZELSUVMI**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zepatier

Products Affected

- **ZEPATIER**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guidance -AND- the member has a contraindication to or is otherwise not a candidate for one of the following regimens recommended by the AASLD/IDSA guidelines containing the following agents: sofosbuvir/velpatasvir (i.e. Epclusa authorized generic), Mavyret.
Age Restrictions	Deny if less than 12 years of age
Prescriber Restrictions	
Coverage Duration	Criteria/duration applied consistent with current AASLD-IDSA guidance
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zepbound

Products Affected

- **ZEPBOUND SUBCUTANEOUS PEN INJECTOR**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zeposia

Products Affected

- **ZEPOSIA**
- **ZEPOSIA STARTER KIT (28-DAY)**
- **ZEPOSIA STARTER PACK (7-DAY)**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of Zeposia and other disease modifying agents such as interferons, Copaxone, Tysabri.
Required Medical Information	Documentation of diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Ulcerative Colitis: Plan Year, Multiple Sclerosis: 24 months
Other Criteria	For moderate to severe active ulcerative colitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, Rinvoq, and Xeljanz/Xeljanz XR. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zolinza

Products Affected

- **ZOLINZA**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zolpidem Capsule

Products Affected

- *zolpidem*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of insomnia characterized by difficulties with sleep onset -AND- therapeutic failure or intolerance to 2 of the following (1-3): 1) eszopiclone, 2) zaleplon, 3) generic zolpidem tablets/zolpidem ER tablets. When using concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators.
Age Restrictions	Deny if greater than 64 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zonisade

Products Affected

- **ZONISADE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of partial-onset seizures -AND- Documentation of adjunctive therapy -AND- Inability to swallow capsules -AND- Therapeutic failure/intolerance to 2 or contraindication to all of the following (1-6): 1) generic carbamazepine suspension/chewable tablet/extended-release capsule, 2) generic gabapentin capsules/solution, 3) generic lacosamide solution, 4) generic levetiracetam solution, 5) generic oxcarbazepine suspension, 6) generic pregabalin capsules/solution.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zoryve 0.15 Cream

Products Affected

- **ZORYVE TOPICAL CREAM 0.15 %**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-3). 1) Documentation of mild to moderate atopic dermatitis -AND- 2) therapeutic failure, contraindication or intolerance to one generic formulary topical corticosteroid -OR- documentation of facial or anogenital involvement -AND- 3) therapeutic failure, contraindication or intolerance to topical generic tacrolimus or topical generic pimecrolimus.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zoryve Cream

Products Affected

- **ZORYVE TOPICAL CREAM 0.3 %**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-3). 1) Documentation of plaque psoriasis -AND- 2) trial and failure or intolerance to at least one generic, formulary medium, high, or ultrahigh potency topical corticosteroid (e.g. fluocinonide, triamcinolone, betamethasone) -OR- psoriasis on facial or intertriginous areas -AND- 3) trial and failure, contraindication, or intolerance to one generic, formulary vitamin D analog (e.g., calcipotriene, calcitriol) -OR- the member has psoriasis on the face.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zoryve Foam

Products Affected

- **ZORYVE TOPICAL FOAM**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-3). 1) Documentation of seborrheic dermatitis -AND- 2) trial and failure or intolerance to at least one generic, formulary topical corticosteroid -OR- seborrheic dermatitis on facial or intertriginous areas -AND- 3) if the member is 12 years of age or older, trial and failure, contraindication, or intolerance to one generic, topical antifungal agent for seborrheic dermatitis (e.g., ketoconazole, ciclopirox).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ztalmy

Products Affected

- **ZTALMY**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZTLido

Products Affected

- **ZTLIDO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of postherpetic neuralgia (PHN) -AND- One of the following (1, 2 or 3): 1) trial and failure of 1 other agent used to treat PHN (e.g. gabapentin) 2) Inability to swallow oral medication 3) Unable to take an oral medication due to potential adverse events (e.g. sedation)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Therapeutic failure, contraindication, or intolerance to generic lidocaine patch 5% is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zunveyl

Products Affected

- **ZUNVEYL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis - AND- therapeutic failure or intolerance to generic galantamine.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zurzuvae

Products Affected

- **ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Pending CMS Review
Required Medical Information	Pending CMS Review
Age Restrictions	Pending CMS Review
Prescriber Restrictions	Pending CMS Review
Coverage Duration	Pending CMS Review
Other Criteria	Pending CMS Review
Indications	Pending CMS Review
Off Label Uses	Pending CMS Review
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zydelig

Products Affected

- **ZYDELIG**

PA Criteria	Criteria Details
Exclusion Criteria	First line treatment. Combination use with benadmustine and/or rituximab for the treatment of FL.
Required Medical Information	Documentation of relapsed chronic lymphocytic leukemia -AND- all of the following (1-2): 1) will be used in combination with rituximab 2) use of rituximab alone would be appropriate due to other due to other comorbidities.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zykadia

Products Affected

- **ZYKADIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- ALK mutations, as detected by an FDA approved test.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zymfentra

Products Affected

- **ZYMFENTRA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- attestation of receiving or currently undergoing at least 3 doses of IV infliximab within 10 weeks of initiating therapy with Zymfentra.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For moderate to severe active ulcerative colitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, Rinvoq, and Xeljanz/Xeljanz XR. For moderate to severe active Crohn's disease, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, and Rinvoq. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Zytiga

Products Affected

- *abiraterone oral tablet 250 mg, 500 mg*
- **ABIRTEGA**
- **ZYTIGA ORAL TABLET 250 MG, 500 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- using in combination with prednisone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For brand Zytiga, intolerance of generic abiraterone or Abirtega is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Index of Drugs

ABILIFY ORAL TABLET 37
abiraterone oral tablet 250 mg, 500 mg 597
ABIRTEGA 597
ABRILADA(CF) 7
ABRILADA(CF) PEN 7
acetaminophen-codeine oral solution 120-12 mg/5 ml 371
acetaminophen-codeine oral tablet 371
acitretin 1
ACTEMRA ACTPEN 485
ACTEMRA SUBCUTANEOUS 485
ACTHAR 2
ACTHAR SELFJECT 4
ACTIMMUNE 6
adalimumab-aacf subcutaneous pen injector kit 7
adalimumab-aacf subcutaneous syringe kit ... 7
ADALIMUMAB-AACF(CF) PEN CROHNS 7
ADALIMUMAB-AACF(CF) PEN PS-UV 7
adalimumab-aaty 7
ADALIMUMAB-AATY(CF) AI CROHNS 7
adalimumab-adaz subcutaneous pen injector 40 mg/0.4 ml, 80 mg/0.8 ml 7
adalimumab-adaz subcutaneous syringe 10 mg/0.1 ml, 20 mg/0.2 ml, 40 mg/0.4 ml 7
adalimumab-adbm 7
adalimumab-fkjp subcutaneous pen injector kit 7
adalimumab-fkjp subcutaneous syringe kit 7
adalimumab-ryvk subcutaneous auto-injector, kit 40 mg/0.4 ml 7
adalimumab-ryvk subcutaneous syringe kit ... 7
adapalene topical cream 492
adapalene topical gel 0.3 % 492
adapalene topical swab 492
adapalene-benzoyl peroxide 492
ADBRY 10
ADCIRCA 382
ADEMPAS 382
ADLARITY 12
AFINITOR 13
AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG, 3 MG, 5 MG . 13
AGAMREE 14
AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML, 70 MG/ML 15
AIRSUPRA 16
AJOVY AUTOINJECTOR 17
AJOVY SYRINGE 17
AKEEGA 18
AKLIEF 492
ALCOHOL PADS 216
ALECENSA 19
ALKINDI SPRINKLE 20
alogliptin 114
alogliptin-metformin 114
alogliptin-pioglitazone 114
alosetron oral tablet 0.5 mg, 1 mg 266
ALPRAZOLAM INTENSOL 371
alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg 371
alprazolam oral tablet extended release 24 hr 0.5 mg, 1 mg, 2 mg, 3 mg 371
alprazolam oral tablet,disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg 371
ALTRENO 492
ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG 22
ALUNBRIG ORAL TABLETS,DOSE PACK 22
ALVAIZ ORAL TABLET 18 MG, 36 MG, 54 MG, 9 MG 482
ALYFTREK ORAL TABLET 10-50-125 MG, 4-20-50 MG 23
ALYQ 382
AMBIEN 371
AMBIEN CR 371
ambrisentan 382
AMITIZA 24
amitriptyline 193
amitriptyline-chlordiazepoxide 193
AMJEVITA(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 40 MG/0.4 ML, 40 MG/0.8 ML, 80 MG/0.8 ML 7

AMJEVITA(CF) SUBCUTANEOUS SYRINGE 10 MG/0.2 ML, 20 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.4 ML, 40 MG/0.8 ML 7
amphetamine sulfate 145
AMPYRA 26
ANAFRANIL 193
ANCOBON 28
ANDEMBRY AUTOINJECTOR 29
ANZUPGO 32
APOKYN 33
apomorphine 33
APRISO 284
AQNEURSA 34
ARALAST NP INTRAVENOUS RECON SOLN 1,000 MG 21
ARAZLO 472
ARCALYST 219
ARIKAYCE 35
aripiprazole oral solution 37
aripiprazole oral tablet,disintegrating 37
armodafinil 316
ASCOMP WITH CODEINE 371
asenapine maleate 421
ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2" 419
ATIVAN ORAL TABLET 0.5 MG, 1 MG, 2 MG 371
ATORVALIQ 442
ATRALIN 492
ATTRUBY 36
AUBAGIO 38
AUGTYRO ORAL CAPSULE 160 MG, 40 MG 39
AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG 40
AUSTEDO XR 40
AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG 40
AUVELITY 41
AVEED 477
AVMAPKI-FAKZYNJA 42
AVONEX INTRAMUSCULAR PEN INJECTOR KIT 218
AVONEX INTRAMUSCULAR SYRINGE KIT 218
AYVAKIT 43
baclofen oral solution 10 mg/5 ml (2 mg/ml), 5 mg/5 ml 44
baclofen oral suspension 44
BAFIERTAM 45
BALVERSA 46
BANZEL 47
BELBUCA 371
BENLYSTA SUBCUTANEOUS 48
benztropine oral 193
bepotastine besilate 334
BEPREVE 334
BERINERT INTRAVENOUS KIT 50
BESREMI 52
BETASERON SUBCUTANEOUS KIT 218
BETHKIS 75
bexarotene oral 464
bexarotene topical 465
BIMZELX AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 160 MG/ML, 320 MG/2 ML 53
BIMZELX SUBCUTANEOUS SYRINGE 160 MG/ML, 320 MG/2 ML 53
BIVIGAM 205
BOMYNTRA 105
BONJESTA 55
BONSITY 162
bosentan oral tablet 382
BOSULIF ORAL CAPSULE 100 MG, 50 MG 56
BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG 56
BRAFTOVI 57
BRINSUPRI 58
BRUKINSA ORAL CAPSULE 59
BUCAPSOL ORAL CAPSULE 15 MG 60
BUPHENYL 61
buprenorphine 371
butalbital-acetaminop-caf-cod oral capsule 50-300-40-30 mg, 50-325-40-30 mg 371
BUTRANS 371
BYLVAY ORAL CAPSULE 1,200 MCG, 400 MCG 62

BYLVAY ORAL PELLET 200 MCG, 600 MCG 62
CABLIVI INJECTION KIT 63
CABOMETYX 64
CABTREO 492
CALQUENCE (ACALABRUTINIB MAL) 65
CAMZYOS 66
CANASA 283
CAPLYTA 68
CAPRELSA ORAL TABLET 100 MG, 300 MG 69
CARBAGLU 71
carbinoxamine maleate oral liquid 72
carbinoxamine maleate oral tablet 72
carglumic acid 71
carisoprodol 193
CAYSTON 73
CERDELGA 74
CHENODAL 76
chlordiazepoxide hcl 371
chlorzoxazone 193
CHOLBAM 77
CIALIS ORAL TABLET 5 MG 78
CIBINQO 79
CIMZIA POWDER FOR RECONST 80
CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2) 80
CINRYZE 82
citalopram oral capsule 84
clemastine oral syrup 85
clindamycin-tretinoin 492
clobazam oral suspension 330
clobazam oral tablet 330
clomipramine 193
clonazepam oral tablet 0.5 mg, 1 mg, 2 mg 371
clonazepam oral tablet,disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg 371
clonidine hcl oral tablet extended release 12 hr 11
clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg 371
COBENFY 86
COBENFY STARTER PACK 86
codeine sulfate 371
codeine-butalbital-asa-caff 371
COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY) 87
CONEXXENCE 106
CONZIP 371
COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML, 40 MG/ML 174
COPIKTRA 88
CORLANOR ORAL SOLUTION 89
CORLANOR ORAL TABLET 5 MG, 7.5 MG 89
CORTROPHIN GEL 385
COSENTYX (2 SYRINGES) 90
COSENTYX PEN (2 PENS) 90
COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML 90
COSENTYX UNOREADY PEN 90
COTELLIC 92
CRENESSITY ORAL CAPSULE 100 MG, 25 MG, 50 MG 93
CRENESSITY ORAL SOLUTION 93
CRESEMBA ORAL 94
CRINONE 95
CTEXLI 96
CUVRIOR 97
CYLTEZO(CF) 7
CYLTEZO(CF) PEN 7
CYLTEZO(CF) PEN CROHN'S-UC-HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML 7
CYLTEZO(CF) PEN PSORIASIS-UV SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML 7
cyproheptadine 193
CYSTADROPS 98
CYSTARAN 98
dalfampridine 26
DANZITEN 99
DARAPRIM 100
dasatinib 441
DAURISMO ORAL TABLET 100 MG, 25 MG 101
DAYBUE 102
DAYTRANA 103
deferasirox 104

deferiprone 152
deflazacort 129
DEMEROL (PF) INJECTION SYRINGE 25 MG/ML 371
DEMEROL INJECTION 371
DEMSER 287
DEPO-TESTOSTERONE 477
DIACOMIT ORAL CAPSULE 250 MG, 500 MG 108
DIACOMIT ORAL POWDER IN PACKET 250 MG, 500 MG 108
DIAZEPAM INTENSOL 371
diazepam oral solution 5 mg/5 ml (1 mg/ml) 371
diazepam oral tablet 371
DIBENZYLINE 357
DICLEGIS 55
diclofenac epolamine 161
diclofenac sodium topical gel 3 % 436
dicyclomine oral tablet 40 mg 109
DIFFERIN TOPICAL CREAM 492
DIFFERIN TOPICAL GEL WITH PUMP 492
dihydroergotamine nasal 110
DILAUDID ORAL LIQUID 371
DILAUDID ORAL TABLET 2 MG, 4 MG, 8 MG 371
dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg 475
DOJOLVI 111
DOPTELET (10 TAB PACK) 112
DOPTELET (15 TAB PACK) 112
DOPTELET (30 TAB PACK) 112
doxepin oral capsule 193
doxepin oral concentrate 193
doxepin oral tablet 193
doxepin topical 113
doxylamine-pyridoxine (vit b6) 55
DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG, 30 MG, 40 MG, 60 MG 117
droxidopa oral capsule 100 mg, 200 mg, 300 mg 308
DUOBRII 119
DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML 120
DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML, 300 MG/2 ML 120
DUVYZAT 122
EBGLYSS PEN 123
EBGLYSS SYRINGE 123
EDLUAR 371
EGRIFTA SV 126
EKTERLY 127
eltrombopag olamine oral powder in packet 12.5 mg, 25 mg 482
eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg 482
ELYXYB 128
EMFLAZA 129
EMGALITY PEN 131
EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML, 300 MG/3 ML (100 MG/ML X 3) 131
EMPAVELI 132
EMROSI 337
ENBREL MINI 143
ENBREL SUBCUTANEOUS SOLUTION 143
ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) 143
ENBREL SURECLICK 143
ENDARI 133
ENDOCET 371
ENSPRYNG 134
ENTRESTO SPRINKLE 135
ENTYVIO PEN 136
EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG, 200-50 MG 137
EPCLUSA ORAL TABLET 137
EPIDIOLEX 138
EPIDUO FORTE 492
EPIDUO TOPICAL GEL WITH PUMP 492
EPRONTIA 139
ERGOMAR 140
ergotamine-caffeine 140

ERIVEDGE 141
ERLEADA ORAL TABLET 240 MG, 60 MG 142
erlotinib 124
ESBRIET ORAL CAPSULE 221
ESBRIET ORAL TABLET 221
estazolam 371
eszopiclone 371
EUCRISA 144
EVEKEO 145
EVENITY SUBCUTANEOUS SYRINGE 210MG/2.34ML (105MG/1.17MLX2) 146
everolimus (antineoplastic) oral tablet 13
everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg 13
EVRYSDI ORAL RECON SOLN 147
EVRYSDI ORAL TABLET 147
exenatide subcutaneous pen injector 10 mcg/dose(250 mcg/ml) 2.4 ml, 5 mcg/dose (250 mcg/ml) 1.2 ml 178
EXJADE 104
FABHALTA 148
FABIOR 472
FANAPT 149
FANAPT TITRATION PACK A 149
FASENRA PEN 150
FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 30 MG/ML 150
febuxostat 505
fentanyl 371
FERRIPROX (2 TIMES A DAY) 152
FERRIPROX ORAL SOLUTION 152
FERRIPROX ORAL TABLET 1,000 MG 152
FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26) 153
FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG 153
FILSPARI 154
FILSUVEZ 155
fingolimod 172
FINTEPLA 156
FIORICET WITH CODEINE 371
FIRAZYR 157
FIRDAPSE 159
FIRMAGON KIT W DILUENT SYRINGE 160
FLECTOR 161
FLEQSUVY 44
FLOLIPID 442
fluorouracil topical cream 0.5 % 70
flurazepam 371
FORTEO 162
FOTIVDA 163
FRUZAQLA ORAL CAPSULE 1 MG, 5 MG 164
FUROSCIX 166
gabapentin oral tablet extended release 24 hr 300 mg, 600 mg 182
GABARONE ORAL TABLET 100 MG, 400 MG 168
GALAFOLD 169
GAMMAGARD LIQUID 205
GAMMAGARD S-D (IGA < 1 MCG/ML) 205
GAMMAKED INJECTION SOLUTION 1 GRAM/10 ML (10 %) 205
GAMMAPLEX 205
GAMMAPLEX (WITH SORBITOL) 205
GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %) 205
GATTEX 30-VIAL 170
GAUZE PAD TOPICAL BANDAGE 2 X 2 " 216
GAVRETO 171
gefitinib 224
GENOTROPIN 184
GENOTROPIN MINIQUICK 184
GILENYA 172
GILOTRIF 124
GIMOTI 173
GLASSIA 21
glatiramer subcutaneous syringe 20 mg/ml, 40 mg/ml 174
GLATOPA SUBCUTANEOUS SYRINGE 20 MG/ML, 40 MG/ML 174
GLEEVEC ORAL TABLET 100 MG, 400 MG 175
GLEOSTINE 177

glutamine (sickle cell).....133
GLYCATE..... 179
glycopyrrolate oral tablet 1.5 mg.....179
GLYXAMBI.....116
GOCOVRI ORAL CAPSULE,EXTENDED RELEASE 24HR 137 MG, 68.5 MG..... 180
GOMEKLI ORAL CAPSULE 1 MG, 2 MG..... 181
GOMEKLI ORAL TABLET FOR SUSPENSION..... 181
GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 300 MG, 450 MG, 600 MG, 750 MG, 900 MG.....182
GRASTEK.....183
griseofulvin ultramicrosize oral tablet 165 mg..... 165
guanfacine oral tablet extended release 24 hr.....11
HADLIMA..... 367
HADLIMA PUSHTOUCH.....367
HADLIMA(CF)..... 367
HADLIMA(CF) PUSHTOUCH.....367
HAEGARDA.....186
HALCION ORAL TABLET 0.25 MG... 371
HARVONI.....188
HEMADY.....189
HERNEXEOS..... 190
HETLIOZ.....191
HETLIOZ LQ.....192
HORIZANT ORAL TABLET EXTENDED RELEASE 300 MG, 600 MG..... 198
HULIO(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT..... 7
HULIO(CF) SUBCUTANEOUS SYRINGE KIT.....7
HUMATROPE INJECTION CARTRIDGE.....184
HUMIRA PEN..... 7
HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML..... 7
HUMIRA(CF)..... 7
HUMIRA(CF) PEN..... 7
HUMIRA(CF) PEN CROHNS-UC-HS..... 7
HUMIRA(CF) PEN PSOR-UV-ADOL HS.....7
hydrocodone bitartrate oral capsule, oral only, er 12hr..... 371
hydrocodone bitartrate oral tablet,oral only,ext.rel.24 hr.....371
hydrocodone-acetaminophen oral solution 10-300 mg/15 ml, 10-325 mg/15 ml, 7.5-325 mg/15 ml..... 371
hydrocodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 2.5-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg.....371
hydrocodone-ibuprofen..... 371
hydromorphone (pf) injection solution 10 (mg/ml) (5 ml), 10 mg/ml.....371
hydromorphone oral liquid.....371
hydromorphone oral tablet 2 mg, 4 mg, 8 mg..... 371
hydromorphone oral tablet extended release 24 hr 12 mg, 16 mg, 32 mg, 8 mg...371
hydroxyzine hcl oral solution 10 mg/5 ml.. 193
hydroxyzine hcl oral tablet..... 193
hydroxyzine pamoate..... 193
HYFTOR..... 199
HYRIMOZ..... 7
HYRIMOZ PEN..... 7
HYRIMOZ PEN CROHN'S-UC STARTER..... 7
HYRIMOZ PEN PSORIASIS STARTER..... 7
HYRIMOZ(CF) PEDI CROHN STARTER SUBCUTANEOUS SYRINGE 80 MG/0.8 ML, 80 MG/0.8 ML- 40 MG/0.4 ML.....7
HYRIMOZ(CF) PEN SUBCUTANEOUS PEN INJECTOR 40 MG/0.4 ML, 80 MG/0.8 ML..... 7
HYRIMOZ(CF) SUBCUTANEOUS SYRINGE 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML..... 7
HYSINGLA ER ORAL TABLET,ORAL ONLY,EXT.REL.24 HR 100 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG..... 371
IBRANCE.....200
IBSRELA.....201

IBTROZI 202
ibuprofen-famotidine 118
icatibant 157
ICLUSIG 203
IDACIO(CF) 7
IDACIO(CF) PEN CROHN-UC STARTR 7
IDACIO(CF) PEN PSORIASIS START 7
IDACIO(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 7
IDHIFA 204
ILUMYA 207
imatinib oral tablet 100 mg, 400 mg 175
IMBRUVICA ORAL CAPSULE 140 MG, 70 MG 208
IMBRUVICA ORAL SUSPENSION 208
IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG 208
imipramine hcl 193
imipramine pamoate 193
IMKELDI 209
INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE 210
INCRELEX 211
INGREZZA INITIATION PK(TARDIV) 212
INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG 212
INGREZZA SPRINKLE 212
INLYTA 213
INQOVI 214
INREBIC 215
INTRAROSA 220
INTUNIV ER 11
IQIRVO 223
IRESSA 224
ISTURISA ORAL TABLET 1 MG, 5 MG 443
ITOVEBI ORAL TABLET 3 MG, 9 MG 225
itraconazole 226
ivabradine oral tablet 5 mg, 7.5 mg 89
ivermectin oral 227
IWILFIN 228
JADENU 104
JADENU SPRINKLE 104
JAKAFI 229
JANUMET 114
JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG, 50-1,000 MG, 50-500 MG 114
JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG 114
JATENZO ORAL CAPSULE 158 MG, 198 MG, 237 MG 477
JAVYGTOR 248
JAYPIRCA ORAL TABLET 100 MG, 50 MG 230
JAYTHARI 129
JENTADUETO ORAL TABLET 2.5-1,000 MG, 2.5-500 MG 114
JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-1,000 MG 114
JOENJA 231
JOURNAVX 232
JUBBONTI 106
JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG 196
JYNARQUE ORAL TABLET 233
JYNARQUE ORAL TABLETS, SEQUENTIAL 233
KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 25 MG, 5.8 MG, 50 MG, 75 MG 234
KALYDECO ORAL TABLET 234
KATERZIA 25
KERENDIA 235
KESIMPTA PEN 236
KEVEYIS 237
KEVZARA 238
KHINDIVI 240
KINERET 241
KISQALI FEMARA CO-PACK ORAL TABLET 400 MG/DAY(200 MG X 2)-2.5 MG, 600 MG/DAY(200 MG X 3)-2.5 MG 243
KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3) 242
KITABIS PAK 75

KLISYRI (250 MG).....244
KLONOPIN ORAL TABLET 0.5 MG, 1 MG, 2 MG..... 371
KORLYM.....245
KOSELUGO ORAL CAPSULE 10 MG, 25 MG..... 246
KRAZATI..... 247
KUVAN.....248
LAMPIT..... 249
lapatinib.....502
LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG, 80 MG.....250
LAZCLUZE ORAL TABLET 240 MG, 80 MG..... 251
ledipasvir-sofosbuvir..... 188
lenalidomide..... 399
LENVIMA.....252
LEQSELVI.....254
LETAIRIS.....382
LEUKINE INJECTION RECON SOLN..... 255
levorphanol tartrate.....371
LIALDA.....284
LICART.....161
lidocaine hcl mucous membrane solution 4 % (40 mg/ml)..... 488
lidocaine topical adhesive patch,medicated 5 %.....257
lidocaine topical ointment..... 488
lidocaine-prilocaine topical cream..... 488
LIDOCAN III.....257
liraglutide..... 178
LITFULO..... 258
LIVDELZI.....259
LIVMARLI ORAL SOLUTION 19 MG/ML, 9.5 MG/ML..... 260
LIVMARLI ORAL TABLET 10 MG, 15 MG, 20 MG, 30 MG.....260
LIVTENCITY.....261
LODOCO..... 262
LOKELMA..... 263
LONSURF..... 264
LORAZEPAM INTENSOL..... 371
lorazepam oral tablet 0.5 mg, 1 mg, 2 mg..371
LORBRENA ORAL TABLET 100 MG, 25 MG..... 265
LOREEV XR ORAL CAPSULE,EXTENDED RELEASE 24HR 1 MG, 1.5 MG, 2 MG, 3 MG.....371
LOTRONEX ORAL TABLET 0.5 MG, 1 MG..... 266
LOVAZA.....267
LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG..... 268
LUMRYZ..... 269
LUMRYZ STARTER PACK..... 269
LUNESTA..... 371
LUPKYNIS..... 270
LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG..... 271
LUPRON DEPOT-PED INTRAMUSCULAR KIT 7.5 MG (PED)..... 271
LUPRON DEPOT-PED INTRAMUSCULAR SYRINGE KIT.....271
lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg.....250
LYBALVI.....272
LYNPARZA.....273
LYRICA CR.....275
LYRICA ORAL CAPSULE 100 MG, 150 MG, 200 MG, 225 MG, 25 MG, 300 MG, 50 MG, 75 MG.....274
LYRICA ORAL SOLUTION.....274
LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5).....276
MAVENCLAD (10 TABLET PACK).....277
MAVENCLAD (4 TABLET PACK).....277
MAVENCLAD (5 TABLET PACK).....277
MAVENCLAD (6 TABLET PACK).....277
MAVENCLAD (7 TABLET PACK).....277
MAVENCLAD (8 TABLET PACK).....277
MAVENCLAD (9 TABLET PACK).....277
MAVYRET ORAL PELLETS IN PACKET..... 278
MAVYRET ORAL TABLET.....278
MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG..... 279
MAYZENT STARTER(FOR 1MG MAINT).....279

MAYZENT STARTER(FOR 2MG MAINT).....279
megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml).....280
megestrol oral tablet.....280
MEKINIST ORAL RECON SOLN.....281
MEKINIST ORAL TABLET 0.5 MG, 2 MG.....281
MEKTOVI.....282
meloxicam submicronized.....528
memantine-donepezil.....298
meperidine (pf) injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml.....371
meperidine oral solution.....371
meperidine oral tablet 50 mg.....371
*mesalamine oral capsule, extended release*355
mesalamine oral tablet,delayed release (dr/ec) 800 mg.....283
mesalamine rectal suppository.....283
metaxalone oral tablet 400 mg, 800 mg.....193
methadone oral solution 10 mg/5 ml, 5 mg/5 ml.....371
methadone oral tablet 10 mg, 5 mg.....371
methamphetamine.....285
METHITEST.....27
methylphenidate.....103
methyltestosterone oral capsule.....27
metronidazole oral tablet 125 mg.....286
metyrosine.....287
mifepristone oral tablet 300 mg.....245
miglustat.....575
MIPLYFFA.....288
modafinil.....380
MODEYSO.....289
morphine concentrate oral solution.....371
morphine oral capsule, er multiphase 24 hr 120 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg.....371
morphine oral capsule,extend.release pellets.....371
morphine oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml).....371
morphine oral tablet.....371
morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg.....371
MOTEGRITY.....290
MOTPOLY XR ORAL CAPSULE,EXTENDED RELEASE 24HR 100 MG, 150 MG, 200 MG.....291
MOUNJARO.....178
MS CONTIN ORAL TABLET EXTENDED RELEASE 15 MG, 30 MG, 60 MG.....371
MULPLETA.....293
MYALEPT.....294
MYCAPSSA.....296
MYFEMBREE.....297
NALOCET.....371
NAMZARIC ORAL CAPSULE,SPRINKLE,ER 24HR.....298
naproxen-esomeprazole.....525
NAYZILAM.....299
NEMLUVIO.....300
NERLYNX.....302
NEURONTIN ORAL CAPSULE 100 MG, 300 MG, 400 MG.....167
NEURONTIN ORAL SOLUTION.....167
NEURONTIN ORAL TABLET 600 MG, 800 MG.....167
NEXAVAR.....303
NEXLETOL.....304
NEXLIZET.....304
NGENLA.....184
nilotinib hcl.....468
NINLARO.....306
nitisinone.....307
NITYR.....307
NORDITROPIN FLEXPRO.....184
NORGESIC.....193
NORGESIC FORTE.....193
NORLIQVA.....25
NORTHERA ORAL CAPSULE 100 MG, 200 MG, 300 MG.....308
NOURIANZ.....309
NOXAFIL ORAL SUSP,DELAYED RELEASE FOR RECON.....362
NOXAFIL ORAL SUSPENSION.....363
NUBEQA.....310
NUCALA SUBCUTANEOUS AUTO-INJECTOR.....311
NUCALA SUBCUTANEOUS RECON SOLN.....311

NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML, 40 MG/0.4 ML 311
NUCYNTA ... 371
NUCYNTA ER ... 371
NUEDEXTA ... 313
NUPLAZID ... 314
NURTEC ODT ... 315
NUTROPIN AQ NUSPIN ... 184
NUVIGIL ... 316
OCALIVA ... 318
OCTAGAM ... 205
octreotide acetate injection solution ... 319
ODACTRA ... 320
ODOMZO ... 321
OFEV ... 221
OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG ... 322
OHTUVAYRE ... 323
OJEMDA ORAL SUSPENSION FOR RECONSTITUTION ... 324
OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4), 500 MG/WEEK (100 MG X 5), 600 MG/WEEK (100 MG X 6) ... 324
OJJAARA ... 325
OLPRUVA ORAL PELLETS IN PACKET 2 GRAM, 3 GRAM, 4 GRAM, 5 GRAM, 6 GRAM, 6.67 GRAM ... 326
OLUMIANT ... 327
OMNITROPE ... 184
OMVOH PEN SUBCUTANEOUS PEN INJECTOR 100 MG/ML, 300MG/3ML(100MG /ML-200 MG/2ML) ... 328
OMVOH SUBCUTANEOUS SYRINGE 100 MG/ML, 300MG/3ML(100MG /ML-200 MG/2ML) ... 328
ONAPGO ... 329
ONFI ORAL SUSPENSION ... 330
ONFI ORAL TABLET ... 330
ONGENTYS ... 331
ONUREG ... 332
ONYDA XR ... 333
OPIPZA ... 335
OPSUMIT ... 382
OPSYNVI ... 382
OPZELURA ... 336
ORACEA ... 337
ORENCIA CLICKJECT ... 338
ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML ... 338
ORENITRAM MONTH 1 TITRATION KT ... 382
ORENITRAM MONTH 2 TITRATION KT ... 382
ORENITRAM MONTH 3 TITRATION KT ... 382
ORENITRAM ORAL TABLET EXTENDED RELEASE 0.125 MG, 0.25 MG, 1 MG, 2.5 MG, 5 MG ... 382
ORFADIN ... 307
ORGOVYX ... 340
ORIAHNN ... 341
ORILISSA ORAL TABLET 150 MG, 200 MG ... 342
ORKAMBI ORAL GRANULES IN PACKET ... 343
ORKAMBI ORAL TABLET ... 343
ORLADEYO ... 344
ORMALVI ... 237
orphenadrine citrate oral ... 193
orphenadrine-asa-caffeine oral tablet 25-385-30 mg ... 193
ORSERDU ORAL TABLET 345 MG, 86 MG ... 346
OSENVELT ... 105
OSPHENA ... 347
OTEZLA ... 348
OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)- 20 MG (51), 10 MG (4)-20 MG (4)-30 MG (47) ... 348
OTREXUP (PF) ... 292
OTULFI SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML ... 507
oxazepam ... 371
OXERVATE ... 349
oxycodone oral capsule ... 371
oxycodone oral concentrate ... 371
oxycodone oral solution ... 371

oxycodone oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg.....371
oxycodone oral tablet, oral only.....371
oxycodone-acetaminophen oral solution 5-325 mg/5 ml.....371
oxycodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 2.5-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg.....371
OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG.371
oxymorphone oral tablet.....371
oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg.....371
OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML).....178
OZOBAX DS.....44
PALYNZIQ SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 2.5 MG/0.5 ML, 20 MG/ML.....350
PANRETIN.....351
PANZYGA.....205
paroxetine hcl.....31
paroxetine mesylate(menop.sym).....352
PAXIL CR.....31
PAXIL ORAL TABLET.....31
pazopanib.....537
PEGASYS.....217
PEMAZYRE.....353
pen needle, diabetic needle 29 gauge x 1/2".....354
PENTASA ORAL CAPSULE, EXTENDED RELEASE 500 MG.....355
PERCOCET ORAL TABLET 10-325 MG, 5-325 MG, 7.5-325 MG.....371
perphenazine-amitriptyline.....193
PHEBURANE.....356
phenobarbital.....195
phenoxybenzamine.....357
PHOSPHOLINE IODIDE.....358
PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2).....359
pirfenidone oral capsule.....221
pirfenidone oral tablet.....221
PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML.....218
PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML.....218
POMALYST.....360
PONVORY.....361
PONVORY 14-DAY STARTER PACK.361
posaconazole oral.....363, 364
PRALUENT PEN.....365
pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg.....274
pregabalin oral solution.....274
pregabalin oral tablet extended release 24 hr.....275
PRENATAL VITAMIN PLUS LOW IRON.....370
pretomanid.....375
PREVYMIS ORAL PELLETS IN PACKET.....376
PRIVIGEN.....205
PROCYSBI ORAL GRANULES DEL RELEASE IN PACKET.....377
PROLASTIN-C INTRAVENOUS SOLUTION.....21
PROLATE ORAL SOLUTION.....371
PROLATE ORAL TABLET.....371
PROLIA.....378
PROMACTA ORAL POWDER IN PACKET 12.5 MG, 25 MG.....482
PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG.....482
promethazine oral.....193
PROVIGIL ORAL TABLET 200 MG...380
prucalopride.....290
PRUDOXIN.....113
PULMOZYME.....384
pyrimethamine.....100
PYRUKYND ORAL TABLET 20 MG, 5 MG, 5 MG (4-WEEK PACK), 50 MG....387

PYRUKYND ORAL TABLETS,DOSE PACK ... 387
PYZCHIVA SUBCUTANEOUS SOLUTION ... 507
PYZCHIVA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML .. 507
QELBREE ORAL CAPSULE,EXTENDED RELEASE 24HR 100 MG, 150 MG, 200 MG ... 388
QINLOCK ... 389
quinine sulfate ... 390
QULIPTA ... 391
RADICAVA ORS STARTER KIT SUSP ... 392
RASUVO (PF) ... 292
RAVICTI ... 393
REBIF (WITH ALBUMIN) ... 218
REBIF REBIDOSE SUBCUTANEOUS PEN INJECTOR 22 MCG/0.5 ML, 44 MCG/0.5 ML, 8.8MCG/0.2ML-22 MCG/0.5ML (6) ... 218
REBIF TITRATION PACK ... 218
RECORLEV ... 443
RELISTOR ORAL ... 394
RELISTOR SUBCUTANEOUS SOLUTION ... 395
RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML, 8 MG/0.4 ML ... 395
REPATHA SURECLICK ... 396
REPATHA SYRINGE ... 396
RESTORIL ... 371
RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG ... 398
RETIN-A ... 492
RETIN-A MICRO ... 492
RETIN-A MICRO PUMP TOPICAL GEL WITH PUMP 0.06 %, 0.08 % ... 492
REVATIO ORAL TABLET ... 382
REVLIMID ... 399
REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG ... 400
REXULTI ORAL TABLET ... 401
REYVOW ORAL TABLET 100 MG, 50 MG ... 402
REZDIFFRA ... 403
REZLIDHIA ... 405
REZUROCK ... 406
RINVOQ LQ ... 410
RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG ... 408
RIVFLOZA SUBCUTANEOUS SOLUTION ... 411
RIVFLOZA SUBCUTANEOUS SYRINGE 128 MG/0.8 ML, 160 MG/ML ... 411
ROMVIMZA ... 412
ROWASA RECTAL ENEMA KIT ... 283
ROXICODONE ORAL TABLET 15 MG, 30 MG ... 371
ROXYBOND ... 371
ROZLYTREK ORAL CAPSULE 100 MG, 200 MG ... 413
ROZLYTREK ORAL PELLETS IN PACKET ... 413
RUBRACA ... 414
RUCONEST ... 415
rufinamide ... 47
RYBELSUS ... 178
RYDAPT ... 417
RYVENT ... 72
SABRIL ... 418
SAJAZIR ... 157
SAMSCA ... 420
SANDOSTATIN INJECTION SOLUTION 100 MCG/ML, 50 MCG/ML, 500 MCG/ML ... 319
SAPHRIS ... 421
sapropterin ... 248
SAVELLA ... 422
saxagliptin ... 114
saxagliptin-metformin oral tablet, er multiphase 24 hr 2.5-1,000 mg, 5-1,000 mg, 5-500 mg ... 114
SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG ... 423
SECUADO ... 424
SELARSDI SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML .. 507
SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG ... 184

sertraline oral capsule 425
SEYSARA 426
SIGNIFOR 443
sildenafil (pulm.hypertension) oral suspension for reconstitution 382
sildenafil (pulm.hypertension) oral tablet .. 382
SILENOR 193
SILIQ 427
SIMLANDI(CF) 367
SIMLANDI(CF) AUTOINJECTOR 367
SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML, 50 MG/0.5 ML 428
SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML, 50 MG/0.5 ML 428
SIRTURO 430
sitagliptin oral tablet 100 mg, 25 mg, 50 mg 114
sitagliptin-metformin oral tablet 114
sitagliptin-metformin oral tablet, er multiphase 24 hr 100-1,000 mg, 50-1,000 mg, 50-500 mg 114
SKYCLARYS 431
SKYRIZI SUBCUTANEOUS PEN INJECTOR 432
SKYRIZI SUBCUTANEOUS SYRINGE 432
SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML) 432
SKYTROFA SUBCUTANEOUS CARTRIDGE 11 MG, 13.3 MG, 3 MG, 3.6 MG, 4.3 MG, 5.2 MG, 6.3 MG, 7.6 MG, 9.1 MG 433
sodium oxybate 569
sodium phenylbutyrate 61
sofosbuvir-velpatasvir 137
SOGROYA 434
SOHONOS ORAL CAPSULE 1 MG, 1.5 MG, 10 MG, 2.5 MG, 5 MG 435
SOMA 193
SOMAVERT 437
sorafenib 303
SOTYKTU 438
SOVALDI 439
SPEVIGO SUBCUTANEOUS 440
SPORANOX ORAL CAPSULE 226
SPRYCEL 441
STEGLUJAN 116
STELARA SUBCUTANEOUS SOLUTION 507
STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML .. 507
STEQEYMA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML .. 369
STIVARGA 444
STOBOCLO 106
STROMECTOL 227
SUCRAID 445
sunitinib malate 448
SUNOSI 446
SUTENT 448
SYMDEKO 449
SYMPAZAN 450
SYMPROIC 451
SYNAREL 452
TABRECTA 453
tadalafil (pulm. hypertension) 382
tadalafil oral tablet 2.5 mg, 5 mg 78
TADLIQ 382
TAFINLAR ORAL CAPSULE 454
TAFINLAR ORAL TABLET FOR SUSPENSION 454
TAGRISSO 456
TAKHZYRO SUBCUTANEOUS SOLUTION 458
TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML (150 MG/ML) 458
TALICIA 460
TALTZ AUTOINJECTOR 461
TALTZ SYRINGE SUBCUTANEOUS SYRINGE 20 MG/0.25 ML, 40 MG/0.5 ML, 80 MG/ML 461
TALZENNA 463
TARGRETIN ORAL 464
TARGRETIN TOPICAL 465
TARPEYO 466
TASCENSO ODT 467
TASIGNA 468
tasimelteon 469

TAVALISSE 470
TAVNEOS 471
tazarotene topical cream 473
tazarotene topical foam 472
tazarotene topical gel 473
TAZORAC TOPICAL CREAM 473
TAZORAC TOPICAL GEL 473
TAZVERIK 474
TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 120 MG, 120 MG (14)- 240 MG (46), 240 MG 475
temazepam 371
TEPMETKO 476
teriflunomide 38
teriparatide subcutaneous pen injector 20 mcg/dose (560mcg/2.24ml) 162
TESTIM 477
testosterone cypionate 477
testosterone enanthate 477
testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %), 20.25 mg/1.25 gram (1.62 %) 477
testosterone transdermal gel in packet 477
testosterone transdermal solution in metered pump w/app 477
tetrabenazine oral tablet 12.5 mg, 25 mg 558
TEZRULY 479
THALOMID ORAL CAPSULE 100 MG, 50 MG 480
THIOLA 481
THIOLA EC 481
TIBSOVO 483
TIGLUTIK 407
tiopronin 481
TLANDO 477
TOBI 75
TOBI PODHALER 75
tobramycin in 0.225 % nacl 75
tobramycin inhalation 75
TOLSURA 487
tolvaptan 420
tolvaptan (polycys kidney dis) oral tablet 233
tolvaptan (polycys kidney dis) oral tablets, sequential 233
TORPENZ 489
TRACLEER ORAL TABLET 382
TRACLEER ORAL TABLET FOR SUSPENSION 382
TRADJENTA 114
tramadol oral capsule,er biphase 24 hr 17-83 371
tramadol oral capsule,er biphase 24 hr 25-75 100 mg, 200 mg 371
tramadol oral tablet 100 mg, 25 mg, 50 mg, 75 mg 371
tramadol oral tablet extended release 24 hr 371
tramadol-acetaminophen 371
TREMFYA PEN INDUCTION PK-CROHN 490
TREMFYA PEN SUBCUTANEOUS PEN INJECTOR 200 MG/2 ML 490
TREMFYA SUBCUTANEOUS AUTO-INJECTOR 490
TREMFYA SUBCUTANEOUS SYRINGE 100 MG/ML, 200 MG/2 ML 490
tretinoin 492
tretinoin microspheres topical gel 492
tretinoin microspheres topical gel with pump 0.08 % 492
triazolam 371
TRIDACAINE II 257
trientine oral capsule 500 mg 493
TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 12.5-2.5-1,000 MG, 25-5-1,000 MG, 5-2.5-1,000 MG 116
TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL 494
TRIKAFTA ORAL TABLETS, SEQUENTIAL 494
trimethobenzamide oral 484
trimipramine 193
TRINTELLIX 495
TRUDHESA 110
TRULANCE 496
TRULICITY 178
TRUQAP 497
TRYNGOLZA 498
TRYVIO 499

TUKYSA ORAL TABLET 150 MG, 50 MG ... 500
TURALIO ORAL CAPSULE 125 MG .. 501
TWYNEO ... 492
TYENNE AUTOINJECTOR ... 485
TYENNE SUBCUTANEOUS ... 485
TYKERB ... 502
TYMLOS ... 503
TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16 MCG, 16(112)-32(112) -48(28) MCG, 32 MCG, 48 MCG, 64 MCG ... 382
UBRELVY ORAL TABLET 100 MG, 50 MG ... 504
ULORIC ... 505
UNDECATREX ... 477
UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG ... 506
UPTRAVI ORAL TABLETS,DOSE PACK ... 506
ustekinumab subcutaneous solution ... 507
ustekinumab subcutaneous syringe 45 mg/0.5 ml, 90 mg/ml ... 507
ustekinumab-aekn subcutaneous syringe 45 mg/0.5 ml, 90 mg/ml ... 507
ustekinumab-ttwe subcutaneous syringe 45 mg/0.5 ml, 90 mg/ml ... 507
VALCHLOR ... 509
VALIUM ... 371
VALTOCO ... 510
VANFLYTA ... 511
VANRAFIA ... 512
VELSIPITY ... 513
VELTASSA ORAL POWDER IN PACKET 1 GRAM, 16.8 GRAM, 25.2 GRAM, 8.4 GRAM ... 514
VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG ... 516
VENCLEXTA STARTING PACK ... 516
venlafaxine besylate ... 515
VENXXIVA ... 481
VEOZAH ... 517
VERKAZIA ... 518
VERQUVO ... 519
VERZENIO ... 520
VFEND IV ... 535
VIBERZI ... 521
VICTOZA 3-PAK ... 178
vigabatrin ... 418
VIGADRONE ... 418
VIGAFYDE ... 522
VIGPODER ... 418
VIIBRYD ORAL TABLET ... 523
VIJOICE ORAL GRANULES IN PACKET ... 524
VIJOICE ORAL TABLET 125 MG, 250 MG/DAY (200 MG X1-50 MG X1), 50 MG ... 524
vilazodone ... 523
VITRAKVI ORAL CAPSULE 100 MG, 25 MG ... 526
VITRAKVI ORAL SOLUTION ... 526
VIVJOA ... 527
VIZIMPRO ... 529
VOGELXO TRANSDERMAL GEL ... 477
VOGELXO TRANSDERMAL GEL IN METERED-DOSE PUMP ... 477
VONJO ... 530
VOQUEZNA DUAL PAK ... 533
VOQUEZNA ORAL TABLET 10 MG, 20 MG ... 531
VOQUEZNA TRIPLE PAK ... 533
VORANIGO ORAL TABLET 10 MG, 40 MG ... 534
voriconazole intravenous ... 535
VOSEVI ... 536
VOTRIENT ... 537
VOWST ... 151
VOXZOGO ... 538
VOYDEYA ... 539
VRAYLAR ORAL CAPSULE ... 540
VTAMA ... 541
VUITY ... 542
VUMERITY ... 543
VYKAT XR ORAL TABLET EXTENDED RELEASE 24 HR 150 MG, 25 MG, 75 MG ... 544
VYNDAMAX ... 36
VYNDAQEL ... 36

VYVGART HYTRULO SUBCUTANEOUS SYRINGE 545
WAINUA 547
WAKIX 548
WEGOVY SUBCUTANEOUS PEN INJECTOR 0.25 MG/0.5 ML, 0.5 MG/0.5 ML, 1 MG/0.5 ML, 1.7 MG/0.75 ML, 2.4 MG/0.75 ML 549
WELIREG 550
WEZLANA SUBCUTANEOUS SOLUTION 507
WEZLANA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML .. 507
WINLEVI 492
WINREVAIR 551
WYOST 105
XALKORI ORAL CAPSULE 552
XALKORI ORAL PELLET 150 MG, 20 MG, 50 MG 552
XANAX ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG 371
XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 0.5 MG, 1 MG, 2 MG, 3 MG 371
XCOPRI 553
XCOPRI MAINTENANCE PACK 553
XCOPRI TITRATION PACK 553
XDEMVY 554
XELJANZ ORAL SOLUTION 557
XELJANZ ORAL TABLET 555
XELJANZ XR 555
XENAZINE ORAL TABLET 12.5 MG, 25 MG 558
XERMELO 559
XGEVA 560
XHANCE 561
XIFAXAN ORAL TABLET 550 MG 562
XOLAIR 563
XOLREMDI 565
XOSPATA 566
XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (10 MG X 4), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK) 567
XTAMPZA ER 371
XTANDI ORAL CAPSULE 568
XTANDI ORAL TABLET 40 MG, 80 MG 568
XYOSTED 477
XYREM 569
XYWAV 571
YARGESA 575
YESINTEK SUBCUTANEOUS SOLUTION 369
YESINTEK SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML .. 369
YONSA 573
YORVIPATH SUBCUTANEOUS PEN INJECTOR 168 MCG/0.56 ML, 294 MCG/0.98 ML, 420 MCG/1.4 ML 574
YUFLYMA(CF) 367
YUFLYMA(CF) AI CROHN'S-UC-HS . 367
YUFLYMA(CF) AUTOINJECTOR 367
YUSIMRY(CF) PEN 7
YUTREPIA INHALATION CAPSULE, W/INHALATION DEVICE 106 MCG, 26.5 MCG, 53 MCG, 79.5 MCG 382
zaleplon oral capsule 10 mg, 5 mg 371
ZAVESCA 575
ZAVZPRET 576
ZEJULA ORAL TABLET 577
ZELBORAF 578
ZELSUVMI 579
ZEMAIRA INTRAVENOUS RECON SOLN 1,000 MG 21
ZEPATIER 580
ZEPBOUND SUBCUTANEOUS PEN INJECTOR 581
ZEPOSIA 582
ZEPOSIA STARTER KIT (28-DAY) 582
ZEPOSIA STARTER PACK (7-DAY) ... 582

ZERVIATE 334
ZIANA 492
ZILBRYSQ SUBCUTANEOUS SYRINGE 16.6 MG/0.416 ML, 23 MG/0.574 ML, 32.4 MG/0.81 ML 295
zileuton 256
ZITUVIMET 114
ZITUVIMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG, 50-1,000 MG, 50-500 MG 114
ZITUVIO ORAL TABLET 100 MG, 25 MG, 50 MG 114
ZOLINZA 583
zolpidem 371, 584
ZOMACTON 184
ZONALON 113
ZONISADE 585
ZORYVE TOPICAL CREAM 0.15 % ... 586
ZORYVE TOPICAL CREAM 0.3 % 587
ZORYVE TOPICAL FOAM 588
ZTALMY 589
ZTLIDO 590
ZUNVEYL 591
ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG 592
ZYDELIG 593
ZYFLO 256
ZYKADIA 594
ZYMFENTRA 595
ZYTIGA ORAL TABLET 250 MG, 500 MG 597

Section:
Step Therapy

Brand ADHD

Products Affected

- **ADDERALL 20 MG TABLET**
- **ADDERALL 5 MG TABLET**
- **ADDERALL 7.5 MG TABLET**
- **ADDERALL XR 10 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 15 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 20 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 25 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 30 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 5 MG CAPSULE,EXTENDED RELEASE**
- **ADZENYS XR-ODT 12.5 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 15.7 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 18.8 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 3.1 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 6.3 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 9.4 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **APTENSIO XR 10 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 15 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 20 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 30 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 40 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 50 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 60 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **AZSTARYS 26.1 MG-5.2 MG CAPSULE**
- **AZSTARYS 39.2 MG-7.8 MG CAPSULE**
- **AZSTARYS 52.3 MG-10.4 MG CAPSULE**
- **CONCERTA 18 MG TABLET,EXTENDED RELEASE**
- **CONCERTA 27 MG TABLET,EXTENDED RELEASE**
- **CONCERTA 36 MG TABLET,EXTENDED RELEASE**
- **CONCERTA 54 MG TABLET,EXTENDED RELEASE**
- **COTEMPLA XR-ODT 17.3 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **COTEMPLA XR-ODT 25.9 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **COTEMPLA XR-ODT 8.6 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **DEXEDRINE SPANSULE 10 MG CAPSULE,EXTENDED RELEASE**
- *dextroamphetamine sulfate er 10 mg capsule,extended release*
- *dextroamphetamine sulfate er 15 mg capsule,extended release*
- *dextroamphetamine sulfate er 5 mg capsule,extended release*
- *dextroamphetamine-amphetamine er 12.5 mg capsule, 3 bead, ext rel 24hr*
- *dextroamphetamine-amphetamine er 25 mg capsule,3 bead,ext release 24hr*

- *dextroamphetamine-amphetamine er 37.5 mg capsule, 3 bead, ext rel 24hr*
- *dextroamphetamine-amphetamine er 50 mg capsule,3 bead,ext release 24hr*
- **DYANAVEL XR 10 MG TABLET, EXTENDED RELEASE**
- **DYANAVEL XR 15 MG TABLET, EXTENDED RELEASE**
- **DYANAVEL XR 2.5 MG/ML ORAL 24 HR EXTENDED RELEASE SUSPENSION**
- **DYANAVEL XR 20 MG TABLET, EXTENDED RELEASE**
- **DYANAVEL XR 5 MG TABLET, EXTENDED RELEASE**
- **FOCALIN 10 MG TABLET**
- **FOCALIN 2.5 MG TABLET**
- **FOCALIN 5 MG TABLET**
- **FOCALIN XR 10 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 15 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 20 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 25 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 30 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 35 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 40 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 5 MG CAPSULE,EXTENDED RELEASE**
- **JORNAY PM 100 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- **JORNAY PM 20 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- **JORNAY PM 40 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- **JORNAY PM 60 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- **JORNAY PM 80 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- *lisdexamfetamine 10 mg capsule*
- *lisdexamfetamine 10 mg chewable tablet*
- *lisdexamfetamine 20 mg capsule*
- *lisdexamfetamine 20 mg chewable tablet*
- *lisdexamfetamine 30 mg capsule*
- *lisdexamfetamine 30 mg chewable tablet*
- *lisdexamfetamine 40 mg capsule*
- *lisdexamfetamine 40 mg chewable tablet*
- *lisdexamfetamine 50 mg capsule*
- *lisdexamfetamine 50 mg chewable tablet*
- *lisdexamfetamine 60 mg capsule*
- *lisdexamfetamine 60 mg chewable tablet*
- *lisdexamfetamine 70 mg capsule*
- **METADATE CD 10 MG CAPSULE,EXTENDED RELEASE**
- **METADATE CD 20 MG CAPSULE,EXTENDED RELEASE**
- **METADATE CD 30 MG CAPSULE,EXTENDED RELEASE**
- **METADATE CD 40 MG CAPSULE,EXTENDED RELEASE**
- **METADATE CD 50 MG CAPSULE,EXTENDED RELEASE**
- **METADATE CD 60 MG CAPSULE,EXTENDED RELEASE**
- **METHYLIN 10 MG/5 ML ORAL SOLUTION**
- **METHYLIN 5 MG/5 ML ORAL SOLUTION**
- *methylphenidate er 10 mg capsule,extended release (40-60) sprinkle*
- *methylphenidate er 15 mg capsule,extended release (40-60) sprinkle*
- *methylphenidate er 18 mg tablet,extended release 24 hr (bx rating)*
- *methylphenidate er 20 mg capsule,extended release (40-60) sprinkle*
- *methylphenidate er 27 mg tablet,extended release 24 hr (bx rating)*
- *methylphenidate er 30 mg capsule,extended*

release (40-60) sprinkle

- *methylphenidate er 36 mg tablet,extended release 24 hr (bx rating)*
- *methylphenidate er 40 mg capsule,extended release (40-60) sprinkle*
- *methylphenidate er 45 mg tablet,extended release 24 hr*
- *methylphenidate er 50 mg capsule,extended release (40-60) sprinkle*
- *methylphenidate er 54 mg tablet,extended release 24 hr (bx rating)*
- *methylphenidate er 60 mg capsule,extended release (40-60) sprinkle*
- *methylphenidate er 63 mg tablet,extended release 24 hr*
- *methylphenidate er 72 mg tablet,extended release 24 hr*
- **MYDAYIS 12.5 MG CAPSULE EXTENDED RELEASE 24 HR**
- **MYDAYIS 25 MG CAPSULE EXTENDED RELEASE 24 HR**
- **MYDAYIS 37.5 MG CAPSULE EXTENDED RELEASE 24 HR**
- **MYDAYIS 50 MG CAPSULE EXTENDED RELEASE 24 HR**
- **QUILLICHEW ER 20 MG CHEWABLE TABLET, EXTENDED RELEASE**
- **QUILLICHEW ER 30 MG CHEWABLE TABLET, EXTENDED RELEASE**
- **QUILLICHEW ER 40 MG CHEWABLE, EXTENDED RELEASE TABLET**
- **QUILLIVANT XR 5 MG/ML (25 MG/5 ML) ORAL SUSPENSION,EXTEND RELEASE 24HR**
- **RELEXXII 18 MG TABLET,EXTENDED RELEASE**
- **RELEXXII 27 MG TABLET,EXTENDED RELEASE**
- **RELEXXII 36 MG TABLET,EXTENDED RELEASE**
- **RELEXXII 45 MG TABLET,EXTENDED RELEASE**
- **RELEXXII 54 MG TABLET,EXTENDED RELEASE**
- **RELEXXII 63 MG TABLET,EXTENDED RELEASE**
- **RITALIN 10 MG TABLET**
- **RITALIN 20 MG TABLET**
- **RITALIN LA 10 MG CAPSULE,EXTENDED RELEASE**
- **RITALIN LA 20 MG CAPSULE,EXTENDED RELEASE**
- **RITALIN LA 30 MG CAPSULE,EXTENDED RELEASE**
- **RITALIN LA 40 MG CAPSULE,EXTENDED RELEASE**
- **VYVANSE 10 MG CAPSULE**
- **VYVANSE 10 MG CHEWABLE TABLET**
- **VYVANSE 20 MG CAPSULE**
- **VYVANSE 20 MG CHEWABLE TABLET**
- **VYVANSE 30 MG CAPSULE**
- **VYVANSE 30 MG CHEWABLE TABLET**
- **VYVANSE 40 MG CAPSULE**
- **VYVANSE 40 MG CHEWABLE TABLET**
- **VYVANSE 50 MG CAPSULE**
- **VYVANSE 50 MG CHEWABLE TABLET**
- **VYVANSE 60 MG CAPSULE**
- **VYVANSE 60 MG CHEWABLE TABLET**
- **VYVANSE 70 MG CAPSULE**
- **XELSTRYM 13.5 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH**
- **XELSTRYM 18 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH**
- **XELSTRYM 4.5 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH**
- **XELSTRYM 9 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH**

Details

Criteria	Require a 1 month trial of 2 of the following generic ADHD medications (Step 1 drug) when being utilized for the same medically accepted indication: methylphenidate (i.e. generics of Concerta, Metadate CD, Methylin, Relexxii, Ritalin/Ritalin LA), atomoxetine, dextroamphetamine/amphetamine (i.e. generics of Adderall/Adderal XR), or dexmethylphenidate in the last 180 days.

Brand Albuterol

Products Affected

- *albuterol sulfate hfa 90 mcg/actuation aerosol inhaler (nda020983)*
- **PROAIR RESPICLICK 90 MCG/ACTUATION BREATH ACTIVATED**

Details

Criteria	Require a 1 month trial of albuterol (generic Proair HFA) in the last 90 days

Brand Epinephrine

Products Affected

- **AUVI-Q 0.1 MG/0.1 ML INJECTION,AUTO-INJECTOR**
- **AUVI-Q 0.15 MG/0.15 ML AUTO-INJECTOR (FOR 33 LB TO 66 LB PATIENTS)**
- **AUVI-Q 0.3 MG/0.3 ML INJECTION, AUTO-INJECTOR**
- **EPIPEN 2-PAK 0.3 MG/0.3 ML INJECTION, AUTO-INJECTOR**
- **EPIPEN JR 2-PAK 0.15 MG/0.3 ML INJECTION,AUTO-INJECTOR**
- **NEFFY 1 MG/SPRAY (0.1 ML) NASAL SPRAY**
- **NEFFY 2 MG/SPRAY (0.1 ML) NASAL SPRAY**

Details

Criteria	Require a trial of generic epinephrine injection in the last 90 days

Brand Levalbuterol

Products Affected

- **XOPENEX HFA 45 MCG/ACTUATION AEROSOL INHALER**

Details

Criteria	Require a 1 month trial of albuterol (generic Proair HFA) and generic levalbuterol in the last 180 days

Celecoxib

Products Affected

- **CELEBREX 100 MG CAPSULE**
- **CELEBREX 200 MG CAPSULE**
- **CELEBREX 400 MG CAPSULE**
- **CELEBREX 50 MG CAPSULE**

Details

Criteria	Require a 1 month trial of generic celecoxib and 1 other formulary generic NSAID (Step 1 drugs) in the last 180 days

Clonidine ER

Products Affected

- *clonidine hcl er 0.17 mg tablet,extended release 24 hr*
- **NEXICLON XR 0.17 MG TABLET,EXTENDED RELEASE**

Details

Criteria	Require a 1 month trial of generic clonidine IR tablet (Step 1 drug) in the last 90 days

Colony Stimulating Factors

Products Affected

- **FULPHILA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE**
- **FYLNETRA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE**
- **GRANIX 300 MCG/0.5 ML SUBCUTANEOUS SYRINGE**
- **GRANIX 300 MCG/ML SUBCUTANEOUS SOLUTION**
- **GRANIX 480 MCG/0.8 ML SUBCUTANEOUS SYRINGE**
- **NEULASTA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE**
- **NEUPOGEN 300 MCG/0.5 ML INJECTION SYRINGE**
- **NEUPOGEN 300 MCG/ML INJECTION SOLUTION**
- **NEUPOGEN 480 MCG/0.8 ML INJECTION SYRINGE**
- **NEUPOGEN 480 MCG/1.6 ML INJECTION SOLUTION**
- **NYVEPRIA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE**
- **RELEUKO 300 MCG/0.5 ML SUBCUTANEOUS SYRINGE**
- **RELEUKO 480 MCG/0.8 ML SUBCUTANEOUS SYRINGE**
- **STIMUFEND 6 MG/0.6 ML SUBCUTANEOUS SYRINGE**
- **UDENYCA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE**
- **UDENYCA AUTOINJECTOR 6 MG/0.6 ML SUBCUTANEOUS AUTO-INJECTOR**
- **ZIEXTENZO 6 MG/0.6 ML SUBCUTANEOUS SYRINGE**

Details

Criteria	Require a 1 month trial of Zarxio and Nivestym (step 1 drugs) in the last 180 days

Dry Eye

Products Affected

- **CEQUA 0.09 % EYE DROPS IN A DROPPERETTE**
- **MIEBO (PF) 100 % EYE DROPS**
- **TRYPTYR 0.003 % EYE DROPS IN A DROPPERETTE**
- **TYRVAYA 0.03 MG/SPRAY NASAL SPRAY**
- **VEVYE 0.1 % EYE DROPS**

Details

Criteria	Require a 1 month trial of Xiidra and one of the following: Restasis or cyclosporine eye drop (i.e. generic Restasis), in the last 180 days

Dymista

Products Affected

- **DYMISTA 137 MCG-50 MCG/SPRAY NASAL SPRAY**
- **RYALTRIS 665 MCG-25 MCG/SPRAY NASAL SPRAY**

Details

Criteria	Require a 1 month trial of generic azelastine/fluticasone spray in the last 90 days

Entresto Tablet

Products Affected

- **ENTRESTO 24 MG-26 MG TABLET**
- **ENTRESTO 49 MG-51 MG TABLET**
- **ENTRESTO 97 MG-103 MG TABLET**

Details

Criteria	Pending CMS Review

Erythroid Stimulants

Products Affected

- **ARANESP 10 MCG/0.4 ML (IN POLYSORBATE) INJECTION SYRINGE**
- **ARANESP 100 MCG/0.5 ML (IN POLYSORBATE) INJECTION SYRINGE**
- **ARANESP 100 MCG/ML (IN POLYSORBATE) INJECTION**
- **ARANESP 150 MCG/0.3 ML (IN POLYSORBATE) INJECTION SYRINGE**
- **ARANESP 200 MCG/0.4 ML (IN POLYSORBATE) INJECTION SYRINGE**
- **ARANESP 200 MCG/ML (IN POLYSORBATE) INJECTION**
- **ARANESP 25 MCG/0.42 ML (IN POLYSORBATE) INJECTION SYRINGE**
- **ARANESP 25 MCG/ML (IN POLYSORBATE) INJECTION**
- **ARANESP 300 MCG/0.6 ML (IN POLYSORBATE) INJECTION SYRINGE**
- **ARANESP 40 MCG/0.4 ML (IN POLYSORBATE) INJECTION SYRINGE**
- **ARANESP 40 MCG/ML (IN POLYSORBATE) INJECTION**
- **ARANESP 500 MCG/ML (IN POLYSORBATE) INJECTION SYRINGE**
- **ARANESP 60 MCG/0.3 ML (IN POLYSORBATE) INJECTION SYRINGE**
- **ARANESP 60 MCG/ML (IN POLYSORBATE) INJECTION**
- **EPOGEN 2,000 UNIT/ML INJECTION SOLUTION**
- **EPOGEN 20,000 UNIT/2 ML INJECTION SOLUTION**
- **EPOGEN 20,000 UNIT/ML INJECTION SOLUTION**
- **EPOGEN 3,000 UNIT/ML INJECTION SOLUTION**
- **EPOGEN 4,000 UNIT/ML INJECTION SOLUTION**
- **MIRCERA 100 MCG/0.3 ML INJECTION SYRINGE**
- **MIRCERA 120 MCG/0.3 ML INJECTION SYRINGE**
- **MIRCERA 150 MCG/0.3 ML INJECTION SYRINGE**
- **MIRCERA 200 MCG/0.3 ML INJECTION SYRINGE**
- **MIRCERA 30 MCG/0.3 ML INJECTION SYRINGE**
- **MIRCERA 50 MCG/0.3 ML INJECTION SYRINGE**
- **MIRCERA 75 MCG/0.3 ML INJECTION SYRINGE**

Details

Criteria	Require a 1 month trial of Procrit and Retacrit (Step 1 drugs) in the last 180 days

Fortamet

Products Affected

- *metformin er 1,000 mg tablet,extended release 24hr (osmotic)*
- *metformin er 500 mg tablet,extended release 24hr (osmotic)*

Details

Criteria	Require a 1 month trial of generic metformin IR tablets and generic metformin ER (i.e. generic Glucophage XR) tablets in the last 180 days

Glumetza

Products Affected

- **GLUMETZA 1,000 MG TABLET,EXTENDED RELEASE**
- **GLUMETZA 500 MG TABLET,EXTENDED RELEASE**
- *metformin er 1,000 mg 24 hr tablet,extended release (gastric reten.)*
- *metformin er 500 mg 24 hr tablet,extended release (gastric retention)*

Details

Criteria	Require a 1 month trial of generic metformin IR tablets and generic metformin ER (i.e. generic Glucophage XR) tablets in the last 180 days

GnRH Agonists

Products Affected

- **ELIGARD 22.5 MG (3 MONTH) SUBCUTANEOUS SYRINGE**
- **ELIGARD 30 MG (4 MONTH) SUBCUTANEOUS SYRINGE**
- **ELIGARD 45 MG (6 MONTH) SUBCUTANEOUS SYRINGE**
- **ELIGARD 7.5 MG (1 MONTH) SUBCUTANEOUS SYRINGE**
- **LUPRON DEPOT 22.5 MG (3 MONTH) INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 30 MG (4 MONTH) INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 45 MG (6 MONTH) INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 7.5 MG INTRAMUSCULAR SYRINGE KIT**
- **LUTRATE DEPOT (3 MONTH) 22.5 MG IM SUSPENSION**
- **TRELSTAR 11.25 MG IM SUSPENSION**
- **TRELSTAR 22.5 MG IM SUSPENSION**
- **TRELSTAR 3.75 MG IM SUSPENSION**

Details

Criteria	Require a trial of Leuprolide 22.5mg (Step 1 drug) in the last 180 days when being utilized for the same medically accepted indication

Herpetic Keratitis

Products Affected

- **ZIRGAN 0.15 % EYE GEL**

Details

Criteria	Require a 1 month trial of generic trifluridine eye drops (Step 1 drug) in the last 90 days

Inhaled LAMA

Products Affected

- **INCRUSE ELLIPTA 62.5 MCG/ACTUATION POWDER FOR INHALATION**
- **SPIRIVA WITH HANDIHALER 18 MCG AND INHALATION CAPSULES**
- *tiotropium bromide 18 mcg capsule with inhalation device*
- **TUDORZA PRESSAIR 400 MCG/ACTUATION BREATH ACTIVATED**
- **TUDORZA PRESSAIR 400 MCG/ACTUATION BREATH ACTIVATED (30 ACTUAT)**

Details

Criteria	Require a 1 month trial of Spiriva Respimat (Step 1 drug) in the last 90 days

Inhaled LAMA/LABA

Products Affected

- *umeclidinium 62.5 mcg-vilanterol 25 mcg/actuation powdr for inhalation*

Details

Criteria	Require a 1 month trial of Anoro Ellipta (Step 1 drug) in the last 90 days

Lactulose

Products Affected

- **KRISTALOSE 10 GRAM ORAL PACKET**
- **KRISTALOSE 20 GRAM ORAL PACKET**
- *lactulose 10 gram oral packet*
- *lactulose 20 gram oral packet*

Details

Criteria	Require a 1 month trial of lactulose solution (Step 1 drug) in the last 90 days

Metformin IR

Products Affected

- *metformin 625 mg tablet*
- *metformin 750 mg tablet*

Details

Criteria	Require a 1 month trial of generic metformin IR 500mg tablets, 850mg tablets, or 1000mg tablets (step 1 drug) in the last 90 days

Mirabegron ER

Products Affected

- *mirabegron er 25 mg tablet,extended release 24 hr*
- *mirabegron er 50 mg tablet,extended release 24 hr*

Details

Criteria	Require a 1 month trial of Myrbetriq (Step 1 drug) in the last 90 days

Mupirocin

Products Affected

- *mupirocin calcium 2 % topical cream*

Details

Criteria	Require a 1 month trial of generic mupirocin ointment (Step 1 drug) in the last 90 days

Pancreatic Enzymes

Products Affected

- **PANCREAZE 10,500 UNIT-35,500 UNIT-61,500 UNIT CAPSULE,DELAYED RELEASE**
- **PANCREAZE 16,800 UNIT-56,800 UNIT-98,400 UNIT CAPSULE,DELAYED RELEASE**
- **PANCREAZE 2,600 UNIT-8,800 UNIT-15,200 UNIT CAPSULE,DELAYED RELEASE**
- **PANCREAZE 21,000 UNIT-54,700 UNIT-83,900 UNIT CAPSULE,DELAYED RELEASE**
- **PANCREAZE 37,000-97,300-149,900 UNIT CAPSULE,DELAYED RELEASE**
- **PANCREAZE 4,200 UNIT-14,200 UNIT-24,600 UNIT CAPSULE,DELAYED RELEASE**
- **PERTZYE 16,000 UNIT-57,500 UNIT-60,500 UNIT CAPSULE,DELAYED RELEASE**
- **PERTZYE 24,000-86,250-90,750 UNIT CAPSULE,DELAYED RELEASE**
- **PERTZYE 4,000 UNIT-14,375 UNIT-15,125 UNIT CAPSULE,DELAYED RELEASE**
- **PERTZYE 8,000 UNIT-28,750 UNIT-30,250 UNIT CAPSULE,DELAYED RELEASE**

Details

Criteria	Pending CMS Review

Pennsaid

Products Affected

- *diclofenac 20 mg/gram/actuation (2 %) topical soln metered-dose pump*

Details

Criteria	Require a 1 month trial of Diclofenac 1.5% (Step 1 drug) in the last 90 days

Prostaglandins

Products Affected

- **IYUZEH (PF) 0.005 % EYE DROPS IN A DROPPERETTE**
- **VYZULTA 0.024 % EYE DROPS**
- **ZIOPTAN (PF) 0.0015 % EYE DROPS IN A DROPPERETTE**

Details

Criteria	Require a 1 month trial of brand Lumigan (Step 1 drug) plus one other preferred generic glaucoma drug (Step 1 drug) in the last 180 days.

Pulmonary Antiinflammatory

Products Affected

- *fluticasone propionate 100 mcg/actuation blister powder for inhalation*
- *fluticasone propionate 110 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 220 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 250 mcg/actuation blister powder for inhalation*
- *fluticasone propionate 44 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 50 mcg/actuation blister powder for inhalation*

Details

Criteria	Require a 1 month trial of Qvar and Asmanex/Asmanex HFA (Step 1 drugs) in the last 180 days

Pulmonary Antiinflammatory Combo

Products Affected

- **ADVAIR DISKUS 100 MCG-50 MCG/DOSE POWDER FOR INHALATION**
- **ADVAIR DISKUS 250 MCG-50 MCG/DOSE POWDER FOR INHALATION**
- **ADVAIR DISKUS 500 MCG-50 MCG/DOSE POWDER FOR INHALATION**
- *fluticasone 113 mcg-salmeterol 14 mcg/actuation breath activated powdr*
- *fluticasone 232 mcg-salmeterol 14 mcg/actuation breath activated powdr*
- *fluticasone 55 mcg-salmeterol 14 mcg/actuation breath activated powder*
- *fluticasone furoate 100 mcg-vilanterol 25 mcg/dose inhalation powder*
- *fluticasone furoate 200 mcg-vilanterol 25 mcg/dose inhalation powder*
- **SYMBICORT 160 MCG-4.5 MCG/ACTUATION HFA AEROSOL INHALER**
- **SYMBICORT 80 MCG-4.5 MCG/ACTUATION HFA AEROSOL INHALER**

Details

Criteria	Require a trial of 2 of the following (Step 1 drugs) when utilized for the same medically accepted indication and age group: Advair HFA, Breo Ellipta and Dulera in the last 180 days

Rapid Acting Insulin

Products Affected

- **ADMELOG SOLOSTAR U-100 INSULIN LISPRO 100 UNIT/ML SUBCUTANEOUS PEN**
- **ADMELOG U-100 INSULIN LISPRO 100 UNIT/ML SUBCUTANEOUS SOLUTION**
- **AFREZZA (REGULAR INSULIN) 8 UNIT (90)/12 UNIT (90) CARTRIDGE,INHALER**
- **AFREZZA 12 UNIT CARTRIDGE WITH INHALER**
- **AFREZZA 4 UNIT (60)/8 UNIT (60)/12 UNIT (60) CARTRIDGE WITH INHALER**
- **AFREZZA 4 UNIT (90)/8 UNIT (90) CARTRIDGE WITH INHALER**
- **AFREZZA 4 UNIT CARTRIDGE WITH INHALER**
- **AFREZZA 8 UNIT CARTRIDGE WITH INHALER**
- **APIDRA SOLOSTAR U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS PEN**
- **APIDRA U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION**
- **LYUMJEV KWIKPEN U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS**
- **LYUMJEV KWIKPEN U-200 INSULIN 200 UNIT/ML (3 ML) SUBCUTANEOUS**
- **LYUMJEV TEMPO PEN (U-100) INSULIN 100 UNIT/ML SUBCUTANEOUS PEN, SENSOR**
- **LYUMJEV U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION**
- **MERILOG 100 UNIT/ML SUBCUTANEOUS SOLUTION**
- **MERILOG SOLOSTAR 100 UNIT/ML (3 ML) SUBCUTANEOUS INSULIN PEN**

Details

Criteria	Pending CMS Review

Rho Kinase Inhibitors

Products Affected

- **RHOPRESSA 0.02 % EYE DROPS** **DROPS**
- **ROCKLATAN 0.02 %-0.005 % EYE**

Details

Criteria	Require a 1 month trial of one preferred glaucoma drug (Step 1 drug) in the last 120 days

Riomet

Products Affected

- *metformin 500 mg/5 ml oral solution*

Details

Criteria	Require a 1 month trial of generic metformin IR tablets in the last 90 days -OR- documentation supporting the inability to swallow or difficulty swallowing tablets containing metformin

Rytary

Products Affected

- **CREXONT 35 MG-140 MG CAPSULE, EXTENDED RELEASE**
- **CREXONT 52.5 MG-210 MG CAPSULE, EXTENDED RELEASE**
- **CREXONT 70 MG-280 MG CAPSULE, EXTENDED RELEASE**
- **CREXONT 87.5 MG-350 MG CAPSULE, EXTENDED RELEASE**
- **DHIVY 25 MG-100 MG TABLET**
- **RYTARY 23.75 MG-95 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 36.25 MG-145 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 48.75 MG-195 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 61.25 MG-245 MG CAPSULE,EXTENDED RELEASE**

Details

Criteria	Require a trial of generic carbidopa/levodopa product (Step 1 drug) in the last 90 days

SGLT2 Agents

Products Affected

- *dapagliflozin propaned 10 mg-metformin er 1,000 mg tablet,ext rel 24hr*
- *dapagliflozin propaned 5 mg-metformin er 1,000 mg tablet, ext rel 24hr*
- **INPEFA 200 MG TABLET**
- **INPEFA 400 MG TABLET**
- **INVOKAMET 150 MG-1,000 MG TABLET**
- **INVOKAMET 150 MG-500 MG TABLET**
- **INVOKAMET 50 MG-1,000 MG TABLET**
- **INVOKAMET 50 MG-500 MG TABLET**
- **INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE**
- **INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE**
- **INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE**
- **INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE**
- **INVOKANA 100 MG TABLET**
- **INVOKANA 300 MG TABLET**
- **SEGLUROMET 2.5 MG-1,000 MG TABLET**
- **SEGLUROMET 2.5 MG-500 MG TABLET**
- **SEGLUROMET 7.5 MG-1,000 MG TABLET**
- **SEGLUROMET 7.5 MG-500 MG TABLET**
- **STEGLATRO 15 MG TABLET**
- **STEGLATRO 5 MG TABLET**

Details

Criteria	Pending CMS Review

Sleeper Meds

Products Affected

- **BELSOMRA 10 MG TABLET**
- **BELSOMRA 15 MG TABLET**
- **BELSOMRA 20 MG TABLET**
- **BELSOMRA 5 MG TABLET**
- **DAYVIGO 10 MG TABLET**
- **DAYVIGO 5 MG TABLET**
- **QUVIVIQ 25 MG TABLET**
- **QUVIVIQ 50 MG TABLET**

Details

Criteria	Require a trial of 2 of the following (Step 1 drug): generic zolpidem tablet/zolpidem ER tablet, zaleplon or eszopiclone in the last 180 days

Soaanz

Products Affected

- **SOAANZ 40 MG TABLET**

Details

Criteria	Pending CMS Review

Suboxone

Products Affected

- **SUBOXONE 12 MG-3 MG SUBLINGUAL FILM**
- **SUBOXONE 2 MG-0.5 MG SUBLINGUAL FILM**
- **SUBOXONE 4 MG-1 MG SUBLINGUAL FILM**
- **SUBOXONE 8 MG-2 MG SUBLINGUAL FILM**

Details

Criteria	Require a 1 month trial of Zubsolv (Step 1 drug) in the last 90 days

Topical Antifungals

Products Affected

- **ERTACZO 2 % TOPICAL CREAM**
- **EXELDERM 1 % TOPICAL CREAM**
- **EXELDERM 1 % TOPICAL SOLUTION**
- **KETODAN 2 % TOPICAL FOAM**
- *naftifine 1 % topical cream*
- *naftifine 2 % topical cream*
- *naftifine 2 % topical gel*
- **NAFTIN 2 % TOPICAL GEL**
- *oxiconazole 1 % topical cream*
- **OXISTAT 1 % LOTION**

Details

Criteria	Require a 1 month trial of generic econazole cream and one of the following: generic ketoconazole cream or ketoconazole shampoo (Step 1 drugs),when being utilized for the same medically accepted indication, in the last 180 days

Topical Psoriasis

Products Affected

- *calcipotriene 0.005 % topical foam*
- *calcipotriene-betamethasone 0.005 %-0.064 % topical ointment*
- *calcipotriene-betamethasone 0.005 %-0.064 % topical suspension*
- *calcitriol 3 mcg/gram topical ointment*
- **ENSTILAR 0.005 %-0.064 % TOPICAL FOAM**
- **SORILUX 0.005 % TOPICAL FOAM**
- **TACLONEX 0.005 %-0.064 % TOPICAL SUSPENSION**
- **VECTICAL 3 MCG/GRAM TOPICAL OINTMENT**

Details

Criteria	Pending CMS Review

Topical Rosacea

Products Affected

- *azelaic acid 15 % topical gel*
- *brimonidine 0.33 % topical gel with pump*
- **EPSOLAY 5 % TOPICAL CREAM**
- **FINACEA 15 % TOPICAL FOAM**
- *ivermectin 1 % topical cream*
- **METROCREAM 0.75 % TOPICAL**
- **MIRVASO 0.33 % TOPICAL GEL WITH PUMP**
- **NORITATE 1 % TOPICAL CREAM**
- **RHOFADE 1 % TOPICAL CREAM**
- **SOOLANTRA 1 % TOPICAL CREAM**
- **ZILXI 1.5 % TOPICAL FOAM**

Details

Criteria	Require a 1 month trial of generic metronidazole cream, lotion, or gel (Step 1 drug) in the last 90 days.

Ursodiol

Products Affected

- **RELTONE 200 MG CAPSULE**
- **RELTONE 400 MG CAPSULE**
- *ursodiol 200 mg capsule*
- *ursodiol 400 mg capsule*

Details

Criteria	Require a 1 month trial of generic ursodiol 250mg tablet, 300mg capsule or 500mg tablet (step 1 drug) in the last 90 days

Index of Drugs

ADDERALL 20 MG TABLET.....1
ADDERALL 5 MG TABLET.....1
ADDERALL 7.5 MG TABLET.....1
ADDERALL XR 10 MG CAPSULE,EXTENDED RELEASE.....1
ADDERALL XR 15 MG CAPSULE,EXTENDED RELEASE.....1
ADDERALL XR 20 MG CAPSULE,EXTENDED RELEASE.....1
ADDERALL XR 25 MG CAPSULE,EXTENDED RELEASE.....1
ADDERALL XR 30 MG CAPSULE,EXTENDED RELEASE.....1
ADDERALL XR 5 MG CAPSULE,EXTENDED RELEASE.....1
ADMELOG SOLOSTAR U-100 INSULIN LISPRO 100 UNIT/ML SUBCUTANEOUS PEN..... 30
ADMELOG U-100 INSULIN LISPRO 100 UNIT/ML SUBCUTANEOUS SOLUTION..... 30
ADVAIR DISKUS 100 MCG-50 MCG/DOSE POWDER FOR INHALATION.....29
ADVAIR DISKUS 250 MCG-50 MCG/DOSE POWDER FOR INHALATION.....29
ADVAIR DISKUS 500 MCG-50 MCG/DOSE POWDER FOR INHALATION.....29
ADZENYS XR-ODT 12.5 MG EXTENDED RELEASE DISINTEGRATING TABLET..... 1
ADZENYS XR-ODT 15.7 MG EXTENDED RELEASE DISINTEGRATING TABLET..... 1
ADZENYS XR-ODT 18.8 MG EXTENDED RELEASE DISINTEGRATING TABLET..... 1
ADZENYS XR-ODT 3.1 MG EXTENDED RELEASE DISINTEGRATING TABLET..... 1
ADZENYS XR-ODT 6.3 MG EXTENDED RELEASE DISINTEGRATING TABLET..... 1
ADZENYS XR-ODT 9.4 MG EXTENDED RELEASE DISINTEGRATING TABLET..... 1
AFREZZA (REGULAR INSULIN) 8 UNIT (90)/12 UNIT (90) CARTRIDGE,INHALER.....30
AFREZZA 12 UNIT CARTRIDGE WITH INHALER.....30
AFREZZA 4 UNIT (60)/8 UNIT (60)/12 UNIT (60) CARTRIDGE WITH INHALER..... 30
AFREZZA 4 UNIT (90)/8 UNIT (90) CARTRIDGE WITH INHALER.....30
AFREZZA 4 UNIT CARTRIDGE WITH INHALER.....30
AFREZZA 8 UNIT CARTRIDGE WITH INHALER.....30
albuterol sulfate hfa 90 mcg/actuation aerosol inhaler (nda020983).....5
APIDRA SOLOSTAR U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS PEN...30
APIDRA U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION.....30
APTENSIO XR 10 MG CAPSULE,EXTENDED RELEASE SPRINKLE.....1
APTENSIO XR 15 MG CAPSULE,EXTENDED RELEASE SPRINKLE.....1
APTENSIO XR 20 MG CAPSULE,EXTENDED RELEASE SPRINKLE.....1
APTENSIO XR 30 MG CAPSULE,EXTENDED RELEASE SPRINKLE.....1
APTENSIO XR 40 MG CAPSULE,EXTENDED RELEASE SPRINKLE.....1
APTENSIO XR 50 MG CAPSULE,EXTENDED RELEASE SPRINKLE.....1
APTENSIO XR 60 MG CAPSULE,EXTENDED RELEASE SPRINKLE.....1

ARANESP 10 MCG/0.4 ML (IN POLYSORBATE) INJECTION SYRINGE 14
ARANESP 100 MCG/0.5 ML (IN POLYSORBATE) INJECTION SYRINGE 14
ARANESP 100 MCG/ML (IN POLYSORBATE) INJECTION 14
ARANESP 150 MCG/0.3 ML (IN POLYSORBATE) INJECTION SYRINGE 14
ARANESP 200 MCG/0.4 ML (IN POLYSORBATE) INJECTION SYRINGE 14
ARANESP 200 MCG/ML (IN POLYSORBATE) INJECTION 14
ARANESP 25 MCG/0.42 ML (IN POLYSORBATE) INJECTION SYRINGE 14
ARANESP 25 MCG/ML (IN POLYSORBATE) INJECTION 14
ARANESP 300 MCG/0.6 ML (IN POLYSORBATE) INJECTION SYRINGE 14
ARANESP 40 MCG/0.4 ML (IN POLYSORBATE) INJECTION SYRINGE 14
ARANESP 40 MCG/ML (IN POLYSORBATE) INJECTION 14
ARANESP 500 MCG/ML (IN POLYSORBATE) INJECTION SYRINGE 14
ARANESP 60 MCG/0.3 ML (IN POLYSORBATE) INJECTION SYRINGE 14
ARANESP 60 MCG/ML (IN POLYSORBATE) INJECTION 14
AUVI-Q 0.1 MG/0.1 ML INJECTION,AUTO-INJECTOR 6
AUVI-Q 0.15 MG/0.15 ML AUTO-INJECTOR (FOR 33 LB TO 66 LB PATIENTS) 6
AUVI-Q 0.3 MG/0.3 ML INJECTION, AUTO-INJECTOR 6
azelaic acid 15 % topical gel 40
AZSTARYS 26.1 MG-5.2 MG CAPSULE 1
AZSTARYS 39.2 MG-7.8 MG CAPSULE 1
AZSTARYS 52.3 MG-10.4 MG CAPSULE 1
BELSOMRA 10 MG TABLET 35
BELSOMRA 15 MG TABLET 35
BELSOMRA 20 MG TABLET 35
BELSOMRA 5 MG TABLET 35
brimonidine 0.33 % topical gel with pump .. 40
calcipotriene 0.005 % topical foam 39
calcipotriene-betamethasone 0.005 %-0.064 % topical ointment 39
calcipotriene-betamethasone 0.005 %-0.064 % topical suspension 39
calcitriol 3 mcg/gram topical ointment 39
CELEBREX 100 MG CAPSULE 8
CELEBREX 200 MG CAPSULE 8
CELEBREX 400 MG CAPSULE 8
CELEBREX 50 MG CAPSULE 8
CEQUA 0.09 % EYE DROPS IN A DROPPERETTE 11
clonidine hcl er 0.17 mg tablet,extended release 24 hr 9
CONCERTA 18 MG TABLET,EXTENDED RELEASE 1
CONCERTA 27 MG TABLET,EXTENDED RELEASE 1
CONCERTA 36 MG TABLET,EXTENDED RELEASE 1
CONCERTA 54 MG TABLET,EXTENDED RELEASE 1
COTEMPLA XR-ODT 17.3 MG EXTENDED RELEASE DISINTEGRATING TABLET 1
COTEMPLA XR-ODT 25.9 MG EXTENDED RELEASE DISINTEGRATING TABLET 1
COTEMPLA XR-ODT 8.6 MG EXTENDED RELEASE DISINTEGRATING TABLET 1
CREXONT 35 MG-140 MG CAPSULE, EXTENDED RELEASE 33
CREXONT 52.5 MG-210 MG CAPSULE, EXTENDED RELEASE 33

CREXONT 70 MG-280 MG CAPSULE, EXTENDED RELEASE 33
CREXONT 87.5 MG-350 MG CAPSULE, EXTENDED RELEASE 33
dapagliflozin propaned 10 mg-metformin er 1,000 mg tablet,ext rel 24hr 34
dapagliflozin propaned 5 mg-metformin er 1,000 mg tablet, ext rel 24hr 34
DAYVIGO 10 MG TABLET 35
DAYVIGO 5 MG TABLET 35
DEXEDRINE SPANSULE 10 MG CAPSULE,EXTENDED RELEASE 1
dextroamphetamine sulfate er 10 mg capsule,extended release 1
dextroamphetamine sulfate er 15 mg capsule,extended release 1
dextroamphetamine sulfate er 5 mg capsule,extended release 1
dextroamphetamine-amphetamine er 12.5 mg capsule, 3 bead, ext rel 24hr 1
dextroamphetamine-amphetamine er 25 mg capsule,3 bead,ext release 24hr 1
dextroamphetamine-amphetamine er 37.5 mg capsule, 3 bead, ext rel 24hr 1
dextroamphetamine-amphetamine er 50 mg capsule,3 bead,ext release 24hr 1
DHIVY 25 MG-100 MG TABLET 33
diclofenac 20 mg/gram/actuation (2 %) topical soln metered-dose pump 26
DYANAVEL XR 10 MG TABLET, EXTENDED RELEASE 1
DYANAVEL XR 15 MG TABLET, EXTENDED RELEASE 1
DYANAVEL XR 2.5 MG/ML ORAL 24 HR EXTENDED RELEASE SUSPENSION 1
DYANAVEL XR 20 MG TABLET, EXTENDED RELEASE 1
DYANAVEL XR 5 MG TABLET, EXTENDED RELEASE 1
DYMISTA 137 MCG-50 MCG/SPRAY NASAL SPRAY 12
ELIGARD 22.5 MG (3 MONTH) SUBCUTANEOUS SYRINGE 17
ELIGARD 30 MG (4 MONTH) SUBCUTANEOUS SYRINGE 17
ELIGARD 45 MG (6 MONTH) SUBCUTANEOUS SYRINGE 17
ELIGARD 7.5 MG (1 MONTH) SUBCUTANEOUS SYRINGE 17
ENSTILAR 0.005 %-0.064 % TOPICAL FOAM 39
ENTRESTO 24 MG-26 MG TABLET 13
ENTRESTO 49 MG-51 MG TABLET 13
ENTRESTO 97 MG-103 MG TABLET ... 13
EPIPEN 2-PAK 0.3 MG/0.3 ML INJECTION, AUTO-INJECTOR 6
EPIPEN JR 2-PAK 0.15 MG/0.3 ML INJECTION,AUTO-INJECTOR 6
EPOGEN 2,000 UNIT/ML INJECTION SOLUTION 14
EPOGEN 20,000 UNIT/2 ML INJECTION SOLUTION 14
EPOGEN 20,000 UNIT/ML INJECTION SOLUTION 14
EPOGEN 3,000 UNIT/ML INJECTION SOLUTION 14
EPOGEN 4,000 UNIT/ML INJECTION SOLUTION 14
EPSOLAY 5 % TOPICAL CREAM 40
ERTACZO 2 % TOPICAL CREAM 38
EXELDERM 1 % TOPICAL CREAM 38
EXELDERM 1 % TOPICAL SOLUTION 38
FINACEA 15 % TOPICAL FOAM 40
fluticasone 113 mcg-salmeterol 14 mcg/actuation breath activated powdr 29
fluticasone 232 mcg-salmeterol 14 mcg/actuation breath activated powdr 29
fluticasone 55 mcg-salmeterol 14 mcg/actuation breath activated powder 29
fluticasone furoate 100 mcg-vilanterol 25 mcg/dose inhalation powder 29
fluticasone furoate 200 mcg-vilanterol 25 mcg/dose inhalation powder 29
fluticasone propionate 100 mcg/actuation blister powder for inhalation 28
fluticasone propionate 110 mcg/actuation hfa aerosol inhaler 28
fluticasone propionate 220 mcg/actuation hfa aerosol inhaler 28

fluticasone propionate 250 mcg/actuation blister powder for inhalation 28
fluticasone propionate 44 mcg/actuation hfa aerosol inhaler 28
fluticasone propionate 50 mcg/actuation blister powder for inhalation 28
FOCALIN 10 MG TABLET 1
FOCALIN 2.5 MG TABLET 1
FOCALIN 5 MG TABLET 1
FOCALIN XR 10 MG CAPSULE,EXTENDED RELEASE 1
FOCALIN XR 15 MG CAPSULE,EXTENDED RELEASE 1
FOCALIN XR 20 MG CAPSULE,EXTENDED RELEASE 1
FOCALIN XR 25 MG CAPSULE,EXTENDED RELEASE 1
FOCALIN XR 30 MG CAPSULE,EXTENDED RELEASE 1
FOCALIN XR 35 MG CAPSULE,EXTENDED RELEASE 1
FOCALIN XR 40 MG CAPSULE,EXTENDED RELEASE 1
FOCALIN XR 5 MG CAPSULE,EXTENDED RELEASE 1
FULPHILA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE 10
FYLNETRA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE 10
GLUMETZA 1,000 MG TABLET,EXTENDED RELEASE 16
GLUMETZA 500 MG TABLET,EXTENDED RELEASE 16
GRANIX 300 MCG/0.5 ML SUBCUTANEOUS SYRINGE 10
GRANIX 300 MCG/ML SUBCUTANEOUS SOLUTION 10
GRANIX 480 MCG/0.8 ML SUBCUTANEOUS SYRINGE 10
INCRUSE ELLIPTA 62.5 MCG/ACTUATION POWDER FOR INHALATION 19
INPEFA 200 MG TABLET 34
INPEFA 400 MG TABLET 34
INVOKAMET 150 MG-1,000 MG TABLET 34
INVOKAMET 150 MG-500 MG TABLET 34
INVOKAMET 50 MG-1,000 MG TABLET 34
INVOKAMET 50 MG-500 MG TABLET 34
INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE 34
INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE 34
INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE 34
INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE 34
INVOKANA 100 MG TABLET 34
INVOKANA 300 MG TABLET 34
ivermectin 1 % topical cream 40
IYUZEH (PF) 0.005 % EYE DROPS IN A DROPPERETTE 27
JORNAY PM 100 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE 1
JORNAY PM 20 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE 1
JORNAY PM 40 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE 1
JORNAY PM 60 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE 1
JORNAY PM 80 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE 1
KETODAN 2 % TOPICAL FOAM 38
KRISTALOSE 10 GRAM ORAL PACKET 21
KRISTALOSE 20 GRAM ORAL PACKET 21
lactulose 10 gram oral packet 21
lactulose 20 gram oral packet 21

lisdexamfetamine 10 mg capsule 1
lisdexamfetamine 10 mg chewable tablet 1
lisdexamfetamine 20 mg capsule 1
lisdexamfetamine 20 mg chewable tablet 1
lisdexamfetamine 30 mg capsule 1
lisdexamfetamine 30 mg chewable tablet 1
lisdexamfetamine 40 mg capsule 1
lisdexamfetamine 40 mg chewable tablet 1
lisdexamfetamine 50 mg capsule 1
lisdexamfetamine 50 mg chewable tablet 1
lisdexamfetamine 60 mg capsule 1
lisdexamfetamine 60 mg chewable tablet 1
lisdexamfetamine 70 mg capsule 1
LUPRON DEPOT 22.5 MG (3 MONTH) INTRAMUSCULAR SYRINGE KIT 17
LUPRON DEPOT 30 MG (4 MONTH) INTRAMUSCULAR SYRINGE KIT 17
LUPRON DEPOT 45 MG (6 MONTH) INTRAMUSCULAR SYRINGE KIT 17
LUPRON DEPOT 7.5 MG INTRAMUSCULAR SYRINGE KIT 17
LUTRATE DEPOT (3 MONTH) 22.5 MG IM SUSPENSION 17
LYUMJEV KWIKPEN U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS 30
LYUMJEV KWIKPEN U-200 INSULIN 200 UNIT/ML (3 ML) SUBCUTANEOUS 30
LYUMJEV TEMPO PEN (U-100) INSULIN 100 UNIT/ML SUBCUTANEOUS PEN, SENSOR 30
LYUMJEV U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION 30
MERILOG 100 UNIT/ML SUBCUTANEOUS SOLUTION 30
MERILOG SOLOSTAR 100 UNIT/ML (3 ML) SUBCUTANEOUS INSULIN PEN 30
METADATE CD 10 MG CAPSULE,EXTENDED RELEASE 1
METADATE CD 20 MG CAPSULE,EXTENDED RELEASE 1
METADATE CD 30 MG CAPSULE,EXTENDED RELEASE 1
METADATE CD 40 MG CAPSULE,EXTENDED RELEASE 1
METADATE CD 50 MG CAPSULE,EXTENDED RELEASE 1
METADATE CD 60 MG CAPSULE,EXTENDED RELEASE 1
metformin 500 mg/5 ml oral solution 32
metformin 625 mg tablet 22
metformin 750 mg tablet 22
metformin er 1,000 mg 24 hr tablet,extended release (gastric reten.) 16
metformin er 1,000 mg tablet,extended release 24hr (osmotic) 15
metformin er 500 mg 24 hr tablet,extended release (gastric retention) 16
metformin er 500 mg tablet,extended release 24hr (osmotic) 15
METHYLIN 10 MG/5 ML ORAL SOLUTION 1
METHYLIN 5 MG/5 ML ORAL SOLUTION 1
methylphenidate er 10 mg capsule,extended release (40-60) sprinkle 1
methylphenidate er 15 mg capsule,extended release (40-60) sprinkle 1
methylphenidate er 18 mg tablet,extended release 24 hr (bx rating) 1
methylphenidate er 20 mg capsule,extended release (40-60) sprinkle 1
methylphenidate er 27 mg tablet,extended release 24 hr (bx rating) 1
methylphenidate er 30 mg capsule,extended release (40-60) sprinkle 1
methylphenidate er 36 mg tablet,extended release 24 hr (bx rating) 1
methylphenidate er 40 mg capsule,extended release (40-60) sprinkle 1
methylphenidate er 45 mg tablet,extended release 24 hr 1
methylphenidate er 50 mg capsule,extended release (40-60) sprinkle 1
methylphenidate er 54 mg tablet,extended release 24 hr (bx rating) 1
methylphenidate er 60 mg capsule,extended release (40-60) sprinkle 1

methylphenidate er 63 mg tablet,extended release 24 hr 1
methylphenidate er 72 mg tablet,extended release 24 hr 1
METROCREAM 0.75 % TOPICAL 40
MIEBO (PF) 100 % EYE DROPS 11
mirabegron er 25 mg tablet,extended release 24 hr 23
mirabegron er 50 mg tablet,extended release 24 hr 23
MIRCERA 100 MCG/0.3 ML INJECTION SYRINGE 14
MIRCERA 120 MCG/0.3 ML INJECTION SYRINGE 14
MIRCERA 150 MCG/0.3 ML INJECTION SYRINGE 14
MIRCERA 200 MCG/0.3 ML INJECTION SYRINGE 14
MIRCERA 30 MCG/0.3 ML INJECTION SYRINGE 14
MIRCERA 50 MCG/0.3 ML INJECTION SYRINGE 14
MIRCERA 75 MCG/0.3 ML INJECTION SYRINGE 14
MIRVASO 0.33 % TOPICAL GEL WITH PUMP 40
mupirocin calcium 2 % topical cream 24
MYDAYIS 12.5 MG CAPSULE EXTENDED RELEASE 24 HR 1
MYDAYIS 25 MG CAPSULE EXTENDED RELEASE 24 HR 1
MYDAYIS 37.5 MG CAPSULE EXTENDED RELEASE 24 HR 1
MYDAYIS 50 MG CAPSULE EXTENDED RELEASE 24 HR 1
naftifine 1 % topical cream 38
naftifine 2 % topical cream 38
naftifine 2 % topical gel 38
NAFTIN 2 % TOPICAL GEL 38
NEFFY 1 MG/SPRAY (0.1 ML) NASAL SPRAY 6
NEFFY 2 MG/SPRAY (0.1 ML) NASAL SPRAY 6
NEULASTA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE 10
NEUPOGEN 300 MCG/0.5 ML INJECTION SYRINGE 10
NEUPOGEN 300 MCG/ML INJECTION SOLUTION 10
NEUPOGEN 480 MCG/0.8 ML INJECTION SYRINGE 10
NEUPOGEN 480 MCG/1.6 ML INJECTION SOLUTION 10
NEXICLON XR 0.17 MG TABLET,EXTENDED RELEASE 9
NORITATE 1 % TOPICAL CREAM 40
NYVEPRIA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE 10
oxiconazole 1 % topical cream 38
OXISTAT 1 % LOTION 38
PANCREAZE 10,500 UNIT-35,500 UNIT-61,500 UNIT CAPSULE,DELAYED RELEASE 25
PANCREAZE 16,800 UNIT-56,800 UNIT-98,400 UNIT CAPSULE,DELAYED RELEASE 25
PANCREAZE 2,600 UNIT-8,800 UNIT-15,200 UNIT CAPSULE,DELAYED RELEASE 25
PANCREAZE 21,000 UNIT-54,700 UNIT-83,900 UNIT CAPSULE,DELAYED RELEASE 25
PANCREAZE 37,000-97,300-149,900 UNIT CAPSULE,DELAYED RELEASE 25
PANCREAZE 4,200 UNIT-14,200 UNIT-24,600 UNIT CAPSULE,DELAYED RELEASE 25
PERTZYE 16,000 UNIT-57,500 UNIT-60,500 UNIT CAPSULE,DELAYED RELEASE 25
PERTZYE 24,000-86,250-90,750 UNIT CAPSULE,DELAYED RELEASE 25
PERTZYE 4,000 UNIT-14,375 UNIT-15,125 UNIT CAPSULE,DELAYED RELEASE 25
PERTZYE 8,000 UNIT-28,750 UNIT-30,250 UNIT CAPSULE,DELAYED RELEASE 25
PROAIR RESPICLICK 90 MCG/ACTUATION BREATH ACTIVATED 5

QUILLICHEW ER 20 MG CHEWABLE TABLET, EXTENDED RELEASE 1
QUILLICHEW ER 30 MG CHEWABLE TABLET, EXTENDED RELEASE 1
QUILLICHEW ER 40 MG CHEWABLE, EXTENDED RELEASE TABLET 1
QUILLIVANT XR 5 MG/ML (25 MG/5 ML) ORAL SUSPENSION,EXTEND RELEASE 24HR 1
QUVIVIQ 25 MG TABLET 35
QUVIVIQ 50 MG TABLET 35
RELEUKO 300 MCG/0.5 ML SUBCUTANEOUS SYRINGE 10
RELEUKO 480 MCG/0.8 ML SUBCUTANEOUS SYRINGE 10
RELEXXII 18 MG TABLET,EXTENDED RELEASE 1
RELEXXII 27 MG TABLET,EXTENDED RELEASE 1
RELEXXII 36 MG TABLET,EXTENDED RELEASE 1
RELEXXII 45 MG TABLET,EXTENDED RELEASE 1
RELEXXII 54 MG TABLET,EXTENDED RELEASE 1
RELEXXII 63 MG TABLET,EXTENDED RELEASE 1
RELTONE 200 MG CAPSULE 41
RELTONE 400 MG CAPSULE 41
RHOFADE 1 % TOPICAL CREAM 40
RHOPRESSA 0.02 % EYE DROPS 31
RITALIN 10 MG TABLET 1
RITALIN 20 MG TABLET 1
RITALIN LA 10 MG CAPSULE,EXTENDED RELEASE 1
RITALIN LA 20 MG CAPSULE,EXTENDED RELEASE 1
RITALIN LA 30 MG CAPSULE,EXTENDED RELEASE 1
RITALIN LA 40 MG CAPSULE,EXTENDED RELEASE 1
ROCKLATAN 0.02 %-0.005 % EYE DROPS 31
RYALTRIS 665 MCG-25 MCG/SPRAY NASAL SPRAY 12
RYTARY 23.75 MG-95 MG CAPSULE,EXTENDED RELEASE 33
RYTARY 36.25 MG-145 MG CAPSULE,EXTENDED RELEASE 33
RYTARY 48.75 MG-195 MG CAPSULE,EXTENDED RELEASE 33
RYTARY 61.25 MG-245 MG CAPSULE,EXTENDED RELEASE 33
SEGLUROMET 2.5 MG-1,000 MG TABLET 34
SEGLUROMET 2.5 MG-500 MG TABLET 34
SEGLUROMET 7.5 MG-1,000 MG TABLET 34
SEGLUROMET 7.5 MG-500 MG TABLET 34
SOAANZ 40 MG TABLET 36
SOOLANTRA 1 % TOPICAL CREAM . 40
SORILUX 0.005 % TOPICAL FOAM 39
SPIRIVA WITH HANDIHALER 18 MCG AND INHALATION CAPSULES .. 19
STEGLATRO 15 MG TABLET 34
STEGLATRO 5 MG TABLET 34
STIMUFEND 6 MG/0.6 ML SUBCUTANEOUS SYRINGE 10
SUBOXONE 12 MG-3 MG SUBLINGUAL FILM 37
SUBOXONE 2 MG-0.5 MG SUBLINGUAL FILM 37
SUBOXONE 4 MG-1 MG SUBLINGUAL FILM 37
SUBOXONE 8 MG-2 MG SUBLINGUAL FILM 37
SYMBICORT 160 MCG-4.5 MCG/ACTUATION HFA AEROSOL INHALER 29
SYMBICORT 80 MCG-4.5 MCG/ACTUATION HFA AEROSOL INHALER 29
TACLONEX 0.005 %-0.064 % TOPICAL SUSPENSION 39
tiotropium bromide 18 mcg capsule with inhalation device 19

TRELSTAR 11.25 MG IM SUSPENSION 17
TRELSTAR 22.5 MG IM SUSPENSION 17
TRELSTAR 3.75 MG IM SUSPENSION 17
TRYPTYR 0.003 % EYE DROPS IN A DROPPERETTE 11
TUDORZA PRESSAIR 400 MCG/ACTUATION BREATH ACTIVATED 19
TUDORZA PRESSAIR 400 MCG/ACTUATION BREATH ACTIVATED (30 ACTUAT) 19
TYRVAYA 0.03 MG/SPRAY NASAL SPRAY 11
UDENYCA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE 10
UDENYCA AUTOINJECTOR 6 MG/0.6 ML SUBCUTANEOUS AUTO-INJECTOR 10
umeclidinium 62.5 mcg-vilanterol 25 mcg/actuation powdr for inhalation 20
ursodiol 200 mg capsule 41
ursodiol 400 mg capsule 41
VECTICAL 3 MCG/GRAM TOPICAL OINTMENT 39
VEVYE 0.1 % EYE DROPS 11
VYVANSE 10 MG CAPSULE 1
VYVANSE 10 MG CHEWABLE TABLET 1
VYVANSE 20 MG CAPSULE 1
VYVANSE 20 MG CHEWABLE TABLET 1
VYVANSE 30 MG CAPSULE 1
VYVANSE 30 MG CHEWABLE TABLET 1
VYVANSE 40 MG CAPSULE 1
VYVANSE 40 MG CHEWABLE TABLET 1
VYVANSE 50 MG CAPSULE 1
VYVANSE 50 MG CHEWABLE TABLET 1
VYVANSE 60 MG CAPSULE 1
VYVANSE 60 MG CHEWABLE TABLET 1
VYVANSE 70 MG CAPSULE 1
VYZULTA 0.024 % EYE DROPS 27
XELSTRYM 13.5 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH 1
XELSTRYM 18 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH 1
XELSTRYM 4.5 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH 1
XELSTRYM 9 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH 1
XOPENEX HFA 45 MCG/ACTUATION AEROSOL INHALER 7
ZIEXTENZO 6 MG/0.6 ML SUBCUTANEOUS SYRINGE 10
ZILXI 1.5 % TOPICAL FOAM 40
ZIOPTAN (PF) 0.0015 % EYE DROPS IN A DROPPERETTE 27
ZIRGAN 0.15 % EYE GEL 18